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Abstract
Introduction: High mobility group A1 (HMGA1) proteins are architectural
transcriptional factors that are overexpressed in a range of human
malignancies. However, their roles in the pathogenesis of pancreatic cancer
are largely unknown. Pancreatic cancer is the deadliest of human
malignancies with its aggressive locoregional invasion, such that the majority
of patients have locally advanced cancer not amenable to surgical therapy at
the time of diagnosis. In patients with advanced disease, the only therapeutic
option is chemotherapy with nucleoside analogue gemcitabine. Further, the
clinical impact of gemcitabine is only modest due to the high degree of
chemoresistance. There is an urgent need to understand the biology of this
cancer.
Hypotheses and aims: We hypothesised that HMGA1 is overexpressed in
pancreatic cancers and plays a role in the malignant phenotype of pancreatic
cancer cells. There are two broad components to this work. The aims of the
first component were to examine the expression of HMGA1 in a large sample
of pancreatic cancer tissues from patients who underwent resection and to
assess if HMGA1 expression could be used as a prognostic biomarker. In the
second component, we addressed the roles of HMGA1 in the pancreatic
cancer progression, and assessed the effects of therapeutic targeting of
HMGA1 in experimental pancreatic cancer models.
Studies: Five complementary studies were performed. 1) Firstly, analysis of
HMGA1 expression in pancreatic cancer tissues was carried out using a
constructed tissue microarray consisting of tumours from 89 consecutive
patients who underwent pancreatic resection over a 12-year period from 1991
to 2002 in a single institute. HMGA1 expression was correlated with
postoperative survival and clinicopathological features. 2) Secondly, a study
was performed to assess the effects of HMGA1 on cellular invasiveness using
loss-of-function (RNA interference, RNAi) and gain-of-function (ectopic
I
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HMGA1 overexpression) experiments. In vivo experiments were performed to
assess the effects of targeted silencing of HMGA1 on the process of
metastasis. 3) Thirdly, the roles of HMGA1 in regulating anoikis resistance
were studied. 4) In the fourth study, the effects of HMGA1 on anchorage-
independent proliferation and in vivo tumour growth were assessed. 5) Lastly,
experiments were performed to assess the ability of HMGA1 to modulate
chemoresistance to gemcitabine in pancreatic cancer cells. This study
assessed the feasibility of RNAi of HMGA1 as a potential chemosensitising
strategy using in vivo model. In each of the above studies, downstream
molecular mediators of HMGA1 were identified and experiments were
performed to assess the mechanistic dependence of HMGA1-induced
phenotype on these pathways.
Results: We showed that HMGA1 is overexpressed in more than 90% of
pancreatic cancers and is associated with poorer postoperative survival.
Further, tumoural HMGA1 expression was found to be an independent
prognostic indicator in patients who underwent resection. Our in vitro studies
suggest that HMGA1 promotes cellular invasiveness in pancreatic cancer
cells through PI3-K/Akt-dependent MMP9 expression. Post-transcriptional
silencing of HMGA1 suppressed metastasis in vivo. Overexpression of
HMGA1 promotes PI3-K/Akt-dependent anoikis resistance and anchorage
independent proliferation. The regulatory roles of HMGA1 on the PI3-K/Akt
and MMP9 pathways are novel and previously undescribed. Although HMGA1
also regulates ERK activity, the contribution of this pathway is less important
in controlling the HMGA1-induced anchorage-independent growth. In vivo
silencing of HMGA1 resulted in attenuation of tumour growth in xenograft
mouse model. Lastly, we found that HMGA1 represents a novel molecular
determinant of chemoresistance to gemcitabine in pancreatic cancer cells.
Targeted silencing of HMGA1 chemosensitised pancreatic cancer cells to
gemcitabine both in vitro and in vivo.
II
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Conclusions: HMGA1 represents a novel prognostic biomarker in pancreatic
cancer. Targeting of HMGA1 may be a novel therapeutic (anti-metastatic,
anti-proliferative and chemosensitising) strategy to ameliorate the aggressive
phenotype of pancreatic cancer cells. PI3-K/Akt, ERK and MMP9 are novel
downstream mediators of HMGA1.
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satisfying. During the course of this work, I have learnt and performed a
comprehensive number of complex techniques in molecular biology, which I
am certain will provide the foundation to be an independent investigator.
The introduction of this thesis outlines the research motivation for this work, a
brief history of pancreatic cancer and describes the epidemiology, risk factors,
pathology, molecular biology, clinical features and current evidence-based
management of this deadly disease. This is followed by a review of the
current understanding of the biology of HMGA1 and its potential roles in
oncology. A background of the emerging field of RNA interference as a
molecular tool and therapeutic strategy is also provided.
In Chapter 2, the materials and methods of all studies are consolidated. A
detailed description of methodology is provided to ensure reproducibility of
results. Chapter 3 describes the results of the clinical study involving the use
of tissue microarrray to look at tumoural HMGA1 expression and its potential
correlations with patient clinicopathological characteristics. Chapter 4
documents the results of in vitro and in vivo experiments investigating the
roles of HMGA1 in regulating cellular invasiveness and metastasis. Chapter 5
deals with HMGA1 and anoikis-resistance in pancreatic cancer cells. Chapter
6 describes the roles of HMGA1 in anchorage-independent cellular
proliferation and in vivo tumour growth. Lastly, roles of HMGA1 in
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chemoresistance to gemcitabine were investigated and the results provided in
Chapter 7. The concluding part of the thesis is in Chapter 8 where the
research strategy is described, all the findings from this thesis are
consolidated and discussed, and ideas for future work to translate this work
into clinical applications are given.
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1.1 RESEARCH MOTIVATION: THE CLINICAL PROBLEM
Pancreatic cancer has a very poor prognosis. The aggressive biology of the
tumour and the late presentation of this disease accounts for the overall low
median survival of less than 6 months and a 5-year survival rate of 0.4-5 per
cent (Bramhall et al., 1995; Hedberg et al., 1998). In UK, USA and Europe,
the incidence of pancreatic adenocarcinoma (PDAC) almost equals the
mortality, indicating a universally lethal disease. Although it is a relatively rare
disease, it stands as one of the leading causes of cancer deaths. Worldwide,
the survival rates of this disease have not improved during the last 25 years
despite medical advancement.
Surgery is the only curative therapy for this cancer. Unfortunately, only a small
minority of patients (10-20%) present early enough with potentially resectable
disease at the time of diagnosis. Even if a curative resection has been
performed, many patients still succumb to local or metastatic recurrence
following surgery. The implication of this is that PDAC must have
metastasised before clinical presentation in most cases. Some improvements
in surgical outcome occur in patients who receive adjuvant chemotherapy,
though the impact on 5-year survival has been minimal. In patients with
advanced disease, chemotherapy remains the only option. Due to the highly
chemoresistant nature of this cancer, only a small number of agents have
been shown to confer modest benefit in terms of survival and clinical
response. Although surgery as a mainstay of curative treatment has made
significant progress over the years, it is the consensus that further
improvement in surgical technique is unlikely to impact on survival of this
deadly disease.
To improve the prognosis of this cancer, better understanding of this cancer at
the molecular level is urgently required (Kern et al., 2001). The work
1
Chapter 1: Introduction
described in this thesis identified HMGA1 gene as a novel molecular
determinant of malignant phenotype in this cancer and its potential role as a
prognostic indicator and therapeutic target in this deadly disease.
1.2 PANCREATIC CANCER: A BRIEF HISTORICAL ACCOUNT
Early description of pancreatic carcinoma was provided by Giovanni Battista
Morgagni (1682-1771), the father of 'pathological anatomy', in his famous
work entitled The Seats and Causes of Diseases' (Morgagni, 1960; Sedivy &
Patzak, 2002). As he astutely noted, Morgagni described the difficulty of
clinically diagnosing pancreatic tumours due to the inaccessible anatomical
location of this organ. With this, it is not surprising that few cases were
reported in the eighteenth and nineteenth centuries. In 1890, Ludwig Georg
Courvoisier (1843-1918) published on his experience with the classic sign of a
palpable distended gallbladder from which the Courvoisier's law originated.
Courvoisier's law states that obstruction of the common bile duct due to stone
rarely results in dilatation of the gallbladder whilst if the obstruction is due to
other causes, dilatation of gallbladder is common. These causes other than
stone imply neoplastic causes including pancreatic cancers. In fact, Louis-
Felix Terrier, a French surgeon, described a case of gallbladder dilatation
associated with pancreatic cancer in 1889 which gave rise to the term
'Courvoisier-Terrier's law' (McClusky et al., 2002).
The first surgical treatment for malignant pancreatic lesions was perhaps a
total pancreatectomy performed by Billroth in 1884 (Howard, 1999). Walter
Kausch first described the technique of pancreaticoduodenectomy in 1912.
The modern era of pancreatic surgery started when Whipple, Parsons and
Mullins presented their paper on pancreaticoduodenectomy to the American
Surgical Association in 1935. Whipple and colleagues initially performed a
two-stage pancreaticoduodenectomy which consisted of biliary diversion and
gastrojejunostomy during the initial operation followed by the resection of
pancreatic head and duodenum up to 3 weeks later. In 1941, Whipple
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modified the procedure to a one-stage pancreaticoduodenectomy with a
pancreaticojejunostomy (Whipple, 1949). It is perhaps to Allen O. Whipple,
more than any other individual, who is due the recognition as being the
'Father of Pancreatic Surgery'.
1.3 PANCREATIC CANCER: EPIDEMIOLOGY AND ITS DISMAL
PROGNOSIS
Currently, there is no effective treatment for this universally lethal disease.
This is in part due to the difficulty of diagnosing this disease at an early stage
given the few early indicators of disease and lack of screening tests.
Prevention of this cancer is difficult as little is known about its aetiology.
Although pancreatic cancer is relatively less common than cancers of lung,
breast, large bowel or prostate, its high mortality rate has ranked it as the
eighth most common cause of cancer mortality worldwide, accounting for
nearly quarter of a million deaths yearly (Parkin et al., 2005). The m ajority
(61%) of pancreatic cancers occur in the developed countries.
Pancreatic cancer is the sixth most common cause of cancer death in the UK
(Cancer Research UK, 2007). In the USA, pancreatic cancer is the fourth
leading cause of cancer-related mortality (Jemal et al., 2006). In 2005,
pancreatic cancer resulted in 3455 male and 3783 female deaths in the UK
(Cancer Research UK, 2007). In USA, the American Cancer Society
estimates that there will be 37170 new cases of pancreatic cancer (18,830
men and 18,340 women) with 33370 deaths from this disease in 2007
(American Cancer Society, 2007).
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In the UK, there has been little improvement in survival over the last 3
decades (Figure 1.1). Survival rates in pancreatic cancer are amongst the
lowest of all cancers (Figure 1.2). Effective treatments for this cancer have not
been forthcoming. Surgical resection remains the only curative treatment
option for this group of patients. The technical advances in pancreatic surgery
together with improvement of surgical outcome due to regionalisation of
pancreatic surgeries in high patient load centres have not impact on the
survival of patients with PDAC. The addition of chemo-, radiotherapy or a
combination of these makes little difference to the survival outcome over the
last 30 years (Jemal et al., 2006). This is in large part due to locoregional
disease recurrence in 50-80% of patients who underwent resection, and a
similar figure will develop liver metastases (Staley et al., 1996).
























































Figure 1.1. Age-standardised mortality rates of pancreatic cancer in UK over the period 1971-
2005 (Cancer Research UK, 2007). Mortality rates in female patients have remained static
over the last 30 years, with only a slight decline in male patients.
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Five year age standardised relative survival (% I, adults diagnosed 1996-1999





























Figure 1.2. Five-year age-standardised relative survival (%) for adults diagnosed between
1996 and 1999 in England and Wales by sex and cancer site (Cancer Research UK, 2007).




1.4 AETIOLOGY AND RISK FACTORS FOR PANCREATIC
CANCER
The only established risk factors for pancreatic cancer are age and smoking
status. In the following sections, the evidence implicating each of these risk
factors in pancreatic cancer is discussed.
1.4.1 Age
The incidence of pancreatic cancer increases exponentially with age and
peaks in the seventh and eighth decades (Figure 1.3). As the populations of
the developed countries age, one can predict that there would be an
increasing incidence of pancreatic cancer.
Numbers of new cases and age-specific incidence rates,
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:igure 1.3. Number of new cases of pancreatic cancer and age-specific incidence rates in UK
for year 2003. Approximately 10% of pancreatic cancers occur prior to age 50. Figure was




Cigarette smoking shows the strongest association with the risk of pancreatic
cancer, accounting for an estimated 25% of all cases (Lowenfels &
Maisonneuve, 2006). The risk of pancreatic cancer is proportional to the
duration and intensity of cigarette smoking. Doll and colleagues confirmed
these findings by showing that ex-smokers were 1.4 times more likely to die
from pancreatic cancer compared to men who had never smoked (Doll et al.,
1994). Further, the risk of pancreatic cancer increases with the number of
cigarettes smoked. The risk of pancreatic cancer increases from 1.8 times in
current smokers of less than 25 cigarettes a day to 3.1 times in those who
smoke 25 or more cigarettes a day. The risk remains high in the heavy
smokers and only returns to a level compatible with never-smokers after 15
years of cessation (Boyle et al., 1996). For light smokers, it takes
approximately 5 years to return to baseline risk after smoking cessation.
It has also been reported that cigarette smoking shows a positive interaction
with family history of pancreatic cancer (Schenk et al., 2001). In relatives who
smoke and had a family history of pancreatic cancer, the risk is significantly
increased at 6.02-fold elevation (95% CI: 1.98-18.29) compared to relatives
who did not smoke and who had no family history of pancreatic cancer. First
degree relatives who did not smoke but had a family history of pancreatic
cancer had an intermediate risk (RR = 3.64, 95% CI: 1.12-11.80). The risk is
even higher in relatives who smoke and had a first degree relatives who had
pancreatic cancer diagnosed before age of 60 (RR = 8.23, 95% Cl=2.18-
31.07). The above findings provide evidence for a potential gene-environment
interaction in the aetiology of pancreatic cancer.
Although the exact chemical component of tobacco that leads to cancer is
unknown, it has been postulated that N-nitroso compounds in tobacco, which
are known to promote pancreatic carcinogenesis in experimental models,
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could potentially be carried to the pancreas via the bloodstream and exerts
their tumourigenic effects there (Risch, 2003).
1.4.3 Chronic pancreatitis
Chronic pancreatitis (CP) develops following recurrent episodes of acute
pancreatitis. The commonest cause in Western countries is heavy alcohol
consumption. Other causes of CP include hereditary pancreatitis and tropical
pancreatitis. Hereditary pancreatitis is an autosomal dominant disease with a
high penetrance level of 80% and the implicated genetic defect being located
on chromosomal locus of 7q35 which codes for cationic trypsinogen gene,
PRSS1 (Whitcomb et al., 1996). Tropical pancreatitis is a form of idiopathic
pancreatitis, primarily found in southern India and in parts of sub-Saharan
Africa. In all forms of CP, the risk of pancreatic cancer is elevated. Cohort and
case-control studies have provided risk estimate ratios for pancreatic cancer
in patients suffering from CP, ranging from a 2- to 27-fold increase in risk
(Bansal & Sonnenberg, 1995; Ekbom et al., 1994; Malka et al., 2002). For
patients with hereditary pancreatitis, the lifetime risk is approximately 30-40%.
Similarly, the risk of pancreatic cancer in patients with tropical pancreatitis is
also elevated (Chari et al., 1994).
The link between CP and pancreatic cancer seems clear. However, the
molecular mechanism of this association remains poorly understood. One can
postulate that chronic inflammation induces epithelial damage and reactive
cellular turnover. This inflammatory cycle provides selection pressure for cells
harbouring pro-oncogenic mutations. Supporting evidence for this principle
can be found in analysis of tissues from CP patients which indicates the
presence of p16 inactivation and K-ras mutations which are frequent




The problem with diabetes as a risk factor for pancreatic cancer concerns the
possibility of diabetes as an early manifestation of pancreatic cancer, rather
than a true risk factor. Everhart et al reported a meta-analysis in 1995
providing a definite association between pre-existing type II diabetes and
pancreatic cancer. The pooled relative risk of pancreatic cancer for diabetics
compared to non-diabetics was 2.1 (Everhart & Wright, 1995). More recently,
Huxley and colleagues reported a further meta-analysis including 9200
pancreatic cancer patients which concluded that there is a modest causal
relationship between type II diabetes and pancreatic cancer. Patients who had
been diagnosed to have type II diabetes for more than 5 years had an odds
ratio of 1.5 (95% CI: 1.3-1.8) for developing pancreatic cancer (Huxley et al.,
2005). The risk was even higher for patients who had diabetes for less than 5
years at odds ratio of 2.1 (95% CI: 1.9-2.3).
1.4.5 Body weight
The link between pancreatic cancer and obesity is less well-defined. Two
large prospective cohort studies have shown that obesity (as defined by body
mass index of at least 30 kg/m2) does increase the risk of pancreatic cancer
(Calle et al., 2003; Michaud et al., 2001). A recent meta-analysis showed that
there is a small positive increase in the risk of pancreatic cancer with
increasing weight. The calculated relative risk of pancreatic cancer per unit
increase in body mass index was 1.02 (95% CI: 1.01-1.03) (Berrington de
Gonzalez et al., 2003). This calculated increase in relative risk translates into
a 19% higher risk of pancreatic cancer for obese people (body mass index
>30 kg/m2) compared to those of normal body weight (22 kg/m2).
1.4.6 Genetic background
Approximately 5-10% of pancreatic cancers have a familial component (Lynch
et al., 1996). In some instances, this is associated with a general familial
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cancer syndrome such as Peutz-Jeghers syndrome, familial atypical multiple
mole melanoma (FAMM) syndrome, hereditary breast ovarian cancer
syndrome, hereditary non-polyposis colorectal cancer (Lynch syndrome) and
familial adenomatous polyposis syndromes (Giardiello et al., 2000; Giardiello
et al., 1993; Lynch et al., 2002).
Familial pancreatic cancer is a rare syndrome with an apparent autosomal
dominant inheritance although the candidate gene or genes responsible have
not been identified yet (Klein et al., 2004). Approximately 19% of the familial
pancreatic cancer families have been found to harbour germline mutations in
the breast cancer susceptibility gene, BRCA2 (Hahn et al., 2003). In one
family with familial pancreatic cancer, the chromosomal locus 4q32-34 has
been found to be a pancreatic cancer susceptibility locus (Eberle et al., 2002).
In those with a family history of pancreatic cancer, the risk of developing
pancreatic cancer in first-degree relatives of an affected individual is
estimated to be 18-fold if there are two affected family members and as high
as 57-fold if there are three or more affected family members (Tersmette et
al., 2001).
1.4.7 Diet and alcohol intake
Over the last two decades, many epidemiological studies have been
performed to elucidate the potential link between pancreatic cancer and
various dietary items. This effort has been largely inconclusive. Most of these
studies have been plagued by methodological issues that led to inconsistent
findings. For instance, many of these reports are case-control studies that are
susceptible to recall bias.
Consumption of a high fibre diet has been proposed to reduce the risk of
cancer. Michaud and colleagues recently reported results from two large
cohort studies comprising of approximately 125,000 subjects, specifically
assessing if the consumption of a 'prudent' diet (high fruit and vegetable diet)
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and a 'Western' diet (high meat and fat intake) have a link to risk of pancreatic
cancer (Michaud et al., 2005). No associations were found between the two
dietary patterns to the risk of developing pancreatic cancer.
1.4.8 Other risk factors
There is evidence to suggest that a small proportion of pancreatic cancers are
due to occupational exposure (Lowenfels & Maisonneuve, 2004).
Occupational exposure to pesticides, chlorinated hydrocarbon solvents (e.g.
dry cleaners) (Ojajarvi et al., 2000) and paint (Brown et al., 2002) or textile
(Zhang et al., 2005) manufacturing process may increase the risk of
developing cancer of the pancreas.
1.5 PATHOLOGY OF PANCREATIC ADENOCARCINOMA
Pancreatic ductal adenocarcinoma is the most common exocrine pancreatic
tumour, accounting for 85% of all malignant pancreatic tumours.
Histologically, PDAC is defined as a malignant epithelial neoplasm of
pancreas in which the neoplastic epithelial cells form glands (Hruban et al.,
2006). One of the characteristic features of PDAC is the frequent occurrence
of an intense surrounding desmoplastic host reaction. Approximately 80-90%
of tumours are located in the head of pancreas with the remaining tumours
located in body and tail of pancreas (Alexakis et al., 2004).
Even a small primary lesion will commonly exhibit perineural and
lymphovascular invasion, suggesting a propensity for aggressive invasion and
early metastasis. PDACs frequently metastasize to multiple lymph node
groups, and lymph node metastases are found in 20-77% of the resection
specimens of patients with pancreatic head adenocarcinomas (Alexakis et al.,
2004). Many patients despite curative resection will develop locoregional
recurrence and metastasis, suggesting the presence of micrometastases at
the time of diagnosis. The most common sites for metastasis are liver and
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peritoneum whilst the most common extraperitoneal metastatic site is the
lung.
1.5.1 Cell of origin of PDAC
The issue of cells of origin of pancreatic cancer is controversial and remains
an area of ongoing study. Traditionally, solid tumours are thought to arise
from multi-step mutational events in differentiated epithelial cells, leading to
carcinogenesis. PDAC is generally thought to arise from pancreatic ductal
cells. The landmark study by Cubilla and Fitzgerald provided the histological
evidence for a ductal cell origin for PDAC based on the observations that
there is an increased incidence of abnormal ductal structures (now designated
pancreatic intraepithelial neoplasia, PanIN), spatially related to malignant cells
which could represent incipient PDAC (Cubilla & Fitzgerald, 1976). It has also
been postulated that PDAC can be derived from acinar or islet cells. The
plasticity of each cell type of adult pancreas and the ability to
'transdifferentiate' from one cell type to another make the identification of
tumour cell origin more complex (Pour et al., 2003).
More recently, the emerging concept of stem cell origin of cancer provides an
alternative model for cancer development. It emphasises the roles of stem
cells as the initiating structure for cancer development, rather than a particular
differentiated cell type. Recent study has identified a subset of cancer cells in
pancreatic tumours that retain the stem cell characteristics of having the
capacity to self-renew, generate and recapitulate the phenotype of the tumour
from which they are derived (Li et al., 2007). These cells have been labelled
cancer stem cells. The existence of cancer stem cells have also been
previously proven in leukemia (Pour et al., 2003), breast (Al-Hajj et al., 2003),
brain (Singh et al., 2004), ovarian (Szotek et al., 2006) and prostate cancers
(Patrawala et al., 2006). At present, we do not have sufficient evidence to
conclude if these pancreatic cancer stem cells arise from a mutated stem cell
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or a downstream progenitor cell that has regained stem cell-like
characteristics through cumulative genetic mutations.
A practical consequence of this model is that strategies aimed at treating this
cancer should take into account the unique characteristics of cancer stem
cells. It has been proposed that failure of conventional cancer treatments is
the result of failure to kill cancer stem cells which have been shown to be
more resistant to standard chemotherapy (Costello et al., 2000; Guzman et
al., 2002). Therapy that misses the stem cells will allow their regeneration and
hence, cancer recurrence. Clearly, treatment that specifically targets cancer
stem cells may prove to be more effective.
1.6 MOLECULAR GENETICS AND ADENOMA-CARCINOMA
SEQUENCE OF PANCREATIC ADENOCARCINOMA
Over the last decade, significant advances have been made in our
understanding of the biology of pancreatic cancer. It is now considered one of
the better characterized tumours at the molecular and genetic levels.
Pancreatic cancer probably represents a genetically-driven disease,
characterized by sequential and cumulative genetic perturbations that dictate
subsequent aberrant molecular signalling and uncontrolled proliferation
(Hruban et al., 2000). Consequently, our line of investigations of pancreatic
cancer has shifted from the histopathological to the molecular and genetic
levels. In the subsequent subsections, a summary of the signature mutations,
their linked pathways and biological significance is provided.
1.6.1 PanlNs and genetic progression model
The common view is that pancreatic cancer evolves through a multistep
process with cells gaining cumulative genetic and phenotypic alterations
resulting in pathological progression from normal pancreas to precursor
lesions known as pancreatic intraepithelial neoplasia (PanIN ), through to
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locally invasive pancreatic adenocarcinoma, and finally metastasis (Hruban et
al., 2000). There is much evidence to support the theory that PDAC develops
from precursor lesions into malignant tumours, similar to the adenoma-
carcinoma sequence described in colorectal adenocarcinoma (Vogelstein et
al., 1988). The nomenclature of PanIN was first proposed in 1994 (Klimstra &
Longnecker, 1994), and further developed by the Pancreatic Cancer Think
Tank sponsored by the National Cancer Institute, USA (Hruban et al., 2001).
Based on the degree of cytological and architectural atypia, the lesions have
been classified into PanlN-1A, PanlN-1B, PanlN-2 and PanlN-3 (Figure 1.4).
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Figure 1.4. Pancreatic intraepithelial neoplasia (PanIN) lesions with schematic diagrams and
histological features being illustrated. PanlN-1A lesions consist of tall columnar mucin-
containing cells showing slight or no atypia. PanlN-1B lesions present epithelial lesions that
have a papillary, micropapillary or basally pseudostratified architecture but otherwise identical
to PanlN-1A. PanlN-2 lesions show moderate atypia including loss of polarity, nuclear
crowding, pseudo-stratification, nuclear enlargement and nuclear hyperchromatism. PanlN-3
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lesions are usually papillary or micropapillary with severe atypia. Diagrams and images were
kindly provided by Department of Pathology, John Hopkins Hospital, Baltimore, USA
(http://patholoqy.ihu.edu/pancreas/panin/) (Hruban et al., 2001).
1.6.2 Genetic signature of PanIN lesions
It is interesting to note that there seems to be an ordered series of mutational
events associated with specific neoplastic stages in the development of PDAC
(Jaffee et al., 2002). Of note, these genetic alterations have not been
correlated with the acquisition of specific histopathologic features.
There is a temporal sequence to the occurrence of these mutations in
preinvasive pancreatic lesions with K-ras mutations occurring early, followed
by p16 and lastly p53 and DPC4/Smad4 mutations (Jaffee et al., 2002;
Wilentz et al., 2000). K-ras mutations are present in 36%, 44% and 87% of
PanlN-1A, PanlN-1B and PanlN2-3 lesions respectively (Lohr et al., 2005).
Loss of p16 expression is seen in 30% of PanlN-1A and -1B, 55% of PanlN-2
and 71% of PanlN-3 lesions (Wilentz et al., 1998). The p53 gene is usually
inactivated in only PanlN3 lesions (Feldmann et al., 2007). On the other hand,
SMAD4/DPC4 is intact in PanlN-1 and PanlN-2 lesions but it is lost in 31%-
41% of PanlN-3 lesions (Wilentz et al., 2000).
1.6.3 Genetic signature of PDAC
Nearly all PDACs have mutation in K-ras (95%) and inactivation of p161NK4a
(80-95%). Other high frequency mutations in spontaneous pancreatic cancer
include p53 (50-75%) and DPC4/Smad4 (55%) genes (Jaffee et al., 2002). As
such, cumulative genetic aberrations probably drive the malignant phenotype




K-ras is a member of the RAS family of GTP-binding proteins. The Ras
protein coded by wild-type K-ras binds to GTPase-activating protein (GAP)
and regulates cell cycle progression. Activated K-ras results in a constitutively
activated molecule that engages downstream effector pathways, notably the
RAF-mitogen activated protein kinase (MAPK) and phosphoinositide-3-kinase
(PI3-K) pathways. These effector pathways mediate a wide variety of cellular
functions including proliferation, differentiation and survival (Malumbres &
Barbacid, 2003).
K-ras mutations occur relatively early during the development of pancreatic
neoplasia, occurring in approximately 30% of lesions with earliest histological
disturbance (Klimstra & Longnecker, 1994). This is important in that tests to
detect mutant K-ras have the potential to detect early, curable non-invasive
pancreatic lesions, before they progress to incurable invasive cancers.
Further, activating point mutations in the K-ras gene are largely restricted to a
single codon in the gene (codon 12). This clearly facilitates the development
of a screening test for mutant K-ras. Such a test is currently being developed
and employed in the research setting for screening programmes for PDAC in
high risk groups as discussed in the Section 1.10.8 (Screening for pancreatic
adenocarcinoma).
The importance of K-ras mutations in the development of PDAC was
emphasized by the elegant study by Hingorani and co-workers, who
established a mouse model in which mutated K-ras gene was directed to
progenitor cells of the pancreas (Flingorani et al., 2003b). In this model,
histological progression was observed to develop progressively through
stages of PanIN leading to invasive and metastatic tumours. The results of
this study have several important implications. Firstly, this model provides
evidence that supports the PanlN/Adenoma-carcinoma sequence model.
Secondly, it shows that K-ras mutation alone is capable of inducing the
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development of PDAC, clearly indicating that K-ras mutations occur early
during tumour development. Further, it supports the emerging theory that
pancreatic progenitor or stem cells could be the cells of origin for pancreatic
adenocarcinoma.
1.6.3.2 p16/CDKN2A tumour suppressor gene
The p16/CDKN2A gene, located at 9p21, encodes two tumour suppressors -
INK4A and ARF - through distinct first exons and alternative reading frames
of shared downstream exons. Loss of function of INK4A is brought about by
intragenic mutation with loss of second allele, homozygous deletion or
promoter hypermethylation that results in gene silencing. Germline mutations
in INK4A are associated with the familial atypical multiple mole melanoma
(FAMM) syndrome and increase the risk of pancreatic cancer by 13-fold
(Goldstein et al., 1995) (as described in Section 1.4.6: Genetic background as
risk factor). Mutations in INK4A occur in moderately advanced PanIN lesions
showing features of dysplasia (see Figure 1.4). INK4A inhibits CDK4/6-
mediated phosphorylation of retinoblastoma protein, thereby blocking entry
into the S-phase of cell cycle.
Given the physical juxtaposition of INK4A and ARF and frequent homozygous
deletion of 9p21 (approximately 40% of PDACs), many PDACs sustain loss of
both INK4A and ARF. Given that ARF stabilises p53 by inhibiting its MDM2-
mediated proteasomal degradation, loss of ARF will lead to degradation of
tumour suppressor p53 and hence, promotes tumourigenesis.
1.6.3.3 p53 tumour suppressor gene
The p53 gene is located on chromosome 17p and is inactivated in PDAC
almost always through a combination of intragenic mutation and loss of the
second allele (Yan et al., 2005). The inactivating mutations usually affect the
DNA binding domain of p53. Mutations in p53 arise late during the PanIN
progression when significant dysplasia has been acquired, indicating its
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function in preventing malignant progression (Feldmann et al., 2007). p53
protein regulates the G-i/S cell cycle checkpoint, maintenance of G2/M arrest
and induction of apoptosis. Given that p53 functions as the 'guardian of the
genome', its mutations will allow cells to bypass DNA damage checkpoints
and apoptotic signals. Loss of p53 functions also contribute to the genomic
instability observed frequently in PDAC as evident by the high degree of
complex cytogenetic rearrangements (Feldmann et al., 2007).
1.6.3.4 SMAD4/DPC4 tumour suppressor gene
The SMAD4/Deleted in Pancreatic Carcinoma 4 (DPC4) gene maps to
chromosome 18q21 and is targeted for deletion or intragenic mutation in late
stages of PanIN lesions (Wilentz et al., 2000). Inactivation of SMAD4 impairs
the intracellular signalling cascades downstream of transforming growth factor
(3 (TGF- (3) family of cell surface receptors. The TGF-P pathway is activated
when the TGF- [3 protein binds to its cognate receptors, triggering an
intracellular cascade that results in nuclear localisation of SMAD4 protein.
Once in the nucleus, SMAD4 exerts its effects on target genes involved in
growth control. As such, inactivating mutations of SMAD4 lead to decreased
growth inhibition and uncontrolled proliferation.
1.6.3.5 Telomeric stability and genomic instability
Telomeres are specialised nucleoprotein complexes that cap chromosomal
ends and confer chromosomal stability during cell division by preventing the
ends from becoming 'sticky'. At the DNA level, telomeres are composed of
hexameric repeats of the sequence TTAGGG at the ends of chromosome
arms. Telomeric shortening is one of the earliest demonstrable genetic
aberrations in PDAC, with >90% of the lowest grade PanIN harbouring this
abnormality (van Heek et al., 2002). Telomeric attrition predispose to
chromosomal rearrangements through breakage-fusion-bridge cycles (Artandi





Mutations in BRCA2 have been observed in approximately 17% of PDAC
patients with a family history (Goggins et al., 2000). Normally BRCA2 protein
is responsible for homologous recombination-based DNA repair and hence,
maintenance of the genomic stability. Loss of BRCA2 gene occurs late and is
restricted to severely dysplastic PanlNs and small proportions of PDACs
(Goggins et al., 2000).
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Figure 1.5. Genetic alterations in PanIN lesions were investigated using a tissue microarray
technique by Maitra et al, demonstrating progressive accumulation of genetic mutations,
leading to invasive cancers (Maitra et al., 2003).
1.7 CLINICAL FEATURES
The clinical features of pancreatic cancer depend on the size and location of
the tumour. Early symptoms can be non-specific. The classic symptom of
painless jaundice is associated with pancreatic head tumours and is present
in 50-60% of patients at diagnosis. The presence of jaundice is generally
indicative of less advanced disease and hence, a higher chance of being
surgically resectable. The more common symptoms include epigastric
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abdominal pain (often radiating to the back), weight loss, fatigue and
anorexia. Back pain can be a premontory symptom of locally invasive disease
whilst systemic symptoms of weight loss and fatigue can be indicative of
metastatic disease. Steatorrhoea and malabsorption can be due to biliary and
pancreatic duct obstruction. The recent onset of diabetes is a common finding
in newly diagnosed pancreatic cancer. As such, this differential diagnosis
should be considered in any patients who develop diabetes late in life.
Apart from jaundice, there are rarely any early clinical signs of pancreatic
cancer. In some patients, there is a palpable distended gallbladder as noted in
the Courvoisier-Terrier's law. Other late signs include ascites, a palpable
mass secondary to peritoneal metastases, left-sided supraclavicular
lymphadenopathy (Virchow's node) and recurring superficial thrombophlebitis
(Trousseau's sign). More importantly, the clinical assessment of the patient's
performance status should be performed to determine patient's suitability for
aggressive surgical and non-surgical therapy.
1.8 CLINICAL AND PATHOLOGIC STAGING
Accurate pathological staging is only possible in patients who have undergone
surgical resection, whereas clinical staging in all other patients is based on
diagnostic imaging. The Union International contre la Cancer (UICC) tumour
node metastasis (TNM) classification is the widely accepted tumour staging
system and is shown in Table 1.1 (Sobin & Wittekind, 2002). In the USA, the
American Joint Committee on Cancer staging system, which was developed
in cooperation with the TNM committee of the UICC, is used and depicted in
Table 1.2. Although the TNM and AJCC staging systems confer prognostic
value for overall survival, they are not particularly useful in guiding treatment.
Most clinicians generally stratify pancreatic cancer patients into 'resectable'
(UICC stage I or II), 'locally advanced' (UICC stage III) or 'metastatic' (UICC
stage IV) disease, based on findings of diagnostic imaging studies. Such
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classification is useful in guiding treatment for patients as well as stratifying
patients for prospective clinical trials.
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Table 1.2. American Joint Committee on Cancer (AJCC) staging of pancreatic
cancer
Stage Tumour Regional lymph Distant
nodes metastases
Stage 0 Tis NO MO
Stage IA T1 NO MO
Stage IB T2 NO MO
Stage IIA T3 NO MO
Stage IIB T1 N1 MO
T2 N1 MO
T3 N1 MO
Stage III T4 N any MO
Stage IV T any N any M1
1.9 DIAGNOSIS AND ASSESSMENT OF SURGICAL
RESECTABILITY
The principal goal of staging in pancreatic cancer is the determination of
resectability. In patients who undergo pancreatic resection surgery, the critical
importance is to achieve microscopically negative surgical margin (i.e. RO
resection). Clearly this will have impact on survival outcome as numerous
studies have shown that patients with microscopic or macroscopic positive
resection margins have survival rates as poor as those treated non-
operatively (Klempnauer et al., 1995; Nitecki et al., 1995; Willett et al., 1993).
Significant morbidity from laparotomising patients who are subsequently found
to be irresectable, combined with the crucial importance of complete surgical
resection, make it critically important to accurately define the anatomical
involvement of the primary tumour with its surrounding structures and also to
detect the presence of metastasis, both of which will impact on the likelihood
of potentially curative surgery.
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1.9.1 CT and MRI scans
The current standard for pancreatic cancer staging is the use of high-quality
thin-section computerized tomography (CT) scans. CT is accurate in defining
the relationship of the primary tumour to the superior mesenteric vein
(SMV)/portal vein (PV) confluence, superior mesenteric artery (SMA) and
coeliac axis. Based on the CT appearance, a patient can be considered
resectable if there is no evidence of extrapancreatic or distant metastatic
disease, whilst the involvement of regional vessels (e.g. PV, SMV or PV/SMV
confluence) may still be resectable if vascular resection and reconstruction is
deemed feasible. Magnetic resonance imaging (MRI) can also be used to
stage pancreatic cancer, though it offers no major advantages over CT and its
use is currently limited to patients with allergies to CT contrast agent.
1.9.2 Endoscopic ultrasound
In cases where the tumours are small or poorly defined on CT scan,
endoscopic ultrasound provides a highly sensitive, non-invasive method of
assessing the extent of primary tumour/vessel relationships and evaluating
surrounding lymph nodes. EUS is currently the method of choice for obtaining
a fine needle aspiration for pathologic diagnosis. In patients who are deemed
resectable by CT criteria, a pretreatment histological diagnosis is
unnecessary. However, pathological confirmation of malignancy is critical for
patients with locally advanced or metastatic disease who will be treated non-
operatively.
1.9.3 Staging laparoscopy
Laparoscopy, including laparoscopic ultrasonography, is sensitive for
detecting small-volume (<1 cm) peritoneal and liver metastases. It remains
controversial if laparoscopy should be used for all patients or applied
selectively. With the use of high-quality CT scan, the yield of laparoscopy in
detecting occult metastatic disease is decreasing. As such, the trend is now to
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use laparoscopy selectively in patients who are deemed resectable on initial
CT scan and at high risk of metastasis (e.g. large tumour > 3cm, tumour in
pancreatic body or tail, high CA 19-9 levels or equivocal findings of locally
advanced or metastatic disease on CT scan). The additional advantage of
laparoscopy is the possibility of obtaining tissue diagnosis through peritoneal
biopsy or fine needle aspiration of liver metastasis especially in cases where
EUS has failed to obtain a sample (Butturini et al., 2007). Additionally,
laparoscopic ultrasound may help to identify vascular invasion and hepatic
metastases.
1.9.4 Endoscopic retrograde cholangiopancreatography
ERCP currently has no role in the primary staging process of pancreatic
cancer. The role of ERCP is confined to the palliative stenting of obstructive
jaundice due to irresectable disease. Pre-operative biliary decompression by
ERCP stenting in patients with resectable pancreatic cancer does not confer
any advantage in terms of surgical outcomes (State-of-the-science panel,
2002). Although ERCP can provide cytological brushings to confirm diagnosis,
its use is now limited in view of the availability of less invasive endoscopic
ultrasound. Brushings during ERCP have high specificity (98%) but sensitivity
is relatively poor.
1.9.5 Percutaneous biopsy
There is a widely held view that transperitoneal biopsy in patients thought to
be potentially resectable should be avoided due to the possibility of peritoneal
tumour seeding. To support this, a recent study has shown that the incidence
of peritoneal carcinomatosis is significantly higher in pancreatic cancer
patients who underwent percutaneous biopsy as compared to EUS-guided
fine needle aspiration (16.3% versus 2.2%) (Micames et al., 2003). Further, if
EUS-guided biopsy is performed in a patient with potentially resectable
disease, there is the theoretical advantage that the needle tract is contained in
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the eventual surgical specimen. Therefore, if tissue diagnosis is required,
EUS-guided biopsy is the method of choice.
1.9.6 Tumourmarker
CA19-9 is a tumour associated antigen that is frequently elevated in
pancreatic cancer (Ritts & Pitt, 1998). It remains uncertain regarding the
correct cutoff level required to diagnose malignancy. Studies have found
accuracy rates of 95% in the diagnosis of pancreatic malignancy when levels
were >200 U/mL (Ritts & Pitt, 1998). When used in combination with CT, a
positive predictive value of 99% can be achieved with levels >120 U/mL.
Currently, CA19-9 can be helpful as supportive evidence of malignancy in
equivocal cases. This tumour marker can also be used as a surrogate for
therapeutic response, recurrence and prognosis. In some centres,
abnormally high CA19-9 levels may also be used to indicate a high risk for
occult metastases and hence, is deemed an indication for additional staging
modalities such as staging laparoscopy.
1.10 MANAGEMENT
It is now commonly accepted that the centralisation of surgery for pancreatic
cancers in high-volume centres improves the results of surgery for all
outcome measures including long-term survival (Birkmeyer et al., 2002;
Birkmeyer et al., 1999; Neoptolemos et al., 1997). Currently, only a small
percentage of patients with pancreatic cancer are diagnosed early enough to
have a resectable disease, with 2.6-9% of patients undergoing pancreatic
resection (Bramhall et al., 1995; Hedberg et al., 1998; Sener et al., 1999). The
current management of pancreatic cancer should be multidisciplinary,
involving the pancreatic surgeon, gasteroenterologists, medical and radiation




1.10.1.1 Preoperative biliary drainage
Preoperative biliary drainage was previously performed routinely due to
concerns that surgery in jaundiced patient carried an increased risk of
postoperative complications (Blarney et al., 1983). However, this has been
proven to be unfounded with current evidence. Recent meta-analysis of
available randomised controlled trials has shown no benefit from preoperative
biliary drainage (Sewnath et al., 2002). In fact, some series have shown an
increase in wound infection rates with no impact on clinical outcome (Pisters
et al., 2001; Povoski et al., 1999; Sohn et al., 2000). Currently, the practice of
biliary drainage is performed in settings when the surgery will be delayed for
logistic reasons or if patients are entered into neoadjuvant trials.
1.10.1.2 Kausch-Whipple resection
The principle aim of the Kausch-Whipple operation is to remove all gross and
microscopic disease within the pancreas and draining lymph nodes to achieve
a margin negative (R0) resection. The anatomic location of the primary
tumour dictates the type of resection. Pancreatic cancer in the head and
uncinate process will require a Kausch-Whipple procedure or
pancreaticoduodenectomy which is the most common operation for pancreatic
cancer given the predominance of tumours in the head of pancreas. Tumours
in the body and tail of pancreas may be amenable to distal pancreatectomy.
However, tumours of the body and tail are notorious for late diagnosis and
hence, often present at a locally advanced stage or with distant metastasis,
precluding surgical treatment. If a central tumour at the neck or body of the
pancreas is resectable, the type of resection will depend on its exact anatomic
location. If the tumour is nearer to the head of pancreas, an extended
pancreaticoduodenectomy will be appropriate. However, if the tumour is
nearer to the tail, a distal subtotal pancreatectomy should be performed.
Given the increased risk of morbidity, a total pancreatectomy is only indicated
28
Chapter 1: Introduction
if there is involvement of the pancreas beyond the division margins of a partial
pancreaticoduodenectomy (Launois et al., 1993). The involvement of regional
vessels is no longer an absolute contraindication to resection. Vascular
resection and reconstruction is now feasible and is only supported if an RO
resection can be obtained (Nakao et al., 2006). In particular, portal venous
resection is safe and does not increase the operative morbidity or mortality
(Bachellier et al., 2001; Nakagohri et al., 2003). Arterial resection has been
described but the data on its benefit are limited (Kondo et al., 2003; Nakano et
al., 2002; Sasson et al., 2002).
The pylorus-preserving pancreaticoduodenectomy was first popularized in the
1980s by Traverso and Longmire (Traverso & Longmire, 1978). The initial
concerns regarding the surgery were whether the preservation of pylorus
would prevent adequate clearance of the suprapyloric and infrapyloric
perigastric nodes, and adversely affect the clinical outcome. However, this
has not been proven to be the case. So far, three prospective randomised
trials have compared the outcomes of standard and pylorus-preserving
Kausch-Whipple procedures and found no significant difference in long term
survival and perioperative morbidity between the two groups (Lin & Lin, 1999;
Seiler et al., 2005; Tran et al., 2004). The general consensus now is that both
operations are equally effective for the treatment of pancreatic and
periampullary carcinoma. Thus, a surgeon's preference and experience
should dictate the type of pancreaticoduodenectomy performed.
Although extended lymph node dissection has been suggested to improve
survival in a previous retrospective study (Ishikawa et al., 1988), randomised
controlled trials have not supported this (Pedrazzoli et al., 1998; Yeo et al.,
2002). Further, a recent meta-analysis of randomised controlled trials has not
shown any survival advantage with extended lymphadenectomy compared to
standard lymphadenectomy following pancreatic resection for pancreatic
cancers (Michalski et al., 2007).
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1.10.2 Adjuvant chemo- and radiotherapy
The high incidence of locoregional recurrence following surgical resection for
PDAC has prompted investigations into the possible roles of adjuvant
chemoradiotherapy. Currently, there is no clear consensus on adjuvant
therapy for PDAC. In the UK and Europe, adjuvant chemotherapy is favoured
based on the results of European Study Group for Pancreatic Cancer
(ESPAC)-1 (Neoptolemos et al., 2004) and CONKO studies (Oettle et al.,
2007). However, in North America, the standard adjuvant regime includes
chemo-radiotherapy followed by chemotherapy, based on the results of the
Gastrointestinal Tumour Study Group (GITSG) study (1987). The role of
radiotherapy is controversial as addition of radiotherapy has been shown to
have a negative effect on survival in ESPAC-1 study. Further, the EORTC
study did not find a significant survival advantage with chemoradiation in
PDAC patients (Klinkenbijl et al., 1999). More recently, meta-analyses of
randomised control trials of adjuvant therapy in PDAC patients have shown
chemoradiation to be ineffective (Stocken et al., 2005; Yip et al., 2006).
The ESPAC-1 study is the largest randomised trial of adjuvant chemoradiation
and chemotherapy. In this study, adjuvant chemotherapy (5-fluorouracil and
folinic acid) has been demonstrated to confer significant survival benefit
(median and 5-year survival rates) in patients following curative resection of
PDAC (Neoptolemos et al., 2004). As mentioned earlier, this study found that
chemoradiation had a negative impact on survival when compared to
chemotherapy alone. Criticisms of this study included its complex 2X2
factorial design and concerns regarding the quality assurance and execution
of radiotherapy. On the other hand, the GITSG showed that adjuvant
chemoradiotherapy in PDAC patients conferred significant survival advantage
compared to no adjuvant therapy (Gastrointestinal Tumor Study Group,
1987). This study was criticised for its small sample size. A summary of the
randomised trials performed so far to address the issue of adjuvant therapy
for pancreatic cancer is provided in Table 1.3.
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The development of gemcitabine is considered a major advance in the
treatment of pancreatic cancer. In a landmark phase III study by Burris and
colleagues, single agent gemcitabine was shown to provide significant
improvements both in survival and clinical benefit (weight loss and tumour-
associated pain) when compared to single agent 5-FU as first line
chemotherapy for advanced pancreatic cancer (Burris et al., 1997). A recent
RCT has shown that adjuvant chemotherapy based on gemcitabine
significantly prolonged disease-free survival and delayed the development of
recurrent disease after curative resection of PDAC (Oettle et al., 2007). It is
now commonly accepted that significant antitumour activity in advanced
disease is a prerequisite for a cytotoxic agent to be effective in the adjuvant
setting for early disease. Given the superiority of gemcitabine over 5-FU,
gemcitabine is now widely accepted to be the treatment standard for
irresectable PDAC. Further, given its efficacy, gemcitabine is now the agent of
choice in the adjuvant setting. However, the ongoing ESPAC-3 study on
completion will provide definitive data on efficacy of gemcitabine versus 5-FU
in the adjuvant setting.
Adjuvant regional chemotherapy has also been explored. The rationale
behind this mode of therapy is to deliver high concentrations of active agent to
the major sites of potential recurrence while limiting systemic toxicity. The
chemotherapeutic agent is usually given through catheters placed in the
coeliac/hepatic artery or portal vein. Currently, there are only a few small,
non-randomised studies on regional chemotherapy. Ishikawa and colleagues
have provided promising data on regional 5-FU therapy through catheters
placed in coeliac trunk and portal vein for infusion in the adjuvant setting
(Ishikawa et al., 1997; Ishikawa et al., 1994). The long term follow-up of these
patients gave a 5-year survival of 39%. The ESPAC-2 study is currently
evaluating the prospect of this form of therapy in a randomised controlled trial.
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The interest in novel targeted therapy in pancreatic cancer is immense given
the dismal prognosis of this disease and the general consensus that survival
benefits from conventional therapy have nearly been maximised. Truly
transforming results will need to come from continuing development of novel
molecular therapies which are more targeted and have high efficacy without
undue toxicity. Investigators are now focusing on new strategies that target
cancer cells at the molecular level. Currently, phase III trials using molecular
agents are being targeted at patients with advanced pancreatic cancers in
whom any advance in therapy that improves survival is urgently needed.
Results of published phase III trials using molecular targeted therapy are
summarised in Table 1.4.
1.10.3.1 Epidermal growth factor inhibition
The most exciting results relate to the use of epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor, Erlotinib (Tarceva®, Genentech, USA). In a
recent placebo-controlled randomised phase III trial, for the first time,
superiority of a gemcitabine combination with an EGFR-targeted agent
(erlotinib) over single agent gemcitabine in advanced pancreatic cancer has
been shown (Moore et al., 2005). Moore et al showed that combination of
gemcitabine and erlotinib conferred a modest but statistically significant
survival benefit compared with gemcitabine and placebo (1 year survival
rates: 23.2% vs. 19.4%, p=0.025). Correspondingly, the progression free
survival (PFS) times were also in favour of the erlotinib-treated group (median
PFS: 3.75 vs. 3.55 months, p=0.003). Given these results, the Food and Drug
Administration in USA has approved erlotinib for use in advanced pancreatic
cancer patients.
Cetuximab is an anti-EGFR monoclonal antibody (Erbitux®, ImClone
Systems, USA). Preliminary findings of a Phase II trial testing the combination
of cetuximab and gemcitabine in advanced pancreatic cancer has shown a
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one-year survival rate of 31,7%, median survival of 7.1 months and median
progression free survival time of 3.8 months (Xiong et al., 2004). This
combination is currently being investigated in a Southwest Oncology Group
(SWOG S0205) phase III trial.
1.10.3.2 Angiogenesis inhibition
Targeting the vascular endothelial growth factor (VEGF) signalling pathway
has also been investigated. Bevacizumab (Avastin®, Genentech, USA) is a
recombinant humanised monoclonal antibody to VEGF with an antiangiogenic
action. In preclinical models, bevacizumab has been shown to suppress the
growth of pancreatic tumours. A recent phase II trial testing the use of
bevacizumab and gemcitabine combination in advanced pancreatic cancer
has shown some promising results; a one-year survival rate of 29% with
median survival of 8.8 months (Kindler et al., 2005). These results had led to
a phase III trial by the Cancer and Leukemia Group B (CALGB 80303 trial).
The preliminary results of this trial has been recently reported at the 2007
American Society of Clinical Oncology meeting (Saif, 2007). Unfortunately,
the trial did not show any survival benefit of adding bevacizumab to
gemcitabine.
1.10.3.3 Matrix metalloproteinase inhibition
Matrix metalloproteinases (MMPs) are a group of proteases that are involved
in tissue remodelling involved in cellular invasion, metastasis, growth and
angiogenesis. The MMPs are frequently overexpressed in pancreatic cancers.
The rationale of MMP inhibitor is to impair the process of local invasion and
early metastasis which is characteristic of pancreatic cancer. Marimastat is an
inhibitor of MMPs. A large phase III trial previously assessed the feasibility of
using marimastat as the first-line therapy for advanced pancreatic cancer.
However, this trial showed that marimastat was inferior to gemcitabine in
terms of overall survival (median survival: 2 vs. 3.8 months, p=0.001)
(Bramhall et al., 2001). In a further phase III placebo controlled trial,
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combination of marimastat and gemcitabine did not have a survival impact
when compared to single agent gemcitabine (Bramhall et al., 2002). As such,
there is no evidence to support the use of marimastat in advanced pancreatic
cancer.
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1.10.4 Treatment of locally advanced ormetastatic disease
Given the poor outcome of advanced pancreatic cancer, the main
consideration in management is ultimately if a patient is a candidate for
aggressive therapy. This decision should be based on the patient's
performance status, extent and intensity of symptoms, nutritional status and
potential toxicity of the proposed therapy and more importantly, its impact on
the quality of life.
Single-agent gemcitabine is the standard therapy for advanced or metastatic
pancreatic cancer with improved overall survival and offering significant
clinical benefit compared with 5-fluorouracil (Burris et al., 1997). Encouraging
interim results were reported by the UK GemCap phase III trial comparing
gemcitabine and capecitabine (GemCap) combination with single agent
gemcitabine in the treatment of advanced pancreatic cancer. The median
overall survival was superior with GemCap compared to gemcitabine alone
(7.4 vs. 6 months, p=0.001) and the one-year survival rates were 26% and
19% respectively (Cunningham et al., 2005). On the other hand, the Swiss
Group for Clinical Cancer Research and the Central European Cooperative
Oncology Group has published their phase III trial results showing no
statistically significant improvement in overall survival with GemCap
compared to standard gemcitabine. However, in a subgroup of patients with
good performance status, median survival was improved significantly with
GemCap (Herrmann et al., 2007).
Apart from the UK GemCap Trial, many other phase III trials have
investigated the efficacy of double chemotherapeutic agents combining
gemcitabine and 5-FU (Berlin et al., 2002), irinotecan (Rocha Lima et al.,
2004), pemetrexed (Oettle et al., 2005), cisplatin (Heinemann et al., 2006) or





There is currently no randomised clinical trial assessing the potential benefit
of neoadjuvant therapy and surgery over surgery alone in pancreatic cancer.
As such, the practice of neoadjuvant therapy is evolving and remains at the
clinical trial phase (Desai et al., 2007; Heinrich et al., 2008). The underlying
rationale for neoadjuvant therapy in pancreatic cancer is logical and
particularly attractive (Quiros et al., 2007). These principles include: 1)
neoadjuvant therapy may downstage the tumour and increase the likelihood
of R0 resection, 2) treatment of micrometastases prior to surgery, 3)
possibility of delivering neoadjuvant therapy without the potential delays
caused by prolonged recovery or postoperative complications, and 4)
avoidance of surgery in patients with metastatic progression found on
restaging following neoadjuvant therapy. Clearly, the downside of this novel
concept is that ineffective neoadjuvant therapy may risk disease progression
during therapy and may compromise the chance of definitive surgical
resection.
1.10.6 Palliative therapy
The majority of patients with pancreatic cancer have irresectable disease at
the time of diagnosis. The major symptom requiring palliation in this group of
patients is malignant obstructive jaundice. In most units, the strategy is to
place an expandable, metal biliary stent endoscopically in patients who have
locally advanced and irresectable disease. However, if the patients are found
to be irresectable at the time of laparotomy, then consideration is given to
surgical biliary (Roux-en-Y hepatojejunostomy) and gastric bypass depending
on the extent of local disease and patient's performance status. Increasingly,
laparoscopic biliary and gastric bypass is being adopted and is a safe and
effective technique. Pain can be controlled by neurolytic coeliac plexus block
administered intraoperatively or under CT/EUS guidance. This has been
shown to be effective in more than 70% of patients with irresectable disease
(Freelove & Walling, 2006).
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1.10.7 Outcome following surgery
The current perioperative mortality following pancreatic resection in high-
volume centres stands at 1-4%. In patients who undergo surgical resection for
an early stage pancreatic cancer, the 5-year survival rates range from 7-25%,
with a median survival of 11-20 months (Alexakis et al., 2004). Patients with
irresectable locally advanced, non-metastatic disease have a median survival
of 6-11 months whilst those with metastatic disease have a median survival of
2-6 months. Patients who develop recurrent disease usually do so after a
mean duration of 9-12 months following surgery.
1.10.8 Screening for pancreatic adenocarcinoma
Given the generally dismal prognosis of PDAC, screening for this cancer may
be a way forward to improve the prognosis. However, the prevalence of
pancreatic cancer remains too low to permit screening of the general
population. Further, the limited sensitivity of current diagnostic techniques
renders screening of the asymptomatic population not feasible. In a small
high-risk subgroup, the prevalence of pancreatic cancer may reach a level
high enough to permit secondary screening. For instance, the lifetime risk of
developing pancreatic cancer for patients with hereditary pancreatitis is
extremely high with a risk of 20% at age of 60 years and up to 40% by the age
of 70 years (Lowenfels et al., 1997).
The primary screening process is the identification of people with high risk of
developing pancreatic cancer whilst secondary screening identifies patients
with early asymptomatic cancer amenable to curative surgical resection.
Secondary screening programme such as the European registry of hereditary
pancreatitis and familial pancreatic cancer (EUROPAC) programme based in
Liverpool, UK is currently under investigation to assess its feasibility in
identifying and screening these high-risk groups. Clearly, the challenge of
such a programme is to have a diagnostic strategy that provides a high
positive predictive value to prevent unnecessary surgery (i.e total
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pancreatectomy) and a high negative predictive value to avoid missing any
resectable cancers. In patients with hereditary pancreatitis, the gross features
of chronic pancreatitis can seriously undermine the diagnostic accuracy of
conventional imaging techniques. As such, any diagnostic strategy will need
to be multimodal including the use of molecular screening to identify a
genuinely high-risk group.
Under the EUROPAC secondary screening programme, patients who are
over 40 years of age with hereditary pancreatitis or a significant family history
of familial pancreatic cancer are screened for early pancreatic cancer using
multimodality imaging (CT and/or endoscopic ultrasound) and molecular
analysis of pancreatic juice obtained at ERCP (for K-ras, p53 and p16
mutations) (Yan et al., 2005). The application of molecular screening is
potentially the most powerful method and adds to the specificity and
sensitivity of imaging techniques. Although K-ras mutation can be detected in
the pancreatic juice of most patients with pancreatic cancer, it is also
detectable in patients with benign conditions (e.g. non-inherited chronic
pancreatitis) and older populations with no pancreatic disease. Bearing this in
mind, K-ras mutational status remains useful to risk stratify patients to focus
additional imaging and molecular diagnostics in a genuinely high-risk group.




Figure 1.6. The screening protocol of the European registry of hereditary pancreatitis and
familial pancreatic cancer (EUROPAC) programme for pancreatic cancer developed in




1.11 HMGA1: AN ARCHITECTURAL TRANSCRIPTIONAL
FACTOR AND A PUTATIVE ONCOGENE
1.11.1 In search of a novel therapeutic target: HMGA1 identified from
global transcriptomic profiling ofpancreatic cancers
The genetic abnormalities described in PDAC (in Section 1.6: Molecular
genetics and adeno-carcinoma sequence of PDAC) exert their effects by
altering gene expression and production of specific proteins. These proteins
can serve as the crucial driving forces behind the development of pancreatic
cancer and the maintenance of its malignant phenotype. The gene expression
patterns in PDAC have been studied using state-of-the-art technologies that
profile the expression of multiple genes simultaneously. Such global gene
expression profiling technologies that have been applied to PDAC include the
serial analyses of gene expression (SAGE), cDNA arrays and oligonucleotide
arrays (i.e. 'gene chips'). The application of such technologies allowed the
discovery of a comprehensive list of genes which are either selectively
overexpressed or suppressed in PDAC compared to normal pancreas. Such
technologies have led to discovery of novel molecular targets with
considerable potential for developing rational early detection and therapeutic
strategies for PDAC.
Several large-scale analyses of human PDAC tissues and cell lines have
identified a number of differentially overexpressed genes (Crnogorac-Jurcevic
et al., 2003; Friess et al., 2003; Logsdon et al., 2003). Using a cDNA
microarray format, lacobuzio-Donahue and colleagues identified HMGA1 as
highly overexpressed in both pancreatic cancer tissues and cell lines when
compared to normal pancreatic tissue (lacobuzio-Donahue et al., 2003).
Similarly, Han and co-workers showed that HMGA1 is significantly
overexpressed (between 4 to 14-fold higher) in PDAC cell lines compared to
normal pancreas (Han et al., 2002). At a smaller scale (about 15 PDAC tissue
specimens), Abe and colleagues studied the protein expression of HMGA1 in
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PDAC tissues using immunohistochemistry. This analysis revealed that
HMGA1 is overexpressed in the sample of PDAC tissues and there is a strong
correlation between HMGA1 expression and a diagnosis of carcinoma (Abe et
al., 2000).
Using the orthotopic SCID mouse model for pancreatic cancer, Tarbe et al set
out to identify genes associated with metastasis of PDAC cells (Tarbe et al.,
2001). They demonstrated that cell lines derived from metastatic lesions
showed remarkable upregulation of the HMGA1 expression when compared
to cell lines derived from primary tumours using the oligonucleotide array
technology. In studies by Bussemakers and colleagues, the Dunning R-3327
benign rat prostatic tumour cell line was compared with the highly metastatic
MatLyLu cells derived from this cell line using the technique of differential
hybridisation (Bussemakers et al., 1991). They found that HMGA1 was
overexpressed in metastatic cell lines and its expression correlated with
metastatic ability, rather than with proliferation rate. As such, it was suggested
that HMGA1 may represent a gene of functional significance in the context of
metastasis.
Based on the observations from gene expression profiling, HMGA1 has been
identified as a novel candidate gene to be differentially overexpressed in
PDACs and may have functional roles in cancer biology. In this thesis, we
sought to establish the clinical relevance of HMGA1 in patients with PDAC
and to characterise the roles of HMGA1 in the malignant phenotype of PDAC
cells and in particular, to identify its downstream molecular mediators, which
hitherto have not been described. There is accumulating evidence that
HMGA1 is functionally involved in the pathobiology of cancer cells. In the
following sections, the current evidence supporting the roles of HMGA1 in
tumourigenesis will be discussed.
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1.11.2 HMGA1 proteins: nomenclature and molecular structure
Thirty years ago, the high mobility group (HMG) proteins were originally
discovered and isolated from mammalian cells (Goodwin et al., 1973). They
were named according to their high electrophoretic mobility in polyacrylamide
gels and were characterised by their solubility in 2-5% trichloroacetic acid
(Lund et al., 1983). Despite early purification and biochemical
characterisation, their functions remained elusive for many years. Following
the cloning of cDNAs encoding HMG proteins, it became apparent that this
group of heterogenous proteins could be classified into several families
(Mouse Gene Nomenclature Committee, 2007)(see this reference for full
classification of HMG proteins). One of these families is the high mobility
group A (HMGA) protein family which consists of HMGAIa, HMGAlb and
HMGA2 proteins. The first two members (HMGAIa and HMGAlb) are
alternatively-spliced proteins which are identical except for internal deletion of
11 amino acids in HMGA1 b and are encoded by the same gene (i.e. HMGA1).
The HMGA2 protein is the product of a different gene located at 12q 14-15
(Chau et al., 1995).
In this thesis, the focus will be on the roles of HMGA1 proteins which have
been found to be upregulated in PDAC cells. In human, the HMGA1 gene is
located on short arm of chromosome 6 (6p21) (Friedmann et al., 1993). The
HMGA1 proteins are small non-histone chromatin-associated proteins that
bind DNA with little or no sequence specificity (Bustin et al., 1990). HMGA1
proteins have a low molecular weight (10.6-12kDa), but their molecular weight
in vivo can be higher due to post-translational modifications. HMGA1 proteins
have little, if any, secondary structure when free in solution but adopt a
disordered-to-ordered structured conformation when bound to DNA or other
proteins (Huth et al., 1997). It has been proposed that the high degree of
intrinsic flexibility due to a lack of secondary structure enables the HMGA1
proteins to participate in a wide range of biological processes (Reeves, 2001).
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Each HMGA1 protein has three DNA-binding motifs called the 'AT-hooks' that
preferentially bind to adenine and thymine (AT)-rich DNA sequences in the
minor groove of DNA by recognising structure rather than nucleotide
sequence (Reeves & Nissen, 1990) (Figure 1.7). The AT-hook domain
consists of the palindromic pentapeptide sequence of Pro-Arg-Gly-Arg-Pro
(PRGRP) which is highly conserved in the HMGA family of proteins (Figure
1.8).
Figure 1.7. Schematic diagrams showing the binding of second AT-hook motif (PRGRP) (A
and B) of the human HMGAIa protein to minor groove of an AT-rich segment of DNA. C and
D, Various projection views of the peptide bound to DNA (side and along the long axis) are
shown. E-G, Three dimensional reconstruction of the HMGA1 AT-hook bound to the minor




HMGAla RGRIKGSKNKGAAKT- -RKTTTTPGRKP RGRI KK LEK EEEEGISQESSEEEQ 107
HMGAlb RGRI KGSKNKGAAKT - -RKTTTTPGRKP RGREKK LEK EEEEGISQESSEEEQ 96
HMGA2 RGRI KGSKNKSPSKAAQKKAEATGEKRP RGRI RKWPQQWQKKPAQEETEETSSQESAEED 109
B
HMGAlb £
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Figure 1.8. Aligned amino acid sequences of the members of HMGA family with the position
of the DNA binding domains (DB1-3) shown. In HMGA1, the DBs are known as the AT-hooks.
Figure adapted from (Giannini et al., 2005).
1.11.3 Mechanisms of actions of HMGA1
HMGA1 proteins are known as 'architectural transcriptional factors'. Although
they do not directly act as transcription factors, they are able to induce
allosteric changes in DNA that promote gene regulation. There are several
mechanisms proposed for their actions. These mechanisms are not
necessarily mutually exclusive.
Firstly, HMGA1 is capable of binding to AT-rich promoter regions of genes.
When bound to AT-rich promoter elements, HMGA1 proteins induce a
conformational change in DNA to promote binding of transcriptional factors.
Further, they form and stabilise multiprotein complexes together with other
sequence-specific transcriptional factors through direct protein-protein
interaction. These complexes are known as 'enhanceosomes' which act as
transcription activating complexes (Figure 1.9). HMGA1 proteins are known to
physically interact with transcriptional factors such as Oct 2, ATF-2/c-Jun, AP-
1, NFkB, Elf-1, SRF, PU-1, RAR, NFAT, Sp1 and CAAT/enhancer binding
protein-p to modulate gene activation (Reeves, 2001). Their multiple protein
partners provide FIMGA1 proteins with considerable flexibility in modulating
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transcriptional activity of a large number of genes. Of note, HMGA1 is not only
capable of positively regulating gene expression, it can also negatively
regulate human interleukin 4 (Chuvpilo et al., 1993) and GP91-PHOX (a
respiratory burst gene expressed in phagocytic cells) genes (Skalnik &
Neufeld, 1992). However, the mechanisms underlying gene expression
inhibition are largely unknown.
Secondly, HMGA1 proteins can enhance the binding of transcriptional factors
to DNA. This function is performed through direct protein-protein interactions
with transcriptional factors and hence, increasing their affinity for DNA
binding. The enhancement of serum-response factor by HMGA1 is a classic
example of this mechanism (Chin et al., 1998).
Finally, HMGA1 proteins can act as 'antirepressor' molecules by competing
out histones (known transcriptional repressor) in binding to scaffold
attachment regions (SAR) of specific DNA segments and thus, induce an
open chromatin conformation that promotes binding of transcriptional factors
and transcriptional activation (Zhao et al., 1993).
Post-translational modifications such as phosphorylation, acetylation and
methylation can also influence the functions of HMGA1 proteins (Sgarra et al.,
2006). Interestingly, upon inspection of the peptide sequence of the AT-hook
region of HMGA1, it matches the consensus sequence for phosphorylation by
cdc2 kinase. With this, it was further demonstrated that HMGA1 is
phosphorylated in a cell cycle-dependent manner by cdc2 kinase in vitro, and
this modification reduces the binding affinity of HMGA1 proteins for DNA
(Nissen et al., 1991; Reeves et al., 1991).
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Figure 1.9. HMGA1 facilitates
formation of enhanceosomes.
I) HMGA1 binds to AT-rich
sequences of
enhancing/promoter element
of genes, II) Through binding
to these sequences, HMGA1
proteins are capable of
'bending' the DNA and
reduces the free energy
needed for subsequent
binding of transcriptional
activators (TA) (which include
transcriptional factors), III) A
further mode of action is
through direct protein-protein
interaction with TAs, resulting
in the formation of a very
stable nucleoprotein complex
known as enhanceosome
which strongly activates transcription of the downstream gene. Figure redrawn based on
(Cerignoli et al., 2004).
1.11.4 HMGA1 is a bona fide oncogene
HMGA1 proteins are present at high levels during embryogenesis while their
expression is low or completely absent in adult differentiated tissues
(Chiappetta et al., 1996). In the mouse, HMGA1 proteins are detected at a
very high level in all embryonic tissues up to 8.5 days of gestation. This
represents the period critical for organogenesis. Following this, the HMGA1
expression remains at a low level until the end of gestation. Collectively, these
observations suggest the roles of HMGA1 proteins in cellular differentiation
and proliferation. Further, these proteins are undetectable or present only at
very low levels in normal adult tissues in both rodents and humans.
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In queiescent, non-transformed cells, HMGA1 expression is rapidly induced
following treatment with phorbol esters or growth factors such as EGF and
PDGF (Friedmann et al., 1993; Ogram & Reeves, 1995). Moreover,
transformation with viral oncogenes such as v-ras, v-mos and polyoma middle
T antigen results in increased expression of HMGA1 proteins in the
transformed cells (Giancotti et al., 1987). Similar effects are also seen in
tumour cell lines when exposed to growth stimuli. In highly metastatic breast
cancer cell lines, there was a dramatic induction of HMGA1 mRNA expression
when the cells were treated with EGF or 17(3-estradiol (Holth et al., 1997).
In an elegant study by Ram and colleagues, they followed the expression of
FIMGA1 during the process of transformation of mouse mammary epithelial
cells (Ram et al., 1993). Expression of HMGA1 was examined in cell lines
derived from spontaneously arising mammary epithelial hyperplasia in
BALB/C mice. Three cell lines (CL-S1, +SA and -SA) were derived from the
same hyperplastic cell line, called the D1 parent line. The CL-S1 cell line is an
immortalised cell line that will not form colonies in soft agarose or tumour in
vivo. The +SA and -SA cell lines were derived from an adenocarcinoma
which developed spontaneously from the original D1 line when the cells were
retransplanted in vivo. +SA and -SA cells were differentiated by their ability
(+SA) or inability (-SA) to grow in soft agar. Notably, the expression of
HMGA1 was highest in the highly tumourigenic +SA line which formed poorly
differentiated adenocarcinomas that metastasized early. Intermediate levels of
FIMGA1 were found in the -SA line which formed well-differentiated
adenocarcinomas with low propensity for metastasis. The lowest levels were
found in the non-tumourigenic CL-S1 line. One of the important observations
from this study was that the elevated expression of FIMGA1 was probably
related to the stage of neoplastic transformation rather than the rate of cellular
proliferation.
More convincing evidence supporting the roles of FIMGA1 in tumourigenesis
came from a mouse model developed by Xu and co-workers. Transgenic mice
49
Chapter 1: Introduction
expressing HMGA1 under control of the murine H-2K promoter and
immunoglobulin p enhancer drove the overexpression of HMGA1 transgene in
B and T-cells. The mice spontaneously developed aggressive lymphoma
consistent with a mature T-cell phenotype, leading to death between 1 and
8.5 months of age (Xu et al., 2004). More recently, it was shown that
transgenic mice with HMGA1 overexpression targeted to uterine tissues
developed adenocarcinomas by 9 months of age (Tesfaye et al., 2007).
1.11.5 Roles of HMGA1 in malignant tumours
Although HMGA1 overexpression is a phenomenon observed in several
cancer types (Section 1.11.7), the basis for the elevated expression remains
mostly unknown. So far, HMGA1 has been shown to be a c-Myc target gene
indicating that binding of c-Myc oncoprotein to HMGA1 promoter induces its
transcription (Wood et al., 2000b). More recently, it was shown that HMGA1
promoter is strongly regulated by oncogenic Ras (Cleynen et al., 2007). This
suggests that in tumours with a mutated Ras gene, the Ras GTPase
signalling could be a mechanism through which the tumours overexpress
HMGA1. This could be particularly important in PDAC cells which have a high
incidence of K-ras mutations.
In Burkitt's lymphoma cell lines which are known to overexpress c-Myc
protein, abrogation of HMGA1 expression through antisense ribozyme
approach prevents their transformation (Wood et al., 2000b). Similarly,
HMGA1 gene suppression using antisense approach inhibited the
transformation of human breast cancer cells (Reeves et al., 2001). In a study
by Reeves and co-workers, the human breast epithelial cells harbouring the
tetracycline-regulated HMGA1 transgene developed primary and metastatic
tumours in nude mice only when the transgene was actively expressed,
implicating the roles of HMGA1 in carcinogenesis (Reeves et al., 2001).
Overexpression of HMGA1 proteins induces transformation of Rat-1 fibroblast
cells and CB33 human lymphoblastoid cells (Wood et al., 2000a; Wood et al.,
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2000b). Studies using Rat-1 cells have indicated that HMGA1 is required for
c-Jun/Ap-1 induced transformation (Hommura et al., 2004). Antisense-
mediated targeting of HMGA1 prevents or inhibits retrovirus-induced
transformation of rat thyroid cell line (Berlingieri et al., 2002) and induces
apoptosis in two human thyroid anaplastic carcinoma cell lines (Scala et al.,
2000). Of note, the suppression of HMGA1 expression did not have an impact
on normal thyroid cells.
Interestingly, HMGA1 has been found to bind to the BRCA1 gene promoter
and downregulates its expression in breast cancer cells (Baldassarre et al.,
2003). Given that BRCA1 functions as a tumour suppressor gene involved in
DNA damage response, the ability of HMGA1 to suppress its expression will
render HMGA1 a pro-oncogenic protein. Moreover, it was speculated that the
downregulation of BRCA1 commonly found in aggressive breast tumours
could be due to the inhibitory effect of HMGA1 overexpression in these
tumours. More recently, HMGA1 has been found to be capable of interfering
with p53 tumour suppressor functions, in particular cellular apoptosis
(Pierantoni et al., 2006; Pierantoni et al., 2007). Pierantoni and colleagues
found that HMGA1 binds p53 in vitro and in vivo and interferes with p53-
mediated transcription of p53 effectors (i.e. BCL2-associated X protein and
cyclin-dependent kinase inhibitor 1A). Further, HMGA1 is able to cooperate
with p53 to activate transcription of p53 inhibitor MDM2. The HMGA1 has also
been found to interfere with functions of p53 by another mechanism: HMGA1
promotes HIPK2 (homeodomain-interacting protein kinase 2) relocalisation in
cytoplasm which inhibits p53 functions as HIPK2 nuclear localisation is
required for p53 activity (Pierantoni et al., 2007). Taking the above together,
HMGA1 is able to inhibit p53-mediated apoptosis by modulating p53 target
genes and cytoplasmic relocalisation of HIPK2.
Interestingly, Takaha and colleagues demonstrated that HMGA1
overexpression may predispose tumour cells to accumulate unbalanced
translocation leading to cumulative mutations, and potentially more
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aggressive tumour phenotype (Takaha et al., 2002). Using cDNA array
analyses, Reeves and co-workers demonstrated that HMGA1 overexpression
in a breast epithelial cell line resulted in a dramatic elevation of integrin
expression and their potential signalling pathways (Reeves et al., 2001).
Though the array used was only limited in the number of genes investigated, it
was hypothesized that HMGA1 may execute its pro-tumourigenic functions by
enhancing the integrin and its related downstream pathways. This 'model' was
based purely on 'piecing' together a list of potentially related genes whose
expression was elevated by HMGA1 overexpression. To date, there have not
been any functional studies demonstrating the dependence of HMGA1-
induced tumourigenesis on integrin-related signalling pathways.
HMGA1 is also known to regulate several genes involved in inflammation. It is
now commonly accepted that inflammation represents a risk factor for
carcinogenesis. It is possible that HMGA1 is capable of stimulating the
inflammatory pathways which in turn promote cancer progression.
Inflammatory genes regulated by HMGA1 include cyclooxygenase 2 (COX2)
(Ji et al., 1998), inducible nitric oxide (NO) synthase (iNOS) (Perrella et al.,
1999), E-selectin (Whitley et al., 1994), IL2 (Kim et al., 2001b) and IL4 (Himes
et al., 1996). Some of these genes have been implicated in different stages of
cancer development. For instance, COX2 has been implicated in growth and
progression of several human cancers (Harris, 2007).
HMGA1 proteins are multifunctional and probably play a complex role in
cellular functions. HMGA1 has been shown to modulate the expression of a
large constellation of genes involved in tumourigenesis. These included genes
associated with cell signalling, proliferation, migration, tissue invasion,
angiogenesis and metastatic progression (Reeves, 2001). Further, Reeves
and co-workers have shown a potential link between HMGA1 expression and
metastatic progression (Reeves et al., 2001). The basis for the roles of
HMGA1 in the metastatic process remains unclear. Athough there are some
functional data suggesting the roles of HMGA1 in tumourigenesis, the
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mechanisms through which these roles are achieved have so far been
relatively unstudied. The molecular events induced by HMGA1
overexpression to execute its functions are largely unknown.
1.11.6 Chromosomal translocations in benign tumours
HMGA1 gene at 6p21 locus has been shown to be rearranged in lipomas,
uterine leiomyomas, endometrial polyps and pulmonary chondroid
hamartomas (Williams et al., 1997; Xiao et al., 1997). In tumours with
epithelial and mesenchymal components such as pulmonary hamartomas and
endometrial polyps, the aberrant chromosomal rearragements involving the
6p21 locus are interestingly only seen in the stromal component, suggesting
that only the mesenchymal component is neoplastic or undergoing aberrant
growth. Xiao et al described an occurrence of pericentric inversion in
chromosome 6 with inversion breakpoints at 6p21 and 6q21 (Xiao et al.,
1997). This created an intragenic fusion between the HMGA1 and the laminin
a4 (LAMA4) genes. The resultant chimeric protein fused the AT hook region
of HMGA1 to a cysteine-rich EGF-like domain of the LAMA4 protein.
The discovery that the genes encoding HMGA1 proteins undergo aberrant
translocations in benign mesenchymal tumours raises many interesting
questions. The reason behind the propensity of the HMGA1 gene for
chromosomal rearrangements is unknown. Further, it is unknown if any of the
chimeric fusion proteins formed as a result of translocations are oncogenic.
The frequency and consistency in the occurrence of chromosomal
rearrangements involving FIMGA1 gene may suggest, though unproven, that




1.11.7 Extensive correlative evidence for HMGA1 in neoplastic
transformation and metastatic progression
Many studies have shown that HMGA1 gene is up-regulated in many types of
cancer. More specifically, HMGA1 overexpression seems to correlate with
neoplastic transformation and metastatic progression. Current evidence has
been summarised in Table 1.5. There is also some evidence to suggest that
HMGA1 protein expression correlates with presence of metastasis and with a
reduced patient survival (as evident in Table 1.5).
Colon carcinoma is one of the cancers in which HMGA1 is best studied. In
one study, the majority of colorectal carcinoma samples were HMGA1-
positive with no expression being detected in normal colon mucosa tissue or
in most hyperproliterative lesions (Fedele et al., 1996). In colonic adenomas,
HMGA1 expression was high and correlated closely with increasing cellular
atypia. It is thought that HMGA1 expression is induced during the early stages
of colonic neoplastic transformation. Finally, HMGA1 expression was
significantly correlated with presence of lymph node metastasis and advanced
Duke's staging, indicative of poor prognosis for patients with HMGA1-positive
colorectal cancers.
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1,12 LIMITATIONS OF CURRENT RESEARCH
1.12.1 Relatively few studies of HMGA1 in pancreatic cancer
As shown in Table 1.5, overexpression of HMGA1 proteins has been
correlated with appearance of highly malignant phenotype in colon, prostate,
thyroid and cervical carcinomas. Clinically, high tumour expression of HMGA1
has been correlated with poor prognosis in patients with several cancers. Of
note, most of these studies suggest that HMGA1 is overexpressed in many
tumour types and provide only correlative evidence with little direct evidence
for the role of HMGA1 in tumourigenesis. Although there are some data
suggesting that HMGA1 is overexpressed in pancreatic cancer (Section
1.11.1), the clinical relevance of HMGA1 in this cancer type remains largely
unknown. In a small study using immunohistochemistry by Abe and co¬
workers, high levels of HMGA1 expression were found PDAC tissues (Abe et
al., 2000). Moreover, HMGA1 expression seems to correlate with cellular
atypia in cases of pancreatic cystic neoplasm.
1.12.2 Relatively small number of cancer specimens
In the majority of studies correlating the expression of HMGA1 to malignant
tumours, the number of cancer tissue samples investigated is small, ranging
from 10-20 samples. This obviously does not provide an overall profile of the
expression of HMGA1 in malignant tumours and certainly, it will be difficult to
substantiate the possible use of HMGA1 expression in tissue samples as a
diagnostic or prognostic marker. Studies assessing the value of HMGA1
expression as a prognostic marker will need far larger number of tissue
samples. To date, no study has investigated the expression of HMGA1 in
more than 50 tumour samples.
58
Chapter 1: Introduction
1.12.3 Functional roles of HMGA1 in pancreatic cancer remain unknown
Few studies have investigated the role of HMGA1 in pancreatic cancer cells in
terms of hallmark features of cancer cell such as proliferation, invasion,
metastasis, anoikis and chemoresistance (Kolb et al., 2007). Although we can
postulate the roles of HMGA1 in pancreatic cancer through the limited
functional studies available on HMGA1 and tumourigenesis in other cancer
types, specific investigations to study the roles of HMGA1 in pancreatic
cancer cells are needed. This is especially important as accumulating
evidence suggests that HMGA1 overexpression in different cellular context
might account for different effects (Fedele et al., 2001).
One important issue that has not been addressed so far is if HMGA1
overexpression in tumours is an epiphenomenon related to the rapid cell
growth (i.e. HMGA1 overexpression is a surrogate marker of rapid cell cycle
progression) or if HMGA1 overexpression is truly an oncogenic event
responsible for neoplastic progression. Although accumulating evidence
suggests that HMGA1 has an pro-oncogenic property, few studies have
elucidated an oncogenic downstream pathway or target gene of HMGA1 that
mediates its oncogenic property. To date, the oncogenic MAPK/ERK pathway
has been described as a downstream mediator pathway of FIMGA1 (Treff et
al., 2004). No study has so far demonstrated if the malignant phenotype
induced by HMGA1 is dependent on any of its downstream target pathways.
Although we have some evidence from gene array studies which identified
genes potentially regulated by HMGA1, there has been limited functional data
supporting the roles of these genes in mediating the pro-oncogenic properties
of HMGA1 (Reeves, 2001).
1.12.4 Limitations of antisense approach for functional studies
As mentioned in Section 1.11.5, earlier in vitro studies using the 'loss-of-
function' approach to investigate the roles of HMGA1 in tumourigenesis were
largely based on antisense gene suppression techniques. Interpretation of the
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results of such experiments was hampered by the potential non-specificity of
this technique and the significant off-target effects (Lebedeva & Stein, 2001).
With the advent of RNA interference, a major step forward has been with the
use of this technique in 'loss-of-function' experiments. RNA interference is
highly efficient and specific. Cellular toxicity is low and reliable experimental
results can be achieved if the experiments are conducted with appropriate
controls. The use of RNA interference as a novel molecular strategy is
discussed in the following sections.
1.13 RNA INTERFERENCE AS A NOVEL MOLECULAR AND
THERAPEUTIC STRATEGY
1.13.1 Discovery ofRNA interference
Andrew Fire and Craig Mello first described RNA interference (RNAi) in
nematode worms Caenorhabditis elegans as a phenomenon whereby double-
stranded RNA molecules are capable of inducing post-transcriptional gene
silencing (Fire et al., 1998). Introduction of double-stranded RNA into these
worms resulted in silencing of a specific gene with a sequence
complementary to that of the double-stranded RNA. Furthermore, it was noted
that only a few RNA molecules were required to reduce the population of
target mRNA, implying an extremely potent mechanism of action. These
findings proved crucial for the discovery of the RNAi phenomenon in
mammalian cells. For this, Andrew Fire and Craig Mello were awarded the
2006 Nobel Prize for Physiology or Medicine.
The RNAi phenomenon is primarily mediated by short interfering RNA
(siRNA) which can be generated from long double-stranded RNA derived
endogenously or exogenously (Zamore et al., 2000). After intracellular
introduction, the long double-stranded RNA is cleaved by ribonuclease III
(RNAse lll)-type protein called Dicer. Long double-stranded RNA is cleaved
into RNA duplexes with 21-23 nucleotides. These RNA duplexes are known
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as short interfering RNA (siRNA). The siRNA then gets incorporated into a
protein complex, known as the RNA induced silencing complex (RISC), and
loses the sense strand of the duplex by helicase activity. The antisense strand
bound to RISC interacts with the complimentary target sequence of the mRNA
resulting in site-specific cleavage of the mRNA, thus inhibiting protein
synthesis (Zamore et al., 2000).
Other emerging mechanisms of siRNA have also been described. This
includes inhibition of mRNA transcription (Verdel et al., 2004) and translation
(Hannon, 2002).
Figure 1.10. Mechanism of RNA interference. Long double-stranded RNA is cleaved by dicer
into short interfering RNAs (siRNAs) which associate with RNA-induced silencing complex
















1.13.2 RNAi as a potent gene knockdown tool and potential therapeutic
strategy in oncology
In 2001, Elbashir, Tuschl and colleagues in the Max Planck Institute published
their observations that synthetic siRNA, consisting of approximately 21-23
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nucleotides, can silence target genes in mammalian cells (Elbashir et al.,
2001a). In mammalian cells, the administration of long double-stranded RNA
led to an interferon response and subsequently cellular toxicity. However, the
discovery that 21- to 23-nucleotide long RNA sequences can effectively
silence gene expression in many mammalian cells without triggering the
interferon response was a major step forward (Elbashir et al., 2001b).
The relatively few years since have seen an expansion on the applications to
harness the potential of RNAi both as a molecular tool to elucidate gene
function as well as a potential therapeutic strategy. With RNAi, targeting of
specific genes involved in cancer development is now a reality. This has been
facilitated by the completion of the human genome project which provided us
with the genomic information required to identify genes that are dysregulated
in cancer cells.
1.13.3 Molecular strategies to achieve RNA interference
RNAi can be achieved in mammalian cells by introduction of synthetic double-
stranded short interfering RNA (siRNA) of 21-23 base pairs in length or by
plasmid or viral vector systems that express double-stranded short hairpin
RNAs (shRNAs) that are subsequently processed to siRNAs by the cellular
machinery. Gene silencing using synthetic siRNAs is only transient in
mammalian cells and the duration of activity depends on the proliferative
status of the cells, such that siRNA activity lasts for 3-7 days in actively
proliferating cells, but can persist for up to 3 weeks in terminally differentiated
cells such as neurones (Omi et al., 2004). To get around this problem, vector-
based systems for induction of RNAi have been developed. These vectors
express shRNAs and once stably transfected through selection for a drug
resistance marker can achieve efficient and stable knockdown of target
genes. Recent work has suggested that the shRNA approach is a more
effective inducer of RNAi than the siRNA approach (Siolas et al., 2005).
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In our laboratory, we have identified vector- and lentivirus-based shRNA
strategies to silence HMGA1 gene. We have identified effective shRNA
sequences that are capable of inducing profound silencing of HMGA1
expression. Our preliminary studies using multiple sequences of synthetic
siRNA could achieve only a modest degree of silencing of HMGA1 expression
at the protein levels. As such, subsequent in vitro experiments focused on the
use of the shRNA-based silencing strategy. This strategy has proven to be a
potent tool to study the roles of HMGA1 in PDAC cells.
1.13.4 Clinical applications of RNA interference
Due to the exquisite specificity and efficiency of RNA interference, it has
drawn much attention as a therapeutic strategy, especially in oncology. Proof-
of-principle experiments have demonstrated the therapeutic potential of RNAi
in many disease models such as HIV infection (Novina et al., 2002), hepatitis
(Giladi et al., 2003), inflammatory bowel disease (Zhang et al., 2006a),
neurological disorders (Harper et al., 2005; Xia et al., 2004), respiratory
infectious diseases (Bitko et al., 2005; Li et al., 2005) and ocular
neovascularisation causing macular degeneration (Shen et al., 2006).
In oncology, RNA interference has been used to suppress tumour growth by
targeting oncogenes such as K-ras, HER2 and VEGF genes. siRNA targeting
K-ras transcripts carrying the valine-12 oncogenic mutation has been used as
a therapeutic strategy in pancreatic and colon cancer with constitutively active
K-ras mutation (Zhang et al., 2006b; Zhu et al., 2006). Suppression of HER2
expression in HER2-positive tumour cells results in growth inhibition and
apoptosis (Yang et al., 2004). In addition, silencing of VEGF, a known potent
stimulator of tumour angiogenesis, has been used to promote anti-
angiogenesis in cancer cells (Kerbel & Folkman, 2002). In a number of cancer
types, failure of chemotherapy is accounted by overexpression of MDR-1
gene which codes for P-glycoprotein, a membrane-bound efflux pump that
actively eliminates a diverse range of anticancer drugs from cells (Gottesman
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et al., 2002). As such, siRNA targeting MDR-1 gene is a highly promising
application of RNAi in cancer therapy. Downregulation of P-glycoprotein by
silencing MDR-1 enhances intracellular accumulation of chemotherapeutic
agents (e.g doxorubicin, paclitaxel) and reinstates sensitivity to such agents.
1.14 AIMS OF STUDIES, RESEARCH QUESTIONS AND
HYPOTHESIS
It is now widely accepted that the prognosis for patients with pancreatic
cancer will only be improved by our understanding of the biology of this
cancer. Subtle changes in surgical techniques will not improve the prognosis
further given that the majority of local failure is due to the aggressive nature of
the cancer rather than a failure of surgical techniques. The general consensus
is that surgery has reached its limits. Major break-through therapies will
probably come from the advancement of our understanding the basic biology
of this cancer. This thesis was aimed at characterising the roles of a novel
mediator of malignant phenotype in pancreatic adenocarcinoma cells: the
HMGA1 gene. This research work was designed initially to examine the
clinical relevance of HMGA1 in patients with PDAC. This was followed by in
vitro and in vivo studies to examine the specific roles of HMGA1 in the
malignant phenotype of PDAC cells. We utilised three investigative
methodologies to achieve our aims. The first was the use of human pancreatic
cancer specimens; the second was the human PDAC cell lines and finally, the
xenograft mouse models of PDAC.
Study 1 (Chapter 3): Clinical relevance of HMGA1 in PDAC and its
potential role as a prognostic indicator in patients with PDAC
Hypothesis:
We hypothesised that HMGA1 is overexpressed in tissues of patients with
PDAC and its expression could be an indicator of the degree of
64
Chapter 1: Introduction
aggressiveness of the tumour and hence, may have a role as a prognostic
indicator in these patients.
Aims:
1. To determine the prevalence of HMGA1 overexpression in tumour
tissues from patients with PDAC using a constructed tissue microarray
2. To correlate the expression of HMGA1 to clinicopathological features of
patients with PDAC
3. Using univariate and multivariate analyses, to assess if HMGA1
expression could represent a prognostic indicator in PDAC patients
Study 2 (Chapter 4): Roles of HMGA1 in cellular invasiveness and
metastatic potential of PDAC cells
Hypothesis:
Given the extensive evidence that HMGA1 expression may be correlated with
metastastic phenotype, we tested if HMGA1 expression would have a
functional role in the cellular invasive capacity of pancreatic adenocarcinoma
cells. Given the previous evidence suggesting that HMGA1 regulates the
activity of the MAPK/ERK oncogenic pathway (Treff et al., 2004) and that PI3-
K/Akt pathway is intrinsically linked to MAPK/ERK activity (Rodriguez-Viciana
et al., 1994), we hypothesised that modulating the level of HMGA1 expression
would have an impact on the pro-survival PI3-K/Akt pathway. If PI3-K/Akt was
indeed a downstream pathway of HMGA1, we would further assess if the
cellular invasiveness induced by HMGA1 was dependent on this pathway.
Aims:
1. To assess the effects of modulating HMGA1 expression by RNA
interference and ectopic overexpression on cellular invasiveness
2. To identify the downstream pathways (e.g. MAPK/ERK, PI3-K/Akt and
matrix metalloproteinase 9) that mediate the actions of HMGA1 in the
context of cellular invasiveness and metastasis
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3. To assess the effects of in vivo HMGA1 gene silencing on the
metastatic process using an orthotopic nude mouse model
Study 3 (Chapter 5): Effects of HMGA1 modulation on anoikis resistance
in PDAC cells
Hypothesis:
The phenomenon of apoptosis when cells lose their attachment to substratum
is known as anoikis. Cancer cells are inherently anoikis-resistant and the
degree of such resistance is a major determinant of metastatic potential in
vivo (Zhu et al., 2001). We hypothesised that targeting HMGA1 may impair
anoikis resistance in PDAC cells.
Aims
1. To assess the effects of ectopic overexpression and silencing of
HMGA1 on anoikis resistance in PDAC cells using flow cytometric
experiments
2. To assess the potential involvement of PI3-K/Akt signalling pathway in
the HMGA1-mediated anoikis resistance using specific small molecule
inhibitors
3. To investigate the effects of HMGA1 modulation on anoikis-induced
caspase activation
Study 4 (Chapter 6): Roles of HMGA1 in cellular proliferation in vitro
under anchorage-independent and -dependent conditions and tumour
growth in vivo
Hypothesis:
Previous study has shown that HMGA1 can have an impact on cellular
transformation in breast and haematological cancers (Reeves et al., 2001;
Wood et al., 2000b). It remains unknown if these effects of HMGA1 are cell
type-specific and if HMGA1 expression would influence cellular transformation
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and proliferation in PDAC cells. Given that PI3-K/Akt has previously been
shown to be crucial in anchorage-independent growth (Nakanishi et al., 2002;
Yao et al., 2002), we hypothesised that modulating HMGA1 expression may
have an impact on this signalling pathway and HMGA1-induced growth may
be dependent on this pathway.
Aims
1. To investigate the effects of targeted silencing of HMGA1 expression
on anchorage-independent and -dependent growth in PDAC cell lines
2. To assess if ectopic overexpression of HMGA1 promotes anchorage-
independent and -dependent growth
3. To determine if anchorage-independent growth mediated by HMGA1 is
dependent on the PI3-K/Akt pathway
4. To assess the effects of targeting HMGA1 on tumour growth in vivo
and to examine the effects of in vivo HMGA1 silencing on apoptosis
and proliferation using immunohistochemical analyses
Study 5 (Chapter 7): Roles of HMGA1 in chemoresistance to qemcitabine
in PDAC cells
Hypothesis:
One of the characteristic features of PDAC cells is the extreme
chemoresistance. To date, only one chemotherapeutic agent (i.e.
gemcitabine) has been proven to have a modest impact on survivals in
advanced pancreatic cancer. We hypothesised that HMGA1 modulation may
also have an effect on chemosensitivity to gemcitabine in PDAC cells.
Aims
1. To characterise the roles of HMGA1 in chemoresistance to
gemcitabine in PDAC cells
2. To explore if targeted silencing of HMGA1 using a lentiviral RNAi
vector could be a potential chemosensitising strategy in PDAC cells
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3. To assess if HMGA1 modulation has an impact on gemcitabine-
induced apoptotic process (i.e. caspase cascade activation)
4. To assess if HMGA1 silencing could chemosensitise tumours in vivo
using a subcutaneous xenograft mouse model
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Chapter Two: Materials and methods
2.1 TISSUE MICROARRAY
Permission to use archival specimens of pancreatic adenocarcinomas was
granted by the Institutional Review Board for Medical Research (Brigham and
Women's Hospital, Boston, USA; Protocol No: 03328; Molecular analysis of
metastatic pancreatic cancer).
2.1.1 Clinical outcomes database
The work in this thesis involved the use of an existing clinical outcomes
database for patients having undergone surgical resection for pancreatic
cancer at the Brigham and Women's Hospital. During the construction of this
database, pathology reports were searched to identify patients who
underwent curative surgical resection for pancreatic adenocarcinoma between
the years 1991 and 2002, at the Brigham and Women's Hospital. The
exclusion criteria were the presence of metastases or local invasion
precluding surgical resection of the pancreatic cancer. The database
contained demographic information including the results of diagnostic tests,
operative and pathologic findings (i.e. tumour size, stage, lymphovascular
invasion (LVI), perineural invasion (PNI), differentiation, surgical resection
margin status, and lymph node status), survival and recurrence data, and
information of adjuvant therapies administered. Pathologic staging was
updated according to current American Joint Committee on Cancer guidelines
(see Table 1.2). All data was saved in the form of a Microsoft Access
database. The final database consisted of 89 patients (42 males, 47 females)
with a median age of 63 years. The mean follow-up period was 19.5 months.
2.1.2 Construction of tissue microarray
Under an IRB-approved protocol, our laboratory has also previously
assembled a corresponding tissue bank of paraffin-embedded pancreatic
69
Chapter 2: Materials and methods
cancer specimens for the cohort of patients within our clinical outcomes
database. Formalin-fixed, paraffin-embedded specimens were used to
construct the pancreatic adenocarcinoma tissue microarray (TMA). Standard
H&E-stained slides from each tumour specimen were reviewed by a single
pathologist (Dr. Mark Redston, Consultant Pathologist, Brigham and Women's
Hospital). Representative tumour regions were selected from each tissue
block and two tissue cores (0.6mm diameter) were taken from each region
using an automated tissue arrayer (Beecher Instruments, Sun Prairie, Wl,
USA). In addition, cores were also taken from normal adjacent pancreas for
use as internal controls. Cores were transferred to recipient blocks. Five pm
sections were cut from each recipient block to make the TMA slides.
2.1.3 Immunohistochemistry of tissue microarray
Expression of HMGA1 in pancreatic cancers and adjacent non-cancerous
tissues was assessed using standard immunohistochemical techniques. TMA
slides were deparaffinized, rehydrated through graded alcohol, washed with
Tris-buffered saline, and processed using a streptavidin-biotin-peroxidase
complex method. Antigen retrieval was performed by microwaveheating
sections in 10 mM sodium citrate buffer (pH 6) for 10 minutes. After
quenching of endogenous peroxidase activity and blocking of nonspecific
binding, anti-HMGA1 antibody (Santa Cruz) was added at a 1:50 dilution, after
which slides were incubated at 4°C overnight. The secondary biotinylated
rabbit anti-goat antibody (DAKO, Carpinteria, CA) was used at a dilution of
1:200 for 30 minutes at 37°C. After further washing with Tris-buffered saline,
sections were incubated with StrepABComplex/horse radish peroxidase (1:
100, DAKO) for 30 minutes at 37°C. Chromogenic immunolocalization was
performed by exposure to 0.05% 3,3-diaminobenzidine tetrahydrochloride.
Cores containing pancreatic adenocarcinoma served as positive controls for
HMGA1 expression. Normal serum was used in the place of primary antibody
as a negative control. Slides were counterstained with hematoxylin before
dehydration and mounting.
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2.1.4 TMA analysis
Slides were reviewed by 2 independent observers (Siong-Seng Liau, Flavio
Rocha) blinded to clinical and pathologic data. HMGA1 expression was
scored according to nuclear staining intensity as follows: 0, no staining or
weak intensity staining in less than 5% of cells; 1, weak intensity; 2, moderate
intensity; 3, strong intensity. For statistical analyses, expression was
dichotomized into a HMGA1-negative group (score 0) and a HMGA1-positive
group (scores 1, 2, or 3). In cases of disagreement, a consensus was reached
by joint review.
2.1.5 Data analysis
Each patient was represented by staining of 3 tumour cores and 3 cores of
normal adjacent pancreas (internal controls) in the tissue microarray. The
median staining intensity of tumour sections for each patient was used for the
final data analysis. The univariate associations between FIMGA1 expression
and each of the pathologic variables were assessed using the chi-square or
Fisher's exact test as appropriate. Overall survival was calculated from the
date of surgical resection of the pancreatic cancer to the date of death or last
follow-up. Deaths within 30 days of surgery were excluded from analysis. For
disease specific survival, data for patients who died from other causes other
than pancreatic cancer were censored at the time of death. Overall disease
specific survival curves were calculated using the Kaplan-Meier method and
compared using the log-rank test.
71
Chapter 2: Materials and methods
2.2 CELLS AND CELL CULTURE
2.2.1 Cell lines
BxPC3, MiaPaCa2 and PANC1 human pancreatic ductal adenocarcinoma
cells were obtained from American Type Culture Collection, ATCC
(Manassas, VA). Cells were tested negative for mycoplasma contamination at
six monthly intervals by Yale University Cell Culture Service (New Haven,
Connecticut, USA).
2.2.2 General technique
Cells were maintained in Dulbecco's modified Eagle's medium (DMEM)
containing 10% fetal bovine serum (Life Technologies Inc., Gaithersburg, MD,
USA) and incubated in a humidified (37°C, 5% C02) incubator, grown in 75-
cm2 culture flasks, and passaged on reaching 80% confluence and reseeded
at the density shown in Table 2.1.
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Table 2.1. Cell lines used in this project. Each cell line was used in experiments to a
maximum passage number of 10 before returning to lower passage cells for further
experiments.
Cell line Source of Lineage Protocol for Established
tumour splitting by
cells
BxPC3 Primary Moderately Split 1:5 (Tan et al.,
(ATCC ID: CRL-1687) tumour differentiated Every 7 days 1986)
PDAC
MiaPaCa2 Primary Poorly Split 1:10 (Yunis et al.,
(ATCC ID: CRL-1420) tumour differentiated Every 4 days 1977)
PDAC
'.-I -








Split 1:10 (Lieber et al.,
Every 5 days 1975)
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2.2.3 Cryopreservation
Cell lines obtained from ATCC were expanded at passages 1-3 and frozen in
cryovials using a freezing container (Mr Frosty, Nalgene, Rochester, NY,
USA) at a cooling rate of 1 °C per min in -80°C overnight followed by long term
storage in liquid nitrogen. Freezing medium consisted of DMEM with 5%
DMSO and 10% FBS.
2.3 TRANSFECTION OF CULTURED CELLS
2.3.1 Transfection with siRNA duplexes
HMGA1-targeting short interfering RNA (siRNA) and control siRNA, bearing
no homology to human genes, were used in experiment to achieve transient
gene silencing. Cells (5X105) were plated onto wells of 35mm six-well culture
plates and allowed to adhere for 24 hours. Five microlitres of Lipofectamine
2000 transfection reagent (Invitrogen, Carlsbad, CA) per well were diluted into
120 pL of OptiMEM I media (Invitrogen). The siRNAs diluted in 120 pL Opti-
MEM media to a final concentration of 100nM were added to the
Lipofectamine 2000 transfection mix, gently mixed and incubated at room
temperature for 20 min. The transfection agent/siRNA complex was added
into the wells containing 800 pi DMEM and incubated under normal cell
culture conditions for 12 hrs, after which the media was changed to DMEM
with 10% FBS. Antibiotics were omitted from all media used during
transfection. All assays were performed 48 h post-treatment.
2.3.2 Transfection with plasmid DNA
Transient transfection of plasmid DNA was performed using Lipofectamine
2000 transfection reagent (Invitrogen). Cells (1x106) were plated onto wells of
35mm six-well culture plates and allowed to adhere for 24 hours. This should
achieve a confluency of 70% on the day of transfection. Five micrograms of
plasmid DNA per well were diluted in 500 pL of OptiMEM I (Invitrogen) media.
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Five microlitres of Lipofectamine 2000 per well were diluted in 500 pL of
OptiMEM I media. Diluted plasmid DNA and Lipofectamine were left to stand
for 10min and subsequently mixed gently to generate the transfection
agent/plasmid DNA complex mixture which was incubated at room
temperature for 20 min. Following aspiration of culture medium from cells, one
millilitre of transfection agent/plasmid DNA complex mixture was added to
each well. Cells were incubated for 8 hours and the medium was replaced
with fresh DMEM containing serum. Again, antibiotics were omitted from
media used during transfection. Experiments were performed on the cells at
48 hours following transfection.
To generate stable transfectants, cells were subjected to puromycin-
containing medium starting at 1pg/mL, with puromycin concentration being
increased at 1pg/mL every 3 days to a final concentration of 3 pg/mL. Final
stable transfectants were maintained in medium with 3 pg/mL of puromycin.
2.4 DNA ANALYSIS
2.4.1 General techniques
All solutions used in experiments involving nucleic acids were made with
DNAse- and RNAse-free water (Sigma, St Louis, MO, USA). Tubes and
disposable tips were autoclaved before use. Disposable rubber gloves were
worn when handling nucleic acids. TE buffer (Sigma) was used to suspend
DNA. All suspended DNA solutions were stored at -20°C.
2.4.2 Quantification of nucleic acids
DNA concentrations were determined by measuring the UV absorbance at
260nm of 100x diluted samples using a SpectraMax M5 microplate
spectrophotometer (Molecular Devices, Sunnyvale, CA). DNA concentration
was calculated using the formula: concentration (pg/mL) = Absorbance at 260
nm (A260nm) x 50 x dilution factor. This is based on the assumption that the
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molecular weight of a nucleotide pair is 600Da, giving rise to the formula: 1
unit of A260nm is equivalent to 50 pg/mL of double stranded DNA, 33 pg/mL
of single stranded DNA and 40 pg/mL of RNA.
The purity of DNA was estimated by the ratio of A260nm/A280nm. DNA
absorbs light at 260 nm, and protein absorbs UV light at 280 nm; a pure
sample of DNA has the A260nm/A280nm ratio at 1.8 or higher. A DNA
preparation that is contaminated with protein will have an A260nm/A280nm
ratio lower than 1.8.
2.4.3 Digestion ofDNA with restriction endonucleases
Restriction endonucleases were obtained from New England Biolabs (Ipswich,
MA, USA). DNA was digested using the manufacturer's recommended 10x
restriction buffers and digestion temperatures. A standard protocol involved
digestion of 1-5pg DNA overnight at 37°C in a total volume of 20-30pL using
5-10 units of restriction endonucleases.
2.4.4 DNA gel electrophoresis
Separation of DNA fragments was performed using the E-gel electrophoresis
system (Invitrogen) which utilised pre-cast agarose gels with ethidium
bromide. Agarose concentrations of 0.8 to 2% were used depending on the
size of fragments to be separated. DNA solutions were mixed with a tenth
volume of 10x DNA loading buffer and loaded into wells of the gel. The
samples were electrophoresed at 100V for 30 minutes in parallel with a DNA
size marker (New England Biolabs). DNA fragments were visualised under
UV illumination and gels were photographed using a conventional gel camera
(Kodak, Rochester, NY, USA).
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2.4.5 Purification of DNA samples
DNA was extracted and purified from agarose gel slices using the QIAquick kit
(Qiagen, Valencia, CA, USA). Briefly, agarose was dissolved in 3 volumes of
buffer QG (assuming 100pg agarose = 100pL) at 50°C for 10 minutes. If the
DNA fragment size was less than 500bp, 1 gel volume of isopropanol was
added. The mixture was added to a silica-gel spin column to bind the DNA.
The flow-through following centrifugation at 15000 x g for one minute was
discarded. The silica-gel-DNA complex was washed with buffer PE. DNA was
finally eluted by addition of TE buffer to the spin column and centrifuged for 1
minute at 15000 x g. The purified DNA was analysed by gel electrophoresis to
confirm the approximate DNA size and concentration.
2.4.6 Transformation of E.coli
Plasmid DNA was expanded in chemically competent E coli (TOP10 cells,
Invitrogen, Carlsbad, CA, USA). Generally, either 5 pL of ligation reaction or
plasmid DNA solution was mixed with 50 pL of competent bacteria. The
bacteria were chilled on ice for 30 minutes and heat shocked at 42°C for 30
seconds and replaced on ice for 5 minutes. The bacteria were then mixed with
100 pL of LB medium (Appendix) and incubated for 1 hour at 37°C in a
shaking incubator. Bacteria were then plated on LB agar plate containing 100
pg/mL of ampicillin and incubated overnight at 37°C.
2.4.7 Preparation ofplasmid DNA
A single bacterial colony was picked from the selection plate and inoculated
into 10mL of LB medium with 100 pg/mL of ampicillin. This was incubated for
8 hours as a starter culture. Following this, 1 mL of the starter culture was
added into 200 mL of LB with ampicillin and incubated in a shaking incubator
overnight at 37°C. The use of starter culture will ensure a healthy exponential
growth of bacteria without nutrient exhaustion.
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2.4.8 Extraction and purification ofplasmid DNA
Plasmid DNA was purified using the GenElute Maxiprep kit (Sigma Aldrich).
Bacterial cells grown, as described above, were harvested by centrifugation at
5000 x g for 10 min at room temperature. The pellet was resuspended in 5 ml
of resuspension buffer with RNAse A. Resuspended cells were lysed with
addition of 5 mL of lysis buffer and mixed gently by inverting 4-6 times. The
mixture was incubated at room temperature for not more than 5 minutes. The
cellular debris was precipitated by addition of 4 mL of neutralisation solution.
The precipitated material formed contained genomic DNA, proteins, cell
debris and SDS. The cellular debris was pelleted by centrifugation at 5000 x g
for 20 minutes at 4°C. The supernatant containing plasmid DNA was removed
and mixed with 4 mL of DNA bind solution. The DNA binding column was
prepared by adding 12 mL of Column preparation solution and centrifuging at
5000 x g for 5 minutes. The supernatant was loaded into the prepared column
seated in a collection tube and centrifuged at 3000 x g for 3 minutes.
Following this, the column was washed with 2 x 10 mL of Wash buffer before
eluting the DNA with 5 mL of endotoxin-free water. The DNA was precipitated
by adding 10 mL of isopropanol and then, centrifuged at 15 000 x g for 30
minutes at 4°C. The DNA pellet was washed with room-temperature 70%
ethanol and centrifuged at 15 000 x g for 10 minutes. The pellet was air-dried
for 5-10 minutes before being re-dissolved in a suitable volume of TE buffer.
2.4.9 Polymerase chain reaction (PCR)
Typically, each reaction consisted of a final volume of 100 pL. The following
components were mixed on ice: template DNA (1 pg), 0.2pmol/pL primers and
50 pL of Taq PCR master mix (5 units of Taq DNA polymerase, 2 x PCR
buffer, 400 pM dNTP, 3 mM MgCb) (QIAgen). The reactions were performed
using a pre-programmed thermal cycler (GeneAmp PCR systems, Applied
Biosystems, Foster City, CA, USA). PCR reactions were started with an initial
denaturation step of 95°C for 3 minutes followed by 35 cycles at 95°C for 30
seconds (denaturation), 50-68°C for 30 seconds (annealing) and 72°C for 60
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seconds (elongation). The reactions were ended with a final extension step at
72°C for 10 minutes. Gel electophoresis of 5 pL of the PCR reaction was
performed to confirm the size and yield of the product.
2.5 RNA ANALYSIS
2.5.1 General techniques
Dedicated work areas for RNA analysis was designated and cleaned with
RNAse decontamination solution (RNAseZap, Ambion, Austin, TX, USA).
Gloves were worn at all times when handing RNA samples. All tips and
containers used were RNAse-free.
2.5.2 RNA isolation
Total RNA was extracted from cells using the mirVana® RNA isolation kit
according to the manufacturer's recommendation (Ambion). Typically, 1 x 106
cultured cells were used to harvest RNA. Cells were lysed with 600 pL of
Lysis/Binding Buffer and vortexed vigorously to completely disrupt the cells.
This was followed by addition of 60 pL of RNA Homogenate Additive and
mixed thoroughly. Further addition of an equal volume of Acid Phenol:
Chloroform solution resulted in separation into two phases: aqueous and
organic. The upper aqueous phase which contains RNA was carefully
removed without disrupting the lower organic phase consisting of protein and
DNA. The aqueous phase was mixed with 1.25 volumes of 100% ethanol and
the mixture was loaded into the filter cartridges and centrifuged at 15 000 g for
15 seconds. The filters were washed twice with each of the Wash solutions
provided. The total RNA was subsequently eluted from the filter using 100 pL
of nuclease-free water containing 0.1 mM EDTA. The amount of total RNA
isolated was quantified using the method described in Section 2.3.2.
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2.5.3 Reverse transcription
First-strand cDNA was synthesized from 5 [jg of total RNA using the
Superscript III First-Strand Synthesis System, according to manufacturer's
instructions (Invitrogen). The system, containing random primers, allowed
reverse transcription of all RNA present into cDNA. The initial reaction mixture
contained 5 pg of RNA, 1 pL of random primers (250 ng), 1 pL 10mM dNTP
mix and RNAse-free water made up to 13 pL. This mixture was heated to
65°C for 5 minutes and chilled on ice for 1 minute. This was followed by
addition of 4 pL of 5X First-Strand Buffer, 1 pL of 0.1 M DTT, 1 pL of
RNaseOUT Recombinant RNase Inhibitor (40 units/pl) and 1 pi of
Superscript™ III Reverse Transcriptase (200 units/pl). The final reaction
volume of 20 pL was mixed thoroughly and incubated for 5 minutes at 25°C.
This was followed by incubation at 50°C for 60min and final inactivation step
of 70°C for 15 minutes. Samples containing cDNA were stored at -20°C.
2.5.4 Quantitative Real-time PCR
Transcript analysis by quantitative real-time PCR was performed using the
Taqman assay, based on the manufacturer's instructions (Applied
Biosystems, Foster City, CA). Hybridization probe and primer sets for human
MMP-9 gene (Hs00234579_m1 MMP9) and P-actin endogenous control were
obtained from Applied Biosystems. PCR reactions were performed in
triplicates and data acquired using the GeneAmp Sequence Detection System
(Applied Biosystems). Each reaction was performed in 25 pL and contained 5
ng of cDNA, 12.5 pL Taqman 2x PCR Master Mix (Applied Biosystems) and
1.25 pL of the probe/primer set. Typically, thermal cycling was initiated with a
denaturation step for 10 minutes at 95°C followed by 40 cycles done in two
steps: for 15 seconds at 95°C and for 1 minute at 60°C. During each PCR
cycle, the Taqman probe is digested by nuclease activity and generates a
fluorescent signal proportional to the amount of cDNA amplified. The
detection hardware quantifies the fluorescence level and constructs a kinetic
profile of DNA amplification over the 40-cycle PCR reaction. The cycle
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threshold (Ct) is defined as the PCR cycle at which an increase in reporter
fluorescence above a baseline signal can first be detected. The sequence
detection software converts the measured cycle thresholds into relative copy
numbers using primer-specific standard curves by interpolation. Results are
expressed as the ratio of MMP9 to p-actin.
2.6 RNA INTERFERENCE OF HMGA1 GENE
HMGA1 gene silencing was achieved using RNA interference (Section 1.13).
RNA interference in mammalian cells can be achieved through several
methods. Firstly, transient silencing can be achieved using chemical
transfection of synthesised short double stranded RNA known as short
interfering RNA (siRNA). Plasmid DNA expressing short hairpin RNA can be
transfected into cells to utilise the cell's endogenous machinery to generate
hairpin RNA (shRNA) which is then processed into siRNA within the cells,
hence achieving gene silencing. Further, virus that encodes hairpin RNA can
be generated and is capable of integrating into the cellular chromosome upon
transduction. Viral integration will result in endogenous production of shRNA
that can effect gene silencing. In this thesis, we explored the utility of all three
methods of effecting gene silencing in pancreatic adenocarcinoma cell lines.
2.6.1 Short-interfering RNA (siRNA) sequences
Early on during this project, we utilised a panel of pre-designed, commercially
available siRNA sequences to attempt to silence the HMGA1 gene (Table
2.2). The sequences of siRNA were pre-designed using conventional
algorithms with proprietary modifications. The use of commercially available
pre-designed sequences increases the likelihood of finding an effective
sequence. The siRNA duplexes were synthesized by the various companies
and were supplied as HPLC-purified, lyophilised pellets. The pellets were
resuspended in nuclease-free water.
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Table 2.2. Sequences of siRNA used in pilot experiments to silence HMGA1 gene. For
control sequences (in italic), scr denotes scramble sequence and non-t denotes non-targeting
sequence with no homology to any human gene.
Duplex Source Design Region of HMGA1 Level of
algorithm HMGA1 transcript HMGA1
mRNA variant knockdown
homology targeted (protein level)
SC-37115 Santa Proprietary Proprietary All 7 30-50%
Cruz sequence variants
Control duplex Santa Proprietary Scr - -
SC-37007 Cruz
Pre-designed Ambion Proprietary Proprietary All 7 30%
#217139 sequence variants
Pre-designed Ambion Proprietary Proprietary All 7 Minimal
#38139 sequence variants
Pre-designed Ambion Proprietary Proprietary All 7 Minimal
# 38308 sequence variants
Negative Ambion Proprietary Non-t - -
control
We found that transient silencing with the chemical transfection of siRNA was
only modestly effective in one out of the 4 sequences of siRNA used. Level of
HMGA1 knockdown was determined using Western blotting. There are
several reasons that could potentially render transient silencing by siRNA
ineffective. Firstly, transient siRNA transfection may not be effective as
HMGA1 protein has a long half-life intracellular^ (Holth et al., 1997), as such,
persistence of intracellular HMGA1 store may render transient RNA
interference (i.e. siRNA) ineffective in reducing the overall HMGA1 protein
levels. Secondly, pancreatic adenocarcinoma cell lines are inherently difficult
to transfect using chemical transfection. We achieved approximately 30-50%
transfection efficiency in the cell lines used (Figure 2.1). Transfection
efficiency was monitored using fluorescein-labelled siRNA (Invitrogen). As
such, the low transfection efficiency may render siRNA ineffective.
Fluorescence microscopy was performed using Olympus BX6 fluorescence
microscope (Olympus America, Center Valley, PA, USA) equipped with
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appropriate filter cube (Exciter BP460-490, Dichroic DM500, Emitter BA515).
Cells were visualised directly from tissue culture plates.
A) B)
Figure 2.1. Transfection efficiency for siRNA was monitored in MiaPaCa2 cells by
transfection of fluorescein-labelled siRNA (BLOCK-IT Oligo, Invitrogen). Confocal microscopy
image (x20 magnification) of MiaPaCa2 cells (A) and the corresponding fluorescence
microscopy image of the same cells (B), indicating an approximate transfection efficiency of
30-50%.
2.6.2 Short haipin RNA (shRNA) design
A brief summary of the hairpin RNA (shRNA) design process has been
described (Broad Institute at Massachusetts Institute of Technology, 2007). All
sequences used for RNAi experiments were chosen using guidelines
described by Elbashir et al (Elbashir et al., 2001a). Despite the rules for
shRNA design, shRNA sequences still have to be experimentally assessed for
knockdown efficiency, as not all sequences matching the design criteria are
potent. The sequence of each shRNA was subjected to a BLAST-search
against the expressed-sequence-tagged libraries (EST) on the NCBI
database to ensure that the RNAi sequence would only target the HMGA1
transcripts. The control sequences were also BLAST-searched to verify that
they were non-targeting and would not affect expression of any genes.
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2.6.3 Plasmid-based shRNA sequences
Hairpin RNA interference plasmids (pLK0.1-HMGA1, TRCN0000018949),
constructed as described previously (Stewart et al., 2003), were obtained from
The RNAi Consortium (Mission TRC Hs. 1.0, Sigma Aldrich, St Louis, MO)
(see Figure 2.2). shRNA sequences were designed to target all transcript
variants of HMGA1 gene to ensure effective silencing. The sequences of short
hairpin RNA targeting the human HMGA1 gene (GenBank accession no.
NM_002131) are given in Table 2.3. Each of these vectors had been
sequence-verified.
Pooled stable transfectants were established using puromycin selection
(3pg/ml of puromycin) for each of the shRNA plasmids and the silencing
efficiency was determined by Western blotting. As shown, shHMGA1-1 and
shHMGA1-2 plasmids most effectively silenced the HMGA1 expression and
hence, were selected for subsequent in vitro and in vivo experiments. Of note,
the use of at least two independent RNAi target sequences helped to control
for potential off-target effects of RNAi.
In subsequent experiments, we used the plasmid- and virus-based shRNA
approaches to assess the effects of HMGA1 silencing as our experience
suggested that these approaches allowed stable RNA interference and were
more effective than transient transfection of siRNA duplexes.
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Figure 2.2. A, Map of pLK0.1-puro plasmid containing an shRNA insert and a puromycin
resistance gene (Puro R) for selection in mammalian cells. B, The human U6 promoter allows
transcription of the shRNA insert (i.e shHMGA1-1, 1-2 etc.). The shRNA contains a 21-base
'sense' sequence that is identical to the target region of the HMGA1 gene (see Table 2.3), a
6-base 'loop' sequence (forming the 'head' of hairpin RNA), and a 21-base 'antisense'
sequence that is complementary to the 'sense' sequence.
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Table 2.3. Targeting sequences of shRNA plasmids used in pilot experiments to silence
HMGA1 gene. For control sequences (in italic), scr denotes scramble sequence and non-t
denotes non-targeting sequence with no homology to any human gene.
shRNA source Region of HMGA1 mRNA homology Coding region of Level
HMGA1 transcript HMGA1 of
variant 2 targeted knockdown
(protein
level)
shHMGA1-1 Sigma 5-CAACTCCAGGAAGGAAACCAA-3 446-466
Aid rich
shHMGA1-2 Sigma 5-CCTTGGCCTCCAAGCAGGAAA-3' 281-301
Aldrich
shHMGA1-3 Sigma 5'-CCAGCGAAGTGCCAACACCTA-3' 359-379
Aldrich










2.6.4 Small-scale generation of lentiviral particles expressing hairpin
RNA
To generate lentiviral particles, human embryonic kidney 293 cells (ATCC)
were co-transfected with the lentiviral RNAi vector (shHMGA1-1, shHMGA1-2
or shControl plasmids) and compatible packaging plasmid mixture (Virapower
lentiviral packaging system, Invitrogen) using Lipofectamine 2000 (Invitrogen).
The co-transfection ratio was lentiviral RNAi vectorpackaging plasmid mixture
= 1pg:3pg. Virus supernatant was harvested at 72 hours post-transfection.
Pancreatic adenocarcinoma cells were exposed to lentivirus-containing
supernatant for 16 hours in the presence of 6pg/ml polybrene (Sigma). Pooled
stable transfectants were established using puromycin selection as described
above (Section 2.2.2).
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2.6.5 High-titre lentiviral particles production
High-titre lentivirus expressing shHMGAI (shHMGA1-1) and control shRNA
were generated from five-plasmid transient transfection into 293T cells.
Helper plasmids including pHDM-Hgpm2, pMD-tat, pRC/CMV-rev and pCMV-
VSV-G were obtained from Harvard Gene Therapy Initiative (Harvard Medical
School, Boston, MA). The lentiviral transfer vectors were either shControl
(non-targeting shRNA sequence) or shHMGAI-1 plasmids as described
above. shHMGAI-1 plasmid was chosen for generation of lentivirus, as it
induces the greatest degree of HMGA1 silencing (Table 2.3). Virus
preparations were concentrated by ultracentrifuge and titred by Southern
blotting. We achieved titre of 7.2X108/ml_ for control shRNA lentivirus and
2.5X108/ml_ for shHMGAI lentivirus. All virus preparations were made in
affiliation with Harvard Gene Therapy Initiative. Pooled stable transfectants
were developed following infection of lentivirus at MOI of 10 for 48 hours, and
stable selection in puromycin was achieved as described above.
2.7 CLONING OF HMGA1 GENE AND GENERATION OF
HMGA1 GENE EXPRESSION VECTOR
2.7.1 Generation of HMGA1 expression vector
To construct the HMGA1 expression vector, HMGA1 coding sequence was
PCR amplified (see Section 2.3.9) from the IMAGE clone 5399570 (GenBank
accession no. BC063434) plasmid purchased from Open Biosystems
(Huntsville, AL, USA). The gene-specific primers were modified to include the
appropriate restriction sites at their 5' ends. The primers used were: forward,
5'- TTTTGATATCATGAGTGAGTCGAGCTCGAAG-3' and backward, 5'-
TTTTGAATTCTCACTGCTCCTCCTCCGAGGA-3'. These primers included
the EcoRV and EcoRI restriction enzyme sites respectively. Purified PCR
products were digested with EcoRV and EcoRI before ligation into the
corresponding sites in plRES-puro3 vector (Clontech, Palo Alto, CA). The
expression plasmids were named plRES-HMGA1, after sequence verification.
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The plRES-puro3 vector permits two genes of interest (i.e. two open reading
frames for HMGA1 and puromycin resistance [puromycin-N-acetyl-
transferase] genes) to be translated from a single mRNA transcript, using the
internal ribosome entry site (IRES) of the encephalomyocarditis virus (Jang et
al., 1988; Rees et al., 1996) (Figure 2.3). The vector utilises the strong
















Figure 2.3. A, plRES-puro3 (Clontech) vector incorporates an internal ribosomal entry stie
(IRES) which allows transcription of one mRNA from two genes of interest (i.e. gene of
interest and a selectable marker e.g puromycin resistance gene). B, Generation of HMGA1
DNA by PCR followed by ligation into the plRES-puro3 expression vector which has a
puromycin resistance selection marker gene. The HMGA1-plRES-puro3 vector was
transfected into MiaPaCa2 cells, followed by selection of stable clones.
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2.7.2 Creation of HMGA1-overexpressing stable transfectants
MiaPaCa2 cells were transfected with plRES-HMGA1 or empty plRES-puro3,
which acted as a control, using Lipofectamine 2000 (Invitrogen). Stable clones
were selected by exposure to incrementally increasing concentrations of
puromycin (Invivogen, San Diego, CA, USA), isolated using cloning cylinders,
and maintained in medium containing 3pg/ml puromycin (Invivogen). Clones
plRES-HMGA1.1 and plRES-HMGA1.2, which expressed the highest levels of
HMGA1 as confirmed on Western blotting, were used for further studies.
2.8 PROTEIN ANALYSIS
2.8.1 Harvesting ofmonolayer culture and total lysate extraction
Cells in monolayer were disaggregated, harvested and rinsed twice with ice-
cold PBS. Cell extracts were prepared with lysis buffer containing 20mM Tris,
0.1% Triton X, 0.5% deoxycholate, 1mM PMSF, 10 mg/ml, aprotinin, 10
mg/ml leupeptin. Lysis was completed by incubation on ice for 20 minutes and
sonication of sample for 10 seconds on ice. Protein was cleared by
centrifugation at 15000 x g, 4°C. Protein samples were stored at -80°C.
2.8.2 Nuclear protein extraction
Nuclear extracts were prepared using NE-PER Nuclear and Cytoplasmic
Extraction Reagents based on the manufacturer's instruction (Pierce,
Rockford, IL, USA). Nuclear extracts were used for the analysis of HMGA1
expression. Briefly, 5X106 cells were harvested and centrifuged at 15 000 x g,
4 °C. The cell pellet was resuspended in 200 pL of CERI Buffer and allowed to
incubate on ice for 10 minutes. This was followed by addition of 11 pL of
CERII Buffer and intermittent vortexing at high speed for 1 minute. Addition of
CERI and II buffers will result in the disruption of cytoplasmic membrane and
release of cytoplasmic contents. The intact nuclei were then isolated by
centrifugation at 15 000 x g, 4 "C for 5 minutes. The isolated nuclei were
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further lysed by addition of 50 |jL of ice-cold NER Buffer. This was vortexed at
high speed for 15 seconds every 10 minutes for at least 40 minutes in total.
Final centrifugation at 16 000 x g at 4 °C for 10 minutes gave rise to the
nuclear protein extract in the supernatant which was immediately stored at -
80°C.
2.8.3 Protein quantification
Total protein concentration was measured using the bicinchoninic acid (BCA)
assay kit (Sigma) with bovine serum albumin as a standard, according to the
manufacturer's instructions. The BCA assay utilises the well-known reduction
of Cu2+ to Cu1+ by protein in an alkaline medium with the sensitive
colorimetric detection of the cuprous cation (Cu1+) by bicinchoninic acid. The
BCA/copper complex exhibits a strong linear absorbance at 562 nm with
increasing protein concentrations. In short, 50 parts of reagent A were mixed
with 1 part of reagent B and 200 pL was added to 10 pL of protein (including
protein standards) in each well of a 96-well plate. Protein standards range
from 200-1,000 pg/mL of bovine serum albumin (BSA). Following 20 minutes
of incubation at 37 °C, the protein concentration was analysed using a
SpectraMax M5 microplate spectrophotometer (Molecular Devices,
Sunnyvale, CA, USA) at 562 nm. The protein concentration was intrapolated
from a standard curve generated using BSA standards.
2.8.4 Polyacrylamide gel electrophoresis (PAGE) and Western transfer
Electrophoresis was applied to separate proteins according to molecular
weight. Cell lysates were mixed with a quarter volume of 4X LDS sample
buffer (Invitrogen) and denatured at 95°C for 5 minutes followed by
centrifugation at 5000 x g for 30 seconds to collect condensation. Cell extracts
containing 50 pg total protein or 10 pg nuclear protein were loaded into each
well of the pre-cast Bis-Tris-HCI buffered (pH 6.4) 10% PAGE minigel
(NuPAGE Novex Bis-Tris minigel system, Invitrogen). Upon loading into the
wells, the protein samples were subjected to a constant running voltage of
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120V for 45 minutes in parallel with molecular weight marker (Kaleidoscope
Protein Standard, Biorad, Hercules, CA, USA). The running buffer used was 1
x MES SDS buffer (Invitrogen). Following PAGE, the resolved proteins on the
gel were transferred electrophoretically to PVDF membranes (Invitrogen)
using the XCell II Blot Module and 1 x NuPAGE transfer buffer (Invitrogen) at
a constant transfer voltage of 45 V for 2 hours. Prior to the removal of minigel
from its casing, the PVDF membrane was activated in 100% ethanol for 2
seconds. Two similarly sized filter papers, 6 pieces of sponge pads and the
activated PVDF membrane were soaked in the transfer buffer. The PVDF
membrane was laid gently on the gel, ensuring no air bubbles were caught in
between. This was then sandwiched between two filter papers. The stack was
compressed to remove any air bubbles that might interfere with uniform
transfer. The stack was then laid between 3 pieces of sponge pads on each
side and placed within the transfer unit with the PVDF membrane closer to the
cathode side. A constant voltage of 45V was applied for 2 hours to achieve
transfer of proteins to the PDVF membrane. Equal protein loading and
transfer was confirmed by Coomassie (BioRad) staining of the gel.
2.8.5 Western immunoblotting
Once the proteins were transferred, the PVDF membrane was blocked in PBS
containing 0.1% Tween 20 (PBST) and 3% bovine serum albumin (BSA) for 1
h at room temperature to prevent non-specific antibody binding. Membranes
were blocked for 1 hour at room temperature or overnight at 4°C on a shaking
platform. The membranes were cut in half horizontally based on the molecular
weight marker band if more than one protein was to be probed on the same
membrane. For example, to assess HMGA1 expression and lamin B1 levels,
the membrane was cut at 40 kDA marker. The top half (>40 kDa) was
incubated with primary antibody for lamin B1 (molecular weight of 60kDa) and
the bottom half (<40 kDa) was probed for HMGA1 (molecular weight of ~ 20
kDa). The membranes were incubated with the protein side down to ensure
uniform exposure to the antibody. The optimal duration and temperature of
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incubation depended on the specific antibody. Blocking membrane with BSA
reduced background non-specific binding especially when using phosphor-
specific antibodies.
Following incubation with primary antibody, the membrane was washed 3 x
with PBST and incubated with secondary antibody, diluted 1: 1000 to 1:10000
in PBST. Antibodies used in this project are listed in Table 2.4. The secondary
antibody was either goat anti-rabbit or goat anti-mouse conjugated with horse¬
radish peroxidase (HRP) (Vector lab). Membranes were washed as before
and the detected bands were visualised with ECL system (Amersham
Biosciences, NJ, USA). This method used HRP-induced catalytic oxidation of
luminol in ECL detection reagent in the presence of hydrogen peroxide. The
light emitted as luminol decayed from its excited state was visualised on X-ray
(Biomax MR film, Kodak). Radiographs were scanned and imported into
Photoshop software (Adobe Systems Inc., USA). Faint exposures were used
to quantitate to minimise error due to overexposure or signal saturation. Band
intensity was quantified and typically normalised to loading controls such as 3-
actin or laminin, using the Image Pro Plus software (Media Cybernetics, Silver
Spring, MD, USA).
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Table 2.4. Primary antibodies used for Western blotting.
Protein Phospho- Supplier/Cat Dilution Animal Incubation
epitope Number source time
HMGA1 Santa Cruz
Sc-1564
1:200 Goat 2 hrs
p-Akt Ser473 Santa Cruz
Sc-7985
1: 200 Rabbit 2 hrs
p-Akt Ser473 Cell Signaling
587F11-
#4051
1: 200 Mouse 2 hrs
Akt1 " Santa Cruz
Sc-7126





1:200 Rabbit 2 hrs
ERK1/2 " Santa Cruz
Sc-93
1:200 Rabbit Overnight
p-mTOR Ser2448 Cell Signalling
#2971
1:1000 Rabbit Overnight
mTOR " Cell Signalling
#2972
1:1000 Rabbit Overnight






MMP2 " Lab Vision
MS-805
1:100 Mouse Overnight
P-Actin - Lab Vision
RB-9421
1:500 Rabbit 2 hrs
Lamin B " Santa Cruz
Sc-6216
1:200 Goat 2 hrs
Hemagglutinin - Santa Cruz 1:200 Mouse 2 hrs
(HA) Sc-57592
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2.9 IN VITRO CELLULAR INVASION ASSAY
Cellular invasion was quantified using a modified Matrigel Boyden chamber
assay. The BD BioCoat Matrigel invasion chambers (BD Bioscience, Bedford,
MA, USA) were used according to the manufacturer's instructions. The upper
surface of the invasion chamber was coated with 250pg/ml growth factor-
reduced Matrigel matrix. In principle, the Matrigel matrix mimics the basement
membrane through which tumour cells will invade. The chambers were
rehydrated once with 0.1% BSA in DMEM for 1 hour at room termperature
and then placed in 24-well tissue culture plates. Following this, cells were
removed from tissue culture plates by trypsinisation, washed once in PBS and
counted. Then, 2.5X104 pancreatic cancer cells in serum-free DMEM were
seeded onto Matrigel-coated chambers. In the lower chambers, 5% FBS was
added as a chemoattractant. After 12-24 hours' incubation, the cells from the
upper surface of the membrane were removed by wiping with a cotton swab.
The membranes were stained using the Diff-Quik kit (BD Biosciences), and
the number of cells that had invaded through the filter was counted under
X400 magnification (randomly selected high-power fields). The counting was
performed for twenty fields in each sample, and mean values from three
independent experiments were calculated. The number of invading cells from
the control group was assigned a value of 1.0 in each experiment to facilitate
comparison. Each determination represents a mean of three separate
experiments.
In additional studies, the effect of matrix metalloproteinase-9 (MMP-9)
antagonism was determined by performing invasion assays in the presence of
10 mg/ml anti-MMP-9 neutralizing antibody (Santa Cruz) or isotype-matched
control (irrelevant) immunoglobulin (IgG) (Santa Cruz).
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2.10 FLUOROMETRIC MMP-9 ACTIVITY ASSAY
Matrix metalloproteinase-9 activities of cell or tumour lysates were assessed
using the Enzolyte Plus™ 520 Enhanced Selectivity MMP-9 activity assay, in
accordance with the manufacturer's instructions (AnaSpec, San Jose, CA,
USA). This assay was highly specific for human MMP-9 without any cross-
reactions with other MMPs. The assay utilised 96-well microplate coated with
anti-human MMP9 monoclonal antibody. The monoclonal antibody was
therefore used to pull down MMP-9 from biological samples. The proteolytic
activity of the MMP-9 was then quantitated using a 5-FAM/QXL™520
fluorescence resonance energy transfer (FRET) peptide. The fluorescence of
5-FAM (fluorophore) was quenched by QXL™520 (quencher) in the intact
FRET peptide. However, in the presence of MMP-9, the FRET peptide was
cleaved by MMP-9 to release 5-FAM which when not linked to its quencher,
released a fluorescent signal.
The standard protocol for the assay included preparation of cell or tumour
lysates. Cells or tumour xenografts were lysed in assay buffer G containing
0.1% Triton-X100, Protein content was normalised between samples using
the BCA assay. Six serial dilutions of the MMP-9 standard (recombinant
human MMP-9 protein) were performed. In a microplate, 100 pi of MMP-9
standards, blank controls and samples to be tested were added to their
respective wells. Plates were incubated at 4°C overnight on a microplate
shaker. Following this, the wells were washed 4 times with wash buffer. The
immobilised MMP-9 was then activated by adding 100 pi of 1mM APMA
solution to each well. Again, the plate was washed 4 times. The final step
included addition of the FRET peptide substrate to each well and incubation at
room temperature in the dark for 1 hour. Fluorescence intensities were then
quantified using SpectraMax M5 microplate spectrophotometer (Molecular
Devices) at excitation = 490 nm and emission = 520 nm. Total MMP-9 activity
was quantitated by interpolation using the constructed standard curve.
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2.11 ASSESSMENT OF MATRIXMETALLQPROTEINASE-9
(MMP-9) GENE PROMOTER ACTIVITY
2.11.1 Construction of MMP-9 gene promoter reporter plasmid
The MMP-9 promoter reporter construct (pGL4-MMP9) was custom-
synthesized by Aviva Systems Biology (San Diego, CA, USA). Cloning of the
MMP-9 promoter sequence into the pGL4.12 vector upstream of the firefly
luciferase (Photinus pyralis) gene allows the assessment of MMP-9 promoter
activity using the surrogate expression of firefly luciferase protein. Briefly, the
full-length human MMP-9 promoter region ranging from -992 to+304 bps,
relative to the transcription initiation site, was amplified by PCR from human
placental DNA, using primers designed according to the MMP-9 gene
sequence. The primers were: forward, 5'-
GGTACCTCTTTCTGGGCTCAAGCAATC-3' and backward, 5'-
CTCGAGCTAACCCTGGACACCTCTGTTC-3'. These primers included the
Xhol and Kpnl restriction sites respectively. The amplified promoter fragment
was cloned into the pGL4.12 vector (Promega, Madison, Wl, USA) at the
Xhol/Kpnl site upstream of the firefly luciferase gene. By direct sequencing,
the sequence of the cloned promoter region was confirmed. The empty
pGL4.12 vector (pGL4e) was used as control.
2.11.2 Quantitation ofMMP-9 promoter activity using luciferase assay
Cells were plated onto 6-well cell culture plates at a concentration of 5X105
cells per well and allowed to adhere for 12 hours in serum-containing medium.
To assess the effects of modulating HMGA1 expression on MMP-9 promoter
activity, transient transfection experiments were performed on MiaPaCa2
cells. For HMGA1 suppression experiments, 5 pg of shHMGAI or control
shRNA plasmid was co-transfected with 5 pg of pGL4-MMP9 or pGL4e and
0.5pg of pRLCMV vector (Promega), which contains a cytomegalovirus
promoter upstream of a renilla luciferase (Renilla reniformis) gene. For
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HMGA1 overexpression experiments, either plRES-HMGA1 or control vector,
plRES-puro3 was used in co-transfection.
Luciferase activity in lysate of the transfected cells was measured using the
dual-luciferase reporter assay, according to the manufacturer's recommended
protocol (Promega). This assay allowed sequential measurement of the firefly
and renilla luciferase activities. After 48 hours, cells were lysed directly on the
cell culture plate using 500pL of PLB reagent. Using luminometer tube, 20 pL
of each cell lysate was mixed thoroughly with 100 pL LARII reagent. The
firefly luciferase activity was measured for 10 seconds using the SpectraMax
M5 luminometer (Molecular Devices). This was followed by addition of 100 pL
Stop and Glow reagent. A second reading for the renilla luciferase activity was
performed for 10 seconds. Relative luciferase activity was calculated as fold-
induction of luciferase activity above the background (taken as activity
associated with promoterless vector, pGL4.12). The activity of renilla
luciferase was used to normalise any variation in transfection efficiencies.
2.12 PROLIFERATION ASSAY
Cell proliferation was quantified using the MTS (3-(4,5 dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl-2-(4-sulfophenyl)-2H-tetrazolium) assay (Cell Titer
96 Aqueous One Solution Assay, Promega, Madison, Wl, USA) where the
viable cells convert the tetrazolium dye into a chromogenic product. The
absorbance values of the chromogen were correlated with the number of
viable, proliferating cells. The results of the MTS assay was confirmed by cell
counting using the Neubauer haemocytometer (Fisher Scientific, Orlando, FL,
USA) in each experiment.
Logarithmically-growing cells were seeded into 96-well plates at 5X103cells
per well and allowed to adhere overnight in medium containing 10% or 2%
FBS. Cellular proliferation was determined after 48 hours. Plates were read
with the use of the SpectraMax M5 microplate spectrophotometer (Molecular
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Devices, Sunnyvale, CA, USA) at a wavelength of 490nm. Ten samples were
used for each experimental condition, and experiments were performed in
triplicates. At identical time points, cell counting was performed and the
results concurred with MTS assay.
2.13 ANCHORAGE-INDEPENDENT GROWTH
Soft agar assays were performed using the cell transformation detection
assay, according to the manufacturer's instruction (Chemicon, Temecula, CA,
USA). Briefly, assays were performed in 6-well plates with 5X103 cells,
resuspended as a single cell suspension, in 0.4% agar and layered on top of
0.8% agar. Plates were incubated for 10-12 days. Colonies were stained and
counted manually at high power (X400) magnification. The counting was
performed for ten fields in each well, and at least 6 wells per condition were
performed in each experiment. Average values from three independent
experiments were calculated. The relative number of colonies was calculated
by dividing the average number of colonies for each group with that of the
control group such that the ratio between the groups could be more easily
interpreted.
2.14 ASSESSMENT OF CHEMOSENSITIVITY TO
GEMCITABINE
2.14.1 Cytotoxicity assay
Gemcitabine-induced cytotoxicity was quantified by the MTS as described
above (Section 2.12). Cells were seeded into 96-well plates at 5X103 cells per
well and allowed to adhere overnight in medium containing 10% FBS. Cell
viability was determined after 48-72 hours in the presence of 0-10 pM
gemcitabine. Six samples were used for each experimental condition. Each
independent experiment was performed three times. The concentration of
gemcitabine required to inhibit proliferation by 50% (IC50) was calculated
from these results.
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2.14.2 Apoptosis assay
After exposure to gemcitabine (1 pM) for 48 hours, 1X106 cells were washed,
trypsinized and resuspended in 0.5 ml of PBS containing 2% FBS and 0.1 pM
EDTA. Apoptosis staining was performed using 1 pl/ml YO-PRO-1 and
propidium iodide (Vybrant Apoptosis Assay Kit #4; Molecular Probes, Eugene,
OR, USA). Cells were incubated for 30 min on ice. If there was a delay in
analysis, the cells were centrifuged at 500 g for 5 min and fixed in 300pL of
PBS containing 3.7% paraformaldehyde. Samples were analyzed by
FACScan (Becton Dickinson, Franklin Lakes, NJ) two-colour flow cytometer
(FL1 =530/30, FL2=610/20) equipped with a single argon laser (488nm). Cells
were gated to exclude debris. Cells stained with the green fluorescent dye
YO-PRO-1 were counted as apoptotic; necrotic cells were stained with
propidium iodide. The number of apoptotic cells was divided by the total
number of cells (minimum of 104 cells) to calculate the apoptotic fraction. Data
were analyzed using CellQuest software (Becton Dickinson). All assays were
reproduced at least three times in independent experiments.
2.14.3 Fluorometric caspase profiling assay
Whole cell lysates were assayed for caspase 2, 3, 8 and 9 activities using the
BD ApoAlert Caspase Assay Plate (BD Biosciences, Palo Alto, CA, USA)
according to the manufacturer's instructions. This assay utilised caspase-
specific fluorogenic substrates immobilised in the wells of a 96-well
microplate. Upon addition of a cell lysate containing activated caspase, the
immobilised fluorogenic substrate was cleaved by the corresponding activated
caspase to release a fluorescent product that could be detected.
In short, following treatment with gemcitabine (1 pM) for 48 hours, 1X106 cells
were harvested and lysed in 100 pL of lysis buffer provided. Fifty microlitres of
lysates (equivalent to 5X105 cells) were transferred into each well of the
microplate and incubated for 2 hours at 37°C. Plates were then read
(excitation, 360 nm; emission, 480 nm) using SpectraMax M5 microplate
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reader in fluorescence mode (Molecular Devices). The levels of fluorescence
by the various activated caspases were determined and expressed as the
number of fold increase relative to control cells. Independent experiments




Anoikis was assayed by plating cells on polyHEMA-coated plates. The
polyHEMA coat created a non-adherent surface which prevented the cells
from attaching. Cells which normally grew adherently would undergo
apoptosis with the loss of attachment. To make the polyHEMA-coated plate, a
solution of 120 mg/ml polyHEMA (Sigma, St Louis, Ml, USA) in 100% ethanol
was made and diluted 1 : 10 in 95% ethanol. This solution (0.95 ml per mm2)
was overlaid onto 35mm 6-well plates and left to dry in a heated dryer system
(Fisher Scientific, Waltham, MA, USA) for 12 hours. Prior to use, wells were
washed twice with PBS and once with DMEM.
In all experiments, 1x106 cells suspended in 2ml DMEM with 10% FBS were
incubated in the polyHEMA-coated wells for 12-18 hours in a humidified
(37°C, 5% C02) incubator. Cells were harvested and resuspended in 0.3 ml
of PBS containing 2% FBS and 0.1 pM EDTA before apoptosis staining.
2.15.2 Flow cytometric analysis
Following induction of anoikis, apoptosis staining was performed using 1pl/ml
YO-PRO-1 and propidium iodide (Vybrant® Apoptosis Assay Kit #4; Molecular
Probes, Eugene, OR). The methods for staining apoptotic cells have already
been described in Section 2.14.2. Each experiment was reproduced three
times with at least three replicate samples in each condition.
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2.16 FLUOROMETRIC REAL-TIME AKT KINASE ASSAY
Assay was performed using the Omnia® Lysate Akt kinase assay (Biosource-
Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions.
This assay uses the chelation-enhanced fluorophore 8-hydroxy-5-(N, N-
dimethysulfonamido)-2-methylquinoline (referred to as Sox). The Sox peptide
is linked to an Akt substrate peptide using standard solid-phase peptide
chemistry. With phosphorylation of the Akt substrate, Mg2+ is chelated to form
a bridge between the Sox moiety and phosphate group added by Akt to the
substrate. Formation of this bridge results in an increase in fluorescence
signal which can be quantitated.
Briefly, cell lysate was prepared using the Omnia cell extraction buffer. Total
cell lysate equivalent to 5pg per pL was loaded into each well of a 96-well
microplate. Following the addition of 45pL of a master mix (10pM Akt
substrate-Sox peptide, 1X kinase buffer, 1mM ATP, 1mM DTT, 2pM
GF109203X, 2pM Calmidazolium, 4pM PKC and 0.4pM PKA inhibitor
peptides), the fluorescent signal was acquired real-time (excitation, 360nm;
emission, 485) for 60 minutes using the SpectraMax M5 microplate reader
(Molecular Devices). The Akt kinase activity was calculated from the slope of
the activity curve. Experiments were performed in triplicates on at least three
occasions.
2.17 MOLECULAR REAGENTS USED FOR PATHWAY
DISSECTION
2.17.1 Specific small molecule inhibitors
PI3-kinase inhibitor LY294002 and MEK inhibitor PD98059 were purchased
from Calbiochem (San Diego, CA, USA). LY294002 is a selective and
reversible inhibitor of PI3-kinase (Vlahos et al., 1994). PD 98059 is a
selective inhibitor of MAPK/ERK kinase or MEK.
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2.17.2 Adenovirus expressing dominant negative or active Akt
constructs
Adenovirus carrying HA-tagged dominant negative (Ad-DN-Akt), dominant
active (Ad-myr-Akt) Akt1 and control virus (Ad-CMV-null) (all titred at 1X1010
PFU per ml_) were purchased from Vector Biolabs (Philadelphia, PA).
Adenoviral infection was performed at multiplicity of infection of 10 in the
presence of 6 pg/ml polybrene for 8 hours. Experiments were performed on
cells 48 hours following infection. Infection efficiency was confirmed by
performing Western blotting on cell lysates using anti-HA antibody.
2.18 XENOGRAFT MOUSE MODELS OF PANCREATIC
CANCER
Male athymic nu/nu mice 5 weeks of age, weighing 20-22 g and specific
pathogen-free were obtained from Harlan Sprague Dawley (Indianapolis, IN,
USA). Nude mice were chosen as human cancer cells are tumourigenic in
these mice. Human cancer cells do not form tumour in immunocompetent
mice.
Mice were housed in microisolator cages in a specific pathogen-free facility
with 12-hr light-dark cycles. They received water and food ad libitum. Animals
were observed for signs of tumour growth, activity, feeding and pain in
accordance with the guidelines of the Harvard Medical Area Standing
Committee on Animals.
2.18.1 Nude mouse orthotopic xenograft model
To determine the effects of HMGA1 gene silencing on in vivo metastasis,
MiaPaCa2 cells stably expressing the control or HMGA1 shRNA (shHMGAI-
1) constructs were orthotopically implanted into the pancreata of nude mice.
The use of this model offers a more 'physiological' microenvironment for
evaluating tumour progression, especially the metastatic process.
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2.18.1.1 Surgical procedure
Mice were anesthetized with intraperitoneal ketamine (200 mg/kg) and
xylazine (10 mg/kg). In a laminar flow hood, the abdomen was cleaned with
isopropyl alcohol, and a left upper transverse incision was made. The
pancreas was exposed and 1X106 cells suspended in 75 pi of PBS were
slowly injected into the body of the pancreas. The pancreas was returned and
the abdomen closed with 5-0 Vicryl (Ethicon, Somerville, NJ, USA). Ten mice
for each cell line were observed over 4 weeks and killed by overdose of
ketamine (400 mg/kg) and xylazine (50 mg/kg). The liver of each animal was
harvested, and metastatic foci were counted under a dissecting microscope
(Gorelik et al., 1993). The primary tumours were excised and the tumour
lysates were assayed for HMGA1 expression and MMP-9 activity using
Western blotting and MMP-9 activity assay (Section 2.9), respectively.
2.18.1.2 Postoperative care
Following orthotopic implantation, mice received postoperative analgesia in
the form of buprenorphine 0.05-0.1 mg/kg subcutaneously every 12 hours for
at least 48 hours. The mice receiving subcutaneous implantation typically did
not require analgesia. Animals were checked at least once a day for the
duration of the study with records kept on each animal with regards to feeding
habits, pain and level of activity.
2.18.2 Nude mouse subcutaneous xenograft model
To determine the effects of HMGA1 gene silencing on in vivo growth, the
subcutaneous xenograft model was used.
2.18.2.1 Tumour implantation
The mice were restrained in a head down position in a sterile laminar flow
hood. The injection site was cleaned with alcohol swabs. Injection site was on
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the flank well away from the limbs so that the tumour would not impede
mobility. Two million cells (MiaPaCa2 and PANC1 stable transfectants
expressing the control or HMGA1 shRNA i.e shHMGA1.1 sequence) in 100
pL PBS were subcutaneously implanted using a 30G needle. Tumour
dimensions were measured weekly using micrometer calipers. Tumour
volumes were calculated using the following formula: Volume = 1/2 a x b2,
where a and b represent the larger and smaller tumour diameters,
respectively. Eight weeks following implantation, the primary tumour was
excised, formalin-fixed and paraffin-embedded.
2.19 XENOGRAFT TUMOUR ANALYSIS
2.19.1 Harvesting protein from xenograft tumours
At the end of the experimental period, the xenograft tumours were harvested
from the mice and snap-frozen in liquid nitrogen. To extract proteins from
tumours for Western blot analysis, a modified protocol for the NE-PER
Nuclear and Cytoplasmic Extraction Reagents (Pierce, Rockford, IL, USA)
was used (Section 2.7.2).
The harvested tumour was pulverised in 500-1000 pL of CERI Buffer using a
tissue homogeniser (Omni International, Marietta, GA, USA) and allowed to
incubate on ice for 30 minutes. This was followed by addition of 100-200 pL of
CERII Buffer and intermittent vortexing at high speed for a further 20 minutes.
Addition of CERI and II buffers will result in the disruption of cytoplasmic
membrane and release of cytoplasmic contents. The cytoplasmic extract and
intact nuclei were separated by centrifugation at 15 000 x g, 4 °C for 5
minutes. The cytoplasmic extract was stored at -80°C until further analysis.
The isolated nuclei were further lysed by addition of 100-200 pL of ice-cold
NER Buffer. This was vortexed at high speed for 15 seconds every 10
minutes for at least 40 minutes in total. Final centrifugation at 16 000 x g at 4
°C for 10 minutes gave rise to the nuclear protein extract in the supernatant
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which was immediately stored at -80°C. Nuclear extracts from tumour
xenografts were used for the analysis of HMGA1 expression.
2.19.2 Ki-67 and HMGA1 immunohistochemistry
Tumour sections (5 pm) were cut using a microtome (Olympus America Inc,
Melville, NY, USA) and mounted onto polylysine-coated slides (Vector
Laboratories, Burlingame, CA, USA). Slides were deparaffinised and
processed using a streptavidin-biotin-peroxidase complex method (Section
2.1.3). Following quenching of endogenous peroxidase activity and blocking
of nonspecific binding, sections were incubated with anti-Ki-67 (DAKO,
Carpinteria, CA) or anti-HMGA1 (Santa Cruz) at 4°C overnight at a 1:200 or
1:50 dilution respectively. The secondary antibody was biotinylated rabbit
antimouse or rabbit anti-goat antibody (DAKO) used at a dilution of 1:200 for
30 minutes at 37°C. Tumour cells were considered positive for the Ki67
antigen or HMGA1 expression if there was intranuclear staining. Images of
the slides were acquired at X40 magnification with a Nikon microscope using
ImagePro Plus software (Mediacybernetics, Bethesda, MD, USA). The cells
with positively stained nuclei were counted in four to five random fields from
each section.
2.19.3 Apoptosis staining
Following preparation of 5 pm tumour sections, apoptosis was quantified
using a commercially available terminal deoxynucleotidyl transferase nick-end
labeling (TUNEL) kit, in accordance with the manufacturer's protocol (Apoptag
Peroxidase In Situ Apoptosis Detection Kit, Chemicon, Temecula, CA, USA).
The TUNEL assay detects single or double stranded DNA breaks associated
with apoptosis. Digoxigenin-conjugated nucleotides are added to the DNA
breaks by terminal deoxynucleotidyl transferase (TdT). The digoxigenin-
labelled DNA breaks are then detected by antibody conjugated to a
peroxidase reporter molecule which gives an intense colour from chromogenic
substrate. The intense staining identifies apoptotic cells in the sections.
105
Chapter 2: Materials and methods
Briefly, the slides were pre-treated with Proteinase K (20pg/ml_) for 15
minutes after deparaffinising the section. This was followed by application of
75pl_/5cm2 of equilibration buffer and 55 pL/5 cm2 of TdT enzyme. The final
step included staining with anti-digoxigenin conjugate followed by peroxidase
colour development. The number of apoptotic cells in four to five random
fields from each section was counted.
2.20 STATISTICAL ANALYSIS
Statistical analysis was performed using SPSS Ver 12 (SPSS Inc., USA) and
Statistica 5.5 (Stat Soft Inc., Tulsa, OK, USA) softwares. Differences between
the groups were analyzed using Student's t-test, ANOVA or Mann-Whitney U-
test as appropriate. The unpaired Student's t-test was utilised to compare two
independent groups with the assumption that the variable has a normal
distribution. The One-Way Analysis of Variance (ANOVA) was used to
compare three or more groups if the data sets had a normal distribution.
However, it the data was non-parametric, the Mann-Whitney test was used to
compare two independent groups. In cases in which averages were
normalised to controls, the standard deviations of each nominator and
denominator were taken into account in calculating the final standard
deviation. When the data was nominal in nature, the chi-square test was used
to determine the presence of association between two qualitative variables. In
cases with a 2x2 table, Fisher's exact test was used instead of chi-square
test. P<0.05 was considered statistically significant.
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Chapter Three: Evidence for the clinical
relevance of HMGA1 expression in
pancreatic cancer
3.1 ABSTRACT
Background: HMGA1 proteins are architectural transcription factors that are
overexpressed in a range of human malignancies. However, limited data is
available on the expression of HMGA1 in pancreatic adenocarcinomas.
Aims: To establish the clinical relevance of HMGA1, we evaluated tumoural
HMGA1 expression status and investigated if HMGA1 expression could be a
prognostic biomarker in pancreatic adenocarcinomas.
Methods and results: Using a tissue microarray format, tumoural HMGA1
expression was examined by immunohistochemical analysis of tissues from
89 consecutive patients undergoing resection for pancreatic adenocarcinoma.
Tumoural HMGA1 expression was detected in 83 (93%) cases of pancreatic
adenocarcinoma. Little or absent expression of HMGA1 was present in
normal pancreas. Based on Kaplan-Meier analysis, patients with HMGA1-
negative cancers had a significantly longer median survival (3-fold longer; 4.3
years versus 1.3 years; p<0.05) than patients with HMGA1-expressing
cancers. HMGA1 expression represents a novel prognostic factor in univariate
(p=0.0028) and multivariate (p<0.05) analyses. However, HMGA1 expression
was not correlated with any of the clinico-pathological features in this patient
cohort.
Conclusions: Our findings suggest HMGA1 is an independent prognostic
indicator in pancreatic adenocarcinoma patients. Given these promising
clinical data, we embarked on the study of biology of HMGA1 in pancreatic
cancer cells (see Chapters 4-7).
107
Chapter 3: Clinical relevance of HMGA1 in pancreatic cancer
3.2 INTRODUCTION
Pancreatic adenocarcinoma is the fourth leading cause of cancer-related
death in the United States. Overall prognosis for patients diagnosed with this
malignancy remains dismal, with 5-year survival rates averaging less than 5%
(Jemal et al., 2006). Rational identification of molecular targets, based on an
understanding of their clinical relevance and biological roles in the aggressive
behaviour of pancreatic cancer is a high-priority goal. Dividends from this
approach include identification of novel therapeutic target and biomarkers that
facilitate early detection, prognostication and monitoring of response to
therapy.
HMGA1 proteins are overexpressed in a range of human cancers (Section
1.11.7, Table 1.5). Further, the degree of tumoural HMGA1 expression has
been reported to be inversely correlated with patient survivals for a range of
human cancers (Chang et al., 2005; Sarhadi et al., 2006). In Chapter 1, we
have previously discussed the rationale behind the study of the HMGA1 gene
in pancreatic adenocarcinoma. Based on gene profiling studies, HMGA1 has
been identified to be overexpressed in PDAC tissues and cell lines (see
Section 1.11.1). These studies assessed only a small number of tissue
specimens (up to 20 specimens). Using immunohistochemistry, Abe and co¬
workers demonstrated that HMGA1 is overexpressed in a small series of 15
PDAC specimens (Abe et al., 2000).The clinical relevance of HMGA1
expression in PDAC tissues has been relatively unstudied. Further,
expression of HMGA1 in PDAC has not been correlated with clinical
outcomes.
In this study, we hypothesised that HMGA1 is overexpressed in the majority of
pancreatic cancer tissues and that expression of HMGA1 is indicative of
adverse clinical prognosis. Firstly, we investigated the prevalence of HMGA1
overexpression in pancreatic cancer tissues using a tissue microarray format.
As pancreatic cancer is a relatively rare disease, the cohort of patients in our
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study represents one of the largest series with full clinicopathological
correlates/information. Secondly, we evaluated the correlation of HMGA1
expression with clinicopathological characteristics of pancreatic cancer
patients. Lastly, we assessed if tumoural HMGA1 expression status could be
used as a novel biomarker that can be used to predict postoperative survival
in patients having undergone surgical resection for pancreatic
adenocarcinoma.
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3.3 RESULTS
3.3.1 Characteristics of patients included in pancreatic adenocarcinoma
tissue microarray
Using a constructed tissue microarray (TMA), we performed
immunohistochemical analysis of tumoural HMGA1 expression in pancreatic
resection specimens in a cohort of 89 patients with pathologically-proven
pancreatic adenocarcinoma (42 men and 47 women) treated at the Brigham
and Women's Hospital in Boston, USA over the period between 1991 and
2002. A summary of the clinicopathological characteristics of the cohort is
provided in Table 3.1. The mean age at diagnosis was 63 years (median 63
years; range 34-84 years). Median survival was 16.6 months (range 91-3462
days). The actuarial 1-year survival rate was 70.3%, with a 5-year survival
rate of 8.1%. The median tumour size was 2.7 cm with a range of 0.1-8.4 cm.
Majority (55/89, 61.8%) of tumours were positive for lymph node metastasis.
Most of the tumours were moderately differentiated (47/89, 53%), 9% (8/89)
were well differentiated and 38% (34/89) were poorly differentiated. The
staging of disease was performed using the American Joint Committee on
Cancer (AJCC) classification system (see Table 1.2). Thirteen patients were
staged as AJCC stage I, 74 as stage II, none as stage III, and 2 as stage IV.
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3.3.2 Analysis of tissue microarray
Paraffin-embedded specimens were used to construct the pancreatic
adenocarcinoma tissue microarray (Figure 3.1 A). For each patient within the
TMA, cores were also taken from adjacent normal pancreas to act as internal
controls as well as to assess the expression of HMGA1 in normal pancreas.
Following immunostaining with anti-HMGA1 antibody, HMGA1 expression
was scored according to nuclear intensity (see Section 2.1). HMGA1
expression was scored according to nuclear staining intensity as follows: 0, no
staining or weak intensity staining in less than 5% of cells; 1, weak intensity;
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2, moderate intensity; 3, strong intensity. Expression was dichotomised into a
HMGA1 negative group (Score 0) and HMGA1 positive group (Score > 1).
3.3.3 HMGA1 expression in normal tissue and pancreatic
adenocarcinoma specimens.
We detected the presence of nuclear HMGA1 expression in 93% (83/89) of
pancreatic adenocarcinomas in our cohort. In the majority (52%) of tumour
specimens, the degree of HMGA1 staining was graded with score > 2 [score
1=42% (37/89), score 2=35% (31/89), score 3=17% (15/89)]. HMGA1 staining
was predominanty localised to the nucleus of cancerous cells, with some
staining of the cytoplasm (Figure 3.1 F). The majority of normal pancreatic
ducts had no detectable nuclear HMGA1 expression, while some had very
weak expression (Figure 3.1C). Detailed pathology case review of the 6
specimens with absent tumoural HMGA1 expression demonstrated no
atypical features for pancreatic adenocarcinoma.
3.3.4 Association of HMGA1 expression with clinicopathological
variables
To identify associations of HMGA1 expression (HMGA1-negative versus -
positive) with clinicopathological variables, the variables were dichotomised
as shown in Table 3.2. Comparing patients with positive or negative tumoural
HMGA1 expression, there were no significant differences in the distribution of
patient age, gender, tumour size, differentiation, lymphovascular involvement
(LVI), perineural involvement (PNI), margin status, lymph node involvement,
disease stage and receipt of chemotherapy (Fisher exact test, p>0.05) (Table
3.2).
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Figure 3.1. Overview of the pancreatic adenocarcinoma tissue microarray stained with H&E
(A) and HMGA1 immunostaining (B). Magnified view (Magnification X100) of HMGA1
immunostaining in normal pancreas and pancreatic adenocarcinoma specimens of the tissue
microarray: (C) Normal pancreas (HMGA1-negative), (D) Pancreatic adenocarcinoma
(HMGA1 -negative), (E) Pancreatic adenocarcinoma (HMGA1-positive). F) A high power
magnification of HMGA1-positive section showing intense nuclear staining for HMGA1
(Magnification X400) as indicated by red arrows.
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Table 3.2. Associations of HMGA1 expression with clinicopathological features
HMGA1 Status




<64 3 44 1.000
>64 3 39
Gender
Male 2 40 0.680
Female 4 43
Tumour differentiation




<2.5 3 38 0.416
>2.5 3 55
Nodal metastasis
No 4 30 0.197
Yes 2 53
LVI
No 5 49 0.397
Yes 1 34
PNI
No 3 40 1.000
Yes 3 43
Microscopic margin
Negative 3 49 0.690
Positive 3 34
Tumour location
Head 6 77 1.000
Tail 0 6
T stage
T1/2 2 11 0.210
T3/4 4 72
Chemo
No 1 4 0.272
Yes 3 59
LVI: lymphovascular invasion, PNI: perineural invasion. Fisher's exact and
Chi-square tests were used as appropriate to compare variables.
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3.3.5 Absence of HMGA1 expression predicts favourable clinical
outcome
Survival analysis was performed using the Kaplan-Meier method. Patients
with absent HMGA1 expression (HMGA1 -ve) had significantly longer overall
postoperative survival (mean 5.7 years, median 4.3 years), compared to those
with HMGA1-positive tumours (mean 1.6 years, median 1.3 years; log-rank


















Figure 3.2. Kaplan-Meier analysis for overall survival for pancreatic adenocarcinoma patients
based on HMGA1 expression. Survival of immunohistochemically HMGA1-negative patients
were compared with HMGA1 positive patients using log-rank test (P=0.0028).
3.3.6 HMGA1 represents an independent prognostic indicator in
pancreatic adenocarcinoma
To assess if HMGA1 expression was an independent predictor of overall
postoperative survival, a Cox proportional hazards model was created in a
forward fashion including only those covariates that showed a statistically
significant (inclusion threshold of p<0.05) relation with postoperative survival.
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Univariate analysis showed that increasing tumour size, poor tumour
differentiation and HMGA1 positivity were predictors of poorer survival (Table
3.3). Further, multivariate analysis demonstrated that after correction for
confounding variables, HMGA1 expression remained a significant
independent prognosticator for postoperative survival. HMGA1 positivity
resulted in a hazard ratio of 10.87 (95% CI: 2.65-45.45, p=0.001) for poorer
survival when compared to HMGA1-negative group. As expected, tumour
size, tumour differentiation and HMGA1 expression were also independent
prognostic markers.
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3.4 DISCUSSION
The primary aim of this study was to examine HMGA1 expression in
pancreatic adenocarcinomas. HMGA1 expression was observed in more than
90% of PDAC specimens. Although HMGA1 expression was not significantly
associated with any of the clinicopathological variables, HMGA1 negativity
predicted improved survival in patients with PDAC and this relationship
persists even after adjusting for other confounding variables. More
importantly, our study demonstrates that HMGA1 expression may help to
identify subsets of cancers with distinct clinical outcomes despite similar
pathological characteristics. The median survival time was significantly longer
(up to 3-fold) in HMGA1-negative patients than that of HMGA1-positive
patients. Although HMGA1 has been shown to be indicative of poor prognosis
in patients with other cancers, our current study is novel in that it is the first
study to demonstrate that HMGA1 is an independent prognostic indicator in
pancreatic adenocarcinoma patients.
Although our current study represents one of the largest
immunohistochemical studies of pancreatic adenocarcinoma, our cohort size
is relatively small and this limits interpretation beyond the results presented.
Given that the current study had only 6 HMGA1-negative patients, further
conclusion will require a study involving a greater cohort with greater number
in each subgroup. However, we believe the current results are promising and
highlight the clinical importance of HMGA1. Clearly, identification of HMGA1
as a prognostic indicator could be potentially useful in that it allows
identification of patients who would benefit from more aggressive treatment of
their disease. Our data regarding the role of HMGA1 as a prognostic indicator
in PDAC is consistent with studies by other groups investigating other
cancers. In colorectal cancers, HMGA1 expression has been correlated with
development of distant metastases (Balcerczak et al., 2003). HMGA1-
positivity in hepatocellular carcinoma has also been shown to predict disease
recurrence and metastases (Chang et al., 2005). Further, in breast cancer,
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HMGA1 expression correlates closely with the expression of Her2/neu,
indicating its prognostic significance (Chiappetta et al., 2004).
In addition, the vast majority of pancreatic cancers in our study were positive
for HMGA1 whilst the normal pancreatic tissues had little or no expression of
HMGA1. Potentially, HMGA1-positivity can be used as a diagnostic marker for
pancreatic cancer. This had been previously suggested by Abe and
colleagues when they found HMGA1 overexpression correlated strongly with
diagnosis of pancreatic adenocarcinoma (Abe et al., 2000). Our current study
was not designed to address this issue as the TMA did not include benign
tumours or non-neoplastic conditions that would allow assessment if HMGA1
differentiated a cancer from other benign conditions. In our TMA, the internal
controls were normal adjacent pancreatic tissue. One may argue that the
adjacent tissue surrounding a pancreatic cancer is often not 'normal' and may
have features of fibrosis or pre-malignant ductal changes. To address this
issue during the TMA construction, we selected only areas of pancreas
surrounding the tumour which are morphologically normal (with no evidence
of desmoplastic or pre-malignant features) as internal controls. This was
verified by our collaborator, Dr Mark Redston who is a Consultant Pathologist
at the Department of Pathology, Brigham and Women's Hospital (Boston, MA,
USA).
Taken together, our results indicate that HMGA1 expression is associated
with adverse prognosis in patients undergoing resection for PDAC. This study
is the first to demonstrate that HMGA1 may represent a novel prognosticator
in PDAC patients. Beyond its prognostic value, it is possible that HMGA1 may
have a role in the pathogenesis of PDAC and may show promise as a
therapeutic target in this deadly disease. HMGA1 would be an ideal target as
it has little or absent expression in the surrounding normal pancreas, and as
such, theoretically should not affect normal cells when HMGA1 is targeted.
The fact that HMGA1 expression predicts poor prognosis supports its roles in
the malignant phenotype of PDAC cells.
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Having established the clinical relevance of HMGA1 in patients with PDAC,
we embarked on further studies to elucidate the roles of HMGA1 in the
aggressive phenotype of PDAC cells using a series of in vitro and in vivo
experiments (see Chapters 4-7).
120
Chapter 4: HMGA1 promotes cellular Invasiveness and metastasis in pancreatic cancer
Chapter Four: HMGA1 promotes cellular
invasiveness and in vivo metastatic
potential in pancreatic adenocarcinoma
4.1 ABSTRACT
Background: HMGA1 proteins are architectural transcription factors that are
overexpressed in a range of human malignancies, including pancreatic
adenocarcinoma. We hypothesized that HMGA1 expression is a determinant
of cellular invasiveness and metastasis in pancreatic cancer.
Methods and results: Stable silencing of HMGA1 in MiaPaCa2 and PANC1
pancreatic adenocarcinoma cells was achieved by transfection of short hairpin
RNA-generating vectors. Additionally, stable overexpression of HMGA1 in
MiaPaCa2 cells (characterized by low levels of inherent HMGA1 expression)
was achieved. HMGA1 silencing resulted in significant reductions in cellular
invasiveness through Matrigel, in cellular MMP-9 activity, mRNA levels and
gene promoter activity, and in Akt phosphorylation at Ser473. Conversely,
forced HMGA1 overexpression resulted in significant increases in cellular
invasiveness, in cellular MMP-9 activity, mRNA levels and promoter activity,
and in Akt phosphorylation at Ser473. HMGA1 overexpression-induced
increases in invasiveness were MMP-9-dependent. The role of PI3-K/Akt in
mediating HMGA1-dependent invasiveness was elucidated by specific PI3-K
inhibitor (LY294002), constitutively active and dominant negative Akt
adenoviral constructs. Akt-dependent modulation of MMP-9 activity
contributed significantly to HMGA1 overexpression-induced increases in
invasive capacity. Furthermore, HMGA1 silencing resulted in reductions in
metastatic potential and tumour growth in vivo and in tumoural MMP-9
activity.
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Conclusion: Our findings suggest that HMGA1 may be a novel molecular
determinant of invasiveness and metastasis, as well as a potential therapeutic
target, in pancreatic adenocarcinoma.
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4.2 INTRODUCTION
Pancreatic adenocarcinoma is the fourth and sixth leading cause of cancer-
related deaths in the United Kingdom and United States respectively (Cancer
Research UK, 2007; Jemal et al., 2006). Its biology is characterized by the
propensity for early and aggressive invasion and metastasis, such that less
than 10% of patients have surgically resectable disease at the time of
diagnosis (Sener et al., 1999). Even among patients able to undergo resection
of all apparent disease, most are destined to succumb to locally-recurrent and
metastatic cancer. Hence, further understanding of the molecular
mechanisms underlying pancreatic adenocarcinoma cellular invasion and
metastasis is needed, as this information may facilitate the identification of
novel molecular targets for the rational therapy of this deadly disease.
In Chapter 3, we have shown that HMGA1 overexpression is highly prevalent
in resected pancreata from patients with pancreatic adecarcinoma. Further,
expression of HMGA1 in tumours of these patients predicts an adverse
clinical outcome. Hence, HMGA1 may be both biologically and clinically
relevant in this deadly disease entity. The human HMGA1 gene, located on
chromosomal locus 6p21, encodes two HMGA1 splice variants (HMGAIa and
HMGAlb) (Friedmann et al., 1993). These HMGA1 proteins are architectural
transcription factors that play a role in both positive and negative
transcriptional regulation of human gene expression (Du et al., 1993; Thanos
& Maniatis, 1995) (see Section 1.11.3). HMGA1 protein overexpression has
been reported to be associated with metastasis in hepatocellular carcinoma
(Chuma et al., 2004) and breast cancer (Liu et al., 1999). In addition, HMGA1
has been shown to promote transcriptional up-regulation of genes implicated
in promoting metastasis (Reeves et al., 2001). However, the molecular
mechanisms through which HMGA1 mediates the metastatic process remain
largely unknown.
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The purpose of this study was to test the hypothesis that HMGA1 is a
molecular regulator of cellular invasiveness and metastasis in pancreatic
adenocarcinoma. Using the RNA interference methodology, we sought to
examine the roles of HMGA1 in pancreatic adenocarcinoma cellular
invasiveness in vitro and metastasis in vivo. Ectopic overexpression of
HMGA1 using HMGA1 cDNA construct was used to elucidate further the
effects of modulating HMGA1 expression on cellular invasiveness. We also
sought to investigate the mechanism through which HMGA1 mediates this
process. Finally, we sought to prove that HMGA1 overexpression
mechanistically promoted metastasis in PDAC, and not merely associated
with this phenomenon.
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4.3 RESULTS
4.3.1 Effect of HMGA1 Gene Silencing on Cellular Invasiveness
Experiments were performed on MiaPaCa2 and PANC1 pancreatic
adenocarcinoma cells which are highly invasive cell lines. We analyzed
HMGA1 gene expression using Western blot analysis. Cellular invasiveness
was quantified using Matrigel-coated Boyden chambers. We used two short-
hairpin RNA (shRNA) expressing plasmids with different target sequences to
induce HMGA1 gene silencing. MiaPaCa2 and PANC1 cell lines were stably
transfected with each of the HMGA1-targeting shRNA expression vectors
(shHMGA1-1 and shHMGA1-2). The use of two independent target
sequences for RNAi helps to control for any non-specific off-target effects.
The shRNA approach was associated with high efficacies in HMGA1 silencing
(as confirmed on Western blot analysis, Fig 4.1 A). Greater suppression of
HMGA1 expression was achieved in MiaPaCa2 cells (up to 90%) compared to
PANC1 cells, which have HMGA1 silenced to a lesser degree. To assess
cellular invasiveness, we used a modified Boyden chamber assay with 5%
FBS as a chemoattractant (see Section 2.8). Silencing of HMGA1 significantly
attenuated cellular invasiveness in both MiaPaCa2 and PANC1 cells (Fig
4.1B). For these experiments, controls were cells stably transfected with a
vector encoding a non-targeting shRNA.
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Figure 4.1. A, Stable silencing of HMGA1 expression using short hairpin RNA (shRNA)
expression vectors with two independent shRNA target sequences (shHMGA1-1 and
shHMGA1-2) was confirmed on Western blot analysis. Controls were cells stably transfected
with non-targeting, scrambled shRNA. Greater suppression of HMGA1 expression was
achieved in MiaPaCa2 cells (up to 90%) compared to PANC1 cells, which have HMGA1
silenced to a lesser degree. * P<0.05 versus control shRNA. B, Cellular invasiveness was
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determined using Matrigel-coated Boyden chamber assays. Stable suppression of HMGA1
expression resulted in significant reductions in cellular invasiveness in both MiaPaCa2 and
PANC1 cells. * P<0.05 versus control shRNA.
4.3.2 Effect of HMGA1 Overexpression on Cellular Invasiveness
Next, we sought to determine the impact of HMGA1 overexpression on
cellular invasiveness. HMGA1 cDNA was cloned into plRES-puro3 vector as
described in Section 2.6. This expression vector was named plRES-HMGA1.
Using MiaPaCa2 cells, which have relatively low levels of inherent HMGA1
expression, we developed the clones plRES-HMGA1.1 and plRES-HMGA1.2
which stably overexpress HMGA1 following transfection of plRES-HMGA1
vector. Methods used in development of HMGA1-overexpressing clones were
provided in Section 2.6.2. Overexpression of HMGA1 was confirmed on
Western blot analysis (Figure 4.2A). MiaPaCa2 cells stably transfected with
empty plRES-puro3 vector served as controls. HMGA1 expression in parental
MiaPaCa2 cells and empty plRES-puro3 transfectants did not differ (Figure
4.2A). plRES-HMGA1.1 and plRES-HMGA1.2 clones exhibited approximately
3- to 3.5 fold increases in cellular invasiveness, compared to control cells
(Figure 4.2B).
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Figure 4.2. A, Two clones of MiaPaCa2 cells were confirmed to stably overexpress HMGA1
(plRES-HMGA1.1 and 1.2) on Western blot analysis. Controls were cells stably transfected
with empty plRES-puro3 vector. * P<0.05 versus empty plRES-puro3 vector and parental
MiaPaCa2 cells. Blots shown are representative of three independent experiments.
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Densitometry values are mean (± s.d.). B, Cellular invasiveness was determined using
Matrigel-coated Boyden chamber assays. Forced overexpression of HMGA1 in MiaPaCa2
cells (plRES-HMGA1.1 and 1.2) resulted in approximately three-fold increases in cellular
invasive capacity when compared to empty plRES-puro3 transfectants. * P<0.05 versus
empty plRES-puro3 vector. Invasion assays were performed in triplicate. Mean values (± s.d.)
from 20 randomly selected fields are shown.
4.3.3 Effects of Modulating HMGA1 Expression on Matrix
Metalloproteinase 9 (MMP-9) Activity, mRNA Expression and Promoter
Activity
Given the importance of MMP-9 as a mediator of malignant cellular
invasiveness and metastasis (Itoh et al., 1999; MacDougall et al., 1999;
Sehgal et al., 1998), we hypothesized that MMP-9 is a downstream effector
that plays a critical role in HMGA1-dependent cellular invasiveness. Using a
sensitive fluorometric MMP-9 activity assay, the total MMP-9 activities from
cellular lysates were determined (described in Section 2.9). HMGA1 silencing
in MiaPaCa2 cells was found to be associated with a reduction in total MMP-9
activities (Figure 4.3A). In addition, HMGA1 silencing led to reductions in
MMP-9 mRNA levels as quantified by real-time quantitative RT-PCR (Figure
4.3B). Conversely, MMP-9 activities and mRNA levels were significantly
higher in plRES-HMGA1.1 and plRES-HMGA1.2 clones than in controls (Fig
4.3A and B). We further constructed the MMP-9 promoter reporter construct
to assess the transcriptional activity of MMP-9 gene (see Section 2.10 for
methods used to construct reporter plasmid). To assess the effect of
modulating HMGA1 expression on MMP-9 promoter activity, we performed
co-transfection experiments in which MiaPaCa2 cells were transiently
transfected with either shHMGAI or plRES-HMGA1 vector together with
MMP-9 promoter reporter vector. MMP-9 promoter activities were significantly
lower with HMGA1 silencing, whereas MMP-9 promoter activity levels were
markedly higher with HMGA1 overexpression, compared to controls (Figure
4.3C).
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4.3.4 Matrix Metalloproteinase 9 is a Mediator of HMGA1-dependent
Increases in Cellular Invasiveness
The contribution of MMP-9 to the increased cellular invasiveness induced by
HMGA1 overexpression was determined by performing the invasion assay in
the presence of anti-MMP-9 neutralizing antibody. Isotype matched control
IgG was used in control experiments. MMP-9 immunoneutralization reduced
the cellular invasiveness of MiaPaCa2 plRES-HMGA1.1 and pIRES-
HMGA1.2 clones by approximately 70% (Figure 4.3D). This suggests that
HMGA1-induced increases in cellular invasiveness are dependent on MMP-9
expression and activity.
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Figure 4.3 A-B. For full legend, see p 133.
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Control Anti-MMP9 Control Anti-MMP9
IgG IgG
plRES-HMGA1.1 plRES-HMGA1.2
Figure 4.3 C-D. For full legend, see p 133.
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Legend
Figure 4.3. HMGA1 expression positively regulates matrix metalloproteinase-9 (MMP-9)
activities, mRNA levels and promoter activities. A, Cellular MMP-9 activities were quantitated
using a fluorometric MMP-9 activity assay. Targeted suppression of HMGA1 expression
(shHMGA1-1 and shHMGA1-2) resulted in significant reductions in MMP-9 activity in
MiaPaCa2 cells while forced overexpression of HMGA1 led to increased cellular MMP-9
activity. Both plRES-HMGA1.1 and plRES-HMGA1.2 clones exhibited approximately 2- to
2.5-fold increases in MMP-9 activity. * P<0.05 versus control shRNA and t P<0.05 versus
empty plRES-puro3 transfectants. B, HMGA1 modulates MMP-9 mRNA levels. On
quantitative real-time RT-PCR, MMP-9 levels were significantly lower in shHMGA1-1 and
shHMGA1-2 transfectants compared to control shRNA transfectants. Overexpression of
HMGA1 led to increases in MMP-9 mRNA levels. * P<0.05 versus control shRNA and f
P<0.05 versus empty plRES-puro3 transfectants. C, The effects of HMGA1 silencing and
overexpression on MMP-9 gene promoter activities in MiaPaCa2 cells were determined using
transient transfection and luciferase reporter assays. Co-transfection experiments were
performed. MiaPaCa2 cells were transiently transfected with shRNA (shHMGA1-1,
shHMGA1-2 or control shRNA) or overexpression vectors (plRES-HMGA1 or empty pIRES-
puro3 control) together with the reporter plasmids. Reporter plasmids included pGL4e (empty
firefly luciferase vector) or pGL4-MMP9, containing the full-length MMP9 promoter and pRL
vector containing a renilla luciferase gene. Forty-eight hours following transfection, luciferase
activity in cell lysates was assayed. Renilla luciferase activities were used to normalise results
for transfection efficiencies. Consistent with MMP-9 activity and mRNA studies, targeted
suppression of HMGA1 expression using shRNA resulted in a significant reduction in MMP-9
promoter activities while forced overexpression of HMGA1 in MiaPaCa2 cells led to significant
increases in MMP-9 promoter activities. * P<0.05 versus control shRNA and t P<0.05 versus
empty plRES-puro3 vectors. D, The contribution of MMP-9 to the increased cellular
invasiveness induced by HMGA1 overexpression was determined by performing the invasion
assay in the presence of anti-MMP-9 neutralising antibody. MMP-9 immunoneutralisation
reduced the cellular invasiveness of plRES-HMGA1.1 and plRES-HMGA1.2 clones by
approximately 70%.
4.3.5 Effects ofHMGAI Modulation on Akt Activation
Activation of the serine/threonine kinase Akt is common in pancreatic
adenocarcinoma (Semba et al., 2003) and is an important determinant of
malignant cellular invasiveness (Kim et al., 2001a). The phosphatidylinositol-
3 kinase (PI-3K)/Akt signaling pathway has previously been reported to be
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important in the regulation of MMP-9 expression (Ellerbroek et al., 2001; Lu &
Wahl, 2005; O. Charoenrat et al., 2004). Given our observations that HMGA1
expression regulates MMP-9 activity via transcriptional activation, we
hypothesized that HMGA1 modulates Akt activation. We found that HMGA1
silencing results in a reduction in Akt phosphorylation at Serine 473 (Figure
4.4A), whereas HMGA1 overexpression results in increased levels of
phospho-Akt (Ser473) (Figure 4.4B). The antibody used for this study was the
anti-phospho Akt (ser473) purchased from San Cruz Biotechnology (San
Cruz, CA, USA). Of note, the upper band corresponds to a non-specific band
as the phospho-Akt band (lower band) remained constant when
immunoblotted with a different phospho-specific Akt antibody (Cell Signaling
Technology, Danvers, MA, USA) (see Figure 5.3). For further confirmation,
phospho-Akt (ser 473) was immunoprecipitated using anti-phospho-Akt
antibody and this yielded a same band as the lower band (data not shown).
Modulating FIMGA1 expression had no effect on total Akt levels.
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Untreated Empty p|RES pIRES
plRES-puro3 -HMGA1.1 -HMGA1.2
Figure 4.4. The effects of
HMGA1 modulation on Akt
phosphorylation in MiaPaCa2
cells were confirmed on
Western blot analysis using a
phosphospecific antibody. A, In
MiaPaCa2 cells, stable
silencing of HMGA1 resulted in
a decreased level of
phosphorylation of Akt at Ser
473, a marker of Akt activation.
* P<0.05 versus MiaPaCa2
cells and control shRNA
transfectants. 6,
Overexpression of HMGA1 led
to increased activation of Akt,
as evident from increased
levels of phospho-Akt. There
was no difference in the level
of expression of total Akt with
suppression or overexpression
of HMGA1. * PO.05 versus
MiaPaCa2 cells and empty
plRES-puro3 transfectants.
Blots shown are representative
of three independent
experiments. Densitometry
values are mean (± s.d.).
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4.3.6 HMGA1-induced Cellular Invasiveness and MMP-9 activity is Pl-
3K/Akt-dependent
Given our findings that HMGA1 modulates Akt activation, we tested whether
cellular invasiveness mediated by HMGA1 is dependent on PI-3K/Akt
signaling. First, we determined if the invasive phenotype in MiaPaCa2 cells in
which HMGA1 had been stably silenced could be rescued using constitutively
active Akt. MiaPaCa2 stable transfectants shHMGA1-1 and shHMGA1-2 were
infected with adenovirus expressing myristoylated Akt (Ad-myr-Akt) and
infection efficiency was monitored by immunoblotting for HA (hemagglutinin)-
tagged Akt. Constitutively active Akt was able to rescue the invasive
phenotype in shHMGA1-1 and shHMGA1-2 transfectants resulting in an
increased invasiveness compared to cells infected with control adenovirus
(Figure 4.5A). Next, given that PI-3K is an upstream regulator of Akt, we
assessed the effects of PI-3K inhibition on cellular invasiveness in MiaPaCa2
cells overexpressing HMGA1 (plRES-HMGA1.1 and plRES-HMGA1.2).
Inhibition of PI-3K activity using the PI-3K inhibitor LY294002 resulted in
dose-dependent reductions in cellular invasiveness in plRES-HMGA1.1 and
plRES-HMGA1.2 clones (Figure 4.5B). Consistent with this finding, infection
with adenovirus expressing dominant negative Akt resulted in attenuation of
HMGA1-induced invasiveness in plRES-HMGA1.1 and plRES-HMGA1.2
clones (Figure 4.6A). Importantly, dominant negative Akt also induced
reductions in cellular MMP-9 activity in plRES-HMGA1.1 and pIRES-
HMGA1.2 clones, indicating that HMGA1-induced MMP-9-dependent cellular
invasiveness is PI-3K/Akt-dependent (Figure 4.6B).
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clones. The effects of
PI3-K were dose-
dependent (25pM and
50pM). * P<0.05 versus
DMSO controls.
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Ad-CMV-Null Ad-DN-Akt Ad-CMV-Null Ad-DN-Akt
plRES-HMGA1.1 plRES-HMGA1.2
Figure 4.6. A, Dominant negative
Akt attenuates HMGA1-induced
invasiveness and MMP-9 activity.
MiaPaCa2 plRES-HMGA1.1 and
1.2 clones were transduced with
adenovirus expressing dominant
negative Akt (Ad-DN-Akt). 8,
Dominant negative Akt resulted in
reductions in invasiveness and in
MMP-9 activities in both HMGA1-
overexpresing clones, compared to
control adenovirus. Cell lysates
were immunoblotted with anti-HA
to detect expression of HA-tagged
DN Akt. * P<0.05 versus control
adenovirus (Ad-CMV-null).
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4.3.7 Modulation of HMGA1 Expression Has No Impact on Cellular
Proliferation in Monolayer Culture
The effects of modulating HMGA1 expression on cellular proliferation in
monolayer culture were determined. Using the MTS assay, we observed no
impact on cellular proliferation in low (2% FBS) and high (10% FBS) serum
conditions with either HMGA1 gene silencing or overexpression (Figure 4.7).
















Figure 4.7. Based on MTS assay, modulation of HMGA1 expression did not affect cellular
proliferation in monolayer culture. Experiments were performed at low (2% FBS) and high
(10%) conditions.
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4.3.8 Effects of HMGA1 Modulation on Phosphorylation of ERK and
mTOR
Previous studies have shown that HMGA1 modulates ERK activation (Treff et
al., 2004). In our study, HMGA1 silencing had no impact on ERK
phosphorylation, whereas HMGA1 overexpression resulted in increased ERK
phosphorylation with no effects on the total ERK levels (Figures 4.8A and B).
Given that mTOR is a well-known downstream mediator of the PI-3K/Akt
pathway (Nave et al., 1999; Peterson et al., 2000), we sought to determine
the effects of HMGA1 modulation of mTOR phosphorylation. HMGA1
silencing resulted in reductions in mTOR phosphorylation at Ser2448, while
HMGA1 overexpresssion led to increases in mTOR phosphorylation (Figures
4.8C and D). Modulation of HMGA1 expression had no impact on levels of
total mTOR expression.
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Figure 4.8. The effects of
HMGA1 modulation on ERK
phosphorylation in MiaPaCa2
cells confirmed on Western blot
analysis using a phosphospecific
antibody. A-B, Although HMGA1




There were no differences in the
levels of total ERK.
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Untreated Empty pIRES- pIRES-
plRES-puro3 HMGA1.1 HMGA1.2
Figure 4.8. C-D, Targeted
suppression of HMGA1
expression resulted in
reductions in phosphorylation of
mTOR at Ser2448 in both
shHMGA1-1 and shHMGA1-2
transfectants while
overexpression of HMGA1 led
to increases in phospho-mTOR
levels. There was no difference
in total mTOR levels among
groups. * P<0.05 versus control
shRNA or empty plRES-puro3
transfectants, as appropriate.
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4.3.9 HMGA1 Silencing Suppresses In Vivo Metastatic Potential of
Pancreatic Cancer Cells and Reduces Tumoural Growth and MMP-9
Activity
Given these in vitro findings, we sought to determine the impact of modulating
HMGA1 expression on metastatic potential in vivo. Four weeks following
surgical orthotopic implantation of MiaPaCa2 stable transfectants expressing
control shRNA (n=10) or shHMGAI (n=10), necropsy was performed.
Methodology of orthotopic pancreatic adenocarcinoma mouse model is
provided in Section 2.17.1 and xenograft immunohistochemistry is described
in Section 2.18. All mice in the control shRNA group were found to have
histologically-confirmed liver metastases (Figure 4.9), and six of these mice
were found to have gross ascites. In the shHMGAI group, only one mouse
developed metastases (Table 4.1, P<0.05), and none of them had ascites. No
lung metastases were detected in either group. There were no apparent
differences in the histological appearance of haematoxylin and eosin-stained
sections of xenografts harvested from animals in the shHMGAI and control
groups (Figure 4.1 OA). Stable silencing of tumoural HMGA1 expression in the
shHMGAI group in vivo was confirmed by immunohistochemistry (Figure
4.9A) and Western blotting (Figure 4.1 OB). Additionally, HMGA1 silencing
was associated with significant reductions in tumour growth in the explanted
tumours compared to the control group (Figure 4.10C). To confirm our in vitro
results, lysates from explanted tumours were analysed for total MMP-9 activity
using the fluorometric MMP-9 activity assay. We found that there were
significant reductions in MMP-9 activity in tumours with HMGA1 knockdown,
implying that HMGA1 silencing could alter tumour behaviour in vivo (Fig
4.10C and D). We speculated that in vivo HMGA1 silencing reduced the
MMP-9 dependent cellular invasiveness and finally, metastasis.
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Figure 4.9. Macroscopic evidence of liver metastases at laparotomy of a mouse four weeks
following orthotopic implantation of MiaPaCa2 cells with control shRNA. Liver metastases
were shown in the red square.
J
Table 4.1. HMGA1 gene silencing by RNA interference suppresses the metastatic potential of
pancreatic adenocarcinoma cells in vivo
Control shRNA shHMGAI
(n = 10) (n=10)
Median no. of metastases (range) 6 (1-20) 0* (0-3)
Mice with metastases 100% 10%*
At 4 weeks following orthotopic implantation of 1X10B MiaPaCa2 cells stably expressing
control or shHMGAI constructs, necropsy was performed. Liver metastases were counted
and confirmed histologically. HMGA1 silencing significantly inhibited metastasis in this nude
mouse model. *P<0.05 vs. control shRNA group.
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Figure 4.10. C, Final volume of
primary tumours harvested from
shHMGAI group was markedly
reduced compared to those of the
control shRNA group. D, MMP-9
activities in lysates obtained from
HMGA1 shRNA transfectant-derived
tumours were significantly lower than
those of control shRNA transfectant-
derived tumours. Mean values (±
s.d.). * P <0.05 vs. control shRNA
transfectant-derived tumours.
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4.4 DISCUSSION
Pancreatic adenocarcinoma is among the most aggressive of human
malignancies. The prognosis associated with this cancer remains dismal,
despite the considerable advances in medical and surgical management of
patients diagnosed with pancreatic cancer. There is an urgent need to identify
new therapeutic approaches. This study was designed to determine the role
of HMGA1 in pancreatic adenocarcinoma cellular invasiveness and
metastasis. We have demonstrated that HMGA1 overexpression promotes
cellular invasiveness and that specific suppression of HMGA1 expression
inhibits cellular invasiveness in vitro and metastasis in vivo. HMGA1-induced
cellular invasiveness is in part due to PI3-K/Akt-dependent modulation of
MMP-9 activity. Together, these findings suggest that HMGA1 architectural
transcriptional factors represent a molecular determinant of cellular
invasiveness and a potential therapeutic target in pancreatic adenocarcinoma.
HMGA1 previously has been reported to be associated with malignant cellular
behaviour in a range of human cancers. HMGA1 has been shown to confer
the ability of non-tumourigenic breast epithelial cells to grow under
anchorage-independent conditions (Reeves et al., 2001). Antisense
oligonucleotide-mediated suppression of HMGA1 expression has been
reported to inhibit neoplastic transformation in breast cancer (Dolde et al.,
2002) and in Burkitt's lymphoma cells (Wood et al., 2000b). Although there is
extensive correlative evidence suggesting a role for HMGA1 in tumour
metastasis (Abe et al., 2003; Balcerczak et al., 2003; Chang et al., 2005),
there have been few studies showing a direct functional link between HMGA1
expression and invasion and metastasis (Liu et al., 1999; Reeves et al., 2001;
Wood et al., 2000a).
Our study is the first to demonstrate a role for HMGA1 in pancreatic
adenocarcinoma cellular invasiveness and metastasis, and provides evidence
that HMGA1 expression mediates cellular invasiveness through a PI3-K/Akt-
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MMP-9-dependent pathway. While MMP-9 is unlikely to be the sole effector of
HMGA1-dependent invasiveness, this pathway represents a potential
mechanism that may contribute to the decrease in cellular invasiveness
induced by HMGA1 gene silencing. Our finding that PI-3K/Akt signaling
mediates regulatory actions of HMGA1 is novel. Our finding that HMGA1
promotes mTOR activation provides further support for the relationship
between HMGA1 and PI-3K/Akt signaling, as mTOR is a downstream target
of this pathway (Nave et al., 1999; Peterson et al., 2000).
Our finding that HMGA1 overexpression results in increased ERK
phosphorylation is consistent with findings of previously reported studies
suggesting that HMGA1 is able to positively regulate the Ras-extracellular
signal-related kinase (Ras/ERK) mitogenic signaling pathway (Treff et al.,
2004). The Ras/ERK signaling pathway is intrinsically linked to PI-3K/Akt
pathways. PI-3K/Akt has been shown to be downstream of Ras/ERK signaling
pathway (Gupta et al., 2001; McKenna et al., 2003), and Ras can also directly
activate the PI-3K/Akt signaling pathway (Rodriguez-Viciana et al., 1994).
Alternatively, HMGA1 has been shown to transcriptionally regulate the human
insulin receptor gene (Brunetti et al., 2001; Foti et al., 2005), and given that
PI-3K/Akt are downstream mediators of insulin signaling (Hara et al., 1994), it
is not surprising that HMGA1 expression affects PI-3K/Akt signalling. Both
Ras/ERK and PI-3K/Akt signaling pathways have been found to be critical in
mediating cellular invasion in pancreatic cancer cells (Veit et al., 2004).
Our observation that HMGA1 silencing suppresses Akt activity is significant,
as Akt is now recognized as an important mediator of malignant cellular
behaviour, including the capacity for resisting apoptotic stimuli, in pancreatic
adenocarcinoma (Maitra & Hruban, 2005; Shah et al., 2001; Takeda et al.,
2004). Trapasso and colleagues have reported that antisense-mediated
suppression of HMGA1 expression results in an apoptotic response in three
pancreatic cancer cell lines (Trapasso et al., 2004). Our findings that HMGA1
positively regulates PI3-K/Akt signaling provides a possible mechanism
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through which HMGA1 suppression promotes apoptosis. Unlike Trapasso et
al, we found that modulating HMGA1 expression has no impact on cellular
proliferation in 2-dimensional monolayer culture. However, our data indicate
that HMGA1 silencing does inhibit tumour growth in vivo.
Our study provides support to the hypothesis that the HMGA1 proteins are
potential therapeutic targets for inhibiting the activation of the PI-3K/Akt
pathway in cancer cells. From a therapeutic standpoint, targeting HMGA1 is
attractive in that it is overexpressed in a range of human malignancies.
HMGA1 expression is absent or present at only very low levels in normal adult
tissues (Chiappetta et al., 1996). As such, targeting HMGA1 may have little or
no effect on non-cancerous tissues. Given our finding that RNA interference-
mediated HMGA1 silencing inhibits invasive and metastatic potential, HMGA1
represents a rational molecular therapeutic target. The feasibility of in vivo
gene silencing induced by the delivery of therapeutic siRNA has already been
demonstrated (Zimmermann et al., 2006). Technological advances, such as
the development of improved delivery systems for siRNAs, will facilitate this
approach.
In summary, our findings suggest that HMGA1 promotes pancreatic cancer
cellular invasive and metastatic potential. Our findings also indicate that
HMGA1 represents a potential therapeutic target for strategies designed to
inhibit the progression of pancreatic cancer.
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Chapter Five: Overexpression of HMGA1
promotes anoikis resistance through
constitutive Akt activation
5.1 ABSTRACT
Background: HMGA1 proteins are architectural transcription factors that are
overexpressed by pancreatic adenocarcinomas. Roles of HMGA1 in
mediating the malignant phenotype of this cancer are poorly understood. We
tested the hypothesis that overexpression of HMGA1 promotes resistance to
anoikis (apoptosis induced by anchorage deprivation) in pancreatic cancer
cells.
Methods and results: HMGA1 cDNA was stably transfected into MiaPaCa2
human pancreatic adenocarcinoma cells (which have low baseline expression
levels of HMGA1). Cells were grown in suspension on PolyHEMA-coated
plates, and their susceptibility to anoikis was assayed using flow cytometry.
Overexpression of HMGA1 was associated with marked reductions in
susceptibility to anoikis in concert with increases in Akt phosphorylation
(Ser473) and in Akt kinase activity and with reductions in caspase 3
activation. Inhibition of PI3-kinase/Akt pathway with either the small molecule
inhibitor LY294002 or dominant negative Akt resulted in reversal of anoikis
resistance induced by HMGA1 overexpression. Further, RNA interference-
mediated HMGA1 silencing in MiaPaCa2 and BxPC3 (a human pancreatic
adenocarcinoma cell line with high baseline levels of HMGA1 expression)
cells resulted in significant increases in susceptibility to anoikis.
Conclusions: Our findings suggest HMGA1 promotes anoikis resistance
through a PI3-kinase/Akt-dependent mechanism. Given the putative
associations between anoikis resistance and metastatic potential, HMGA1
represents a potential therapeutic target in pancreatic adenocarcinoma.
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5.2 BACKGROUND
Pancreatic adenocarcinoma is among the deadliest of all human cancers, with
5-year survival rates averaging less than 5% (Jemal et al., 2006). The
propensity for pancreatic adenocarcinoma cells to metastasize early in the
course of disease progression makes this cancer particularly refractory to
standard therapies. Characterizing the underlying mechanisms mediating
metastatic dissemination in pancreatic adenocarcinoma may reveal novel
targets for inhibiting this process, which is so aggressive in this cancer. In
Chapter 4, we have demonstrated that HMGA1 is a molecular determinant of
cellular invasiveness and metastatic potential in PDAC cells. However,
cellular invasion is only a part of the complex and inter-related processes
involved in metastasis. For cancer cells to transfer from a primary tumour
focus to distant sites will involve invasion of normal surrounding tissues,
penetration of lymphatic and vascular channels, survival of cancer cells within
the lymphatic or circulatory systems followed by extravasation from the walls
of these lymphovascular channels in distant organs and establishment of a
viable metastatic focus.
Anoikis, derived from a Greek word meaning 'homelessness', was used in
describing the observation that depriving cells from attachment to matrix
triggers apoptosis in these cells (Frisch & Francis, 1994). Increasingly,
metastasis is conceptualised to be a multi-step process facilitated by the
evolution of anoikis resistant subsets of cancer cells that are capable of
surviving in the blood stream or lymphatic system during dissemination after
they detach from the primary tumour and its stroma. Indeed, numerous
studies suggest a close correlation between signaling events mediating
cellular anoikis resistance in vitro and those mediating metastatic potential in
vivo (Berezovskaya et al., 2005; Douma et al., 2004; Yawata et al., 1998; Zhu
et al., 2001).
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Given that we have previously shown that HMGA1 plays an important role in
the metastatic potential of PDAC cells, we examined in this study if HMGA1
had an impact on the process of anoikis resistance in cancer cells. This line of
investigation will help to clarify the potential role and underlying biology for
HMGA1 in the context of cancer progression, especially in the metastatic
process, which hitherto remains poorly understood. The purpose of this study
was to test the hypothesis that HMGA1 promoted anoikis resistance in
pancreatic adenocarcinoma. We further assessed the roles of PI3-K/Akt
pathway and caspase activation as possible mediators of this process.
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5.3 RESULTS
5.3.1 HMGA1 overexpression promotes anoikis resistance in MiaPaCa2
pancreatic adenocarcinoma cells
Stable overexpression of HMGA1 was achieved in MiaPaCa2 cells, which
have low inherent expression levels of HMGA1. Two stable HMGA1-
overexpressing clones were selected and named plRES-HMGA1.1 and
plRES-HMGA1.2. HMGA1 overexpression was confirmed on Western blot
analysis (Figure 5.1). Levels of HMGA1 overexpression in plRES-HMGA1.1
and plRES-HMGA1.2 were 4- and 3.5-fold higher than in control cells,
respectively. There was no difference in the levels of HMGA1 expression
between the empty plRES-puro3 transfectants and parental MiaPaCa2 cells.
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normalised to Lamin B signals, are mean (± s.d.). P<0.05 versus empty plRES-puro3 vector
and parental MiaPaCa2 cells.
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The anoikis assay was performed by culturing cells on poly-2-
hydroxyethylmethacrylate (polyHEMA)-coated plates which prevent cellular
attachment, allowing cells to grow or survive in suspension (see Section
2.14). This technique was originally described by Folkman and Moscona in
1978 and has since been used extensively to induce this subset of apoptosis
by depriving cells of its normal substratum attachment (Folkman & Moscona,
1978). Following 18 hours of anchorage-deprivation (on polyHEMA plates),
anoikis (or apoptosis with deprivation of attachment) was quantified using flow
cytometric assessment of YO-PRO-1- and propidium iodide-stained cells. In
short, the green-fluorescent dye YO-PRO-1 identifies apoptotic cells and
propidium iodide stains necrotic cells. The anoikis fraction was calculated
from the ratio of apoptotic cells to total cells counted. plRES-HMGA1.1 and
plRES-HMGA1.2 clones showed significantly increased anoikis resistance
(mean anoikis fractions of 11% and 13% respectively) when compared to
controls (mean anoikis fractions for parental MiaPaCa2 and empty pIRES-
puro3 transfectants were 26% and 27% respectively, Figure 5.2A and B).
Interestingly, plRES-FIMGA1.1 and plRES-HMGA1.2 clones adopt a rounder
morphology and tend to grow in clumped colonies even when grown in
standard adherent culture conditions.
5.3.2 HMGA1 overexpression results in protection from caspase-
mediated apoptosis
Given that disruption of cell-matrix interactions can trigger anoikis via
caspase-dependent apoptosis, we examined the effects of HMGA1
overexpression on caspase 3 activity (a central mediator of apoptosis) in the
context of anchorage deprivation. During induction of anoikis on polyFIEMA
plates, FIMGAI-overexpressing clones demonstrated markedly reduced levels
of caspase 3 activity compared to parental MiaPaCa2 or plRES-puro3
controls (Fig 5.2C).
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Figure 5.2. A-B, Forced HMGA1 overexpression protected MiaPaCa2 cells, which have low
inherent expression of HMGA1, from anoikis. Representative flow cytometric images are
shown with anoikis fractions highlighted in the inserted square (Fig 5.2A). Clones pIRES-
HMGA1.1 and plRES-HMGA1.2 exhibited 2- to 2.5-fold reductions in anoikis fraction
compared to parental MiaPaCa2 and plRES-puro3 control stable transfectants (Fig 5.2B). *
P<0.05 versus empty plRES-puro3 vector. C, FIMGA1 overexpression protected MiaPaCa2
cells from caspase-mediated anoikis. plRES-FIMGA1.1 and plRES-FIMGA1.2 clones showed
significant reductions in caspase 3 activity, compared to parental MiaPaCa2 cells and empty
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plRES-puro3 transfectants, following induction of anoikis on polyHEMA plates for 18 hours.
*P<0.05 versus empty plRES-puro3 vector.
5.3.3 Overexpression of HMGA1 increases levels ofAkt phosphorylation
and Akt kinase activity
Phosphoinositidyl-3 kinase/Akt signaling pathway is of critical importance in
mediating anoikis resistance and enhancing anchorage-independent cell cycle
progression (Moore et al., 1998; Nguyen et al., 2002) . Using a different
phospho-specific antibody (Cell Signaling Technology, 587F11-#4051) to that
used in Chapter 3, we sought to confirm if HMGA1 overexpression would
modulate Akt phosphorylation at Ser473, a marker of Akt activation. HMGA1
overexpression resulted in elevated Akt (Ser473) phosphorylation (Figure
5.3A). Consistent with this finding, HMGA1 overexpression was found to be
associated with increases in Akt kinase activity (Figure 5.3B), as assessed
using a fluorometric real-time Akt kinase assay.
5.3.4 Inhibition of phosphoinositidyl-3 kinase/Akt signaling reverses
HMGA1 overexpression-induced anoikis resistance.
Having demonstrated that HMGA1 overexpression induces constitutive
activation of PI3-K/Akt pathway, we next examined the effects of inhibiting this
pathway in cells overexpressing HMGA1. First, we used a specific small
molecule inhibitor of PI3-K, LY294002, to assess the effects of inhibiting PI3-K
on anoikis resistance of these cells. Addition of 25pM of LY294002
significantly increased anoikis fractions in plRES-HMGA1.1 and pIRES-
HMGA1.2 clones (Figure 5.3C). Treatment of parental MiaPaCa2 and empty
plRES-puro3 controls with LY294002 also inhibited anoikis resistance,
although to lesser extent than for plRES-HMGA1.1 and plRES-HMGA1.2
clones. Second, infection of plRES-HMGA1.1 and plRES-HMGA1.2 clones
with adenovirus expressing a dominant negative Akt construct also
significantly increased anoikis fractions in both HMGA1-overexpressing
clones (Figure 5.3D). Parental MiaPaCa2 and empty plRES-puro3 controls
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also exhibited increased anoikis fractions with infection of adenovirus
expressing dominant negative Akt construct but to a lesser extent than the
HMGA1 overexpressing clones. Taken together, these results suggest that
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Figure 5.3. A, Overexpression of HMGA1 led to increased activation of Akt, as evident from
increased levels of phospho-Akt (Ser473), a marker of Akt activation. Both plRES-HMGA1.1
and plRES-HMGA1.2 clones exhibited a higher degree of Akt phosphorylation compared to
control cells. There were no differences in the level of expression of total Akt with
overexpression of HMGA1. * P<0.05 versus parental MiaPaCa2 cells or empty plRES-puro3
transfectants. Blot shown is representative of three independent experiments. B,
Correspondingly, overexpression of HMGA1 results in increased Akt kinase activities as
determined by fluorometric real-time Akt kinase assays. Slope of Akt kinase activity curves
indicates the levels of Akt kinase activity. Representative results of Akt kinase activity assay
from three independent experiments are shown. plRES-HMGA1.1 and plRES-HMGA1.2
clones showed steeper activity curve slopes and hence Akt kinase activities, when compared
to empty plRES-puro3 controls. * P<0.05 versus empty plRES-puro3 vector transfectants. C,
Anoikis resistance induced by HMGA1 overexpression in plRES-HMGA1.1 and pIRES-
HMGA1.2 clones was reversed by pre-incubating cells in 25pM LY294002, a specific inhibitor
of PI-3K. Inhibiting PI-3K resulted in increases in anoikis fractions in plRES-HMGA1.1 and
plRES-HMGA1.2 clones, to levels similar to parental MiaPaCa2 and empty plRES-puro3
controls. Controls were cells treated with the DMSO vehicle. *p<0.05 versus DMSO controls.
D, Similarly, infection of plRES-HMGA1.1 and plRES-HMGA1.2 clones with adenovirus
carrying dominant negative Akt1 resulted in reversal of anoikis resistance with increases in
anoikis fractions in both HMGA1 overexpressing clones. Controls were cells infected with
adenovirus expressing an empty CMV promoter (Ad-CMV-null). *p<0.05 versus control
adenovirus (Ad-CMV-Null).
5.3.5 Targeted RNA interference of HMGA1 in MiaPaCa2 and BxPC3
pancreatic adenocarcinoma cells increases susceptibility to anoikis.
Given the effects of HMGA1 overexpression on anoikis resistance in
MiaPaCa2 cells, we asked if silencing of HMGA1 in the same cell line will
have the reverse effects. In addition, we also selected BxPC3 pancreatic
adenocarcinoma cell line for RNA interference experiments as these cells
have high levels of HMGA1 expression at baseline. Generation of lentivirus
capable of silencing HMGA1 expression is provided in Section 2.5.4. In these
lentivirus-mediated RNAi experiments, we developed pooled stable
transfectants. Stable transfectants derived from infection with lentivirus
developed from empty PLKO.1 and scramble shRNA transfer plasmids served
as controls. We achieved at least 90% silencing of HMGA1 expression in
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both MiaPaCa2 and BxPC3 cells (Figure 5.4A). Of note, neither HMGA1
overexpression nor silencing had any impact on Lamin B expression (used to
normalise for protein loading, Figures 5.1 and 5.4A). HMGA1 silencing was










Figure 5.4. A, Using lentivirus-mediated RNA interference (RNAi) of HMGA1, we achieved up
to 90% silencing of HMGA1 expression in both MiaPaCa2 and BxPC3 cell lines. A
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representative Western blot performed on nuclear extracts showing the degree of HMGA1
silencing is shown. Controls were stable transfectants developed following infection with
lentivirus expressing a scramble RNAi or empty PLKO.1 sequence. B, Silencing of HMGA1
promoted anoikis in both cell lines following culture in polyHEMA plates for 18 hours (for
MiaPaCa2) and 12 hours (for BxPC3). Representative images of flow cytometric analyses of
anoikis fractions with apoptotic populations highlighted in triangles drawn are shown.
Targeted suppression of HMGA1 resulted in significant increases in anoikis fractions in both
MiaPaCa2 and BxPC3 cells, compared to empty PLKO.1 and scramble RNAi stable
transfectants. * p<0.05 vs. empty PLKO.1 or scramble RNAi transfectants.
5.4 DISCUSSION
Pancreatic adenocarcinoma is associated with dismal prognosis, in large part
resulting from metastatic disease, even in patients initially deemed to be
surgically resectable. We have focused our efforts in studying the
mechanisms underlying metastasis in pancreatic adenocarcinoma, with the
goal of rationally identifying molecular targets that can be exploited to inhibit
this process. In our work, we have used cellular invasiveness (Chapter 4) and
anoikis resistance as an in vitro correlates of metastatic potential. In this
study, we have shown that HMGA1 overexpression confers anoikis resistance
to pancreatic adenocarcinoma cells by activating the pro-survival PI3-K/Akt
signaling pathway. This is the first report describing a regulatory role of
HMGA1 on anoikis resistance in a cancer model.
Recently, data suggesting mechanisms by which HMGA1 may mediate
cancer progression have begun to emerge. For example, HMGA1 proteins
have been demonstrated to promote tumour progression and epithelial-
mesenchymal transition in human breast epithelial cells (Reeves et al., 2001).
In immortalized rat embryonic fibroblast Rati a cells, HMGA1 was found to be
a c-Jun target gene and its suppression by antisense methodology was found
to reduce the ability of c-Jun overexpressing cells to grow under anchorage-
independent conditions (Hommura et al., 2004).
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Although previous reports have implicated HMGA1 as having the capacity to
promote tumourigenesis and anchorage independent growth in normal
epithelial cells (Reeves & Beckerbauer, 2001), no studies reported to date
have examined specifically the role of HMGA1 in mediating anoikis resistance
in the context of cancer cells. Our findings suggest that HMGA1
overexpression represents a molecular determinant of anoikis resistance in
pancreatic adenocarcinoma cells. The biological significance of this finding
relates to emerging understanding that anoikis resistance is a phenotypic
hallmark of metastatic cancer cells (Douma et al., 2004). Although the
underlying mechanisms rendering anoikis resistance in cancer cells are
incompletely understood, our findings provide evidence for a novel role for
HMGA1 in mediating this process. Further, our findings provide a potential
mechanism by which HMGA1 overexpression induces anoikis resistance:
activation of the anti-apoptotic PI3-K/Akt signaling pathway.
Description of regulatory roles for HMGA1 in the context of apoptosis is not
without precedent. HMGA1 has been found to associate in vivo with p53
family members and inactivate their functions. As such, overexpression of
HMGA1 may lead to suppression of p53-induced apoptosis and tumour
suppressor activity (Frasca et al., 2006). In addition, antisense-mediated
suppression of HMGA1 expression in thyroid carcinoma cell lines has been
reported to induce an apoptotic response (Scala et al., 2000). Our findings
that HMGA1 overexpression results in the constitutive activation of PI3-K/Akt
pathway provide another mechanism through which FIMGA1 mediates its anti-
apoptotic functions. HMGA1-dependent activation of Akt signaling is likely to
protect cancer cells from a broad array of pro-apoptotic stimuli, not just those
related to anchorage deprivation. Indeed, we have begun work investigating if
FIMGA1 protects pancreatic adenocarcinoma cells from gemcitibine-induced
apoptosis and in this context, may represent a potential molecular
determinant of chemoresistance in pancreatic cancer (Chapter 7).
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Our findings, taken together with those previously reported, provide a
mechanistic basis for conceptualizing the known correlations between
HMGA1 expression and poor prognosis in cancer patients (Chapters 1 and 3).
These findings also have obvious therapeutic implications. Future studies will
need to address whether targeted therapies directed against HMGA1 will
inhibit other features of malignant phenotype that make pancreatic cancer so
lethal.
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Chapter Six: HMGA1 promotes anchorage-
independent growth in pancreatic
adenocarcinoma
6.1 ABSTRACT
Background: We previously showed that HMGA1 proteins are architectural
transcription factors that are overexpressed by pancreatic adenocarcinomas.
We tested the hypothesis that HMGA1 promotes anchorage-independent
cellular proliferation and in vivo tumourigenicity. Having identified PI3-K/Akt
pathway as a downstream mediator of HMGA1, we examined if this aspect of
malignant phenotype was also dependent of this pathway.
Methods: shRNA-mediated RNAi was used to silence HMGA1 expression in
MiaPaCa2 and PANC1 pancreatic cancer cells. Anchorage-independent
proliferation was assessed using the soft agar assays. The roles of PI3-K/Akt
and extracellular signal-regulated kinase (ERK) signaling were investigated
using specific inhibitors and adenoviral dominant negative/active Akt
constructs. In vivo tumourigenicity was assessed using a nude mouse
subcutaneous xenograft model.
Results: shRNA-mediated HMGA1 silencing resulted in significant reductions
in anchorage-independent colony formation in soft agar, tumourigenicity in
vivo, and Akt phosphorylation (Ser473), without changes in ERK1/2
phosphorylation. Forced HMGA1 overexpression promoted colony formation
in soft agar, Akt phosphorylation (Ser473), and ERK 1/2 phosphorylation.
HMGA1 overexpression-induced increases in anchorage-independent growth
were dependent on PI3-K/Akt- but MEK/ERK signaling. Further, HMGA1
silencing in vivo resulted in reductions in cellular proliferation (Ki-67 index)
and increases in apoptosis (TUNEL staining).
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Conclusions: Our findings suggest HMGA1 promotes tumourigenicity through
a PI3-K/Akt-dependent mechanism in pancreatic adenocarcinoma cells.
HMGA1 warrants further evaluation, both as a therapeutic target and a
prognostic marker in pancreatic cancer.
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6.2 INTRODUCTION
Our group has previously shown that HMGA1 overexpression is a common
occurrence in pancreatic adenocarcinomas and its tumoural expression
indicates a poor clinical outcome in patients with this deadly disease (Chapter
3). Dysregulated overexpression of HMGA1 has been reported in numerous
human cancers (reviewed in Section 1.11.7). HMGA1 proteins are
architectural transcription factors that were once thought to be merely
'associated' with tumourigenesis (Evans et al., 2004). However, evidence is
accumulating that HMGA1 has a functional importance in tumourigenesis.
Known functions of HMGA1 proteins include forming stereo-specific,
multiprotein complexes termed "enhanceosomes" on the promoter/enhancer
regions of genes, where they bind to the minor groove of AT-rich DNA
sequences (Reeves & Nissen, 1990; Thanos & Maniatis, 1995). This mode of
action seems to transcriptionally regulate the expression of many genes.
However, the mechanism through which HMGA1 mediates its pro-
tumourigenic effects remains unclear.
In breast cancer, HMGA1 has been shown to promote malignant
transformation of breast epithelial cell lines (Reeves et al., 2001). It was
suggested that HMGA1 overexpression promotes epithelial-mesenchymal
transition during the process of breast tumourigenesis. In leukemia,
unequivocal evidence exist whereby transgenic mice with HMGA1
overexpression targeted to lymphoid tissue developed spontaneous
aggressive lymphomas (Xu et al., 2004). In pancreatic cancer, there is a
paucity of data on the roles of HMGA1 in pancreatic tumourigenesis. Although
we have previously described evidence for the roles of HMGA1 in mediating
invasion, anoikis resistance and ultimately, metastasis, one other important
determinant of biological aggressiveness that has yet to be studied is the
tumourigenic potential of the cells. Traditionally, one of the most stringent
tests for tumourigenicity of malignant cells is the anchorage-independent
growth assay in soft agar. The ability to form tumours in vivo requires the cells
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to have two sets of capabilities: firstly, to be able resist apoptosis under
anchorage-independent conditions, and secondly, to be able to proliferate
under similar conditions. Apoptosis under conditions of inappropriate or
inadequate contact with substratum is termed anoikis (see Chapter Five). If a
particular subset of tumour cells is more biologically aggressive and
malignant, they are generally less susceptible to anoikis and proliferate more
readily in soft agar. Hence, the soft agar assay is a stringent assay that
closely corresponds with in vivo tumourigenicity.
To further evaluate the potential roles of HMGA1 in mediating the malignant
phenotype, we tested the hypotheses that HMGA1 promotes anchorage-
independent cell proliferation in pancreatic adenocarcinoma and that
suppression of HMGA1 expression would impair anchorage-independent
colony formation in vitro and tumour growth in vivo. We also hypothesised that
effects of HMGA1 silencing on in vivo tumour growth will be mediated by a
reduction in cellular proliferation and an increase in apoptosis. Our
observations indicate that HMGA1 indeed promotes pancreatic
adenocarcinoma tumourigenesis and that a key effector of HMGA1-induced
anchorage-independent growth is the anti-apoptotic phosphoinositidyl-3
kinase/Akt pathway.
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6.3 RESULTS
6.3.1 Stable RNAi-mediated suppression of HMGA1 expression inhibits
anchorage-independent growth
Both MiaPaCa2 and PANC1 pancreatic adenocarcinoma cell lines express
HMGA1, with MiaPaCa2 cells having a lower expression level of HMGA1 at
baseline. We used two independent shRNA target sequences (named
shHMGA1-1 and shHMGA1-2) to suppress HMGA1 expression. Each of
these shRNA sequences was associated with an 80% reduction in HMGA1
expression in MiaPaCa2 cells (Figure 6.1), as confirmed by Western blot
analyses of nuclear extracts. These same shRNA sequences were
associated with 61% (shHMGA1-1) and 56% (shHMGA1-2) reductions in
HMGA1 expression in PANC1 cells.
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Figure 6.1. Stable silencing
of HMGA1 expression
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In MiaPaCa2 cells, the high degree of HMGA1 silencing induced by each of
the shRNA sequences was associated with marked reductions in growth in
soft agar (Figure 6.2A). Similar, although less marked, reductions in growth in
soft agar were observed for PANC1 cells (Figure 6.2B), corresponding to
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MiaPaCa2 cells















Control shRNA shHMGA1.1 shHMGA1.2
MiaPaCa2
Figure 6.2A. For full legend, see pg 170
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Control shRNA shHMGA1.1 shHMGA1.2
PANC1
Figure 6.2B. For full legend, see below.
Legend
Figure 6.2. The effects of HMGA1 silencing on anchorage-independent growth was assessed
using soft agar assays. Stable HMGA1 silencing using each of two independent shRNA
sequences (shHMGA1-1 and shHMGA1-2) resulted in reductions in soft agar colony
formation in both MiaPaCa2 (A) and PANC1 cells (B) when compared to the scrambled
control shRNA-transfected cells. Effects on soft agar growth were greater in MiaPaCa2 cells,
corresponding to greater silencing of HMGA1 in these cells. *P<0.05 versus control shRNA.
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6.3.2 Forced HMGA1 overexpression promotes anchorage-independent
growth.
Given the relatively low baseline expression level of HMGA1 in MiaPaCa2
cells, we chose this cell line to test the effects of forced HMGA1
overexpression. We transfected this cell line with an overexpression vector
carrying the full-length HMGA1 cDNA. Two clones stably overexpressing
HMGA1 were selected and named (plRES-HMGA1.1 and plRES-HMGA1.2).
The degree of HMGA1 overexpression (2.5-fold and 3-fold overexpression,
respectively, over controls) was documented on Western blot analyses of
nuclear extracts (Figure 6.3A). HMGA1 overexpression was associated with
increased colony formation in soft agar (Figure 6.3B).
Figure 6.3A. Two clones
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Figure 6.3B. Overexpression of HMGA1 in MiaPaCa2 clones (plRES-HMGA1.1 and pIRES-
HMGA1.2) resulted in unequivocal increases in anchorage-independent growth in soft agar.
The number and size of colonies in soft agar were clearly larger with overexpression of
HMGA1. *P<0.05 versus empty plRES-puro3 transfected cells. Values are means (± SD).
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6.3.3 HMGA1-induced increases in anchorage-independent growth are
PI-3K/Akt- but not MEK/ERK-dependent.
We have previously shown in Chapters 4 and 5 that HMGA1 is able to
positively regulate Akt and ERK activation. To assess if the effects of HMGA1
were dependent on Akt activation, we performed soft agar assays in the
presence of PI-3K inhibitor LY294002. LY294002 (at concentrations of either
25pM or 50 pM) was associated with significant reductions in soft agar growth
by plRES-HMGA1.1 and plRES-HMGA1.2 clones to levels similar to those
exhibited by parental MiaPaCa2 cells and MiaPaCa2 cells stably transfected
with empty plRES-puro3 vector (Figure 6.4A). In contrast, the MEK/ERK
inhibitor PD98059 (at concentrations of either 50 pM and 100 pM) had no
impact on soft agar growth by plRES-HMGA1.1 and plRES-HMGA1.2 clones
(Figure 6.4B). In addition, infection of adenovirus carrying dominant negative
(Ad-DN-Akt) abrogated soft agar growth in plRES-HMGA1.1 and pIRES-
HMGA1.2 clones (Figure 6.5A). Further, infection of dominant active Akt
adenovirus (Ad-myr-Akt) rescued the ability to grow in soft agar of MiaPaCa2
cells with HMGA1 silencing (i.e. shHMGA1-1 and shHMGA1-2) (Figure 6.5B).
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MEK/ERK inhibitor PD98059 had no effects on HMGA1 overexpression-induced increases in
soft agar growth, as both plRES-HMGA1.1 and plRES-HMGA1.2 clones exhibited no
significant reductions in growth even in high 50pM and 100 pM concentrations of PD98059.
This is in contrast to the significant inhibition of soft agar growth when the plRES-puro3
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Figure 6.5. A, Infection of plRES-HMGA1.1 and 1.2 clones with dominant negative Akt
adenovirus resulted in significant reductions in HMGA1 overexpression-induced increase in
soft agar growth. Dominant negative Akt adenovirus resulted in a small effect in soft agar
growth in the empty plRES-puro3 control cells. *P<0.05 versus control adenovirus (Ad-CMV-
Null). B, Conversely, infection of adenovirus expressing constitutively active Akt (Ad-myr-Akt)
rescued the ability to grow under anchorage-independent conditions in shHMGA1-1 and
shHMGA1-2 stable transfectants. No effects were seen when empty plRES-puro3 controls
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were infected with constitutively active Akt adenovirus. *P<0.05 versus control adenovirus
(Ad-CMV-Null). Values are means (± SD).
6.3.4 HMGA1 silencing resulted in significant inhibition of tumour
growth in vivo.
Tumours derived from subcutaneous implantation of MiaPaCa2 and PANC1
cells stably transfected with HMGA1 shRNA vectors exhibited reduced growth
rates in nude mice compared to corresponding controls (tumours derived from
MiaPaCa2 and PANC1 cells stably transfected with control shRNA vectors)
during the 8-week period following implantation (Figure 6.6A and B). Stable
knockdown of HMGA1 was confirmed by performing Western blot analysis on
nuclear extracts of tumour xenografts (Figure 6.7A and B).
Immunohistochemical analysis of tumours harvested at the end of this
observation period suggests that HMGA1 silencing is associated with an
inhibition in tumoural cell proliferation (Ki-67 reactivity) and an increase in
tumoural apoptosis (TUNEL-staining) (Figure 6A and B).
Modulation of HMGA1 expression had no impact on cellular proliferation in
monolayer culture. Neither HMGA1 silencing nor overexpression had a
significant effect on the cellular proliferation in standard monolayer culture as
determined by MTS assay (see Chapter 4, Figure 4.7).
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Legend
Figure 6.6. A, Stable silencing of HMGA1 resulted in significant attenuation in growth of
tumours derived from subcutaneous implantation of MiaPaCa2 and PANC1 cells in nude
mice. Mice (n=6 per group) were subcutaneously implanted with stable transfectant cells
(either scrambled shRNA control or shHMGA1-1 plasmid). Subcutaneous tumour size was
monitored weekly for 8 weeks. Stable HMGA1 silencing was confirmed by Western blot
analysis of nuclear extracts from explanted xenograft tumours. Values are means (± SEM).
*P<0.05 versus control shRNA xenografts.
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A. In vivo proliferation (Ki-67 reactivity)
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Figure 6.7A. For full legend, see pg 181.
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B. In vivo apoptosis (TUNEL staining)
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Figure 6.7B. For full legend, see pg 181.
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Legend
Figure 6.7. A, Suppression of HMGA1 resulted in reduction of Ki-67 immunoreactivity in vivo.
Each tumour slide was stained for Ki-67 and the number of Ki-67 positive cells were counted
in at least 5 randomly selected fields at X40 magnification. Representative tumour sections
stained for Ki-67 immunoreactivity in MiaPaCa2 and PANC1 tumour xenografts are shown.
*P<0.05 versus control shRNA transfectant-derived xenografts. B, HMGA1 silencing led to
increased apoptosis in tumour xenografts as demonstrated on TUNEL staining. TUNEL-
positive cells were counted in at least 5 randomly selected fields at X40 magnification in each
xenograft slide. Representative tumour sections stained for TUNEL in MiaPaCa2 and PANC1
tumour xenografts are shown. *P<0.05 versus control shRNA transfectant-derived xenografts.
Values are means (± SD).
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6.4 DISCUSSION
This study was designed to investigate the role of HMGA1 in a further aspect
of the malignant phenotype: anchorage-independent growth. We have shown
that HMGA1 overexpression promotes pancreatic adenocarcinoma
tumourigenesis via a PI3-K/Akt-dependent mechanism. Taken together, this
study suggests that HMGA1 may be a mechanism by which pancreatic
tumour cells acquire their biological aggressiveness which is so evident
clinically. Clearly, HMGA1 may represent a novel therapeutic target in
pancreatic cancer.
Our findings indicate that HMGA1 promotes colony formation by pancreatic
cancer cells under anchorage-independent conditions in vitro and
tumourigenesis in vivo. In contrast, modulating HMGA1 expression in
pancreatic cancer cells has no impact on their proliferation under standard
monolayer culture conditions, an observation suggesting that HMGA1 does
not act simply as a mitogenic stimulus. This implies that HMGA1 assumes a
greater functional importance under anchorage-independent conditions,
suggesting HMGA1 may influence important cancer survival pathways. In
addition, these findings are not surprising, given that kinetics of three-
dimensional colony formation in vitro more closely approximates those of in
vivo tumour growth than cells in monolayer culture (Demicheli et al., 1989).
The normal cellular response to deprivation from appropriate contact with
substratum is to undergo apoptosis which, in this context, is termed anoikis
(Frisch & Francis, 1994). A defining feature of transformed cells is resistance
to anoikis and the ability to proliferate under anchorage-independent
conditions (e.g., in soft agar). This feature of the malignant phenotype is
conceptualized to contribute to tumourigenesis and metastasis in a wide
range of cancers (Douma et al., 2004; Takaoka et al., 1997; Yawata et al.,
1998). Anchorage independent growth is probably a result of the ability to
proliferate in the absence of substratum and to resist apoptosis due to loss of
substratum. To address the question of which aspect is modulated by
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HMGA1, our group previously investigated the specific roles of HMGA1 in
anoikis by investigating the apoptotic status of pancreatic adenocarcinoma
cells grown in polyHEMA-coated plates (Chapter 5) (Liau et al., 2007). We
found that HMGA1 overexpression promotes anoikis resistance in pancreatic
adenocarcinoma cells. Potentially, HMGA1 mediates its function in
tumourigenesis by enhancing resistance to apoptosis and allowing continued
three-dimensional growth.
Our findings are consistent with those of a previously reported study in which
HMGA1 overexpression was shown to induce anchorage-independent growth
in breast epithelial cells (Reeves et al., 2001). Our study builds on this
observation by defining a novel mechanism through which HMGA1 mediates
anchorage-independent cellular proliferation: PI-3K/Akt signaling. Our data
clearly demonstrate that intact PI-3K/Akt signaling is necessary for HMGA1
overexpression to promote colony formation in soft agar. They also
demonstrate that constitutively active PI-3K/Akt signaling is sufficient to
maintain the capacity for colony formation in soft agar in the context of
HMGA1 silencing. In Chapter 4, we confirmed the effects of modulating
HMGA1 expression on the functional status of Akt-dependent pathways by
assessing its effects of mTOR phosphorylation, a well-known downstream
target of Akt (Liau et al., 2006). We found that modulation of HMGA1
expression had a direct effect on mTOR phosphorylation, indicating that
HMGA1 does have a functional effect on the PI3-K/Akt/mTOR pathway.
Although the mechanism through which HMGA1 modulates the activity of PI3-
K/Akt pathway remains unknown, clues can be obtained from a previous
study which identified genes regulated by HMGA1 using cDNA microarray
analysis (Reeves et al., 2001). Among the list of genes, multiple fibroblast
growth factor (FGF) pathway components (e.g. FGFR1, FGF2b, FGF6, FGF7,
FGF9) seem to be positively regulated by HMGA1. It is plausible that
induction of the FGF pathway, by binding of FGF to its receptors could result
in downstream stimulation of survival signaling pathways such PI3-K/Akt as
demonstrated in this study (Wente et al., 2006). Further, our study adds to the
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growing body of evidence suggesting that Akt represents a molecular hub for
signaling events mediating cellular proliferation and resistance to apoptosis
under conditions in which cells are deprived of contact with matrix (Nakanishi
et al., 2002). Our in vivo data provide corroborating findings: HMGA1
silencing was associated with reductions in cellular proliferation and increases
in apoptosis, corresponding to overall reductions in tumour growth. These
findings are important as they demonstrate that HMGA1 silencing alters the
tumour behaviour in vivo and confirms our hypothesis that HMGA1
suppression promotes tumour apoptosis and reduces tumour proliferation in
vivo. This corroborates with our in vitro findings that the PI3-K/Akt survival
pathway is downstream of HMGA1 and may mediate the in vitro and in vivo
apoptotic and anti-growth effects of HMGA1 suppression.
It is now clear that HMGA1 exerts its effects not only by altering the
conformational structure of DNA. More importantly, accumulating evidence
suggests that HMGA1 exerts its functions by other mechanisms. Recent
studies have suggested that HMGA1 is capable of inhibiting the functions of
p53, a well-known oncosuppressor gene, by cytoplasmic relocalization of its
proapoptotic activator HIPK2 (Frasca et al., 2006; Pierantoni et al., 2007).
Nuclear HMGA1 has also been described to directly influence mitochondrial
functions (Dement et al., 2006). Further study is likely to reveal increasing
complexity in the mechanisms mediating the biological actions of HMGA1.
HMGA1 is already known to modulate the expression of a wide array of
genes, many of which are implicated in mediating the malignant phenotype
(reviewed by Reeves et al) (Reeves, 2001). Which of these genes represent
critical downstream effectors of HMGA1 signaling remain to be defined.
Given a previous report suggesting a role for HMGA1-dependent MEK/ERK
signalling (Treff et al., 2004), we tested the effects of inhibiting this pathway.
In our study, although overexpression of FIMGA1 resulted in ERK activation,
inhibition of this pathway with the small molecule inhibitor PD98059 had no
impact on proliferation in soft agar by cells with ectopic HMGA1
overexpression. Further, HMGA1 silencing clearly resulted in reductions in
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cellular proliferation in soft agar but had no impact on ERK phosphorylation.
Taken together, these findings suggest that HMGA1-induced cellular
proliferation in soft agar growth is independent of MEK/ERK signaling.
In summary, HMGA1 promotes anchorage-independent growth by pancreatic
cancer cells through a PI-3K/Akt-dependent mechanism. Given the minimal
or absent expression of HMGA1 in normal adult tissues, HMGA1 represents a
potential therapeutic target in pancreatic cancer.
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Chapter Seven: HMGA1 is a novel
molecular determinant of chemoresistance
to gemcitabine
7.1 ABSTRACT
Background: HMGA1 proteins are architectural transcription factors that are
overexpressed by pancreatic adenocarcinomas. In this study, we tested the
hypothesis that HMGA1 promotes chemoresistance to gemcitabine in
pancreatic cancer cells.
Methods and results: Stable shRNA-mediated HMGA1 silencing in BxPC3,
MiaPaCa2 and PANC1 cells promoted chemosensitivity to gemcitabine, with
reductions in gemcitabine IC50 and increases in gemcitabine-induced
apoptosis and caspase activation. In contrast, forced HMGA1 overexpression
in MiaPaCa2 cells promoted chemoresistance to gemcitabine, with increases
in gemcitabine IC50 and reductions in gemcitabine-induced apoptosis and
caspase activation. Given that HMGA1 modulates Akt activation, dominant
negative Akt abrogated HMGA1 overexpression-induced increases in
chemoresistance to gemcitabine. Finally, HMGA1 silencing promoted
chemosensitivity to gemcitabine in vivo in a nude mouse xenograft model of
pancreatic adenocarcinoma.
Conclusions: Our findings suggest that HMGA1 promotes chemoresistance to
gemcitabine through an Akt-dependent mechanism. Targeted therapies
directed at HMGA1 represents a potential strategy for ameliorating
chemoresistance in pancreatic adenocarcinoma.
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7.2 INTRODUCTION
Overall prognosis for patients diagnosed with pancreatic adenocarcinoma
remains dismal. At the time of diagnosis, most patients have locally-advanced
or metastatic disease precluding surgical resection (Sener et al., 1999). First
line therapy for most patients with advanced pancreatic cancer is based on
the nucleoside analogue gemcitabine. However, the clinical response rate to
gemcitabine remains modest, in large part due to the profound
chemoresistance inherent in pancreatic cancer cells. Therefore,
characterization of molecular mechanisms mediating chemoresistance in
pancreatic adenocarcinoma is an important priority. Furthermore,
chemosensitizing strategy through the use of a novel molecular therapy is an
appealing concept as it allows maximum tumour cell kill with the low serum
chemotherapy levels achieved, to allow for tolerable toxicity.
In Chapter 4, we have previously reported the roles of HMGA1 in mediating
cellular invasiveness and metastatic potential of pancreatic adenocarcinoma
cells (Liau et al., 2006). Overexpression of HMGA1 promotes cellular invasion
in vitro whilst post-transcriptional silencing of HMGA1 inhibits the ability of
pancreatic adenocarcinoma cells to form metastases in vivo. Furthermore, we
demonstrated that overexpression of HMGA1 is associated with increased
soft agar growth (see Chapter 6) and resistance to apoptosis under
anchorage-independent culture ('anoikis resistance') (see Chapter 5) (Liau et
al., 2007). In the above studies, we have reported that Akt is a key
downstream effector of HMGA1-dependent signaling in pancreatic cancer.
Given the central role of Akt in mediating chemoresistance to gemcitabine
(Duxbury et al., 2004; Ng et al., 2000; Ng et al., 2001), we hypothesized that
HMGA1 would promote chemoresistance to this agent through an Akt-
dependent mechanism. In this study, we have found that overexpression of
HMGA1 promotes chemoresistance to gemcitabine through an Akt-dependent
process. Lastly, we have demonstrated that targeted post-transcriptional
silencing of HMGA1 promotes chemosensitivity in vivo, further confirming our
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in vitro findings. Our findings are of particular clinical importance as they
suggest that targeted therapies directed against HMGA1 may ameliorate
chemoresistance to gemcitabine.
7.3 RESULTS
7.3.1 Targeted silencing of HMGA1 promotes chemosensitivity to
gemcitabine in pancreatic adenocarcinoma cells
To begin to test our hypothesis that HMGA1 expression is a determinant of
chemoresistance to gemcitabine, we used stable shRNA-mediated gene
silencing to suppress HMGA1 expression in MiaPaCa2 cells. To help control
for potential off-target effects of RNA interference, we transfected cells with
one of two shRNA-expressing plasmid vectors, each carrying one of two
independent shRNA target sequences (shHMGA1-1 and shHMGA1-2).
HMGA1 silencing was confirmed on Western analysis; shHMGA1-1 was
associated with a greater degree of HMA1 silencing than shHMGA1-2 (Figure
7.1). Suppression of HMGA1 expression using either shRNA target sequence
resulted in significant reductions in IC50 to gemcitabine, as compared with
control cells stably expressing non-targeting shRNA (Figure 7.1).
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Figure 7.1. Plasmid-
mediated stable silencing of
HMGA1 expression in
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7.3.2 Generation of high-titer lentiviral particles expressing shHMGAI
and lentivirus-mediated HMGA 1 silencing
Having shown that HMGA1 silencing promotes chemosensitivity to
gemcitabine using two independent shRNA target sequences, we generated
high-titre lentivirus particles (see Section 2.6.5) expressing shHMGA1-1, the
sequence which was consistently associated with greater silencing efficacy
than shHMGAI-2. In the following experiments, lentivirus-mediated HMGA1
silencing with the shHMGAI-1 target sequence was used. Lentivirus-
mediated silencing of HMGA1 is highly consistent and reproducible in the
three pancreatic adenocarcinoma cell lines used, BxPC3, PANC1 and
MiaPaCa2. Following lentiviral transduction (MOI of 10) and selection in
puromycin, we achieved almost complete silencing of HMGA1 (Figure 7.2).
190
Chapter 7: HMGA1 and chemoresistance in pancreatic adenocarcinoma
Figure 7.2. Following the generation of high-titre lentivirus particles carrying shHMGAI
(shHMGA1-1 sequence), BxPC3, MiaPaCa2 and PANC1 cells were transduced with lentivirus
at MOI of 10 and stable transfectants were developed following selection with puromycin.
Robust suppression of HMGA1 was achieved using lentivirus with a high degree of silencing
of HMGA1 as compared to plasmid-mediated shRNA. In all three cell lines, lentivirus-
mediated shHMGAI achieved almost complete silencing of HMGA1. Controls were stable
transfectants developed using lentivirus carrying scrambled, non-targeting shRNA. *P<0.05
versus control shRNA.
7.3.3 HMGA1 silencing promotes chemosensitivity to gemcitabine
Lentivirus-mediated HMGA1 silencing resulted in a marked increase in
chemosensitivity to gemcitabine in BxPC3 cells, with approximately four-fold
reductions in IC50 to gemcitabine (mean IC50: control shRNA versus.
shHMGAI; 50nM versus 12 nM, p=0.001) (Figure 7.3A, B and C).
Interestingly, BxPC3 cells in which HMGA1 had been silenced developed
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spiculated morphology on exposure to 1pM gemcitabine for 48 hours,
whereas control cells did not (Figure 7.3A). There were no morphological
changes in PANC1 cells when exposed to gemcitabine apart from reductions
in viability with HMGA1 silencing (Figure 7.3A). Lentivirus-mediated HMGA1
silencing had similar effects on PANC1 (Figure 7.3D and E) and MiaPaCa2
(Figure 7.4A and B) cells, with shifting of the gemcitabine IC50 curves to the
left and approximately two-fold reductions of IC50. In MiaPaCa2 cells, the
mean gemcitabine IC50 reduced from 60 nM (control shRNA) to 30nM
(shHMGAI) with silencing of FIMGA1 (p=0.001). In PANC1 cells, suppression
of FIMGA1 led to reduction of mean gemcitabine IC50 from 128 nM (control
shRNA) to 65 nM (shHMGAI) (p=0.001).
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Figure 7.3. A, The effects of lentivirus-mediated HMGA1 silencing on chemosensitivity to
gemcitabine were assessed. When BxPC3 cells in which HMGA1 had been silenced were
exposed to 1pM gemcitabine for 48 hours, they adopted a less healthy, spiculated
morphology as compared to control cells. Photomicrographs were taken using an inverted
microscope at 40X magnification. In PANC1, there were no morphological changes apart from
reductions in viability on exposure to gemcitabine, with HMGA1 silencing. B-E, Survival
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curves following exposure to 0-1 OpM gemcitabine were analyzed following MTS assay.
Lentivirus-mediated stable HMGA1 silencing in BxPC3 cells shifted the survival curve to the
left indicating an increased in chemosensitivity to gemcitabine, when compared to the
controls. Correspondingly, there was 4-fold reductions in the mean IC50 to gemcitabine with
silencing of HMGA1 when compared to the controls. In PANC1 cells, there was similar effect
with two-fold reduction in mean IC50. *P<0.05 versus control shRNA.
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Figure 7.4. A, The effects of modulating HMGA1 expression on chemosensitivity to
gemcitabine in MiaPaCa2 cells were assessed. In MiaPaCa2 cells, lentivirus-mediated
silencing of HMGA1 resulted in marked reductions in cellular viability as compared to controls
when exposed to 1pM gemcitabine for 72 hours. In contrast, MiaPaCa2 cells with HMGA1
overexpression (plRES-HMGA1.1 and 1.2) demonstrated increased viability following
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exposure to IpM gemcitabine, when compared to empty plRES-puro3 transfectants.
Photomicrographs were taken using an inverted microscope at 40X magnification. B-C,
Lentivirus-mediated RNA interference of HMGA1 in MiaPaCa2 cells resulted in increases in
chemosensitivity to gemcitabine with shifting of survical curves to the left while
overexpression of HMGA1 led to increases in chemoresistance to gemcitabine with shifting of
the survival curves to the right in both plRES-HMGA1.1 and 1.2 clones, compared to their
respective controls. D, Targeted suppression of HMGA1 using lentivirus-mediated shHMGAI
resulted in 2-fold reductions in IC50 compared to control, while overexpression of HMGA1 in
plRES-HMGA1.1 and 1.2 clones resulted in approximately 2.2- and 1.7-fold increases in IC50
to gemcitabine respectively. *P<0.05 versus control shRNA transfectants. **P<0.05 versus
empty plRES-puro3 transfectants.
7.3.4 HMGA1 is a molecular determinant of chemoresistance to
gemcitabine in pancreatic adenocarcinoma cells.
We then tested the impact of forced overexpression of HMGA1 on cellular
chemoresistance to gemcitabine. MiaPaCa2 cells (which have low inherent
expression of HMGA1) were stably transfected with the plRES-HMGA1
vector, as described in Section 2.6. We selected two transfectant clones with
highest expression levels of HMGA1 (plRES-HMGA1.1 and pIRES-
HMGA1.2). In our previous studies (Chapters 4, 5 and 6), we have
characterized the plRES-HMGA1.1 and plRES-HMGA1.2 clones and verified
their overexpression of HMGA1 by Western analysis. plRES-HMGA1.1 and
plRES-HMGA1.2 clones overexpress HMGA1 by 4-fold and 3.5-fold
respectively, when compared with empty plRES-puro3 transfectants.
Overexpression of HMGA1 resulted in significant increases in
chemoresistance to gemcitabine, with increases in IC50 to gemcitabine (Fig
7.4D) and shifting of the IC50 curves to the right for both plRES-HMGA1.1
and plRES-HMGA1.2 clones (Fig 7.4C). The mean IC50s for pIRES-
HMGA1.1 and plRES-HMGA1.2 were 130nM and 100nM respectively,
compared to 60nm of empty plRES-puro3 controls (p=0.003 and p=0.006
versus empty plRES-puro3 controls). Of note, plRES-FIMGA1.1 consistently
overexpressed FIMGA1 at a greater level than plRES-FIMGA1.2 and
consequently, the IC50 for plRES-HMGA1.1 was also greater. This implies
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that the level of HMGA1 expression does correspond closely with degree of
chemoresistance. Forced HMGA1 overexpression enhanced the viability of
cells exposed to 1pM of gemcitabine for 72 hours, whereas HMGA1 silencing
was associated with the opposite effect (Figure 7.4A).
7.3.5 HMGA1 expression status modulates gemcitabine-induced
apoptosis and caspase 3 activation
Following exposure to 1 pM gemcitabine for 24 hours, cells were subjected to
flow cytometric quantitation of apoptosis and fluorometric caspase 3 profiling.
Lentivirus-mediated HMGA1 silencing was associated with increases in
gemcitabine-induced apoptosis (Figure 7.5A) and caspase 3 activation
(Figure 7.6A) in BxPC3, MiaPaca2 and PANC1 cells. In contrast, HMGA1
overexpression was associated with reductions in gemcitabine-induced


























Figure 7.5B. For full legend, see below.
Legend
Figure 7.5. A, Lentivirus-mediated silencing of HMGA1 promoted gemcitabine-induced
apoptosis as assessed by flow cytometric analyses of YO-PRO-1/Propidium iodide-stained
cells. Silencing of HMGA1 resulted in approximately 2-fold increases in the relative apoptotic
rates in both BxPC3, MiaPaCa2 and PANC1 cells following exposure to 1pM gemcitabine for
24 hours. *P<0.05 versus control shRNA. Representative flow cytometric images of three
experiments are shown, with the apoptotic fractions being highlighted in triangles drawn. B,
Forced overexpression of HMGA1 in plRES-FIMGA1.1 and 1.2 clones protected the cells from
gemcitabine-induced apoptosis with approximately 70-80% reductions in relative apoptotic
rates, as assessed by flow cytometry.* indicates p<0.05 versus empty plRES-puro3 control.
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7.3.6 HMGA1-specific silencing enhances gemcitabine-induced
activation of caspases 3, 8, 9 and 2
Caspase activation is required for gemcitabine-induced cytotoxicity in cancer
cells (Nabhan et al., 2002). Having shown that HMGA1 modulation affects
gemcitabine-induced caspase 3 activation, we sought to profile the effect of
HMGA1 silencing on the caspase cascade after exposure to gemcitabine for
24 hours. Gemcitabine-induced activation of caspases 3, 8, 9 and 2 was
markedly increased with targeted suppression of HMGA1 in MiaPaCa2 cells,
compared to controls (Figure 7.6C).
A B





Caspase 3 Caspase 8 Caspase 9 Caspase 2
Figure 7.6. A, Relative caspase 3 activities were determined using a fluorometric caspase 3
substrate assay following exposure of cells to 1pM gemcitabine for 24 hours. Lentivirus-
mediated silencing of HMGA1 promoted gemcitabine-induced caspase 3 activities. *P<0.05
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versus control shRNA transfectants. B, As expected, overexpression of HMGA1 in pIRES-
HMGA1.1 and 1.2 clones resulted in reductions in caspase 3 activation following exposure to
1pM gemcitabine for 24 hours, indicating protection from gemcitabine-induced caspase-
mediated apoptosis. *P<0.05 versus empty plRES-puro3 transfectants. C, Activities of
caspases 3, 8, 9 and 2 were quantified using a fluorometric profiling assay after exposure to
1pM gemcitabine for 24 hours. Activities of each of the four caspases profiled exhibited a
significant increase in MiaPaCa2 cells with lentiviral-mediated HMGA1 silencing, compared to
controls. * P<0.05 versus control shRNA transfectants.
7.3.7 HMGA1-induced chemoresistance to gemcitabine is dependent on
Akt signalling
We have previously reported that the Akt signaling pathway is a downstream
mediator of HMGA1 (see Chapters 4, 5 and 6). In our previous reports,
silencing of HMGA1 reduces Akt phosphorylation (a marker of Akt activation)
whilst ectopic overexpression of HMGA1 results in an increase in Akt kinase
activity through an increase in Akt phosphorylation (see Chapter 5). Given the
importance of the PI3-K/Akt pathway in anti-apoptotic signaling, particularly in
the context of chemoresistance, we sought to determine if chemoresistance to
gemcitabine induced HMGA1 overexpression is Akt-dependent. Each of
plRES-HMGA1.1 and 1.2 clones were transduced with dominant negative Akt
adenovirus at MOI of 10. The efficiency of transduction and expression of
dominant negative Akt were confirmed by immunoblotting for the HA tag of
the dominant negative Akt construct (Fig 7.7). We next assessed the effects
of dominant negative Akt on chemosensitivity to gemcitabine in each HMGA1
overexpressing clone. Dominant negative Akt was found to reverse the
chemoresistance induced by HMGA1 overexpression, with reductions of IC50
to gemcitabine in both plRES-HMGA1.1 and 1.2 clones to levels similar to
control and untreated cells. As such, HMGA1 overexpression-induced
chemoresistance is dependent on Akt signaling.
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Figure 7.7. A, HMGA1-induced increases in chemoresistance to gemcitabine were
dependent on the Akt signaling pathway. The roles of Akt in mediating the HMGA1-induced
chemoresistance was assessed by transducing plRES-HMGA1.1 and 1.2 clones with
adenovirus carrying HA-tagged dominant negative Akt. Transduction efficiency and
expression of dominant negative Akt were assessed by Western blotting for hemagglutinin
(HA). Infection of plRES-HMGA1.1 and 1.2 clones with adenovirus carrying dominant
negative Akt (Ad-DN-Akt) resulted in significant reductions in IC50 to gemcitabine when
compared to cells infected with control adenovirus (Ad-CMV-Null). Dominant negative Akt
resulted in reductions in IC50 to gemcitabine in plRES-HMGA1.1 and 1.2 clones to levels
similar to parental MiaPaCa2 cells or empty plRES-puro3 transfectants, indicating abrogation
of the increased chemoresistance associated with HMGA1 overexpression. *P<0.05 versus
control adenovirus (Ad-CMV-Null).
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7.3.8 HMGA1 silencing promotes chemosensitivity to gemcitabine in
vivo
BxPC3 cells in which HMGA1 had been silenced through stable lentiviral
shRNA-mediated RNAi or control BxPC3 cells transduced with lentivirus
carrying non-targeting shRNA were subcutaneously implanted into nude mice.
Once the resulting xenograft tumours had grown to reach approximately
50mm3 in diameter, a 6-week course of gemcitabine administration was
initiated. Tumours derived from BxPC3 cells in which HMGA1 had been
silenced (n=8 animals) regressed during the treatment period while tumours
derived from control cells (n=8 animals) continued to grow during the
treatment period (Fig 7.8A-C). Stable suppression of HMGA1 expression in
tumours derived from shHMGAI transfectants was confirmed on Western
blotting of nuclear extracts of tumour homogenates (Fig 7.9A) and on
immunohistochemical analysis of xenografts harvested at the end of the study
period (Fig 7.9B). TUNEL staining revealed a significantly higher apoptotic
index in shHMGAI transfectant-derived tumours than in control cell-derived
tumours (Fig 7.9B and C).
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Figure 7.8. A, Stable silencing of HMGA1 promoted chemosensitivity to gemcitabine in vivo
with evidence of tumour regression in nude mouse subcutaneous model. Mice (n=8 per
group) were subcutaneously implanted with 2X106 lentivirus-mediated stable transfectant
BxPC3 cells (either shHMGAI or control shRNA). Gemcitabine treatment was commenced in
each group 14 days after implantation when the tumours were approximately 50mm3 in
volume. Mice received gemcitabine (150 mg/kg) in 100 pL of PBS vehicle by twice-weekly i.p.
injection. Subcutaneous tumour size was monitored weekly during the 6 weeks of treatment.
Tumours with HMGA1 silencing showed evidence of regression in size during the treatment
period while tumours in the control group continued to grow with time. Values are means (±
SD). *P<0.05 versus control shRNA xenografts. B, The size of the explanted tumours at the
end of the 6-week treatment period was shown. Of note, one of the mice in the shHMGAI had
the tumour completely regressed following 6 weeks of gemcitabine treatment.
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Figure 7.9. A, In vivo HMGA1 silencing was confirmed by Western blot analysis of nuclear
extracts from explanted xenograft tumours. Densitometric values are means (± SD). *P=0.001
versus control shRNA xenografts. B-C, Immunohistochemistry of xenograft sections
demonstrated little or absent staining for HMGA1 in the shHMGAI xenografts, when
compared to the control shRNA xenografts which showed intense staining for HMGA1.
Photomicrograph of HMGA1 staining was obtained at 40X magnification. In the same
sections, TUNEL staining was performed. In each tumour slide stained with TUNEL, the
number of TUNEL-positive cells were counted in at least 5 randomly selected fields at 40X
magnification. HMGA1 silencing led to significant increases in relative apoptotic index when
compared to control shRNA xenografts. Representative tumour sections stained for TUNEL
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photographed at X20 magnification are shown. *P<0.001 versus control shRNA xenografts.
Values are means (± SD).
7.4 DISCUSSION
HMGA1 proteins are overexpressed in a wide range of human cancers,
including pancreatic adenocarcinoma (see Chapter 3). Experimental data
implicating biologically important roles for HMGA1 in cancer pathogenesis are
rapidly accumulating (Reeves & Beckerbauer, 2001; Wood et al., 2000a). Our
study provides the first data suggesting that HMGA1 may mediate a critical
feature of malignant phenotype: chemoresistance. First, our findings
demonstrate that forced HMGA1 overexpression promotes chemoresistance
to gemcitabine in pancreatic cancer cells in vitro, while HMGA1 silencing
promotes gemcitabine-induced cytotoxicity and therefore abrogates
chemoresistance to gemcitabine. Second, we have confirmed that HMGA1
silencing promotes gemcitabine-induced cytotoxicity and increases
chemosensitivity in vivo in a nude mouse xenograft model of pancreatic
cancer. Finally, our findings suggest a plausible mechanism by which
HMGA1 promotes chemoresistance to gemcitabine: activation of Akt
signaling. These findings imply that targeted suppression or inactivation of
F1MGA1 could be a potential therapeutic manoeuvre to induce
chemosensitivity to gemcitabine in this highly-chemoresistant cancer.
The pro-survival phosphatidylinositol 3-kinase (PI-3K)/Akt pathway is
frequently activated in pancreatic cancer (Asano et al., 2004). The
chemoresistant phenotype in pancreatic cancer cell lines has been associated
with overexpression of genes involved in the PI-3K/Akt pathway (Akada et al.,
2005). A previous study has highlighted the importance of PI-3K/Akt pathway
in mediating the chemoresistance to gemcitabine in pancreatic cancer cells
(Ng et al., 2000). The inhibition of PI-3K pathway has been shown to improve
the therapeutic index of gemcitabine in pancreatic cancer in vivo (Ng et al.,
2001). The exact mechanism through which PI-3K/Akt pathway induces
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chemoresistance remains largely unknown. The primary mode of action of
gemcitabine is to inhibit DNA synthesis by competing for incorporation into
DNA. Gemcitabine is a nucleoside analogue (diflourodeoxycytidine) that is
phosphorylated by deoxycytidine kinase. Gemcitabine triphosphate is
incorporated into nascent DNA to inhibit DNA synthesis (Shore et al., 2003).
Although we speculate that the primary action of HMGA1 in chemoresistance
to gemcitabine is mediated through the PI3-K/Akt survival pathway, it is likely
that HMGA1 may have some actions on the gemcitabine metabolism
pathway. This will require further elucidation in future studies.
Mechanisms of HMGA1 action has been shown to be largely due to its ability
to alter DNA conformation. Proposed mechanisms for gene regulation include
derepression of gene promoter by displacement of histone H1 nucleoproteins,
a strong repressor of gene transcription, from scaffold attachment regions
(SAR), allowing for a more open chromatin structure that facilitates
transcriptional activation (Zhao et al., 1993). Further, HMGA1 is able to bind
to AT-rich promoter regions, and modify DNA conformation to encourage
attachment of other transcriptional factors that promote gene transcription (Yie
et al., 1999). By binding to promoter regions, HMGA1 is also able to form
multiprotein complexes, the "enhanceosomes", that serve as transcription
activating complexes (Yie et al., 1999). Given these putative functions, it is not
surprising that HMGA1 is involved in the regulation of a large number of target
genes. Previous studies have shown that HMGA1 overexpression is
associated with increased expression of growth factors/cytokines (e.g.
fibroblast growth factors (FGF), interferons a and (3, interleukins 10-14 and
17), growth factor receptors (e.g. FGFR, EGFR, ERBB3 and 4) and multiple
integrins (a1, a6, a9, aE, (31, (33, (38) (Reeves, 2001). Clearly, it is not
surprising that through induction of these growth factor-related signaling
pathways, HMGA1 could have an impact on the pro-survival PI3-K/Akt
pathways. It is also plausible that by increasing integrin expression, HMGA1
may stimulate integrin-linked kinase, which is known to directly interact with
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integrins and phosphorylate Akt in a PI3-K-dependent manner (Tabe et al.,
2007).
In the current study, we have examined the effects of silencing HMGA1 on
chemoresistance in BxPC3 and MiaPaCa2 pancreatic adenocarcinoma cells.
BxPC3 cells are known to inherently overexpress HMGA1 whilst MiaPaCa2
cells have relatively lower inherent HMGA1 expression. Interestingly, although
BxPC3 cells have a higher HMGA1 expression, their IC50 values to
gemcitabine is comparable to MiaPaCa2 cells. On the other hand, PANC1
cells consistently have the highest level of HMGA1 expression and are the
most chemoresistant to gemcitabine (see Figure 7.3). Interestingly, BxPC3
cells are known to have wild type K-ras whilst MiaPaCa2 and PANC1 cells are
K-ras mutants (Aoki et al., 1997). This implies that there are other factors
involved in chemoresistance such as differences in genetic alterations
between cell lines. To examine the effects of modulating HMGA1 expression
in a single cell line system, we performed both loss-of-function (HMGA1
silencing) and gain-of-function (HMGA1 overexpression) experiments on
MiaPaCa2 cells. As such, by using the same cell line and theoretically
controlling for other genetic alterations, we were able to demonstrate that
HMGA1 silencing reduces chemoresistance whilst HMGA1 overexpression
results in the reverse effects on chemoresistance.
The efficacy of gemcitabine-based regimens, although currently standard of
care for the treatment of advanced pancreatic cancer, is limited by profound
chemoresistance. Recently, the combination of gemcitabine and the human
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib has
been reported, for the first time, to provide improved survival over single agent
gemcitabine in patients with advanced pancreatic cancer in a phase III clinical
trial (Moore et al., 2005). Although these results are encouraging, the benefits
provided by the addition of erlotinib are only incremental. Truly transformative
increases in efficacy are likely to arise only through incorporation of targeted
therapies selected on the basis of rational understanding of mechanisms
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mediating chemoresistance in pancreatic cancer. In this context, our findings
suggest that HMGA1 warrants further investigation as a novel therapeutic




8.1 ROLES OF HMGA1 IN PANCREATIC CANCER
8.1.1 HMGA1 is a clinically relevant therapeutic target
The first aim of this research was to address the clinical relevance of HMGA1
in pancreatic cancer. To do this, we determined the prevalence of HMGA1
overexpression in tumours of patients with pancreatic cancer. We found that
more than 90% of pancreatic cancers have HMGA1 overexpression as
determined using our tissue microarray analysis. Importantly, we also found
that HMGA1 expression level is low or absent in normal pancreatic tissues. It
is interesting that although HMGA1 expression is not correlated to any of the
adverse clinicopathological characteristics (e.g. lymphovascular or perineural
involvement), its expression was predictive of poorer patient survival and
remained as an independent prognostic indicator on multivariate analysis.
With these encouraging results, we moved to 'the bench' to perform in vitro
experiments to elucidate the roles of HMGA1 in pancreatic cancer biology.
Pancreatic adenocarcinoma cell lines with differing degrees of HMGA1
overexpression were used. Experiments were performed using the loss-of-
function (RNA interference) and gain-of-function (ectopic overexpression)
approaches to analyse the effects of modulating HMGA1 expression on
cancer phenotype. We demonstrated that targeted suppression of HMGA1
using RNAi significantly attenuated pancreatic cancer progression by
inhibiting cellular invasiveness and anchorage-independent proliferation.
Further, HMGA1 overexpression promoted anoikis resistance, which is a
phenotypic determinant of metastasis. We also showed that HMGA1 is an
important regulator of chemoresistance in PDAC cells. More importantly, we
translated the in vitro findings to the in vivo settings, as we demonstrated that
targeted silencing of HMGA1 significantly attenuated metastasis, tumour
growth and promoted chemosensitivity in xenograft mouse models. Our
research provided compelling data that HMGA1 plays a major role in the
210
Chapter 8: Conclusions
biology of pancreatic cancer and its expression is not just a phenomenon
associated with malignancy with no functional significance, as previously
speculated (Evans et al., 2004). Following on from this, it is not surprising
that patients with HMGA1 overexpressing pancreatic cancers will have a more
aggressive disease and hence, poorer prognosis.
8.1.2 Pro-oncogenic downstream pathways
The strength of this work lies in the mechanistic dissection of the downstream
molecular pathways of HMGA1 which are relatively unstudied so far. Our
preliminary results (see Chapter 4) suggest that HMGA1 is able to regulate
MMP-9 expression through its effects on the transcriptional activity of MMP-9
gene promoter. Given that the PI3-K/Akt is a well-known pathway that
regulates MMP-9 expression (Ellerbroek et al., 2001; Lu & Wahl, 2005; O.
Charoenrat et al., 2004), we speculated that HMGA1 would modulate PI3-
K/Akt activity. Further clues on the nature of downstream molecular mediators
of HMGA1 were gleaned from studies of HMGA1 in non-cancer models. Foti
and colleagues reported a genetic flaw in four diabetic patients that markedly
reduced their HMGA1 expression leading to decreased insulin receptor
expression in their tissues (Foti et al., 2005). They went on to demonstrate
that HMGA1-knockout mice have decreased insulin receptor expression and
impaired insulin signaling leading to phenotype characteristic of type II
diabetes. Given that PI3-K/Akt is a crucial downstream mediator of insulin
receptor, they demonstrated that muscle tissues from HMGA1-knockout mice
have significantly lower PI3-kinase activities and hence lower levels of Akt
activation. Based on the above data, we explored if modulating HMGA1
expression in pancreatic cancer cells would have an effect on PI3-K/Akt
signaling pathway, which is a well-known pro-oncogenic pathway.
We found that HMGA1 modulation directly regulates Akt activation. In
particular, we described a novel pathway of FIMGA1/Akt/MMP9 which controls
cellular invasiveness in PDAC cells. Although we showed that HMGA1 is able
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to regulate the MMP-9 gene promoter transcriptional activity which is
dependent on PI3-K/Akt activity, our study did not address if HMGA1 is able
to bind to the MMP-9 promoter and directly activate the promoter activity as
an alternative mechanism. This mechanism is possible as the analysis of
MMP-9 gene promoter did reveal multiple segments of AT-rich DNA which are
classic positions for HMGA1 binding (personal observation). To study this
aspect, further work will need to utilise chromatin immunoprecipitation (ChIP)
to confirm the binding of HMGA1 to the MMP-9 gene promoter. Then, formal
gene promoter analysis, using vectors cloned with varying lengths of MMP-9
gene promoter containing potential regions for HMGA1 binding, will need to
be performed to ascertain the exact binding site of HMGA1.
To verify that the effects of HMGA1 on Akt activation were functional, we
further demonstrated that HMGA1 expression also directly regulated the
phosphorylation of mammalian target of rapamycin (mTOR) which is a known
downstream target of Akt. As such, HMGA1 functionally regulates the PI3-
K/Akt/mTOR pathway. Interestingly, the HMGA1-induced malignant cellular
characteristics (such as cellular invasiveness, anoikis resistance, soft agar
growth and chemoresistance) were all dependent on the PI3-K/Akt pathway.
In addition to Akt, we also found that ERK and caspase pathways are
downstream mediators of HMGA1. Our findings on the effects of HMGA1 on
ERK activation concur with previous studies by Treff and co-workers who
found that HMGA1 regulates ras/ERK signaling (Treff et al., 2004).
Given that activated Akt provides protection from apoptosis (Peruzzi et al.,
1999) and conventional chemotherapy kills by apoptosis (Arlt et al., 2003;
Blanco-Aparicio et al., 2005; Fahy et al., 2003; Ng et al., 2000), we postulated
that HMGA1 will have an effect on chemoresistance in pancreatic cancer
cells. We found that HMGA1 silencing markedly chemosensitise pancreatic
cancer cells to gemcitabine. This probably represents one of our most
important findings and highlights the potential role for HMGA1 to be a
therapeutic target in pancreatic cancer. Clearly, the ability to increase the
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sensitivity of pancreatic cancer cells to gemcitabine is a major advance given
the high degree of chemoresistance inherent in this cancer type.
Recently, another group has described that HMGA1 positively regulates
insulin receptor expression in pancreatic cancer cells (Kolb et al., 2007). As
such, this provides a possible mechanism through which HMGA1 is able to
regulate the PI3-K/Akt pathway by its regulation of insulin receptor
expression. However, future studies will need to be performed to assess if
regulation of Akt by HMGA1 is dependent on insulin receptor expression. To
examine this dependence, cells overexpressing HMGA1 with overactivity of
the PI3-K/Akt pathway need to be assessed for their insulin receptor
expression. Further, experiments will need to be performed with silencing of
insulin receptors in these cells to examine if PI3-K/Akt pathway activity is
dependent on insulin receptor expression. Alternatively, experiments could be
conducted in cells with stable silencing of HMGA1 by transfecting these cells
with expression vectors with cloned insulin receptor cDNA to investigate if this
can rescue the activity of PI3-K/Akt in these cells. This study would help to
establish if there is a HMGA1-insulin receptor-PI-3K/Akt link.
The findings of this thesis are summarized in Figure 8.1. Taking the findings
together, this thesis has established the clinical relevance of HMGA1 in
pancreatic cancer, and characterised the roles of HMGA1 as a novel mediator
of malignant phenotype in this cancer.
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8.2 TARGETING HMGA1 IN PANCREATIC ADENOCARCINOMA
The aggressive nature of pancreatic cancer and failure of conventional
therapy in improving outcome of patients with this cancer type calls for an
urgent need for novel therapeutic approaches. Accumulating evidence
suggests that targeting HMGA1 in tumour cells may represent a novel and
attractive strategy to treat cancers.
8.2.1 Advantages of targeting HMGA1
Targeting HMGA1 in cancer has several advantages. HMGA1 is expressed at
high levels during embryogenesis, and its expression reduces to almost
absent levels during adulthood (Chiappetta et al., 1996). As such, targeting
HMGA1 would theoretically affect only tumour cells which overexpress
HMGA1, leaving the normal tissues unaffected or with minimal collateral
damage (Chiappetta et al., 1996). Given HMGA1 is overexpressed in a large
number of malignancies, its potential as a therapeutic target in oncology is
immense.
Based on our findings in Chapters 4 and 6, HMGA1 silencing had no effect on
the anchorage-dependent growth (i.e standard monolayer culture) whilst there
was a significant inhibition of anchorage-independent growth. Normal tissue
grows under anchorage-dependent conditions. As such, one could speculate
that targeted suppression of HMGA1 may have a lesser effect on this mode of
growth and hence, with little effects on normal tissue. It is plausible that
suppression of HMGA1 may have preferential effects on malignant tissues.
Given that HMGA1 probably regulates a large number of genes involved in
cancer progression (Reeves, 2001), inhibition of HMGA1 function may




8.2.2 Developing HMGA1-specific therapeutics
Molecular approaches such as antisense oligonucleotides and ribozymes
have been previously used to knockdown HMGA1 expression (Trapasso et
al., 2004). Trapasso and colleagues have shown that suppression of HMGA1
expression may result in an apoptotic response in pancreatic cancer cells.
However, previous experience with these approaches has shown low
efficiency in vitro and in vivo due to premature degradation and significant,
non-specific cellular toxicity (Lebedeva & Stein, 2001). Unlike cell surface
receptors (e.g. Her2/neu), HMGA1 is predominantly localised to the nucleus.
As such, it will not be amenable to monoclonal antibody targeting due to its
inaccessibility in vivo. Development of novel small molecule inhibitors of
HMGA1 will move the field closer to clinical therapy. Development of small
molecule inhibitors of HMGA1 will need a detailed study of the chemical
structure of HMGA1 molecule to identify the potential sites (e.g. AT-hooks) on
the HMGA1 molecule that can be inhibited by designed small molecule
inhibitors. Distamycin A is an antibiotic that has been used as a small
molecule inhibitor of HMGA1 by competing with HMGA1 for binding to AT-rich
minor grooves of DNA. Clearly, this mode of action of Distamycin A will not be
specific for HMGA1 and will affect other nuclear proteins that bind to DNA
minor grooves (Ghersa et al., 1997; Massaad-Massade et al., 2002). Other
means of targeting HMGA1 include cross-linking of HMGA1 molecules to
DNA and hence, limiting its availability for intranuclear actions such as binding
to promoter regions of DNA and forming complexes with other transcriptional
factors. This mechanism was described for mitomycin C which has been
reported to cross-link HMGA1 molecules to DNA (Reeves & Beckerbauer,
2003). Of note, this is not the main mechanism through which mitomycin C
mediates its anti-tumour actions.
In this thesis, we described a highly effective and specific molecular approach
to HMGA1 silencing: the RNA interference. Worldwide, pharmaceutical
companies are actively pursuing RNAi-based therapeutics, confident that
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harnessing the naturally occurring RNAi mechanism will lead to transfer of
pre-clinical success to clinical application. However, there are several
concerns that need to be addressed before RNAi can be a real therapeutic
modality. Firstly, the issue of toxicity and off-target effects of RNAi will need to
be addressed and warrants intense investigation (Grimm et al., 2006).
Secondly, delivery of RNAi to specific tissue sites remains a major stumbling
block. The pace of RNAi-based drug development has been rapid. Clinical
trials using RNAi therapeutics are currently underway for age-related macular
degeneration (e.g. Cand5 is in Phase II trials by Acuity Pharmaceuticals,
Philadelphia, PA, USA) (Behlke, 2006). This disease is chosen for early trials
as it is amenable to local delivery of RNAi therapeutics (i.e. directly to sites of
disease in the eye). However, for other diseases requiring systemic
administration, the clinical utility of RNAi-based therapeutics will depend on
the development of safe and efficacious delivery systems. Cancer can be
considered a systemic disease due to metastatic distribution of disseminated
cells, and thus requires systemic therapy. So far, delivering RNA interference
to target cells remains the major stumbling block. Delivery of siRNA is
complicated by the serum instability of siRNA, low cellular uptake efficiency
and lack of understanding on its pharmacokinetics and biodistribution (Behlke,
2006). The siRNA duplexes are rapidly degraded in serum by naturally
occurring RNAses, and are cleared quickly by the kidneys (Aagaard & Rossi,
2007). However, new molecular innovations are being developed. Chemical
modifications of siRNA oligonucleotides such as cholesterol conjugation
(Soutschek et al., 2004) or phosphorothioate linkage (Braasch et al., 2004)
have been shown to enhance the serum stability and resistance to nuclease
or RNAse digestion. To reduce renal filtration, siRNAs have been complexed
with larger molecules such as encapsulation with liposomes or nanoparticles
(Aagaard & Rossi, 2007). Targeted delivery to specific tissues can be made
by linking siRNA to ligand, antibody or aptamer (Pirollo et al., 2006).
Alternatively, as demonstrated by this thesis, short hairpin RNA as transcribed
from RNA polymerase promoters from plasmid- and virus-based vectors
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provide effective strategies for RNA interference. Established gene therapy
techniques could be utilised to deliver vectors encoding short hairpin RNA.
The disadvantages of traditional gene therapy techniques include insertional
mutagenesis, variable expression efficiency and tissue specific delivery.
However, future advances such as the use of tissue-specific or cell-specific
promoter vectors and development of effective vector delivery systems that
target cancer cells will move vector-based RNAi closer to clinical application.
8.2.3 Potential adverse effects of therapeutic targeting of HMGA1
Although HMGA1 is absent or present at very low levels in adult tissues, it
remains uncertain to what extent HMGA1 expression is required in adult
tissues. The loss of HMGA1 function in transgenic mice has led to the
development of diabetes through the decreased expression of insulin
receptors and impaired insulin signalling pathways (Foti et al., 2005). As such,
any targeting of HMGA1 can be predicted to lead to glucose intolerance and
perhaps, clinical diabetes. Further, in the HMGA1-knockout mouse model,
disruption of HMGA1 resulted in cardiac hypertrophy and development of
haematologic malignancies (Fedele et al., 2006). Fedele and co-workers
found that surprisingly, HmgaT'" and Hmga1+/" mice developed B-cell
expansion, resembling human B-cell lymphomas. This revealed an
unsuspected haploinsufficient tumour suppressor role of HMGA1. More
recently, HMGA1 has been shown to be an essential component of the
senescence machinery (Narita et al., 2006). Given that senescence is a
barrier to malignant transformation, this implies that HMGA1 also acts in the
tumour suppressor network. The above tumour suppressor roles of HMGA1
are in contrast to its pro-oncogenic properties. It is possible that the dual
effect of HMGA1 might depend on cellular context. Clearly, any future clinical
trials involving therapeutic targeting of HMGA1 will require close monitoring
for possible cardiac, haematological and endocrine complications.
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8.3 OTHER POTENTIAL CLINICAL APPLICATIONS OF HMGA1
In Chapter 3, we showed that tumoural HMGA1 expression is an indicator of
poor prognosis in pancreatic cancer patients. HMGA1 protein detection could
be introduced in tumour analysis for patients who underwent pancreatic
resection to help identify patients who would benefit from aggressive
management of their disease.
Future development of techniques for detection of HMGA1 proteins or mRNA
in clinical samples (e.g. blood samples of pancreatic cancer patients) will be
useful to monitor response to chemotherapy and allow early diagnosis of
recurrence following surgical resection. Given our findings that HMGA1
expression is low or absent in normal pancreas, there may be a role for
HMGA1 as a diagnostic marker for pancreatic cancer. The ability to detect
HMGA1 protein or mRNA in pancreatic juice sampled during ERCP could be
used as part of a panel of markers to screen for early pancreatic cancer in
secondary screening programme such as the EUROPAC programme (see
Section 1.10.8).
In addition, the expression of HMGA1 may be an important factor in the
choice of therapy. We have shown in Chapter 7 that HMGA1 expression
correlates with resistance to gemcitabine. It may be that detection of high
HMGA1 expression in tumour samples may indicate a high degree of
gemcitabine chemoresistance, and may affect the clinician's choice of
chemotherapeutic agents.
8.4 FUTURE WORK
The development of cancer is a multistep process including initiation, growth,
invasion and ultimately establishment of metastatic disease. In this thesis, we
have addressed the roles of HMGA1 in pancreatic cancer progression in
particular with respect to growth, invasion and metastasis. However, we have
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not addressed the roles of HMGA1 in tumour initiation. There are three main
studies that will help our understanding of the roles of HMGA1 in pancreatic
cancer development. These include: 1) study examining the expression of
HMGA1 in the pre-malignant PanIN lesions, 2) development of a mouse
model with HMGA1 overexpression targeted to the pancreas and 3) study
investigating the roles of HMGA1 in pancreatic cancer stem cells.
Although we have shown that HMGA1 overexpression is a common
phenomenon in pancreatic cancers, our study did not address the issue
whether HMGA1 overexpression is an 'early' or 'late' event in pancreatic
carcinogenesis. To address this, future studies would need to examine the
expression of HMGA1 in early and late stages of PanIN lesions, possibly
through the construction of a PanIN tissue microarray. This will allow the
characterisation of HMGA1 expression in pancreatic cancer precursor lesions,
giving evidence for the roles of HMGA1 in early stages of cancer
development.
Further, the creation of a transgenic mouse model with HMGA1
overexpression specifically targeted to the developing pancreas using
techniques previously described (Hingorani et al., 2003a) will help to address
the question if HMGA1 has a role in the development of pancreatic cancer.
Recent evidence suggests that cancer development could be initiated in a
cellular entity known as the 'cancer stem cells' (see Section 1.5.1). It is
interesting that HMGA1 is overexpressed during embryonic development but
its expression then subsides to very low or absent levels in adult tissues. We
speculate that HMGA1 may have a role in cancer stem cells. We propose that
future studies should examine the expression of HMGA1 in isolated
pancreatic cancer stem cells (Li et al., 2007). Interestingly, cancer stem cells
have been shown to be more chemoresistant (Wicha et al., 2006) and more
invasive (Hermann et al., 2007) than other cancer cells. Given that HMGA1
promotes a malignant phenotype in pancreatic cancer cells, it is possible that
HMGA1 may promote the expansion of the stem cell compartment in the
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cancer cell population and hence, lead to more invasive and chemoresistant
cancer as described by this thesis.
Lastly, gene array analysis can also be used to identify the downstream
molecular mediators of HMGA1 in pancreatic cancer cells. Although we have
identified PI3-K/Akt is an important downstream mediator of HMGA1, it is
more likely that the effects of HMGA1 are mediated by a range of other pro-
oncogenic proteins that have yet to be identified. Investigations along this line
will be useful to identify other novel therapeutic targets and biomarkers that
will help to progress our understanding, treatment and detection of pancreatic
cancers.
8.5 CONCLUDING REMARK
In this thesis, we have dissected out the roles of HMGA1 in each of the
aspects of a malignant phenotype. We have provided compeling evidence to
support the potential use of HMGA1 as a prognostic biomarker and
therapeutic target in pancreatic cancer.
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Abstract
HMGAl proteins are architectural transcription factors
that are overexpressed in a range of human malignancies,
including pancreatic adenocarcinoma. We hypothesized that
HMGAl expression is a determinant of cellular invasiveness
and metastasis in pancreatic cancer. Stable silencing of
■HMGAl in MiaPaCa2 and PANC1 pancreatic adenocarcinoma
cells was achieved by transfection of short hairpin RNA-
.generating vectors. Additionally, stable overexpression of
■HMGAl in MiaPaCa2 cells (characterized by low levels of
inherent HMGAl expression) was achieved. HMGAl silencing
resulted in significant reductions in cellular invasiveness
through Matrigel; in cellular matrix metalloproteinase-9
(MMP-9) activity, mRNA levels, and gene promoter activity;
and in Akt phosphorylation at Ser473. Conversely, forced
HMGAl overexpression resulted in significant increases in
cellular invasiveness; in cellular MMP-9 activity, mRNA levels,
and promoter activity; and in Akt phosphorylation at Ser473.
HMGAl overexpression-induced increases in invasiveness
were MMP-9 dependent. The role of phosphatidylinositol-3
-kinase (PI3K)/Akt in mediating HMGAl-dependent invasive¬
ness was elucidated by a specific PI3K inhibitor (LY294002)
and constitutively active and dominant-negative Akt ade¬
noviral constructs. Akt-dependent modulation of MMP-9
activity contributed significantly to HMGAl overexpression-
induced increases in invasive capacity. Furthermore, HMGAl
silencing resulted in reductions in metastatic potential and
tumor growth in vivo and in tumoral MMP-9 activity. Our
■findings suggest that HMGAl may be a novel molecular
determinant of invasiveness and metastasis, as well as a
■potential therapeutic target, in pancreatic adenocarcinoma.
(Cancer Res 2006; 66(24): 11613-22)
■Introduction
Pancreatic adenocarcinoma is the fourth leading cause of
cancer-related death in the United States (1). Its biology is
characterized by the propensity for early and aggressive invasion
and metastasis, such that <10% of patients have surgically
resectable disease at the time of diagnosis (2). Even among
patients able to undergo resection of all apparent disease, most are
destined to succumb to locally recurrent and metastatic cancer.
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Hence, further understanding of the molecular mechanisms
underlying pancreatic adenocarcinoma cellular invasion and
metastasis is needed, as this information may facilitate the
identification of novel molecular targets for the rational therapy
of this deadly disease.
The human HMGAl gene, located on chromosomal locus 6p21,
encodes two HMGA1 splice variants (HMGAla and HMGAlb;
ref. 3). These HMGAl proteins are architectural transcription
factors that play a role in both positive and negative transcriptional
regulation of human gene expression in vivo (4, 5). They form
stereo-specific, multiprotein complexes termed "enhanceosomes"
on the promoter/enhancer regions of genes, where they are able
to bind to the minor groove of AT-rich DNA sequences to induce
DNA helix bending (4, 6). HMGAl proteins are overexpressed in
a range of human cancers, including pancreatic adenocarcinoma
(7-11). Furthermore, HMGAl protein overexpression has been
reported to be associated with cancer metastasis (12-14) and
transcriptional up-regulation of genes implicated in promoting
metastasis (15).
The purpose of this study was to test the hypothesis that HMGAl
is a molecular determinant of cellular invasiveness and metastasis
in pancreatic adenocarcinoma. Our findings indicate that HMGAl
promotes cellular invasiveness through phosphatidylinositol-3
kinase (PI3K)/Akt-dependent modulation ofmatrix metalloprotei¬
nase-9 (MMP-9) activity.
Materials and Methods
Cells and cell culture. MiaPaCa2 and PANC1 human pancreatic ductal
adenocarcinoma cells were obtained from the American Type Culture
Collection (Manassas, VA). Cells were maintained in DMEM containing 10%
fetal bovine serum (FBS; Life Technologies, Inc., Gaithersburg, MD) and
incubated in a humidified (37 °C, 5% C02) incubator, grown in 75-cm2
culture flasks, and passaged on reaching 80% confluence.
Reagents. The PI3K inhibitor LY294002 was purchased from Calbiochem
(San Diego, CA). Anti-HMGAl, anti-actin, anti-phospho-Akt (Ser473), anti-
Aktl, anti-phospho-extracellular signal-regulated kinase 1/2 (anti-phos-
pho-ERKl/2), anti-ERKl/2, and anti-hemagglutinin (anti-HA) tag antibodies
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-
phospho-mammalian target of rapamycin (anti-phospho-mTOR; Ser2448)
and anti-mTOR antibodies were obtained from Cell Signaling Technology
(Danvers, MA).
Dominant-negative and dominant-active Akt constructs. Adenovirus
carrying HA-tagged dominant-negative (Ad-DN-Akt), dominant-active
(Ad-myr-Akt) murine Aktl, and control virus (Ad-CMV-null; all tittered at
1 x 1010 plaque-forming units/mL) were purchased from Vector Biolabs
(Philadelphia, PA). Adenoviral infection was done at multiplicity of infection
of 10 in the presence of 6 pg/mL polybrene for 8 hours. Experiments were
done on cells 48 hours following infection.
Stable HMGAl RNA interference. Hairpin RNA interference plasmids
(pLKO.l-HMGAl, TRCN0000018949), constructed as described previously
(16), were obtained from The RNAi Consortium (Mission TRC Hs. 1.0,
Sigma-Aldrich, St Louis, MO). The sequences of short hairpin RNA (shRNA)
targeting the human HMGAl gene (Genbank accession no. NM_002131)
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were shHMGAl-1 plasmid, 5-CAACTCCAGGAAGGAAACCAA-3' (coding
region positions 446-466 of HMGA1 mRNA transcript variant 2) and
shHMGAl-2 plasmid, 5-CCTTGGCCTCCAAGCAGGAAA-3' (coding region
=positions 281-301 of HMGA1 mRNA transcript variant 2). The control
plasmid, which has a scrambled non-targeting shRNA sequence, was
obtained from The RNAi Consortium. Each of these vectors had been
sequence verified. Pooled stable transfectants were established using
puromycin selection. Stable transfectant cells were maintained in medium
containing 3 pg/mL puromycin (Invivogen, San Diego, CA).
Expression vector and transfection. The HMGA1 coding sequence was
PCR amplified from IMAGE clone 5399570 (Genbank accession no.
BC063434) using gene-specific primers modified to include the appropriate
restriction sites at their 5' end. The primers used were forward, 5 -
TTTTGATATCATGAGTGAGTCGAGCTCGAAG-3' and backward, 5'-
TTTTGAATTCTCACTGCTCCTCCTCCGAGGA-3'. Purified PCR products
were digested with EcoRV and EcoVA before ligation into an EcoRV/
EcoRI-digested pIRES-puro3 vector (Clontech, Palo Alto, CA). The
expression plasmids were named pIRES-HMGAl. MiaPaCa2 cells were
transfected with pIRES-HMGAl or empty pIRES-puro3, which acted as a
control, using LipofectAMINE 2000 (Invitrogen, Carlsbad, CA) in accor¬
dance with the manufacturer's protocol. Stable clones were selected by
exposure to incrementally increasing concentrations of puromycin (Inviv¬
ogen), isolated using cloning cylinders, and maintained in medium
containing 3 pg/mL puromycin (Invivogen). Clones pIRES-HMGAl.l and
pIRES-HMGA1.2, which expressed the highest levels of HMGA1, were used
for further studies.
MMP-9 gene promoter and luciferase assay. The MMP-9 promoter
reporter construct was custom-synthesized by Aviva Systems Biology (San
Diego, CA). Briefly, the full-length human MMP-9 promoter region ranging
from —992 to +304 bp, relative to the transcription initiation site, was
amplified by PCR from human placental DNA, using proper primers
designed according to the MMP-9 gene sequence. The primers were
forward, 5-GGTACCTCTTTCTGGGCTCAAGCAATC-3' and backward, 5'-
CTCGAGCTAACCCTGGACACCTCTGTTC-3'. The amplified promoter frag¬
ment with the addition of XhoI and Kpnl restriction sites at each end was
cloned into the pGL4.12 vector (Promega, Madison, WI) at the Xho\/Kpn\
site upstream of the firefly luciferase gene. By direct sequencing, the
sequence of the cloned promoter region was confirmed. The empty pGL4.12
vector (pGL4e) was used as control.
Cells were plated onto a six-well cell culture plates at a concentration of
5 x 105 per well and allowed to adhere for 12 hours in serum-containing
medium. To assess the effects ofmodulating HMGA1 expression on MMP-9
promoter activity, transient transfection experiments were done on
MiaPaCa2 cells. For HMGA1 suppression experiments, 5 pg shHMGAl or
control shRNA vector was cotransfected with 5 pg pGL4-MMP9 or pGL4e
and 0.5 pg pRLCMV vector (Promega), which contains a cytomegalovirus
(CMV) promoter upstream of a Renilla luciferase gene. For HMGA1
overexpression experiments, either pIRES-HMGAl or control vector pIRES-
puro3 was used in cotransfection. After 48 hours, luciferase activity in
lysates of the transfected cells was measured using the dual-luciferase
reporter assay, according to the manufacturer's recommended protocol
(Promega).
Relative luciferase activity was calculated as fold-induction of luciferase
activity above the background (taken as activity associated with promoter-
less vector, pGL4.12). The activity of Renilla luciferase was used to
normalize any variation in transfection efficiencies.
Invasion assay. Cellular invasion was quantified using a modified
Matrigel Boyden chamber assay. The BD BioCoat Matrigel invasion
chamber (BD Biosciences, Bedford, MA) was used according to the
manufacturer's instructions. Pancreatic cancer cells (2.5 x 104) in serum-
free media were seeded onto Matrigel-coated filters. In the lower chambers,
5% FBS was added as a chemoattractant. After 24 hours of incubation,
the filters were stained using the Diff-Quik kit (BD Biosciences), and
the number of cells that had invaded through the filter was counted
under magnification (randomly selected high-power fields). The counting
was done for 20 fields in each sample, and mean values from three
independent experiments were calculated. In additional studies, invasion
assays were done in the presence of 10 mg/mL anti-MMP-9-neutralizing
antibody (Santa Cruz, San Ramon, CA) or isotype-matched control
(irrelevant) immunoglobulin (Santa Cruz).
Proliferation assay. Cell proliferation was quantified using an 3-(4,5
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2//-tet-
razolium (MTS) assay (CellTiter 96 Aqueous One Solution Assay, Promega),
in accordance to manufacturer's instructions and confirmed by cell
counting. Logarithmically growing cells were seeded into 96-well plates at
5 x 103 per well and allowed to adhere overnight in medium containing
10% or 2% FBS. Cell proliferation was determined after 48 hours. Plates
were read with the use of the SpectraMax M5 microplate spectrophotom¬
eter (Molecular Devices, Sunnyvale, CA) at a wavelength of 490 nm. Ten
samples were used for each experimental condition, and experiments were
done in triplicate. At identical time points, cell counting was done. Cells
were trypsinized to form a single-cell suspension. Viable cells, determined
by trypan blue exclusion, were counted with the use of a Neubauer
hemocytometer (Hausser Scientific, Horsham, PA).
Fluorometric MMP-9 activity assay. MMP-9 activities of cell or tumor
lysates were assessed using the Enzolyte Plus 520 Enhanced Selectivity
MMP-9 activity, in accordance with the manufacturer's instructions
(AnaSpec, San Jose, CA). Fluorescence intensities were quantified using
SpectraMax M5 microplate spectrophotometer (Molecular Devices) at
excitation of 490 nm and emission of 520 nm.
Quantitative real-time PCR. Total RNA was extracted from cells using
mirVana RNA isolation kit according to the manufacturer's recommen¬
dation (Ambion, TX). First-strand cDNA was synthesized from 5 pg of
total RNA using the Superscript III First-Strand Synthesis System,
according to manufacturer's instructions (Invitrogen). Transcript analysis
was done by quantitative real-time PCR using the Taqman assay, based
on manufacturer's instructions (Applied Biosystems, Foster City, CA).
Hybridization probe and primer sets for human MMP-9 (Hs00234579_ml
MMP9) and (3-actin were obtained from Applied Biosystems. Typically,
thermal cycling was initiated with a denaturation step for 10 minutes at
95°C followed by 40 cycles done in two steps: for 15 seconds at 95°C and
for 1 minute at 60 °C. Reactions were done, and data were analyzed using
the GeneAmp Sequence Detection System (Applied Biosystems). Results are
expressed as the ratio of MMP9 to (3-actin. Measured threshold cycles were
converted to relative copy numbers using primer-specific standard curves.
Western blotting. Cells were harvested and rinsed twice with PBS. Cell
extracts were prepared with lysis buffer [20 mmol/L Tris (pH 7.5), 0.1%
Triton X-100, 0.5% deoxycholate, 1 mmol/L phenylmethylsulfonyl fluoride,
10 mg/mL aprotinin, 10 mg/mL leupeptin] and cleared by centrifugation at
15,000 x g, 4°C. Total protein concentration was measured using the
bicinchoninic acid assay kit (Sigma, St Louis, MO) with bovine serum
albumin as a standard, according to the manufacturer's instructions. Cell
extracts containing 50 pg total protein were subjected to 10% SDS/PAGE,
and the resolved proteins were transferred electrophoretically to poly-
vinylidene difluoride membranes (Invitrogen). Equal protein loading was
confirmed by Coomassie (Bio-Rad, Hercules, CA) staining of the gel. After
blocking with PBS containing 3% bovine serum albumin for 1 hour at room
temperature, membranes were incubated with 3 to 5 mg/mL antibody in
PBS containing 0.1% Tween 20 overnight at 4°C. Chemiluminescent
detection (Amersham Biosciences, Piscataway, NJ) was done in accordance
with the manufacturer's instructions. The densitometric signal was
quantified using ImagePro Plus software version 4.0 and normalized to
that of actin. Blots were done in triplicate. Mean ± SD densitometric values
are shown.
Nude mouse orthotopic xenograft model. Male athymic nu/nu mice
5 weeks of age, weighing 20 to 22 g, and specific pathogen-free were
obtained from Harlan Sprague-Dawley (Indianapolis, IN). Mice were housed
in microisolator cages in a specific pathogen-free facility with 12-hour light/
dark cycles. They received water and food ad libitum. Animals were
observed for signs of tumor growth, activity, feeding, and pain in
accordance with the guidelines of the Harvard Medical Area Standing
Committee on Animals.
To determine the effect of HMGA1 gene silencing on in vivo meta¬
stasis, MiaPaCa2 cells stably expressing the control or HMGA1 shRNA
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shHMGAl-1) constructs were orthotopically implanted into the pan-
:reata of nude mice. Mice were anesthetized with i.p. ketamine (200 mg/kg)
ind xylazine (10 mg/kg). In a laminar-flow hood, the abdomen was
fleaned with isopropyl alcohol, and a left upper transverse incision
.vas made. The pancreas was exposed, and 1 x 106 cells suspended in
75 pL PBS were slowly injected into the body of the pancreas. The pan-
:reas was returned, and the abdomen was closed with 5-0 Vicryl
[Ethicon, Somerville, NJ). Ten mice for each cell line were observed over
\ weeks and killed by overdose of ketamine (400 mg/kg) and xylazine
(50 mg/kg). The liver of each animal was harvested, and metastatic foci
were counted under a dissecting microscope (17). The primary tumors
were excised, and the tumor lysates were assayed for HMGA1 expression
and MMP-9 activity using Western blotting and MMP-9 activity assay,
respectively.
Immunohistochemistry. Tumor sections (5 pm) were deparaffinized,
rehydrated through graded alcohol, and processed using a streptavidin-
biotin-peroxidase complex method. Antigen retrieval was done by
microwave heating sections in 10 mmol/L sodium citrate buffer (pH 6)
for 10 minutes. Following quenching of endogenous peroxidase activity and
flocking of nonspecific binding, sections were incubated with anti-HMGAl
Santa Cruz) at 4°C overnight at a 1:50 dilution. The secondary antibody
vas biotinylated rabbit anti-goat antibody (DAKO, Carpinteria, CA) used at
i dilution of 1:200 for 30 minutes at 37 °C. After further washing with TBS,
sections were incubated with StrepABComplex/horseradish peroxidase
1:100; DAKO) for 30 minutes at 37°C. Immunolocalization was done by
axposure to 0.05% 3,3'-diaminobenzidine tetrahydrochloride as the
:hromogen. Normal serum was used in place of the primary antibody as
a negative control. Slides were counterstained with hematoxylin before
dehydration and mounting. For H&E staining, standard procedures were
used to stain the tumor sections.
Statistical analysis. Differences between groups were analyzed using
Student's t test, multifactorial ANOVA of initial measurements, and Mann-
Whitney U test, for nonparametric data, as appropriate, using Statistica 5.5.
software (StatSoft, Inc., Tulsa, OK). In cases in which averages were
normalized to controls, the SDs of each nominator and denominator were
taken into account in calculating the final SD. P < 0.05 was considered
statistically significant.
Results
Effect of HMGA1 gene silencing on cellular invasiveness. We
analyzed HMGA1 gene expression using Western blot analysis.
Cellular invasiveness was quantified using Matrigel-coated Boyden
chambers. We used two shRNA-expressing plasmids with different
target sequences to induce HMGA1 gene silencing. MiaPaCa2 and
PANC1 cell lines were stably transfected with each of the HMGA1-
targeting shRNA expression vectors (shHMGAl-1 and shHMGAl-
2). The shRNA approach was associated with high efficacies in
HMGA1 silencing (up to 90% silencing, as confirmed on Western
blot analysis; Fig. L4). Silencing of HMGA1 significantly attenuated
cellular invasiveness in both MiaPaCa2 and PANC1 cells (Fig. 1C).
For these experiments, controls were cells stably transfected with a
vector encoding a non-targeting shRNA.
Effect of HMGA1 overexpression on cellular invasiveness.
Next, we sought to determine the effect of FIMGA1 overexpression
on cellular invasiveness. Using MiaPaCa2 cells, which have
relatively low levels of inherent HMGA1 expression, we developed
the clones pIRES-HMGAl.l and pIRES-HMGA1.2, which stably























Tigure 1. A, stable silencing of HMGA1
jxpression using shRNA expression
rectors with two independent shRNA
arget sequences (shHMGA1-1 and
;hHMGA1-2) was confirmed on Western
ilot analysis. Controls were cells stably
ransfected with non-targeting, scrambled
;hRNA. Greater suppression of HMGA1
jxpression was achieved in MiaPaCa2
tells (up to 90%) compared with PANC1
tells, which have HMGA1 silenced to a
esser degree. *, P < 0.05 versus control
ihRNA. B. two clones of MiaPaCa2 cells
vere confirmed to stably overexpress
HMGA1 (PIRES-HMGA1.1 and
)IRES-HMGA1.2) on Western blot
inalysis. Controls were cells stably
ransfected with empty plRES-puro3
rector. *, P < 0.05 versus empty
>IRES-puro3 vector and parental
r1iaPaCa2 cells. Representative blots of
hree independent experiments. Columns,
nean densitometry values; bars, SD.
C, cellular invasiveness was determined
jsing Matrigel-coated Boyden chamber
assays. Stable suppression of HMGA1
jxpression resulted in significant
eductions in cellular invasiveness in
aoth MiaPaCa2 and PANC1 cells.
', P < 0.05 versus control shRNA.
D, forced overexpression of HMGA1 in
,TliaPaCa2 cells (plRES-HMGA1.1 and
1IRES-HMGA1.2) resulted in -3-fold
ncrease in cellular invasive capacity
vhen compared with empty plRES-puro3
ransfectants. *, P < 0.05 versus empty
>IRES-puro3 vector. Invasion assays were
tone in triplicate. Columns, mean from 20
andomly selected fields; bars, SD.
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Western blot analysis (Fig. IB). MiaPaCa2 cells stably transfected
with empty pIRES-puro3 vector served as controls. HMGA1
expression in parental MiaPaCa2 cells and empty pIRES-puro3
transfectants did not differ (Fig. IB). pIRES HMGA1.1 and pIRES-
HMGA1.2 clones exhibited ~3- to 3.5-fold increases in cellular
invasiveness, compared with control cells (Fig. ID).
Effects ofmodulating HMGA1 expression on MMP-9 activity,
mRNA expression, and promoter activity. Given the importance
of MMP-9 as a mediator of malignant cellular invasiveness and
metastasis (18-20), we hypothesized that MMP-9 is a downstream
effector that plays a critical role in HMGAl-dependent cellular
invasiveness. HMGA1 silencing in MiaPaCa2 cells was found to be
associated with a reduction in total MMP-9 activities (Fig. 2A). In
addition, ffMGAl silencing led to reductions in MMP-9 mRNA
levels as quantified by real-time quantitative reverse transcription-
PCR (Fig. 2B). Conversely, MMP-9 activities and mRNA levels were
significantly higher in pIRES-HMGAl.l and pIRES-HMGA1.2 clones
than in controls (Fig. 2A and B). To assess the effect of modulating
HMGA1 expression on MMP-9 promoter activity, we did cotrans-
fection experiments in which MiaPaCa2 cells were transiently
transfected with either shHMGAl or pIRES-HMGAl vector
together with MMP-9 promoter reporter vector. MMP-9 promoter
activities were significantly lower with HMGA1 silencing, whereas
MMP-9 promoter activity levels were markedly higher with F1MGA1
overexpression, compared with controls (Fig. 2C).
MMP-9 is a mediator of HMGAl-dependent increases in
cellular invasiveness. The contribution ofMMP-9 to the increased
cellular invasiveness induced by HMGA1 overexpression was
determined by performing the invasion assay in the presence of
anti-MMP-9-neutralizing antibody. MMP-9 immunoneutralization
reduced the cellular invasiveness ofMiaPaCa2 pIRES-HMGAl.l and
pIRES-HMGA1.2 clones by - 70% (Fig. 2D).
Effects of HMGA1 modulation on Akt activation. Activation
of the serine/threonine kinase Akt is common in pancreatic
adenocarcinoma (21) and is an important determinant of
malignant cellular invasiveness (22). The P13K/Akt signaling
Control shHMGAl-1 shHMGA1-2 Empty pIRES pIRES
shRNA plRES-puro3 HMGA1 1 HMGA1 2
Control sl-HMGAI-1 shHMGAl-2 Empty pIRES pIRES








Control Anti-MMP9 Control Anti-MMP9
igG IgG
pIRES-HMGAl 1 pIRES-HMGA" 2
Figure 2. HMGA1 expression positively regulates MMP-9 activities, mRNA levels, and promoter activities. A, cellular MMP-9 activities were quantitated using a
fluorometric MMP-9 activity assay. Targeted suppression of HMGA1 expression (shHMGA1-1 and shHMGA1-2) resulted in significant reductions in MMP-9 activity in
MiaPaCa2 cells, whereas forced overexpression of HMGA1 led to increased cellular MMP-9 activity. Both plRES-HMGA1.1 and plRES-HMGA1.2 clones exhibited
~2- to 2.5-fold increases in MMP-9 activity. *, P < 0.05 versus control shRNA; t, P < 0.05 versus empty plRES-puro3 transfectants. B, HMGA1 modulates MMP-9
mRNA levels. On quantitative real-time PCR, MMP-9 levels were significantly lower in shHMGA1-1 and shHMGA1-2 transfectants compared with control shRNA
transfectants. Overexpression of HMGA1 led to increases in MMP-9 mRNA levels. *, P < 0.05 versus control shRNA; t, P < 0.05 versus empty plRES-puro3
transfectants. C, the effects of HMGA1 silencing and overexpression on MMP-9 promoter activities in MiaPaCa2 cells were determined using transient transfection and
luciferase reporter assays. Cotransfection experiments were done. MiaPaCa2 cells were transiently transfected with shRNA (shHMGA1-1, shHMGA1-2, or control
shRNA) or overexpression vectors (pIRES-HMGAl or empty plRES-puro3 control) together with the reporter plasmids. Reporter plasmids included pGL4e (empty firefly
luciferase vector) or pGL4-MMP9, containing the full-length MMP9 promoter and pRL vector containing a Renilla luciferase gene. Forty-eight hours following
transfection, luciferase activity in cell lysates was assayed. Renilla luciferase activities were used to normalize results for transfection efficiencies. Consistent with
VIMP-9 activity and mRNA studies, targeted suppression of HMGA1 expression using shRNA resulted in a significant reduction in MMP-9 promoter activities, whereas
forced overexpression of HMGA1 in MiaPaCa2 cells led to significant increases in MMP-9 promoter activities. *, P < 0.05 versus control shRNA; t, P < 0.05
versus empty plRES-puro3 vectors. D, the contribution of MMP-9 to the increased cellular invasiveness induced by HMGA1 overexpression was determined
sy performing the invasion assay in the presence of anti-MMP-9-neutralizing antibody. MMP-9 immunoneutralization reduced the cellular invasiveness of
DIRES-HMGA1.1 and pIRES-HMGAl .2 clones by -70%.
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:igure 3. The effects of HMGA1 modulation
jn Akt phosphorylation in MiaPaCa2 cells were
;onfirmed on Western blot analysis using a
phospho-specific antibody. A, in MiaPaCa2
pells, stable silencing of HMGA1 resulted in a
iecreased level of phosphorylation of Akt at
3er473, a marker of Akt activation. P < 0.05
versus MiaPaCa2 cells and control shRNA
ransfectants. B, overexpression of HMGA1 led
iO increased activation of Akt, as evident from
ncreased levels of phospho-Akt (p-Akt). There
vas no difference in the level of expression of
otal Akt with suppression or overexpression of
HMGA1. *, P < 0.05 versus MiaPaCa2 cells
and empty plRES-puro3 transfectants.
Representative blots of three independent
experiments. Columns, mean densitometry
'alues; bars, SD. C, contribution of Akt to
HMGA1-mediated invasiveness was assessed
)y transductions of MiaPaCa2 shHMGA1-1
and shHMGA1-2 transfectants with adenovirus
expressing constitutively active Akt
Ad-myr-Akt). Constitutively active Akt was
able to rescue the invasive phenotype in the
4iaPaCa2 cells with HMGA1 silencing. Cell
ysates were immunoblotted with anti-HA to
tetect expression of HA-tagged myristoylated
\kt. *, P < 0.05 versus MiaPaCa2 transduced
vith control adenovirus (Ad-CMV-null).
1, inhibition of PI3K with LY294002 attenuated
he HMGA1-induced increases in invasiveness
n plRES-HMGAI.1 and plRES-HMGA1.2
rlones. The effects of PI3K were dose
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rathway has previously been reported to be important in the
egulation of MMP-9 expression (23-25). Given our observations
hat HMGA1 expression regulates MMP-9 activity via transcrip-
ional activation, we hypothesized that HMGA1 modulates Akt
ictivation. We found that HMGA1 silencing results in a reduction
n Akt phosphorylation at Ser473 (Fig. 3A), whereas HMGA1
>verexpression results in increased levels of phospho-Akt (Ser'73;
•ig. 35). Modulating HMGA1 expression had no effect on total Akt
evels.
HMGAl-induced cellular invasiveness and MMP-9 activity is
•I3K/Akt dependent. Given our findings that HMGA1 modulates
\kt activation, we tested whether cellular invasiveness mediated by
1MGA1 is dependent on PI3K/Akt signaling. First, we determined
f the invasive phenotype in MiaPaCa2 cells in which HMGA1 had
leen stably silenced could be rescued using constitutively active
tkt. MiaPaCa2 stable transfectants shFlMGAl-1 and shHMGAl-2
vere infected with adenovirus expressing myristoylated Akt (Ad-
nyr-Akt). Constitutively active Akt was able to rescue the invasive
ihenotype in shFIMGAl-1 and shHMGAl-2 transfectants resulting
in an increased invasiveness compared with cells infected with
control adenovirus (Fig. 3C). Next, given that PI3K is an upstream
regulator of Akt, we assessed the effects of PI3K inhibition on
cellular invasiveness in MiaPaCa2 cells overexpressing FIMGA1
(pIRES-HMGAl.l and plRES-HMGA1.2). Inhibition of PI3K activity
using the PI3K inhibitor LY294002 resulted in dose-dependent
reductions in cellular invasiveness in pIRES-FlMGAl.l and pIRES-
HMGA1.2 clones (Fig. 3D). Consistent with this finding, infection
with adenovirus expressing dominant-negative Akt resulted in
attenuation of FIMGAl-induced invasiveness in pIRES-HMGAl.l
and pIRES-FIMGA1.2 clones. Importantly, dominant-negative Akt
also induced reductions in cellular MMP-9 activity in pIRES-
FIMGA1.1 and pIRES-HMGA1.2 clones, indicating that HMGAl-
induced MMP-9-dependent cellular invasiveness is PI3K/Akt
dependent (Fig. 4A).
Modulation of HMGA1 expression has no effect on cellular
proliferation in monolayer culture. The effects of modulating
HMGA1 expression on cellular proliferation in monolayer culture
were determined. Using the MTS assay, we observed no effect in
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cellular proliferation in low (2% FBS) and high (10% FBS) serum
conditions with either HMGA1 gene silencing or overexpression
(Fig. 45).
Effects of HMGA1 modulation on phosphorylation of ERK
and mTOR. Previous studies have shown that HMGA1 modulates
ERK activation (26). In our study, HMGA1 silencing had no effect
on ERK phosphorylation, whereas HMGA1 overexpression resulted
in increased ERK phosphorylation with no effects on the total ERK
levels (Fig. 5A and B). Given that mTOR is a well-known
downstream mediator of the PI3K/Akt pathway (27, 28), we sought
to determine the effects of HMGA1 modulation of mTOR
phosphorylation. HMGA1 silencing resulted in reductions in mTOR
phosphorylation at Ser2448, whereas HMGA1 overexpression led to
increases in mTOR phosphorylation (Fig. 5C and D). Modulation of
HMGA1 expression had no effect on levels of total mTOR
expression.
HMGA1 silencing suppresses in vivo metastatic potential of
pancreatic cancer cells and reduces tumoral growth and
MMP-9 activity. Given these in vitro findings, we sought to
determine the effect of modulating HMGA1 expression on metas¬
tatic potential in vivo. Four weeks following surgical orthotopic
implantation of MiaPaCa2 stable transfectants expressing control
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Figure 4. A, dominant-negative Akt
attenuates HMGA1-induced invasiveness and
MMP-9 activity. MiaPaCa2 plRES-HMGA1.1
and plRES-HMGA1.2 clones were transduced
with adenovirus expressing dominant-negative
Akt (Ad-DN-Akt). Dominant-negative Akt
resulted in reductions in invasiveness
and in MMP-9 activities in both HMGA1-
overexpressing clones compared with control
adenovirus. Cell lysates were immunoblotted
with anti-HA to detect expression of HA-tagged
DN Akt. *, P < 0.05 versus control adenovirus
(Ad-CMV-null). B, based on MTS assay,
modulation of HMGA1 expression did not affect
cellular proliferation in monolayer culture.
Experiments were done at low (2% FBS) and
high (10%) conditions.
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Figure 5. The effects of HMGA1 modulation
on ERK and mTOR phosphorylation in
MiaPaCa2 cells were confirmed on Western
blot analysis using a phospho-specific
antibody. A and B, although HMGA1
silencing did not alter the levels of ERK
phosphorylation, overexpression of HMGA1
increased ERK phosphorylation. There were
no differences in the levels of total ERK.
C and D, targeted suppression of HMGA1
expression resulted in reductions in
phosphorylation of mTOR at Ser2448 in both
shHMGA1-1 and shHMGAl-2 transfectants,
whereas overexpression of HMGA1 led to
increases in phospho-mTOR levels. There
was no difference in total mTOR levels among
groups. *, P < 0.05 versus control shRNA or
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shRNA (n = 10) or shHMGAl (n = 10), necropsy was done. All mice
in the control shRNA group were found to have histologically
confirmed liver metastases, and six of these mice were found to
have gross ascites. In the shHMGAl group, only one mouse
developed metastases (Table 1; P < 0.05), and none of them had
ascites. No lung metastases were detected in either group. There
were no apparent differences in the histologic appearance of H&E-
stained sections of xenografts harvested from animals in the
shHMGAl and control groups (Fig. 6A). Stable silencing of tumoral
HMGA1 expression in the shHMGAl group in vivo was confirmed
by immunohistochemistry (Fig. 6A) and Western blotting (Fig. 6/1).
Additionally, HMGA1 silencing was associated with significant
reductions in tumor growth and MMP-9 activity (Fig. 6C and D).
Discussion
Pancreatic adenocarcinoma is among the most aggressive of
human malignancies. The prognosis associated with this cancer
remains dismal, despite the considerable advances in medical and
surgical management of patients diagnosed with pancreatic cancer.
There is an urgent need to identify new therapeutic approaches.
This study was designed to determine the role of I1MGA1 in
pancreatic adenocarcinoma cellular invasiveness and metastasis.
We have shown that HMGA1 overexpression promotes cellular
invasiveness, and that specific suppression of HMGA1 expression
inhibits cellular invasiveness in vitro and metastasis in vivo.
HMGAl-induced cellular invasiveness is in part due to PI3K/Akt-
dependent modulation of MMP-9 activity. Together, these findings
suggest that I1MGA1 architectural transcriptional factors represent
a molecular determinant of cellular invasiveness and a potential
therapeutic target in pancreatic adenocarcinoma.
HMGA1 previously has been reported to be associated
with malignant cellular behavior in a range of human cancers
(11, 29, 30). HMGA1 has been shown to confer the ability of non-
tumorigenic breast epithelial cells to grow under anchorage-
independent conditions (31). Antisense oligonucleotide-mediated
suppression of HMGA1 expression has been reported to inhibit
neoplastic transformation in breast cancer (32) and in Burkitt's
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Table 1.HMGA1 gene silencing by RNA interference
suppresses the metastatic potential of pancreatic adeno¬
carcinoma cells in vivo
Control shRNA shHMGAI
(n = 10) (n = 10)
Median no. metastases (range) 6 (1-20) 0* (0-3)
Mice with metastases 100% 10%*
NOTE: At 4 weeks following orthotopic implantation of 1 x 106
MiaPaCa2 cells stably expressing control or shHMGAI constructs,
necropsy was done. Liver metastases were counted and confirmed
histologically. HMGA1 silencing significantly inhibited metastasis in
this nude mouse model.
*P < 0.05 versus control shRNA group.
lymphoma cells (33). Although there is extensive correlative evi¬
dence suggesting a role for HMGA1 in tumor metastasis (9, 34, 35),
there have been few studies showing a direct functional link bet¬
ween HMGA1 expression and invasion and metastasis (14, 30, 31).
Our study is the first to show a role for HMGA1 in pancreatic
adenocarcinoma cellular invasiveness and metastasis and provides
evidence that HMGA1 expression mediates cellular invasiveness
through a PI3K/Akt/MMP-9-dependent pathway. Although MMP-9
is unlikely to be the sole effector of HMGAl-dependent invasive¬
ness, this pathway represents a potential mechanism that may
contribute to the decrease in cellular invasiveness induced by
HMGA1 gene silencing. Our finding that PI3K/Akt signaling
mediates regulatory actions of HMGA1 is novel. Our finding that
HMGA1 promotes mTOR activation provides further support for
the relationship between HMGA1 and PI3K/Akt signaling, as mTOR
is a downstream target of this pathway (27, 28).
Our finding that HMGA1 overexpression results in increased
ERK phosphorylation is consistent with findings of previously
reported studies suggesting that HMGA1 is able to positively
regulate the Ras/ERK mitogenic signaling pathway (26). The Ras/
ERK signaling pathway is intrinsically linked to PI3K/Akt pathways.
PI3K/Akt has been shown to be downstream of Ras/ERK signaling
pathway (36, 37), and Ras can also directly activate the PI3K/Akt
signaling pathway (38). Alternatively, HMGA1 has been shown to
transcriptionally regulate the human insulin receptor gene (39, 40),
and given that PI3K/Akt are downstream mediators of insulin
signaling (41), it is not surprising that HMGA1 expression affects
PI3K/Akt signaling. Both Ras/ERK and PI3K/Akt signaling path¬
ways have been found to be critical in mediating cellular invasion






































Control shRNA shHMGAI Control shRNA shHMGAI
Figure 6. MiaPaCa2 stable transfectant
cells expressing the control shRNA or
shHMGAI (shHMGAI-1) were orthotopically
implanted into the pancreata of nude mice.
Four weeks following implantation, necropsy
was done, and the primary tumors were
explanted. A, histologic appearance of
primary tumors was examined at x400
magnification following H&E staining of
tumor sections. There was no apparent
morphologic difference in tumors harvested
from the two groups of animals. However,
sections stained with anti-HMGA1 antibody
revealed that tumors from shHMGAI group
exhibited reductions in nuclear staining for
HMGA1. B, stable HMGA1 suppression in
lysates of shHMGAI-derived tumors was
further confirmed by Western blot. C, final
volume of primary tumors harvested from
shHMGAI group was markedly reduced
compared with those of the control shRNA
group. D, MMP-9 activities in lysates
obtained from HMGA1 shRNA transfectant-
derived tumors were significantly lower than
those of control shRNA transfectant-derived
tumors. Columns, mean; bars, SD. *,
P < 0.05 versus control shRNA
transfectant-derived tumors.
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Our observation that HMGA1 silencing suppresses Akt activity is
significant, as Akt is now recognized as an important mediator of
malignant cellular behavior, including the capacity for resisting
apoptotic stimuli, in pancreatic adenocarcinoma (43-45). Trapasso
et al. have reported that antisense-mediated suppression of
HMGA1 expression results in an apoptotic response in three
pancreatic cancer cell lines (46). Our findings that HMGA1
positively regulates PI3K/Akt signaling provides a possible
mechanism through which HMGA1 suppression promotes apopto-
sis. Unlike Trapasso et al., we found that modulating HMGA1
expression has no effect on cellular proliferation in two-
dimensional monolayer culture. However, our data indicate that
HMA1 silencing does inhibit tumor growth in vivo.
Our study provides support to the hypothesis that the HMGA1
proteins are potential therapeutic targets for inhibiting the activation
of the PI3K/Akt pathway in cancer cells. From a therapeutic
standpoint, targeting HMGA1 is attractive in that it is overexpressed
in a range of human malignancies. HMGA1 expression is absent or
present at only very low levels in normal adult tissues (47). As such,
targeting HMGA1 may have little or no effect on non-cancerous
tissues. Given our finding that RNA interference-mediated HMGA1
silencing inhibits invasive and metastatic potential, HMGA1
represents a rational molecular therapeutic target The feasibility
of in vivo gene silencing induced by the delivery of therapeutic small
interfering RNA (siRNA) has already been shown (48). Technological
advances, such as the development of improved delivery systems for
siRNAs, will facilitate this approach.
In summary, our findings suggest that HMGA1 promotes
pancreatic cancer cellular invasive and metastatic potential. Our
findings also indicate that HMGA1 represents a potential thera¬
peutic target for strategies designed to inhibit the progression of
pancreatic cancer.
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Overexpression of HMGAI promotes anoikis resistance and
constitutive Akt activation in pancreatic adenocarcinoma cells
S-S Liau1, A Jazag1, K Ito1 and EE Whang*'1
'Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street Boston, MA 021 i 5, USA
HMGAI proteins are architectural transcription factors that are overexpressed by pancreatic adenocarcinomas. Roles of HMGAI in
mediating the malignant phenotype of this cancer are poorly understood. We tested the hypothesis that overexpression of HMGA I
promotes resistance to anoikis (apoptosis induced by anchorage deprivation) in pancreatic cancer cells. HMGAI cDNA was stably
transfected Into MiaPaCa2 human pancreatic adenocarcinoma cells (which have low baseline expression levels of HMGAI). Cells
were grown in suspension on PolyHEMA-coated plates and their susceptibility to anoikis was assayed using flow cytometry.
Overexpression of HMGAI was associated with marked reductions in susceptibility to anoikis in concert with increases in Akt
phosphorylation (Ser473) and in Akt kinase activity and with reductions in caspase 3 activation. Inhibition of phosphoinositidyl-3 (PI3-
K)/Akt pathway with either the small molecule inhibitor LY294002 or dominant-negative Akt resulted in reversal of anoikis resistance
induced by HMGAI overexpression. Further, RNA interference-mediated HMGAI silencing in MiaPaCa2 and BxPC3 (a human
pancreatic adenocarcinoma cell line with high baseline levels of HMGAI expression) cells resulted in significant increases in
susceptibility to anoikis. Our findings suggest HMGA I promotes anoikis resistance through a PI3-K/Akt-dependent mechanism. Given
the putative associations between anoikis resistance and metastatic potential, HMGAI represents a potential therapeutic target in
pancreatic adenocarcinoma.
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Pancreatic adenocarcinoma is among the deadliest of all human
cancers, with 5-year survival rates averaging less than 5% (Jemal
et al, 2006). The propensity for pancreatic adenocarcinoma cells to
metastasise early in the course of disease progression makes this
cancer particularly refractory to standard therapies. Characterising
the underlying mechanisms mediating metastatic dissemination in
pancreatic adenocarcinoma may reveal novel targets for inhibiting
this process, which is so aggressive in this cancer.
Anoikis, derived from a Greek word meaning 'homelessness',
was used in describing the observation that depriving cells from
attachment to matrix triggers apoptosis in these cells (Frisch and
Francis, 1994). Increasingly, metastasis is conceptualised to be a
multistep process facilitated by the evolution of anoikis-resistant
subsets of cancer cells that are capable of surviving in the blood
stream during dissemination after they detach from the primary
tumour and its stroma. Indeed, numerous studies suggest a close
correlation between signalling events mediating cellular anoikis
resistance in vitro and those mediating metastatic potential in vivo
(Yawata et al, 1998; Zhu et al, 2001; Douma et al, 2004;
Berezovskaya et al, 2005).
The human HMGAI gene, located on chromosomal locus 6p21,
encodes two HMGAI splice variants (HMGAla and HMGAlb)
(Friedmann et al, 1993). These HMGAI proteins are architectural
*Correspondence: Dr EE Whang, E-mail: liauss@hotmail.com or
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transcription factors that regulate gene expression in vivo by
forming stereo-specific, multiprotein complexes termed 'enhan-
ceosomes' on the promoter regions of genes (Reeves and Nissen,
1990; Thanos and Maniatis, 1995). HMGAI proteins are over-
expressed in a range of human cancers, notably including
pancreatic adenocarcinoma (Abe et al, 2000; Balcerczak et al,
2003; Chiappetta et al, 2004; Czyz et al, 2004; Donato et al, 2004;
Chang et al, 2005; Sarhadi et al, 2006; Xu et al, 2004). Moreover,
high tumoural expression of HMGAI has been reported to be
predictive of poor prognosis among patients with cancer (Tamimi
et al, 1996; Balcerczak et al, 2003; Chiappetta et al, 2004).
Although these correlative data suggest a potential role for
HMGAI in cancer pathogenesis, the underlying biology ofHMGAI
in the context of cancer progression is poorly understood. The
purpose of this study was to test the hypothesis that HMGAI
promotes anoikis resistance in pancreatic adenocarcinoma. Our
observations indicate that HMGAI promotes anoikis resistance
through the phosphoinositidyl-3 kinase (PI3-K)/Akt pathway.
MATERIALS AND METHODS
Cells and cell culture
MiaPaCa2 and BxPC3 human pancreatic ductal adenocarcinoma
cells were obtained from American Type Culture Collection
(ATCC; Manassas, VA, USA). Cells were maintained in DMEM
containing 10% fetal bovine serum (FBS) (Gibco Life Technologies
Inc., Gaithersburg, MD, USA) and incubated in a humidified
HMGAI and anoikis resistance
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(37°C, 5% C02) incubator, grown in 75-cm2 culture flasks, and
passaged on reaching 80% confluence.
Reagents and dominant-negative Akt adenovirus
The PI3-K-inhibitor LY294002 was purchased from Calbiochem
(San Diego, CA, USA). Anti-HMGAl, anti-lamin B and anti-Akt
antibodies were obtained from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Anti-phospho Akt (ser473) antibody was obtained
from Cell Signaling Technology (Danvers, MA, USA). Adenovirus
expressing dominant-negative murine Aktl and control virus
(Ad-CMV-null) (both titred at 1 x 1010PFUml_1) were purchased
from Vector Biolabs (Philadelphia, PA, USA). Adenoviral infection
was performed at multiplicity of infection of 10 in the presence of
6 fig ml 1 polybrene for 12 h. Experiments were performed on cells
48 h following infection.
Expression vector and transfection
The HMGAI-coding sequence was PCR amplified from IMAGE
clone 5399570 (GenBank accession no. BC063434) using gene-
specific primers modified to include the appropriate restriction
Anoikis induction and flow cytometry
Anoikis was assayed by plating cells on polyHEMA-coated plates. A
solution of 120mgml 1 polyHEMA (Sigma) in 100% ethanol was
made and diluted 1:10 in 95% ethanol; 0.95 ml mm~2 of this solution
was overlaid onto 35-mm wells and left to dry in a heated dryer
system for 12 h. Before use, wells were washed twice with PBS and
once with DMEM. In all, 1 x 106 cells of each line, suspended in 2 ml
DMEM with 10% FBS were incubated in the polyHEMA-coated wells
for 12-18h in a humidified (37°C, 5% C02) incubator. Cells were
harvested and resuspended in 0.3 ml of PBS containing 2% FBS and
0.1 fiu EDTA. Apoptosis staining was performed using 1 pi ml 1 YO-
PRO-1 and propidium iodide (Vybrant Apoptosis Assay Kit #4;
Molecular Probes, Eugene, OR, USA). Cells were incubated for
30min on ice and then analysed by flow cytometry (FACScan;
Becton Dickinson, Franklin Lakes, NJ, USA), measuring fluorescence
emission at 530 and 575 nm. Cells stained with the green fluorescent
dye YO-PRO-1 were counted as apoptotic; necrotic cells were stained
with propidium iodide. The number of apoptotic cells was divided
by the total number of cells (minimum of 104 cells), resulting in the
apoptotic fraction. Data were analysed using CellQuest software
(Becton Dickinson). All assays were performed in triplicates.
sites at their 5' end. The primers used were: forward, 5'-
TTTTGATATCATGAGTGAGTCGAGCTCGAAG-3' and backward,
5'-TTTTGAATTCTCACTGCTCCTCCTCCGAGGA-3'. Purified PCR
products were digested with EcoRV and EcoRI, before ligation into
a EcoRVAEcoRI-digested pIRES-puro3 vector (Clontech, Palo Alto,
CA, USA). The expression plasmid was named pIRES-HMGAl.
MiaPaCa2 cells were transfected with pIRES-HMGAl or empty
pIRES-puro3, which acted as a control, using Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA) in accordance with the manu¬
facturer's protocol. Stable clones were selected by exposure to
incrementally increasing concentrations of puromycin (Invivogen,
San Diego, CA, USA), isolated using cloning cylinders and
maintained in medium containing 3 fig ml 1 puromycin
(Invivogen). Clones pIRES-HMGAl.l and pIRES-HMGA1.2, which
expressed the highest levels of HMGAI, were used for further
studies.
Lentivirus-mediated HMGAI RNAi
Lentiviral hairpin RNA interference (RNAi) plasmids (pLKO.l-
HMGA1, TRCN0000018949), constructed as described previously
(Stewart et al, 2003), were obtained from the RNAi Consortium
(Mission TRC Hs. 1.0, Sigma Aldrich, St Louis, MO, USA).
The sequence of short hairpin RNA (shRNA) targeting the
human HMGAI gene (GenBank accession no. NM_002131) was
5'-AACTCCAGGAAGGAAACCAA-3', corresponding to the coding
region positions 446-466. The controls were lentiviral particles
produced with empty pLKO.l and pLKO.l, which has a scramble
nontargeting shRNA sequence obtained from Addgene (Cambridge,
MA, USA), deposited by Dr David Sabatini (Sarbassov et al, 2005).
Each of these vectors had been sequence-verified. Vectors were
expanded in chemically competent Escherichia coli (TOP 10 cells,
Invitrogen) and purified using Genelute maxiprep kit (Sigma
Aldrich). To generate lentiviral particles, human embryonic kidney
293 cells (ATCC) were cotransfected with the lentiviral vector and
compatible packaging plasmid mixture (Virapower lentiviral
packaging system, Invitrogen) using Lipofectamine 2000 (Invitro¬
gen), in accordance to manufacturer's instruction. Pancreatic
adenocarcinoma cells were exposed to lentivirus-containing
supernatant for 16 h in the presence of 6 fig ml 1 polybrene
(Sigma, St Louis, MI, USA). Pooled stable transfectants were
established using puromycin selection. Stable transfectant cells
were maintained in medium containing 3//gml 1 of puromycin
(Invivogen).
Western blotting
Cells were harvested and rinsed twice with PBS. Total cell extracts
were prepared with lysis buffer (20 mM Tris, pH 7.5, 0.1% Triton X,
0.5% deoxycholate, 1 mM PMSF, lOmgml aprotinin, lOmgmP1
leupeptin) and cleared by centrifugation at 15 000 g, 4°C. Nuclear
extracts were prepared using NE-PER nuclear and cytoplasmic
extraction reagents based on the manufacturer's instruction
(Pierce, Rockford, IL, USA). Total protein concentration was
measured using the BCA assay kit (Sigma) with bovine serum
albumin as a standard, according to the manufacturer's instruc¬
tions. Total cell lysates containing 50 fig total protein or nuclear
protein containing 10 fig total protein were subjected to 10%
SDS/PAGE and the resolved proteins transferred electrophoretically
to PVDF membranes (Invitrogen). Equal protein loading was
confirmed by Coomassie (BioRad, Hercules, CA, USA) staining of
the gel. After blocking with PBS containing 3% bovine serum
albumin for 1 h at room temperature, membranes were incubated
with 3-5mgmP' antibody in PBS containing 0.1% Tween-20
overnight at 4°C. Chemoluminescensce detection (Amersham
Biosciences, Piscataway, NJ, USA) was performed in accordance
with the manufacturer's instructions. The densitometric signal was
quantified using ImagePro Plus software version 4.0 (Media
Cybernetics, Silver Spring, MD, USA) and normalised to that of
loading control as appropriate. Blots were performed in triplicate
in at least three independent experiments. Mean densitometric
values ( +standard Deviation (s.d.)) are shown.
Fluorometric real-time Akt kinase assay
Assay was performed using the Omnia Lysate Akt kinase assay
(Biosource-Invitrogen, Carlsbad, CA, USA), according to the
manufacturer's instructions. Briefly, total cell lysate equivalent
to 5 figfiH' was loaded into each well. Following addition of
fluorescent Akt substrates and kinase buffer, fluorescent signal was
acquired real-time (excitation, 360 nm; emission, 485 nm) for
60min using SpectraMax M5 microplate reader (Molecular
Devices, Sunnyvale, CA, USA). The Akt kinase activity was
calculated from the slope of activity curve. Experiments were
performed in triplicates on at least three occasions.
Fluorometric caspase profiling
Whole-cell lysates were assayed for caspases 3 activity using the
BD ApoAlert Caspase Assay Plate (BD Biosciences Clontech, Palo
British Journal of Cancer (2007) 96(6), 993-1000 © 2007 Cancer Research UK
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Alto, CA, USA) according to the manufacturer's instructions.
Plates were read (excitation, 360 nm; emission, 480 nm) using
SpectraMax M5 microplate reader in fluorescence mode (Mole¬
cular Devices). All measurements were performed in triplicate,
each with three determinations for each condition.
Proliferation assay
Cell proliferation was quantified using an MTS (3-(4,5 dime-
thylthiazol-2-yl)-5-(3-carboxymethoxyphenyl-2-(4-sulfophenyl)-
2H-tetrazolium) assay (CellTiter 96 Aqueous One Solution Assay,
Promega, Madison, WI, USA), in accordance to the manufacturer's
instructions and confirmed by cell counting. Logarithmically
growing cells were seeded into 96-well plates at 5 x 103 cells per
well and allowed to adhere overnight in medium containing 10%
FBS. Cell proliferation was determined after 48 h. Plates were read
with the use of the SpectraMax M5 microplate spectrophotometer
(Molecular Devices) at a wavelength of 490 nm. Ten samples
were used for each experimental condition and experiments were
performed in triplicate. At identical time points, cell counting was
performed. Cells were trypsinised to form a single-cell suspension.
Viable cells, determined by trypan blue exclusion, were counted
with the use of a Neubauer hemocytometer (Hausser Scientific,
Horsham, PA, USA).
Statistical analysis
Differences between groups were analysed using Student's f-test,
multifactorial ANOVA of initial measurements and Mann-
Whitney U-test for nonparametric data, as appropriate, using
Statistica 5.5 software (StatSoft Inc., Tulsa, OK, USA). In cases in
which averages were normalised to controls, the s.d. of each
nominator and denominator were taken into account in calculating
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Figure I Two stable transfectant clones derived from MiaPaCa2 cells
were confirmed to overexpress HMGAI (pIRES-HMGAI,I and 1.2) on
Western blot analysis of nuclear extracts. Lamin B was used as a loading
control. Controls were parental MiaPaCa2 cells or cells stably transfected
with empty plRES-puro3 vector. *Blots shown are representative of three
independent experiments. Densitometry values, normalised to Lamin B
signals, are mean + s.d.. P<0.05 vs empty plRES-puro3 vector and parental
MiaPaCa2 cells.
RESULTS
HMGAI overexpression promotes anoikis resistance in
MiaPaCa2 pancreatic adenocarcinoma cells
Stable overexpression of HMGAI was achieved in MiaPaCa2 cells,
which have low inherent expression levels of HMGAI. Two stable
HMGAl-overexpressing clones were selected and named pIRES-
HMGA1.1 and pIRES-HMGA1.2. HMGAI overexpression was
confirmed on Western blot analysis (Figure 1). Levels of HMGAI
overexpression in pIRES-HMGAl.l and pIRES-HMGA1.2 were
four- and 3.5-fold higher than in control cells, respectively. There
was no difference in the levels of HMGAI expression between the
empty pIRES-puro3 transfectants and parental MiaPaCa2 cells.
Following 18 h of anchorage-deprivation (on polyHEMA plates),
pIRES-HMGAl.l and pIRES-HMGA1.2 clones showed significantly
increased anoikis resistance (mean anoikis fractions of 11 and
13%, respectively) when compared to controls (mean anoikis
fractions for parental MiaPaCa2 and empty pIRES-puro3 transfec¬
tants were 26 and 27%, respectively, Figure 2A and 2B).
HMGAI overexpression results in protection from caspase-
mediated apoptosis
Given that disruption of cell-matrix interactions can trigger
anoikis via caspase-dependent apoptosis, we examined the effects
of HMGAI overexpression on caspase 3 activity (a central
mediator of apoptosis) in the context of anchorage deprivation.
During induction of anoikis on polyHEMA plates, HMGAl-
overexpressing clones demonstrated markedly reduced levels of
caspase 3 activity compared to parental MiaPaCa2 or pIRES-puro3
controls (Figure 2C).
Overexpression of HMGAI increases levels of Akt
phosphorylation and Akt kinase activity
PI3-K/Akt-signalling pathway is of critical importance in mediat¬
ing anoikis resistance and enhancing anchorage-independent
cell cycle progression (Moore et al, 1998; Nguyen et al, 2002).
Given these observations, we sought to determine if HMGAI
overexpression would modulate Akt phosphorylation at Ser473,
a marker of Akt activation. HMGAI overexpression resulted in
elevated Akt (Ser473) phosphorylation (Figure 3A). Consistent
with this finding, HMGAI overexpression was found to be
associated with increases in Akt kinase activity (Figure 3B).
Inhibition of Pl3-K/Akt signalling reverses HMGAI
overexpression-induced anoikis resistance
Having demonstrated that HMGAI overexpression induces con¬
stitutive activation of PI3-K/Akt pathway, we next examined the
effects of inhibiting this pathway in cells overexpressing HMGAI.
First, we used a specific small molecule inhibitor of PI3-K,
LY294002, to assess the effects of inhibiting PI3-K on anoikis
resistance of these cells. Addition of 25 /im of LY294002
significantly increased anoikis fractions in pIRES-HMGAl.l and
pIRES-HMGA1.2 clones (Figure 3C). Treatment of parental
MiaPaCa2 and empty pIRES-puro3 controls with LY294002 also
inhibited anoikis resistance, although to lesser extent than for
pIRES-HMGAl.l and pIRES-HMGA1.2 clones. Second, infection
of pIRES-HMGAl.l and pIRES-HMGA1.2 clones with adenovirus
expressing a dominant-negative Akt construct also significantly
increased anoikis fractions in both HMGAl-overexpressing clones
© 2007 Cancer Research UK British Journal of Cancer (2007) 96(6), 993- 1000
996
HMGAI and anoikis resistance


























10° 101 102 103 104
FL1-H



















SpF:' ' ,\f> ; 5
R2 0
afA7.' '-v ' I MiaPaCa2 Empty pRES piRES- piRES-
-puro3 HMGA1.1 HMGA1.2
MiaPaCa2 Empty pIRES piRES- piRES-
-puro3 -HMGA1.1 -HMGA1.2
Figure 2 (A, B) Forced HMGAI overexpression protects MiaPaCa2 cells, which have low inherent expression of HMGAI, from anoikis. Representative
flow cytometric images are shown with anoikis fractions highlighted in the inserted square (Figure 2A). Clones pIRES-HMGAI.I and plRES-HMGAI.2
exhibited 2- to 2.5-fold reductions in anoikis fraction compared to parental MiaPaCa2 cells and plRES-puro3 control stable transfectants (Figure 2B).
*P<0.05 vs parental MiaPaCa2 cells or empty plRES-puro3 transfectants, (C) HMGAI overexpression protects MiaPaCa2 cells from caspase-mediated
anoikis. pIRES-HMGAI. I and pIRES-HMGAI .2 clones showed significant reductions in caspase 3 activity, compared to parental MiaPaCa2 cells and empty
plRES-puro3 transfectants, following induction of anoikis on polyHEMA plates for 18h. *P<0.05 vs parental MiaPaCa2 cells or empty plRES-puro3
transfectants.
(Figure 3D). Parental MiaPaCa2 and empty pIRES-puro3 controls
also exhibited increased anoikis fractions with infection of
adenovirus expressing dominant-negative Akt construct, but to a
lesser extent than the HMGAI-overexpressing clones. Taken
together, these results suggest that HMGAI overexpression-
induced anoikis resistance is dependent on PI3-K/Akt signalling.
Targeted RNAi of HMGAI in MiaPaCa2 and BxPC3
pancreatic adenocarcinoma cells increases susceptibility
to anoikis
Given the effects of HMGAI overexpression on anoikis resistance
in MiaPaCa2 cells, we asked if silencing ofHMGAI in the same cell
line will have the reverse effects. In addition, we also selected
BxPC3 pancreatic adenocarcinoma cell line for RNAi experiments
as these cells have high levels of HMGAI expression at baseline. In
these lentivirus-mediated RNAi experiments, we developed pooled
stable transfectants. Stable transfectants derived from infection
with lentivirus developed from empty PLKO.l and scramble
shRNA transfer plasmids served as controls. We achieved at least
90% silencing ofHMGAI expression in both MiaPaCa2 and BxPC3
cells (Figure 4A). Of note, neither HMGAI overexpression nor
silencing had any impact on lamin B expression (used to normalise
for protein loading, Figures 1 and 4A). HMGAI silencing was
associated with significant increases in anoikis fractions in both
cell lines (Figure 4B).
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Figure 3 (A) Ovenexpression of HMGAI led to increased activation of Akt, as evident from increased levels of phospho-Akt (Ser473), a marker of Akt
activation. Both pIRES-HMGA 1.1 and plRES-HMGAI.2 clones exhibited a higher degree of Akt phosphorylation compared to control cells. There were no
differences in the level of expression of total Akt with overexpression of HMGAI, *P<0.05 vs parental MiaPaCa2 cells or empty plRES-puro3 transfectants, Blot
shown is representative of three independent experiments. (B) Correspondingly, overexpression of HMGAI results in increased Akt kinase activities as
determined by fluorometric real-time Akt kinase assays. Slope of Akt kinase activity curves indicates the levels of Akt kinase activity. Representative results ofAkt
kinase activity assay from three independent experiments are shown. pIRES-HMGAI.I and plRES-HMGAI.2 clones showed steeper activity curve slopes and
hence Akt kinase activities, when compared to empty plRES-puro3 controls, *P<0,05 vs empty plRES-puro3 vector transfectants. (C) Anoikis resistance induced
by HMGA I overexpression in pIRES-HMGA I. I and pIRES-HMGA 1,2 clones was reversed by preincubating cells in 25 /iM LY294002, a specific inhibitor of PI3-K.
Inhibiting PI3-K resulted in increases in anoikis fractions in pIRES-HMGA I. I and pIRES-HMGA 1.2 clones to levels similar to parental MiaPaCa2 and empty pIRES-
puro3 controls. Controls were cells treated with the DMSO vehicle. *P<0.05 vs DMSO controls. (D) Similarly, infection of pIRES-HMGA 1.1 and pIRES-HMGA 1,2
clones with adenovirus carrying dominant-negative Akt I resulted in reversal of anoikis resistance with increases in anoikis fractions in both HMGAI -overexpressing
clones. Controls were cells infected with adenovirus expressing an empty CMV promoter (Ad-CMV-null). *P<0.05 vs control adenovirus (Ad-CMV-null).
Modulation of HMGAI expression did not have an impact on
growth characteristics of pancreatic adenocarcinoma cells
Neither overexpression (Figure 5A) nor targeted suppression of
HMGAI expression (Figure 5B) had any impact on proliferation
rates of pancreatic adenocarcinoma cells studied.
DISCUSSION
Pancreatic adenocarcinoma is associated with dismal prognosis,
in large part resulting from metastatic disease, even in patients
initially deemed to be surgically resectable. We have focused our
efforts in studying the mechanisms underlying metastasis in
© 2007 Cancer Research UK British Journal of Cancer (2007) 96(6), 993- 1000
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Figure 4 (A) Using lentivirus-mediated RNAi of HMGAI, we achieved up to 90% silencing of HMGAI expression in both MiaPaCa2 and BxPC3 cell
lines. A representative Western blot performed on nuclear extracts showing the degree of HMGAI silencing is shown. Controls were stable transfectants
developed following infection with lentivirus expressing empty PLKO. I or scramble RNAi sequence. (B) Silencing of HMGAI promoted anoikis in both cell
lines following culture in polyHEMA plates for I 8 (for MiaPaCa2) and 12 h (for BxPC3). Representative images of flow cytometric analyses of anoikis
fractions with apoptotic populations highlighted in triangles drawn are shown. Targeted suppression of HMGAI resulted in significant increases in anoikis
fractions in both MiaPaCa2 and BxPC3 cells compared to empty PLKO. I and scramble RNAi-stable transfectants. *P<0.05 ^ empty PLKO. I or scramble
RNAi transfectants.
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Figure 5 (A and B) Cellular proliferation was quantified by MTS assay
48h following seeding wells with 5 x I03 cells. Modulation of HMGAI
expression did not affect cellular proliferation in monolayer culture. Values
are mean + s.d. from triplicate experiments with 10 determinations per
condition.
pancreatic adenocarcinoma, with the goal of rationally identifying
molecular targets that can be exploited to inhibit this process. In
our work, we have used anoikis resistance as an in vitro correlate
of metastatic potential. In this study, we have shown that HMGAI
overexpression confers anoikis resistance to pancreatic adeno¬
carcinoma cells by activating the prosurvival PI3-K/Akt signalling
pathway. This is the first report describing a regulatory role of
HMGAI on Akt signalling in a cancer model.
Numerous reports have described HMGAI overexpression to be
prevalent in a wide range of human malignancies. Increasingly,
tumoural HMGAI expression status is reported to have
prognostic value among patients with cancer (Sarhadi et al,
2006). Recently, data suggesting mechanisms by which HMGAI
may mediate cancer progression have begun to emerge. For
example, HMGAI proteins have been demonstrated to promote
tumour progression and epithelial-mesenchymal transition in
human breast epithelial cells (Reeves et al, 2001). In immortalised
999
rat embryonic fibroblast Rat la cells, HMGAI was found to be a
c-Jun-target gene and its suppression by antisense methodology
was found to reduce the ability of c-Jun-overexpressing cells to
grow under anchorage-independent conditions (Hommura et al,
2004).
Although previous reports have implicated HMGAI as having
the capacity to promote tumourigenesis and anchorage-indepen¬
dent growth in normal epithelial cells (Reeves et al, 2001), no
studies reported to date have examined specifically the role of
HMGAI in mediating anoikis resistance in the context of cancer
cells. Our findings suggest that HMGAI overexpression represents
a molecular determinant of anoikis resistance in pancreatic
adenocarcinoma cells. The biological significance of this finding
relates to emerging understanding that anoikis resistance is a
phenotypic hallmark of metastatic cancer cells (Chuma et al, 2004;
Douma et al, 2004). Although the underlying mechanisms
rendering anoikis resistance in cancer cells are incompletely
understood, our findings provide evidence for a novel role for
HMGAI in mediating this process. Further, our findings provide a
potential mechanism by which HMGAI overexpression induces
anoikis resistance: activation of the antiapoptotic PI3-K/Akt
signalling pathway.
Description of regulatory roles for HMGAI in the context of
apoptosis is not without precedent. HMGAI has been found to
associate in vivo with p53 family members and inactivate their
functions. As such, overexpression of HMGAI may lead to
suppression of p53-induced apoptosis and tumour-suppressing
activity (Frasca et al, 2006). In addition, antisense-mediated
suppression of HMGAI expression in thyroid carcinoma and
pancreatic adenocarcinoma cell lines has been reported to induce
an apoptotic response (Scala et al, 2000; Trapasso et al, 2004). Our
findings that HMGAI overexpression results in constitutive
activation of PI3-K/Akt pathway provide another mechanism
through which HMGAI mediates its antiapoptotic functions.
HMGAI-dependent activation of Akt signalling is likely to protect
cancer cells from broad array of proapoptotic stimuli, not just
those related to anchorage deprivation. Indeed, we have recently
reported that HMGAI protects pancreatic adenocarcinoma cells
from gemcitibine-induced apoptosis and in this context is a
potential molecular determinant of chemoresistance in pancreatic
cancer (Liau et al, 2006).
Our findings, taken together with those previously reported,
provide a mechanistic basis for conceptualising the known
correlations between HMGAI expression and poor prognosis in
cancer patients (Chiappetta et al, 2004). These findings also have
obvious therapeutic implications. Future studies will need to
address whether targeted therapies directed against HMGAI will
inhibit metastasis in pancreatic cancer.
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Lentivirus-Mediated RNA Interference of HMGA1
Promotes Chemosensitivity to Gemcitabine
in Pancreatic Adenocarcinoma














































[Q3] The high mobility group A1 (HMGA1) proteins are overexpressed in pancreatic cancers. They are
architectural nuclear proteins, which regulate expression of multiple genes implicated in the malignant
phenotype. In this study, we hypothesized that HMG A1 silencing will promote chemosensitivity in pan¬
creatic adenocarcinoma. We studied highly malignant pancreatic adenocarcinoma cell lines (MiaPaCa2
and PANC1). Lentiviral short-hairpin RNA (sh HMGA1) expression vectors targeting HMG A1 were
used for generation of lentiviral particles. Stable transfectants were developed after lentiviral transduc¬
tion. Nuclear expression of HMGA1 was assayed using Western blot analysis. Chemosensitivity to gem¬
citabine was determined by IC50 analysis. Caspase activity was quantitated using fluorometric caspase
profiling. Apoptosis was assessed by flow cytometric analysis. Lentivirus-mediated RNA interference
resulted in 90% silencing of HMG A1 expression in each of MiaPaCa2 and PANC1 cell lines.
HMGA1 silencing enhanced chemosensitivity to gemcitabine with an approximately 50% reduction in
IC50 in each cell line. Lentivirus-mediated HMGA1 silencing promoted the activation of caspases 3,
2, 9, and 8, on exposure to gemcitabine. HMGA1 silencing resulted in reduction in Akt kinase activity.
Lentivirus-mediated RNA interference ofHMGA1 promoted chemosensitivity to gemcitabine in pancre¬
atic adenocarcinoma. HMGA1 may represent a novel therapeutic target in pancreatic cancer. (J Gastro-
intest Surg 2006;b:b) © 2006 The Society for Surgery of the Alimentary Tract
Key words: HMGA1, gemcitabine, chemotherapy, pancreatic adenocarcinoma
Pancreatic adenocarcinoma is the fourth leading
cause of cancer-related death in the United States.
Its biology is characterized by the propensity for
early and aggressive invasion and metastasis, such
that less than 10% of patients have surgically resect¬
able disease at the time of diagnosis.2 Gemcitabine,
a nucleoside analog, is generally considered to be
first-line therapy for unresectable pancreatic can¬
cer.3'4 However, the impact of gemcitabine on over¬
all survival and clinical outcomes remains modest,
largely because of chemoresistance. Further under¬
standing of the molecular mechanisms underlying
pancreatic adenocarcinoma chemoresistance may
facilitate the identification of novel strategies for
increasing chemosensitivity in this deadly cancer.
The human HMGA1 gene, located on chromo¬
somal locus 6p21, encodes two high mobility group
A1 (HMGA1) splice variants (HMGAla and
HMGAlb). These HMGA1 proteins are architec¬
tural transcription factors that play a role in both
positive and negative transcriptional regulation of
human gene expression in vivo.6-8 They form ste¬
reo-specific, multiprotein complexes termed "enhan-
ceosomes" on the promoter/enhancer regions of
genes, where they are able to bind to the minor
groove of AT-rich DNA sequences to induce DNA
helix bending.6'' HMGA1 proteins are overex¬
pressed in a range of human cancers, including pan¬
creatic adenocarcinoma.10-1 HMGA1 proteins have
been reported to regulate signaling pathways impli¬
cated in the malignant behavior of cancer cells,
including KIT ligand expression18 and Ras/ERK
signaling.1'' Moreover, HMGA1 is a c-Myc and
AP-1 target gene and has been shown to plav a
role in malignant cellular transformation." ~22
Recently, it has also been reported that HMGA1
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2 Liau et al.
proteins bind to p53 in vivo and inhibit their tumor
suppressor activity in thyroid cancer cells.23
Although there is extensive evidence for the pro-
oncogenic roles of HMGA1, little is known about
its roles in chemoresistance. The purpose of this
study was to test the hypothesis that HMGA1 is a de¬
terminant of pancreatic adenocarcinoma chemore¬
sistance and that suppression of HMGA1 expression
would enhance pancreatic adenocarcinoma chemo-
sensitivity to gemcitabine. Using lentivirus-mediated
RNA interference, we assessed the effect of sup¬
pressing HMGA1 expression on pancreatic adeno¬
carcinoma cell gemcitabine chemoresistance and
apoptotic pathways. Our observations indicate that
HMGA1 represents a rational therapeutic target in
pancreatic adenocarcinoma.
MATERIALS AND METHODS
Cells and Cell Culture
MiaPaCa2 and PANC1 human pancreatic ductal
adenocarcinoma cells were obtained from American
Type Culture Collection (Manassas, VA). Cells
were maintained in DMEM containing 10% fetal
bovine serum (Gibco Life Technologies Inc, Gai-
thersburg, MD) and incubated in a humidified
(37°C, 5% C02) incubator, grown in 75-cm2 culture
flasks, and passaged on reaching 80% confluence.
Lentivirus-Mediated HMGA1 RNA
Interference
Lentiviral hairpin RNA interference plasmids
(pLKO.l-HMGAl, TRCN0000018949), construc¬
ted as described previously (24), were obtained from
The RNAi Consortium (Mission TRC Hs. 1.0;
Sigma Aldrich, St Louis,MO). The sequence ofshort
hairpin RNA targeting the human HMGA1 gene
(GenBank accession no. NM_002131) was 5'—
AACTCCAGGAAGGAAACCAA-3', correspond¬
ing to the coding region positions 446-466. The
control plasmid that has a scramble nontargeting
short-hairpin RNA sequence was obtained from
Addgene (Cambridge, MA), deposited by Dr. David
Sabatini.2' Each of these vectors had been se¬
quence-verified. Vectors were expanded in chemi¬
cally competent Escherichia coli (TOP10 cells;
Invitrogen, Carlsbad, CA) and purified using Gene-
lute maxiprep kit (Sigma Aldrich). To generate lenti¬
viral particles, human embryonic kidney 293 cells
(ATCC) were co-transfected with the lentiviral
vector and compatible packaging plasmid mixture
(Virapower lentiviral packaging system, Invitrogen)
using LipofectAMINE 2000 (Invitrogen), in accor¬
dance to the manufacturer's instruction. Pancreatic
Journal of
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adenocarcinoma cells were exposed to lentivirus-
containing supernatant for 16 hours in the presence
of 6 pg/ml Polybrene (Sigma). Pooled stable transfec-
tants were established using puromycin selection.
Stable transfectant cells were maintained in medium
containing 3 pg/ml puromycin (Invitrogen).
Cytotoxicity Assay
Gemcitabine-induced cytotoxicity was quantified
by an MTS [3-(4,5 dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl -2 -(4-sulfophenyl)-2H-tetrazo-
lium] assay (CellTiter 96; Promega), in accordance
with the manufacturer's instructions. Cells were
seeded into 96-well plates at 5 x 103 cells per well
and allowed to adhere overnight in medium contain¬
ing 10% FBS. Cell viability was determined after
72 hours in presence or absence of 0-10 pM gemci¬
tabine. Plates were read with the use of the Spectra-
Max M5 microplate spectrophotometer (Molecular
Devices, Sunnyvale, CA) at a wavelength of
490 nm. Six samples were used for each experimental
condition, and experiments were performed in tripli¬
cate. IC5o values were calculated using the SoftMax
Pro software (Molecular Devices). At identical time
points, cell counting was performed. Cells were tryp-
sinized to form a single-cell suspension. Viable cells,
determined by Trypan blue exclusion, were counted
with the use of a Neubauer hemocytometer (Hausser
Scientific, Horsham, PA). Cell counts were used to
confirm MTS results.
Western Blotting
Cells were harvested and rinsed twice with PBS.
Total cell extracts were prepared with lysis buffer
(20 mM Tris, pH 7.5, 0.1% Triton X, 0.5% deoxy-
cholate, 1 mM PMSF, 10 mg/ml aprotinin, 10 mg/
ml leupeptin) and cleared by centrifugation at
15,000g, 4°C. Nuclear extracts were prepared using
NE-PER Nuclear and Cytoplasmic Extraction Re¬
agents based on the manufacturer's instruction
(Pierce, Rockford, IL). Total protein concentration
was measured using the BCA assay kit (Sigma) with
bovine serum albumin as a standard, according to
the manufacturer's instructions. Total cell lysates
containing 50 pg of total protein or nuclear protein
containing 10 pg of total protein was subjected to
10% SDS/PAGE, and the resolved proteins were
transferred electrophoretically to PVDF membranes
(Invitrogen). Equal protein loading was confirmed
by Coomassie (BioRad, Hercules, CA) staining of
the gel. After blocking with PBS containing 3% bo¬
vine serum albumin for 1 hour at room temperature,
membranes were incubated with 3-5 mg/ml anti¬
body in PBS containing 0.1% Tween 20 overnight
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at 4°C. Anti- HMGA1 and anti-lamin B1 antibodies
were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA). Chemoluminescent detection
(Amersham Biosciences, NJ) was performed in ac¬
cordance with the manufacturer's instructions. The
densitometric signal was quantified using ImagePro
Plus software version 4.0 (Media Cybernetics, Silver
Spring, MD) and normalized to that of actin. Blots
were performed in triplicate in at least three inde¬
pendent experiments. Mean densitometric values
(±SD) are shown.
Apoptosis Assay
After gemcitabine (1 pM) treatment for 48 hours,
1 x 106 cells were washed, trypsinized, and resus-
pended in 0.5 ml of PBS containing 2% FBS and
0.1 pM EDTA. Apoptosis staining was performed
using 1 pl/ml YO-PRO-1 and propidium iodide
(Vybrant Apoptosis Assay Kit #4; Molecular Probes,
Eugene, OR). Cells were incubated for 30 minutes
on ice and then analyzed by flow cytometry (FACS-
can; Becton Dickinson, Franklin Lakes, NJ), measur¬
ing fluorescence emission at 530 and 575 nm. Cells
stained with the green fluorescent dye YO-PRO-1
were counted as apoptotic; necrotic cells were
stained with propidium iodide. The number of apo¬
ptotic cells was divided by the total number of cells
(minimum of 104 cells), resulting in the apoptotic
fraction. Data were analyzed using CellQuest soft¬
ware (Becton Dickinson). All assays were performed
in triplicate.
Fluorometric Caspase Profiling
Whole cell lysates were assayed for caspase
2, 3, 8, and 9 activities using the BD ApoAlert
fluorometric Caspase Assay Plate (BD Biosciences
Clontech, Palo Alto, CA) according to the manufac¬
turer's instructions. Plates were read (excitation, 360
nm; emission, 480 nm) using SpectraMax M5 mi-
croplate reader in fluorescence mode (Molecular
Devices). All measurements were performed in trip¬
licate, each with three determinations for each
condition.
Akt Kinase Assay
Active Akt was immunoprecipitated from 1 mg of
clarified total cell lysate using the catch and release
reversible immunoprecipitation system (Upstate,
Charlottesville, VA) according to the manufacturer's
protocol. Four micrograms of mouse monoclonal
anti-Akt (PH domain) antibody (Calbiochem, San
Diego, CA) was used per 500 pg of cell lysate. Fol¬
lowing immunoprecipitation, equivalent amounts
of eluate were used for Akt kinase assay withg an
ELISA-based Akt activity assay that uses a biotiny-
lated peptide substrate that is phosphorylated by
Akt kinase (K-LISA Akt activity assay; Calbiochem).
Akt activity was quantified by reading the absorbance
at 450 nm, with a reference wavelength set at 540
nm, using SpectraMax M5 microplate reader (Mo¬
lecular Devices). All measurements were performed
in triplicate, each with three determinations for
each condition.
Statistical Analysis
Differences between groups were analyzed using
Student's /-test, multifactorial ANOVA of initial
measurements, and Mann-Whitney U test, for non-
parametric data, as appropriate, using Statistica 5.5
software (StatSoft, Inc, Tulsa, OK). In cases in which
averages were normalized to controls, the standard
deviations of each nominator and denominator
were taken into account in calculating the final stan¬





Cell lines stably expressing hairpin RNA were de¬
veloped following lentiviral transduction and selec¬
tion with puromycin. Lentivirus-mediated RNA
interference of HMGA1 (shHMGAl) resulted in
up to 90% silencing of HMGA1, as confirmed by
Western blot analysis (Fig. 1). Infection with control
lentivirus encoding scramble hairpin RNA (shCon-
trol) had no effect on HMGA1 expression.
Suppression of HMGAI Expression Enhances
Gemcitabine-Induced Cytotoxicity
The baseline level ofHMGAI protein expression
was approximately 3-fold higher in PANC1 cells
than in MiaPaCa2 cells (Fig. 1). PANC1 cells were
found to be more resistant to gemcitabine-induced
cytotoxicity than MiaPaCa2 cells, with the IC50 of
PANC1 cells being 128 nM compared to 64 nM
for MiaPaCa2 cells. To determine the IC50, cells
were exposed to 0 to 10 pM gemcitabine for 72
hours. The IC50 was calculated from MTS cytotox¬
icity assay data. Suppression of HMGAI expression
resulted in reduction of the gemcitabine IC50 in
both MiaPaCa2 and PANC1 cells (Fig. 2). The
HMGAI silencing-induced increases in gemcita¬





















































































































Fig. 1. Stable silencing of HMGA1 expression using lentivirus encoding short-hairpin RNA (shRNA)
was confirmed on Western blot analysis of nuclear extracts. Up to 90% silencing ofHMGA1 expression
was achieved using the lentivirus-mediated shRNA approach. MiaPaCa2 and PANC1 cell lines differ¬
entially express HA1GA1, with PANC1 cells having higher expression (up to 3-fold higher than MiaPa-
Ca2 cells). In each experiment, controls were cells stably transfected with lentivirus encoding scramble
shRNA (shControi). Densitometry values are mean (± SD). *P < 0.05 versus shControl or untreated
cell line.
significant increases in cellular apoptotic fractions
(Fig. 3).
HMGA1-Specific Silencing Enhances
Gemcitabine-Induced Activation of Caspases
3, 8, 9, and 2
Caspase activation is required for gemcitabine-
induced cytotoxicity in cancer cells."6 As such,
we sought to determine the effect of HMGA1
silencing on caspase activities after exposure to
gemcitabine for 48 hours. Gemcitabine-induced
activation of caspases 3, 8, 9, and 2 was markedly
increased with targeted suppression of HMGA1 in
MiaPaCa2 cells, compared to controls (Fig. 4).
On exposure to 1 pM gemcitabine for a similar du¬
ration of time, PANC1 cells exhibited modest but
statistically significant elevations in activities of
each of the caspases profiled with suppression of
HMGA1.
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Fig. 2. Lentiviral-mediated RNA interference of HMGA1 expression enhances gemcitabine-induced
cytotoxicity in MiaPaCa2 and PANC1 cell lines. Growth curves ofMiaPaCa2 (A) and PANC (B) cells
show the effect of silencing HMGA1 on chemosensitivity to gemcitabine, as determined using the 3-(4,5
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl-2-(4-sulfophenyl)-2//-tetrazolium) assay. Suppres¬
sion of HMGA1 expression shifts the growth curves to the left in both MiaPaCa2 and PANC1 cells,
indicating an increased in chemosensitivity to gemcitabine. (C). The mean IC50 of gemcitabine was
reduced by approximately 2-fold in both MiaPaCa2 (shHMGAI versus shControl: 64 nM versus
29 nM) and PANC1 (128 nM versus 65 nM).
Akt Activity Is Inhibited by Suppression of
HMGA1
Activation of the serine/threonine kinase Akt is
common in pancreatic cancer.27 Akt has been recog¬
nized as a determinant ofpancreatic adenocarcinoma
gemcitabine chemoresistance.2830 As such, we ex¬
amined the effect ofHMGA1 silencing on Akt activ¬
ity using an ELISA-based Akt kinase activity assay.
Suppression of HMGA1 expression resulted in sig¬
nificant reduction Akt kinase activity in MiaPaCa2
and PANC1 cell lines, with a greater effect seen in
MiaPaCa2 cells (Fig. 5). The decrease in Akt activity
we observed with targeted suppression of HMGA1




Pancreatic adenocarcinoma is among the most ag¬
gressive and chemoresistant of human malignancies.
The prognosis associated with this cancer remains
dismal, despite considerable advances in the medical
and surgical management of this disease.31 At the
time of diagnosis, most patients will have unresect¬
able disease. Although the nucleoside analog gemci¬
tabine has proven efficacy against pancreatic cancer,
it is associated with only modest improvement in
clinical outcomes.3'4 There is an urgent need to
identify new therapeutic approaches.
Overexpression of HMGA1 has previously been
reported to be present in a range of human cancers,
including pancreatic adenocarcinoma.10-1' HMGA1
overexpression is causally associated with both
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Fig. 3. Apoptotic fraction was quantitated using flow cytometry after staining of cells with Yo-Pro-1 and
propidium iodide dyes. (A). Consistent with results of the cytotoxicity assay, suppression of HMGA1
expression promotes apoptosis with increases in apoptotic fraction on exposure to gemcitabine 1 pM
for 48 hours. Data are means of at least three determinations ±SD. *P < 0.05 versus shControl trans-
fectants. (B). Representative flow cytometric analyses of apoptotic fraction showing suppression of
HMGA1 expression led to increased apoptotic fractions on exposure to gemcitabine 1 pM for 48 hours.
The apoptotic cell population is shown by the triangle drawn around the cell population in each analysis.
neoplastic transformation and metastatic progression
in breast cancer.32 Furthermore, HMGA1 is a c-Myc
and AP-1 target gene-0 22 and has been reported to
regulate pro-oncogenic signaling pathways, includ¬
ing KIT ligand expression18 and Ras/ERK signal¬
ing.19 Recent reports also suggest that FIMGA1
proteins bind to p53 in vivo and inhibit their tumor
suppressor activity in thyroid cancer cells."' Sup¬
pression of HMGA1 expression by antisense oligo¬
nucleotides has been reported to inhibit pancreatic
cell proliferation.33 In addition, antisense-mediated
suppression of HMGA1 expression has been
reported to inhibit the growth of experimental
pancreatic cancers in vitro and in vivo.33
HMGA1 has received little attention in the con¬
text of chemoresistance. In our study, we have iden¬
tified HMGA1 as a potential target through which
chemosensitivity to gemcitabine may be increased
in pancreatic adenocarcinoma cells. From a therapeu¬
tic standpoint, targeting HMGA1 is attractive in that
although it is overexpressed in a range of human ma¬
lignancies, HMGA1 expression is absent or present
at only very low levels in normal adult tissues. '4 As
such, targeting HMGA1 may have little or no effect
on noncancerous tissues.3' An important caveat is
that the role of HMGA1 in chemoresistance varies
according to the chemotherapeutic agent used. For
instance, overexpression rather than suppression of
HMGA1 has been shown to chemosensitize MCF-
7 human breast adenocarcinoma cells to cisplatin.36
In view of these findings, therapeutic applications
of HMGA1 silencing would need to be carefully
evaluated in the context of cancer characteristics
and the specific chemotherapeutic agents used.
Our observation that HMGA1 silencing sup¬
presses Akt activity is interesting for several reasons.
Inhibition of the PI3K/Akt pathway is reported to
induce chemosensitization in pancreatic cancer cells
both in vitro3 and in vivo.'8 Active AJkt has been
reported to protect cells from apoptotic stimuli by
inhibiting activation of initiator caspase 9 and effec¬
tor caspase 3 at a postmitochondrial level.'9 As such,
we have identified the PI-3K/Akt kinase signaling
pathway as one of the likely molecular mechanisms
by which overexpression of HMGA1 proteins pro¬
motes chemoresistance to gemcitabine. However,
in view of the modest effect ofHMGA 1 suppression
on Akt kinase activity, it is unlikely that PI-3K/Akt
signaling is the sole effector of HMGA 1 -mediated
chemoresistance to gemcitabine.
In this study, we have shown that lentivirus-medi-
ated RNA interference ofHMGA 1 promotes chemo¬
sensitivity to gemcitabine. As such, HMGA1
represents a rational molecular therapeutic target.
The feasibility of in vivo gene silencing using lentivi-
ral vectors has already been demonstrated.40 The
lentivirus vector used in this study is derived from
HIV-1 and is replication deficient on transducing
the first cell with which it comes into contact. The
ability of lentivirus to efficiently transduce cells,

























































































Caspase 3 Caspase 8 Caspase 9 Caspase 2
B PANC1
2.5
Caspase 3 Caspase 8 Caspase 9 Caspase 2
Fig. 4. The effect of targeted suppression ofHMGA1 expression resulted in increased caspase activation
on exposure to gemcitabine. Activities of caspases 3, 8, 9, and 2 were quantified using a fluorometric
assay after exposure to 1 pM gemcitabine for 48 hours. Activities of each of the four caspases profiled
exhibited a significant increase in both MiaPaCa2 (A) and PANC1 (B) cell lines with lentiviral-mediated
HMGA1 silencing, compared to controls. Controls were cells stably transfected with lentivirus encoding
scramble shRNA (shControl). Values are means (±SD) of three experiments with triplicate determina¬
tions. *P < 0.05 versus shControl transfectants.








































































Fig. 5. Akt kinase activity was quantitated using an ELISA-based Akt activity assay following immuno-
precipitation of active Akt from total cell lysates. Targeted suppression ofHMGA1 expression using len-
tivirus-mediated RNA interference resulted in approximately 30M0% reductions in Akt kinase activity
in each ofMiaPaCa2 and PANC1 cells, compared to controls. Silencing of HMGA1 has no effect on the
level of expression of total Akt, as determined on Western blot analysis (data not shown). Controls were
cells stably transfected with lentivirus encoding scramble shRNA (shControl). Values are means (±SD)
of three experiments with triplicate determinations. *P < 0.05 versus shControl transfectants.
even nonproliferating ones, is a considerable advan¬
tage over other vectors. This feature in combination
with the emerging power of RNA interference will
facilitate development of viral RNA interference-
based therapies in oncology. The first clinical trial
involving a HIV-based lentiviral vector in AIDS
patients has already been completed in the United
States in 2005.41
In summary, our findings demonstrate for the first
time that suppression ofHMGA1 expression by len-
tivirus-mediated RNA interference represents a novel
strategy for chemosensitizing pancreatic adenocarci¬
noma to gemcitabine. As such, HMGA1 warrants
further investigation as a therapeutic target in
pancreatic adenocarcinoma.
We gratefully acknowledge the technical assistance of Jan D.
Rounds.
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Mark P. Callery, M.D., Boston, Mass: Thank
you. Dr. Liau, you have shown us that HMGA-1
knockdown chemosensitizes these pancreatic cancer
cell lines to gemcitabine. You achieved this both in
cultured cells and in xenografts generated by these
HMGA-1 knockdown cells. You implicate a reduc¬
tion in Akt kinase activity upon HMGA-1 knock¬
down, and because you could defeat this and
apoptotic survival pathway, you suggest we can use
this molecule as a target for future therapy. Your hy¬
pothesis was tested with a logical series of experi¬
ments and presented to us quite nicely.
Do you have actual data for HMGA-1 overexpres-
sion in human pancreatic cancer specimens, and do
you have any idea as to the mechanism of HMGA-
1 overexpression? Does HMGA-1 correlate or better
cause a particularly malignant phenotype, for exam¬
ple, cellular invasiveness or metastasis? Finally, how
might you suggest targeting FLMGA-l for theraply?
Are there any available drugs today?
Now, I asked you this on Saturday as well, but
your xenografts were all made with customized
knockdown cells, something that is just not possible
in the clinical setting. Can you deliver somehow your
silencer to native xenografts, prove that HMGA-1
knockdown occurs, and in fact sensitizes them to
treatment with gemcitabine?
Congratulations to you and Stan Ashley, and par¬
ticularly Ed Whang. You all can be justifiably proud
of your contribution.
Siong-Seng Liau, M.D., Boston, Mass: Thank
you very much, Dr. Callery. To answer these ques¬
tions, we have embarked on looking at the
expressin of HMGA-1 in pancreatic cancer tissues.
We previously constructed a tissue microarray
containing samples from 89 patients with pan¬
creatic cancer. Of these 89 patients, 92% have
tumoral HMGA-1 overexpression on immunohisto-
chemistry, with little or no expression in normal
pancreas.
In terms of the effect of HMGA-1 on the malig¬
nant phenotype of pancreatic cancers, we previously
have shown that silencing ofHMGA-1 results in sig¬
nificant reductions in cellular invasiveness and in in
vivo metastasis. In addition, we have shown that
overexpression of HMGA-1 allows these cells to
grow under anchorage independent conditions, that
is, in a soft agar colony formation assay. The reverse
is also true; as we silence HMGA-1, there is a signif¬
icant reduction in the ability of these cells to grow
under anchorage independent conditions. HMGA-
1 silencing is also associated with a reduction in
tumor size in a nude mouse xenograft model of
pancreatic cancer.
There is no drug that specifically targets HMGA-
1. There is a family of drugs, related to mitomycin
C, that crosslinks FLMGA-1 to DNA. Howeer, these
agents are by no means specific inhibitors of
HMGA-1 activity.
It is true that the xenografts we implanted to
demonstrate in vivo chemosensitivity were derived
from stably transfected cells. We are currently em¬
barking on a gene therapy approach to pancreatic
cancer in which we generate a high titre lentivirus
expressing hairpin RNA targeting HMGA-1. We
hope to demonstrate that intratumoral injection of
this lentivirus will chemosensitize pancreatic cancer
xenografts.
In closing, I'd like to thank you for insightful
questions and kind comments.
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HMGA1 Is a Molecular Determinant of Chemoresistance
to Gemcitabine in Pancreatic Adenocarcinoma
Siong-Seng Liau and Edward Whang
Abstract Purpose: HMGA1 proteins are architectural transcription factors that are overexpressed by
pancreatic adenocarcinomas. We previously have shown that RNA interference targeting the
HMGA1 gene may represent a potential chemosensitizing strategy in pancreatic adenocarcinoma
cells. In this study, we tested the hypothesis that HMGA1 promotes chemoresistance to gemcitabine
in pancreatic cancer cells.
Experimental Design and Results: Stable short hairpin RNA-mediated HMGA1 silencing in
BxPC3 and MiaPaCa2 cells promoted chemosensitivity to gemcitabine, with reductions in gem¬
citabine IC50 and increases in gemcitabine-induced apoptosis and caspase-3 activation. In con¬
trast, forced HMGA1 overexpression in MiaPaCa2 cells promoted chemoresistance to
gemcitabine, with increases in gemcitabine IC50 and reductions in gemcitabine-induced apopto¬
sis and caspase-3 activation. Dominant negative Akt abrogated HMGA1 overexpression -
induced increases in chemoresistance to gemcitabine. Finally, HMGA1 silencing promoted
chemosensitivity to gemcitabine in vivo in a nude mouse xenograft model of pancreatic adeno¬
carcinoma.
Conclusion: Our findings suggest that HMGA1 promotes chemoresistance to gemcitabine
through an Akt-dependent mechanism.Targeted therapies directed at HMGA1 represent a poten¬
tial strategy for ameliorating chemoresistance in pancreatic adenocarcinoma.
Overall prognosis for patients diagnosed with pancreatic
adenocarcinoma remains dismal, with 5-year survival rates
averaging <5% (1). At the time of diagnosis, most patients
have locally advanced or metastatic disease precluding
surgical resection (2). First line therapy for most patients
with advanced pancreatic cancer is based on the nucleoside
analogue gemcitabine. However, the clinical response rate to
gemcitabine remains modest, in large part due to the
profound chemoresistance inherent in pancreatic cancer cells.
Therefore, characterization of mechanisms mediating chemo¬
resistance in pancreatic adenocarcinoma is an important
priority.
The human HMGA1 gene, located on chromosomal locus
6p21, encodes two HMGA1 splice variants (HMGAla and
HMGAlb; ref. 3). These HMGA1 proteins are architectural
transcription factors that form stereospecific, multiprotein
complexes termed "enhanceosomes" on the promoter/enhancer
regions of genes they regulate (4-6). Each HMGA1 protein has
three AT-hook domains that can bind to the minor groove of
AT-rich DNA sequences (4, 7). HMGA1 proteins are overex-
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pressed in a wide range of human cancers, including pancreatic
adenocarcinoma (8-15). Further, tumoral HMGA1 overexpres¬
sion has been reported to be associated with poor prognosis in
cancer patients (9, 10, 16).
Our group has previously reported the important roles
played by HMGA1 in mediating cellular invasiveness and
metastatic potential of pancreatic adenocarcinoma cells (17).
Overexpression of HMGA1 promotes cellular invasion in vitro
whereas posttranscriptional silencing of HMGA1 inhibits the
ability of pancreatic adenocarcinoma cells to form metastases
in vivo. Furthermore, we showed that overexpression of
HMGA1 is associated with increased resistance to apoptosis
under anchorage-independent culture ("anoikis resistance";
ref. 18). In these studies, we have reported that Akt is a key
downstream effector of HMGA1-dependent signaling in pan¬
creatic cancer (17). Given the central role of Akt in mediating
chemoresistance to gemcitabine (19 - 21), we hypothesized that
HMGA1 would promote chemoresistance to this agent through
an Akt-dependent mechanism. In this study, we have confirmed
this hypothesis to be correct, and in addition, we have shown
that targeted posttranscriptional silencing of HMGA1 promotes
chemosensitivity in vivo. In conclusion, our findings are of
particular clinical importance as they suggest that targeted
therapies directed against HMGA1 may ameliorate chemo¬
resistance to gemcitabine.
Materials and Methods
Cells and cell culture. MiaPaCa2 and PANC1 human pancreatic
ductal adenocarcinoma cells were obtained from American Type
Culture Collection. Cells were maintained in DMEM containing 10%
fetal bovine serum (Life Technologies) and incubated in a humidified
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(37°C, 5% C02) incubator, grown in 75-cm2 culture flasks, and
passaged on reaching 80% confluence.
Reagents and dominant negative Akt constructs. Anti-HMGAl, anti -
lamin Bl, anti-phospho-Akt (Ser473), anti-Aktl, and anti-hemagglutinin
antibodies were obtained from Santa Cruz Biotechnology. Hemaggluti-
nin-tagged dominant negative Akt adenovirus (Ad-DN-Akt) and its
control adenovirus (Ad-CMV-Null), both titered at 1 x lO10 plaque-
forming units per milliliter, were purchased from Vector Biolabs.
Lentivirus-mediated HMGA1 RNA interference. Hairpin RNA in¬
terference plasmids (pLKO.l-HMGAl, TRCN0000018949) were
obtained from The RNAi Consortium (Sigma Aldrich). The sequences
of short hairpin RNA targeting the human HMGA1 gene (Genbank
accession no. NM_002131) was 5'-CAACTCCAGGAAGGAAACCAA-3'
(shHMGAl targets coding region positions 446-466 of HMGA1
mRNA transcript variant 2). The control PLKO.l plasmid, which has
a scrambled nontargeting short-hairpin RNA sequence, was obtained
from Addgene (22). High-titer lentivirus expressing shHMGAl and
control short hairpin RNA (shRNA) were generated from five-plasmid
transient transfection into 293T cells. Helper plasmids included
pHDM-Hgpm2, pMD-tat, pRC/CMV-rev, and pCMV-VSV-G obtained
from Harvard Gene Therapy Initiative (Harvard Medical School,
Boston, MA). The lentiviral transfer vectors were either control
PLKO.l (nontargeting shRNA sequence) or shHMGAl plasmids as
described above. Virus preparations were concentrated by ultracen-
trifuge and titered by Southern blotting. We achieved titer of 7.2 x
108/mL for control shRNA lentivirus and 2.5 x 10s/mL for
shHMGAl lentivirus. Pooled stable transfectants were developed
following infection of lentivirus at multiplicity of infection of 10 for
48 hours, and stable selection in puromycin was achieved as
described above.
Expression vector and transfection. The HMGA1 coding sequence
was PCR amplified from IMAGE clone 5399570 (Genbank accession no.
BC063434) using gene-specific primers modified to include the
appropriate restriction sites at their 5' end. The primers used were as
follows: forward, 5'-TTTTGATATCATGAGTGAGTCGAGCTCGAAG-3'
and backward, 5'-TnTGAATTCTCACTGCTCCTCCTCCGAGGA-3'. Pu¬
rified PCR products were digested with EcoRV and EcoRI, before ligation
into a EcoRV/EcoRI-digested pIRES-puro3 vector (Clontech). The
expression plasmids were named pIRES-HMGAl. MiaPaCa2 cells were
transfected with pIRES-HMGAl or empty pIRES-puro3 (control), using
Lipofectamine 2000 (Invitrogen) in accordance with the manufacturer's
protocol. Stable clones were selected by exposure to incrementally
increasing concentrations of puromycin (Invivogen), isolated using
cloning cylinders, and maintained in medium containing 3 pg/mL puro¬
mycin (Invivogen). Clones pIRES-HMGAl.l and pIRES-HMGA1.2, which
expressed the highest levels of HMGA1, were used for further studies.
Western blotting. Cells were harvested and rinsed twice with PBS.
Total cell extracts were prepared with Phosphosafe lysis buffer
(Novagen). Nuclear extracts were prepared using NE-PER Nuclear and
Cytoplasmic Extraction Reagents based on the manufacturer's instruc¬
tion (Pierce). Protein concentration was measured using the BCA assay
kit (Sigma). Cellular protein was subjected to 10% SDS-PAGE and
transferred electrophoretically to polyvinylidene difluoride membranes
(Invitrogen). After blocking with PBS containing 3% bovine serum
albumin for 1 hour at room temperature, membranes were incubated
with 3 to 5 mg/mL antibody in PBS containing 0.1% Tween 20
overnight at 4°C. Chemoluminescence detection (Amersham Bioscien¬
ces) was done in accordance with the manufacturer's instructions. The
densitometric signal was quantified using ImagePro Plus software
version 4.0 (Media Cybernetics).
Cytotoxicity assay. Gemcitabine-induced cytotoxicity was quantified
by a MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium| assay (CellTiter 96, Promega). Cells
were seeded into 96-well plates at 5 x 103 per well and allowed to ad¬
here overnight. Cell viability was determined after 48 to 72 hours in
presence or absence of0 to 10 pmoI/L gemcitabine. Plates were read with
the use of the SpectraMax M5 microplate spectrophotometer (Molecular
Devices) at a wavelength of 490 nm. IC50 values were calculated. At
identical time points, cell counting was done. Viable cells, identified by
trypan blue exclusion, were counted using a Neubauer hemocytometer
(Hausser Scientific). Cell counting confirmed MTS results.
Apoptosis assay. After exposure to gemcitabine (1 pmol/L) for up to
24 hours, 1 x 106 cells were washed, trypsinized, and resuspended in
0.5 mL of PBS containing 2% fetal bovine serum and 0.1 pmol/L EDTA.
Apoptosis staining was done using 1 pL/mL YO-PRO-1 and propidium
iodide (Vybrant Apoptosis Assay Kit 4; Molecular Probes). Cells were
then analyzed by flow cytometry (FACScan; Becton Dickinson),
measuring fluorescence emission at 530 and 575 nm. Cells stained
with the green fluorescent dye YO-PRO-1 were counted as apoptotic;
necrotic cells were stained with propidium iodide. The number of
apoptotic cells was divided by the total number of cells (minimum of
104 cells) to calculate the apoptotic fraction.
Fluorometric caspase profiling. Whole-cell lysates were assayed for
caspase-3 activity using the BD ApoAlert Caspase Assay Plate (BD
Biosciences) according to the manufacturer's instructions. Plates were
read (excitation, 360 nm; emission, 480 nm) using SpectraMax M5
microplate reader in fluorescence mode (Molecular Devices).
Nude mouse subcutaneous xenograft model. Male athymic nu/nu
mice 5 weeks of age, weighing 20 to 22 g, and specific pathogen-free
were obtained from Harlan Sprague-Dawley. Mice were housed in
microisolator cages in a pathogen-free facility with 12 hours light-dark
cycles. Animals were observed for signs of tumor growth, activity,
feeding, and pain in accordance with the guidelines of the Harvard
Medical Area Standing Committee on Animals. To determine the effect
of HMGA1 gene silencing on in vivo chemosensitivity, 2 x 106 BxPC3
cells stably expressing control or HMGA1 shRNA (shHMGAl. 1
sequence, lentiviral transduction) were s.c. implanted in nude mice.
Mice were anesthetized with i.p. ketamine (200 mg/kg) and xylazine
(10 mg/kg) and inoculated with 2 x 106 cells in 100 pL of PBS s.c.
Gemcitabine administration was commenced 14 days after implanta¬
tion when tumors were -50 mm3 in volume. Mice received
gemcitabine (150 mg/kg) in 100 pL of PBS vehicle by twice-weekly
1.p. injection. Tumor dimensions were measured weekly using
micrometer calipers. Tumor volumes were calculated using the
following formula: volume = 1/2 a x b2, where a and b represent the
larger and smaller tumor diameters, respectively. After 6 weeks of
gemcitabine administration and 4 days after final gemcitabine
injection, necropsy was done, and the primary tumor was excised,
formalin-fixed, and paraffin embedded.
Immunohistochemistry. Tumor sections (5 pm) were deparaffinized,
rehydrated through graded alcohol, and processed using a streptavidin-
biotin-peroxidase complex method. Sections were incubated with anti-
HMGA1 antibody (Santa Cruz Biotechnology) at 4°C overnight at a
1:50 dilution. The secondary antibody was biotinylated rabbit anti-goat
antibody (DAKO) used at a dilution of 1:200 for 30 minutes at 37°C.
Sections were then incubated with StrepABComplex/horseradish
peroxidase (1:100; DAKO) for 30 minutes at 37°C. Immunolocaliza-
tion was done by exposure to 0.05% 3,3'-diaminobenzidine tetrahy-
drochloride as the chromogen. Normal serum was used in the place of
primary antibody as a negative control.
Apoptosis staining. Following preparation of 5-pm tumor sections,
apoptosis was quantified using a commercially available terminal
deoxynucleotidyl transferase nick-end labeling (TUNEL) kit, in accor¬
dance with the manufacturer's protocol (Chemicon). The number of
apoptotic cells in at least five random fields from each section was
counted. The apoptotic index was calculated by dividing the number of
TUNEL-positive cells by the total number of nuclei counted in each field.
Statistical analysis. Differences between groups were analyzed using
Student's t test, multifactorial ANOVA of initial measurements, and
Mann-Whitney U test, for nonparametric data, as appropriate, using
Statistica 5.5 software (StatSoft, Inc.). In cases in which averages were
normalized to controls, the SDs of each nominator and denominator
were taken into account in calculating the final SD. P < 0.05 was
considered statistically significant.
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Results
HMGA1 is a molecular determinant of chemoresistance to
gemcitabine in pancreatic adenocarcinoma cells. Lentivirus-
mediated HMGA1 silencing resulted in a marked increase in
chemosensitivity to gemcitabine in BxPC3 cells (in which we
achieved almost 90% silencing of HMGA1 protein expression;
Fig. 1A), with ~ 4-fold reductions in IC50 to gemcitabine (mean
IC50, control shRNA versus shHMGAl; 50 versus 12 nmol/L,
P = 0.001; Fig. 1C and D). Interestingly, BxPC3 cells in which
HMGA1 had been silenced developed spiculated morphology
on exposure to 1 gmol/L gemcitabine for 48 hours, whereas
control cells did not (Fig. IB). In our previous study, we
achieved up to 90% silencing of HMGA1 expression in
MiaPaCa2 cells using lentivirus-expressing shRNA with the
same target sequence (23). In the current study, we achieved a
similar degree of HMGA1 knockdown in MiaPaCa2 cells (data
not shown). Lentivirus-mediated HMGA1 silencing had similar
effects on MiaPaCa2 cells, with shifting of the gemcitabine IC50
curve to the left (Fig. 2B) and ~ 2-fold reductions on IC50
(mean IC50, control shRNA versus shHMGAl; 60 versus
30 nmol/L, P = 0.001; Fig. 2D).
We then tested the effect of forced overexpression of HMGA1
on cellular chemoresistance to gemcitabine. MiaPaCa2 cells
(which have low inherent expression of HMGA1) were stably
transfected with the pIRES-HMGAl vector, as described in
Materials and Methods. We selected two transfectant clones
with highest expression levels of HMGA1 (plRES-HMGAl.l
and pIRES-HMGA1.2). In our previous studies, we have
characterized the plRES-HMGAl.l and plRES-HMGA1.2 clones
and verified their overexpression of HMGA1 by Western
analysis (17, 18). plRES-HMGAl.l and pIRES-HMGA1.2 clones
overexpress HMGA1 by 4-fold and 3.5-fold, respectively, when
compared with empty pIRES-puro3 transfectants (data not
shown). Overexpression of HMGA1 resulted in significant
increases in chemoresistance to gemcitabine, with increases in
1C50 to gemcitabine (Fig. 2D) and shifting of the IC50 curves to
the right for both plRES-HMGAl.l and pIRES-HMGA1.2 clones
(Fig. 2C). The mean IC50 for plRES-HMGAl.l and pIRES-
HMGA1.2 were 130 and 100 nmol/L, respectively (P = 0.003
and P = 0.006, respectively, versus empty pIRES-puro3
controls). Notably, plRES-HMGAl.l consistently overexpressed
HMGA1 to a greater degree than plRES-HMGA1.2; this
greater HMGA1 overexpression was associated with a higher
mean IC50 value. Forced HMGA1 overexpression enhanced the
viability of cells exposed to 1 pmol/L of gemcitabine for
72 hours, whereas HGMA1 silencing was associated with the
opposite effect (Fig. 2A).
HMGA1 expression status modulates gemcitabine-induced
apoptosis and caspase-3 activation. Following exposure to
1 pmol/L gemcitabine for 24 hours, cells were subjected to
flow cytometric quantitation of apoptosis and fluorometric
caspase-3 profiling. Lentivirus-mediated HMGA1 silencing was
associated with increases in gemcitabine-induced apoptosis
(Fig. 3A) and caspase-3 activation in both BxPC3 and MiaPaca2
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Fig. 1. A, following the generation of high-titer lentivirus particles carrying shHMGAl, BxPC3 was transduced with lentivirus at multiplicity of infection of 10 and stable
transfectants were developed following selection with puromycin. Robust suppression of HMGA1 was achieved using lentivirus with a high degree of silencing of HMGA1.
In BxPC3 cells, lentivirus-mediated shHMGAl achieved almost complete silencing of HMGA1. Controls were stable transfectants developed using lentivirus carrying
scrambled, nontargeting shRNA. B, the effects of lentivirus-mediated HMGA1 silencing on chemosensitivity to gemcitabine were assessed.When BxPC3 cells in
which HMGA1 had been silenced were exposed to 1 pnol/L gemcitabine for 48 h, they adopted a less healthy, speculated morphology compared with control cells.
Photomicrographs were taken using an inverted microscope at x40 magnification. C, survival curves following exposure to 0 to 10 pmol/L gemcitabine were analyzed
following MTS assay. Lentivirus-mediated stable HMGA1 silencing in BxPC3 cells shifted the survival curve to the left, indicating an increase in chemosensitivity
to gemcitabine, when compared with the controls. Correspondingly, there was a 4-fold reduction in the IC50 to gemcitabine with silencing of HMGA1 when compared
with the controls. \ P = 0.001 versus control shRNA.
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Fig. 2. MiaPaCa2 cells were transduced
with shRNA lentivirus at multiplicity of
infection of 10 and stable transfectants
were developed following selection with
puromycin. Stable silencing of HMGA1
was confirmed byWestern analysis (data
not shown). Two previously characterized
clones (plRES-HMGA1.1 and
plRES-HMGA1.2) of MiaPaCa2 cells
that stably overexpress HMGA1 were
used in this study (18). Controls were
cells stably transfected with empty
plRES-puro3 vector. A, the effects of
modulating HMGA1 expression on
chemosensitivity to gemcitabine in
MiaPaCa2 cells was assessed.
In MiaPaCa2 cells, lentivirus-mediated
silencing of HMGA1 resulted in marked
reductions in cellular viability compared
with controls when exposed to 1 jimol/L
gemcitabine for 72 h. In contrast,
MiaPaCa2 cells with HMGA1
overexpression (plRES-HMGA1.1 and
plRES-HMGA1.2) showed increased
viability following exposure to 1 pmol/L
gemcitabine, when compared with
empty plRES-puro3 transfectants.
Photomicrographs were taken using an
inverted microscope at x40 magnification.
B and C, lentivirus-mediated RNA
interference of HMGA1 in MiaPaCa2 cells
resulted in increases in chemosensitivity
to gemcitabine with shifting of survival
curves to the left, whereas overexpression
of HMGA1 led to increases in
chemoresistance to gemcitabine with
shifting of the survival curves to the right in
both plRES-HMGA1.1 and plRES-HMGA1.2
clones, compared with their respective
controls. D, targeted suppression of
HMGA1 using lentivirus-mediated
shHMGAI resulted in 2-fold reductions
in IC50 compared with control (P = 0.001
versus control shRNA), whereas
overexpression of HMGA1 in pIRES-
HMGA1.1 and plRES-HMGA1.2 clones
resulted in - 2.2- and 1.7-fold increases
in IC50 to gemcitabine, respectively
[P = 0.003 (plRES-HMGA1.1) and
P = 0.006 (plRES-HMGA1.2) versus empty
plRES-puro3 control]. *, P < 0.05 versus
control shRNA transfectants. **, P < 0.05
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associated with reductions in gemcitabine-induced apoptosis
and in caspase-3 activation (Fig. 3B and D).
HMGA1-induced chemoresistance to gemcitabine is dependent
on Akt signaling. We have previously reported that Akt is a
downstream effector of HMGA1 (18, 23). We have found that
HMGA1 silencing is associated with reductions in Akt
phosphorylation (a marker of Akt activation), whereas forced
HMGA1 overexpression is associated with increases in Akt
kinase activity and in Akt phosphorylation (17, 18). Given the
importance of the phosphatidylinositol 3-kinase/Akt pathway
in antiapoptotic signaling, particularly in the context of
chemoresistance, we sought to determine if chemoresistance
to gemcitabine-induced HMGA1 overexpression is Akt depen¬
dent. Each of pIRES-HMGAl.l and pIRES-HMGA1.2 clones
were transduced with dominant negative Akt adenovirus at
multiplicity of infection of 10. The efficiency of transduction
and expression of dominant negative Akt were confirmed by
immunoblotting for the hemagglutinin tag of the dominant
negative Akt construct (Fig. 4). We next assessed the effects of
dominant negative Akt on chemosensitivity to gemcitabine in
each FlMGAl-overexpressing clone. Dominant negative Akt was
found to reverse the chemoresistance induced by HMGA1
overexpression, with reductions of IC50 to gemcitabine in both
pIRES-HMGAl.l and pIRES-HMGAl.2 clones. As such,
HMGA1 overexpression - induced chemoresistance is depen¬
dent on Akt signaling.
HMGA1 silencing promotes chemosensitivity to gemcitabine
in vivo. BxPC3 cells in which HMGA1 had been silenced
through stable lentiviral shRNA-mediated RNAi or control BxPC3
cells transduced with lentivirus carrying nontargeting shRNA
were s.c. implanted into nude mice. Once the resulting xenograft
tumors had grown to reach — 50 mm3 in diameter, a 6-week
course of gemcitabine administration was initiated. Tumors
derived from BxPC3 cells in which 1IMGA1 had been silenced
(n = 8 animals) regressed during the treatment period, whereas
tumors derived from control cells (n = 8 animals) continued to
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Fig. 3. A, lentivirus-mediated silencing of HMGA1 promoted gemcitabine-induced apoptosis as assessed by flow cytometric analyses ofYO-PRO-1/propidium
iodide - stained cells. Silencing of HMGA1 resulted in - 2-fold increases in the relative apoptotic rates in both BxPC3 and MiaPaCa2 cells following exposure to 1 pmol/L
gemcitabine for 24 h. #, P - 0.001 versus control shRNA. Representative flow cytometric images of three experiments are shown, with the apoptotic fractions being
highlighted in triangles drawn. B, forced overexpression of HMGA1 in plRES-HMGA1.1 and HMGA1.2 clones protected the cells from gemcitabine-induced apoptosis with
~ 70% to 80% reductions in relative apoptotic rates, as assessed by flow cytometry [P = 0.001 (plRES-HMGA1.1) and P = 0.002 (plRES-HMGA1.2) versus empty
plRES-puro3 control]. *, P < 0.05 versus empty plRES-puro3 control. Representative flow cytometric images of three independent experiments are shown, with the
apoptotic fractions being highlighted in triangles drawn. C, relative caspase-3 activities were determined using a fluorometric caspase-3 substrate assay following
exposure of cells to 1 |imol/L gemcitabine for 24 h. Lentivirus-mediated silencing of HMGA1 promoted gemcitabine-induced caspase-3 activities. *, P = 0.008 (BxPC3)
and P = 0.005 (MiaPaCa2) versus control shRNAtransfectants. D, as expected, overexpression of HMGA1 in plRES-HMGA1.1 and plRES-HMGA1.2 clones resulted in
reductions in caspase-3 activation following exposure to 1 (amol/L gemcitabine for 24 h, indicating protection from gemcitabine-induced caspase-mediated apoptosis.

































































grow during the treatment period (Fig. 5A-C). Stable suppres¬
sion of HMGA1 expression in tumors derived from shHMGAl
transfectants was confirmed on Western blotting of nuclear
extracts of tumor homogenates (Fig. 6A) and on immunohis-
tochemical analysis of xenografts harvested at the end of the
study period (Fig. 6B). TUNEL staining revealed significantly
higher apoptotic index in shHMGAl transfectant-derived
tumors than in control cell-derived tumors (Fig. 6B and C).
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Discussion
HMGAl proteins are overexpressed in a wide range of human
cancers, including pancreatic adenocarcinoma (8). Experimen¬
tal data implicating biologically important roles for HMGAl in
cancer pathogenesis are rapidly accumulating (24, 25). Our
study provides the first data suggesting that HMGAl may
mediate a critical feature of malignant phenotype: chemo¬
resistance. First, our findings show that forced HMGAl over-
expression promotes chemoresistance to gemcitabine in
pancreatic cancer cells in vitro, whereas HMGAl silencing
promotes gemcitabine-induced cytotoxicity and therefore abro¬
gates chemoresistance to gemcitabine. Second, we have
confirmed that HMGAl silencing promotes gemcitabine-
induced cytotoxicity and reduces tumor growth in vivo in a
nude mouse xenograft model of pancreatic cancer. Finally, our
findings suggest a plausible mechanism by which HMGAl
promotes chemoresistance to gemcitabine: activation of Akt
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Fig. 4. We have previously reported that in MiaPaCa2 cells, HMGA1 silencing
reduces Akt phosphorylation whereas HMGA1 overexpression promotes Akt
phosphorylation, and neither HMGA1 silencing nor overexpression have any effect
on the level of expression of total Akt. To assess the role of Akt in mediating
the HMGA1-induced chemoresistance, we transduced plRES-HMGA1.1 and
plRES-HMGA1.2 clones with adenovirus carrying hemagglutinin-tagged dominant
negative Akt to examine its effects on chemoresistance. Transduction efficiency
and expression of dominant negative Akt were assessed byWestern blotting for
hemagglutinin. Infection of plRES-HMGA1.1 and plRES-HMGA1.2 clones with
adenovirus carrying dominant negativeAkt (Ad-DN-Akt) resulted in significant
reductions in IC50 to gemcitabine when compared with cells infected with control
adenovirus (Ad-CMV-Null). Dominant negative Akt resulted in reductions in IC50
to gemcitabine in plRES-HMGA1.1 and plRES-HMGA1.2 clones to levels similar to
parental MiaPaCa2 cells or empty plRES-puro3 transfectants, indicating abrogation
of the increased chemoresistance associated with HMGA1 overexpression.
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Fig. 5. A, stable silencing of HMGA1 promoted chemosensitivity to gemcitabine
in vivo with evidence of tumor regression in nude mouse s.c. model. Mice (n = 8
per group) were s.c. implanted with 2 x 106 lentivirus-mediated stable transfectant
BxPC3 cells (either shHMGAI or control shRNA). Gemcitabine treatment was
commenced in each group 14 d after implantation when the tumors were ~ 50 mm3
in volume. Mice received gemcitabine (150 mg/kg) in 100 jiL of PBS vehicle by
twice-weekly i.p. injection. Subcutaneous tumor size was monitored weekly
during the 6 wk of treatment. Tumors with HMGA1 silencing showed evidence of
regression in size during the treatment period whereas tumors in the control group
continued to grow with time. Points, mean; bars, SD. *, P < 0.05 versus control
shRNA xenografts. B, representative photograph of one mouse from each group
is shown, with tumors located in their flanks. C, the explanted tumors at the end of
the 6-wk treatment period. Of note, one of the mice in the shHMGAI group had its
tumor completely regressed during the 6-wk gemcitabine treatment period.
described as a mediator of chemoresistance to gemcitabine in
the context of pancreatic cancer (19, 26, 27). These findings
imply that targeted suppression or inactivation of HMGAl
could be a potential therapeutic strategy for increasing chemo¬
sensitivity to gemcitabine in this highly chemoresistant cancer.
Proposed mechanisms by which HMGAl regulates gene
expression include derepression of gene promoters by displace¬
ment of histone HI nucleoproteins, which are strong repressors
of gene transcription, from scaffold attachment regions, thus
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allowing for a more open chromatin structure that facilitates
transcriptional activation (28). Further, HMGA1 is able to bind
to AT-rich promoter regions, where it modifies DNA confor¬
mation to facilitate binding of other transcriptional factors that
promote gene transcription (29). By binding to promoter
regions, HMGA1 is also able to form multiprotein complexes,
the enhanceosomes, that serve as transcription-activating
complexes (29). Given these putative functions, it is not
surprising that HMGA1 is involved in the regulation of a large
number of target genes. Previous studies have shown that
HMGA1 overexpression is associated with increased expression
ofgrowth factors/cytokines (e.g., fibroblast growth factors, IFNs
a and (3, and interleukins 10-14 and 17), growth factor
receptors (e.g., fibroblast growth factor receptor, epidermal
growth factor receptor, ERBB3, and ERBB4), and multiple
integrins (o^, a6, a9, aE, f>,, p3, p8; ref. 24). Clearly, it is not
surprising that through induction of these growth factor-
related signaling pathways, HMGA1 could have an effect on
prosurvival phosphatidylinositol 3-kinase/Akt pathways, as
shown in this study. It is also plausible that by increasing
integrin expression, F1MGA1 may stimulate integrin-linked
kinase, which is known to directly interact with integrins
and phosphorylate Akt in a phosphatidylinositol 3-kinase-
dependent manner (30).
In the current study, we have examined the effects of
silencing HMGA1 on chemoresistance in BxPC3 and Mia-
PaCa2 pancreatic adenocarcinoma cells. BxPC3 cells inherently
express relatively high levels of HMGA1 whereas MiaPaCa2
cells inherently express relatively low levels of HMGA1 under
baseline conditions. Because these cell lines differ in ways
other than in HMGA1 expression levels alone, we examined
the effects of modulating HMGA1 expression in a single cell
line system. This approach allowed us to control for potential
confounders, such as variable K-ras mutation status (31),
inherent in comparisons involving multiple cell lines. We did
both loss-of-function (HMGA1 silencing) and gain-of-function
(HMGA1 overexpression) experiments on MiaPaCa2 cells. As
such, by using the same cell line and theoretically controlling
for variations in genetic background, we were able to show
that HMGA1 silencing reduces chemoresistance whereas
HMGA1 overexpression results in the reverse effects on
chemoresistance.
Although gemcitabine-based regimens are currently standard
of care for the treatment of advanced pancreatic cancer, their
efficacy is limited by profound chemoresistance. Recently, the
combination of gemcitabine and the human epidermal growth
factor receptor tyrosine kinase inhibitor erlotinib has been


























*: * *' %. ■*• t ** * M * # -
: ***r- '





Fig. 6. A, in vivo HMGA1 silencing was
confirmed byWestern blot analysis of
nuclear extracts from explanted xenograft
tumors. Columns, mean; bars, SD.
*, P - 0.001 versus control shRNA
xenografts. B and C, immunohistochemistry
of xenograft sections showed little or absent
staining for HMGA1 in the shHMGAI
xenografts, when compared with
the control shRNA xenografts that
showed intense staining for HMGA1.
Photomicrograph of HMGA1 staining was
obtained at x40 magnification. In the same
sections,TUNEL staining was done. In each
tumor slide stained with TUNEL, the number
ofTUNEL-positive cells was counted in at
least five randomly selected fields at x40
magnification. HMGA1 silencing led to
significant increases in relative apoptotic
index when compared with control shRNA
xenografts. Representative tumor sections
stained forTUNEL photographed at x20
magnification. *, P < 0.001 versus control
shRNA xenografts. Columns, mean;
bars, SD.
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survival over single-agent gemcitabine in patients with ad¬
vanced pancreatic cancer in a phase 111 clinical trial (32).
Although these results are encouraging, the benefits provided
by the addition of erlotinib are only incremental. Truly
transformative increases in efficacy are likely to arise only
through incorporation of targeted therapies selected on the
basis of rational understanding of mechanisms mediating
chemoresistance in pancreatic cancer. In this context, our
findings suggest that HMGA1 warrants further investigation as
a novel therapeutic target in this deadly cancer.
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BACKGROUND. High mobility group AT-hook 1 (HMGA1) proteins are architectural
transcription factors that are overexpressed by pancreatic adenocarcinomas. The
authors hypothesized that tumor HMGA1 status represents a novel prognostic
marker in pancreatic adenocarcinoma. They also tested the hypothesis that
HMGA1 promotes anchorage-independent cellular proliferation and in vivo
tumorigenicity.
METHODS. Tumor HMGA1 expression was examined by immunohistochemical
analysis of tissues from 89 consecutive patients who underwent resection for
pancreatic adenocarcinoma. Short-hairpin RNA (shRNA)-mediated RNA interfer¬
ence was used to silence HMGA1 expression in MiaPaCa2 and PANC1 pancreatic
cancer cells. Anchorage-independent proliferation was assessed by using soft
agar assays. The roles of phosphatidylinositol 3-kinase (PI3-K)/Akt and extracellu¬
lar signal-regulated kinase (ERK) signaling were investigated by using specific
inhibitors and adenoviral dominant-negative/active Akt constructs. In vivo
tumorigenicity was assessed by using a nude mouse xenograft model.
RESULTS. Tumor HMGA1 expression was detected in 93% of patients with pan¬
creatic adenocarcinoma. Patients with HMGAl-negative tumors had a signifi¬
cantly longer median survival than patients with HMGA1-expressing cancers in
univariate analysis (P = .0028) and in multivariate analysis (P<05). shRNA-
mediated HMGA1 silencing resulted in significant reductions in anchorage-inde¬
pendent proliferation in soft agar. Forced HMGA1 overexpression promoted pro¬
liferation in soft agar through a process that was dependent on PI3-K/Akt-
activited signaling, but not on mitogen-activated protein kinase (MEKJ/ERK sig¬
naling. Targeted silencing of HMGA1 reduced tumor growth in vivo through
reduced proliferation (Ki-67 index) and increased apoptosis (terminal deoxynu-
cleotidyl transferase nick-end labeling).
CONCLUSIONS. The current findings suggested that HMGA1 is an independent
predictor of poor postoperative survival in patients with pancreatic adenocarci¬
noma. Furthermore, HMGA1 promotes tumorigenicity through a PI3-K/Akt-de-
pendent mechanism. HMGA1 warrants further evaluation as a prognostic marker
and therapeutic target in pancreatic cancer. Cancer 2008;113:302-14. © 2008
American Cancer Society.
KEYWORDS: high mobility group AT-hook 1, Akt, extracellular signal-regulated
kinase, growth, survival, pancreatic adenocarcinoma.
Pancreatic adenocarcinoma is the fourth leading cause of cancer-related death in the United States. Th overall prognosis for
patients who are diagnosed with this malignancy remains dismal,
with 5-year survival rates averaging <5%.1 The rational identifica¬
tion of clinically relevant therapeutic targets based on an under-
© 2008 American Cancer Society
D0I 10.1002/cncr.23560
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standing of the biologic mechanisms underlying the
aggressive behavior of pancreatic cancer is a high-
priority goal.
The human high mobility group AT-hook 1 gene
HMGA1, which is located on chromosomal locus
6p21, encodes 2 HMGA1 splice variants (HMGAla
and HMGAlb).2 These HMGA1 proteins are arc¬
hitectural transcription factors that regulate gene
expression in vivo.3,4 They form stereo-specific, mul-
tiprotein complexes termed "enhanceosomes" on the
promoter/enhancer regions of genes, where they
bind to the minor groove of AT-rich DNA
sequences.3,5 HMGA1 proteins are overexpressed in a
range of human cancers.6-9 By using a small sample
of tumor tissues, Abe and colleagues previously
demonstrated that HMGA1 is overexpressed in pan¬
creatic cancers, although the clinical relevance of
HMGA1 expression in this tumor type remains
uncertain.10 The degree of tumor HMGA1 expression
reportedly is correlated inversely with patient sur¬
vival duration in some human cancers.6,7 These cor¬
relative data suggest that HMGA1 may play an
important role in cancer progression; however, the
mechanisms by which HMGA1 may mediate features
of the malignant phenotype are poorly understood.
We demonstrated previously that HMGA1 promotes
pancreatic cancer cellular invasiveness and that the
targeted suppression of HMGA1 reduces metastasis
in vivo.11 We also demonstrated that HMGA1 pro¬
motes resistance to anoikis (apoptosis caused by the
loss of substratum attachment)12 and chemoresis-
tance to gemcitabine in pancreatic cancer cells.13
Although we have demonstrated that HMGA1 affects
the metastatic and apoptotic processes, its role in
pancreatic tumor growth is unknown, and its poten¬
tial as an antigrowth therapeutic target remains to be
explored.
To establish the clinical relevance of tumor
HMGA1 expression in patients with pancreatic can¬
cer, we examined tumor HMGA1 expression in a
large cohort of patients using a tissue microarray
(TMA) with clinicopathologic correlates. Our findings
suggest that tumor HMGA1 expression status repre¬
sents a biomarker that can be used to predict post¬
operative survival in patients who have undergone
surgical resection for pancreatic adenocarcinoma. In
this study, to further evaluate the potential roles of
HMGA1 in mediating the malignant phenotype, we
tested the hypotheses that HMGA1 promotes anchor¬
age-independent cellular proliferation in pancreatic
adenocarcinoma cells and that suppression of
HMGA1 expression would impair anchorage-inde¬
pendent proliferation in vitro and tumor growth in
vivo. Our observations indicate that HMGA1 indeed
promotes pancreatic adenocarcinoma tumorigenesis
and that a key effector of HMGA1-induced, anchor¬
age-independent growth is the phosphoinositidyl-3
kinase (PI3-K)/Akt pathway.
MATERIALS AND METHODS
Tissue Microarray Construction and Analysis
Under an Institutional Review Board-approved study
protocol, pathology reports were searched to identify
patients who underwent curative surgical resection
for pancreatic adenocarcinoma between the years
1991 and 2002 at Brigham and Women's Hospital. A
pancreatic adenocarcinoma TMA was constructed
from 89 consecutive patients who underwent cura¬
tive resection for pancreatic adenocarcinoma. Forma¬
lin-fixed, paraffin-embedded specimens were used to
construct the pancreatic adenocarcinoma TMA. Rep¬
resentative tumor regions were selected from each
tissue block, and 2 tissue cores (0.6 mm in greatest
dimension) were taken from each region using an
automated tissue arrayer (Beecher Instruments, Sun
Prairie, Wis). Cores also were taken from normal ad¬
jacent pancreas for use as internal controls. To avoid
areas of pancreas that may have harbored premalig-
nant changes (eg, desmoplasia), we selected only
cores that were normal morphologically as internal
controls during the TMA construction. Standard he¬
matoxylin and eosin-stained slides from each tumor
and its surrounding normal pancreas were reviewed
by a single pathologist (M.R.).
Five-micrometer sections were cut from each re¬
cipient block to make the TMA slides. Clinical infor¬
mation, including age, sex, and use of chemotherapy,
was gathered retrospectively from patient records.
Pathologic findings, including tumor size, stage, lym-
phovascular invasion (LVI), perineural invasion (PNI),
differentiation, surgical resection margin status, and
lymph node status, were obtained from original pa¬
thology reports. Pathologic staging was updated
according to current American Joint Committee on
Cancer guidelines.
TMA slides were deparaffinized and processed
using a streptavidin-biotin-peroxidase complex
method. Antigen retrieval was performed by micro¬
wave heating sections in 10 mM sodium citrate
buffer, pH 6.0, for 10 minutes. After quenching of en¬
dogenous peroxidase activity and blocking nonspeci¬
fic binding, anti-HMGAl antibody (Santa Cruz
Biotechnology, Inc., Santa Cruz, Calif) was added at
a 1:50 dilution; then, slides were incubated at 4 °C
overnight. The secondary biotinylated rabbit antigoat
antibody (DAKO, Carpinteria, Calif) was used at a
dilution of 1:200 for 30 minutes at 37 °C. Next, sec-
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tions were incubated with streptavidin-biotin com¬
plex/horseradish peroxidase (1:100 dilution; DAKO)
for 30 minutes at 37 °C. Chromogenic immunolocali-
zation was determined by exposure to 0.05% 3,3-dia-
minobenzidine tetrahydrochloride. Normal serum
was used in the place of primary antibody as a nega¬
tive control. Slides were reviewed by 2 independent
observers who were blinded to clinical and patho¬
logic data. HMGA1 was scored according to nuclear
staining intensity as follows: 0, no staining or weak-
intensity staining in <5% of cells; 1, weak-intensity
staining; 2, moderate-intensity staining; 3, strong-in¬
tensity staining. For statistical analyses, expression
was dichotomized into an HMGA1-negative group
(score 0) and an HMGA1-positive group (scores >1).
In cases of disagreement, a consensus was reached
by joint review.
Cells and Cell Culture
MiaPaCa2 and PANC1 human pancreatic ductal ade¬
nocarcinoma cells were obtained from American
Type Culture Collection (Manassas, Va). Cells were
maintained in Dulbecco Modified Eagle Medium
containing 10% fetal bovine serum (Gibco Life Tech¬
nologies Inc., Gaithersburg, Md).
Reagents and dominant-negative Akt adenovirus
The PI3-K inhibitor LY294002 and mitogen-activated
protein kinase 1/2 (MEK1/2) inhibitor PD98059 were
purchased from Calbiochem (San Diego, Calif). Anti-
HMGA1 and antilamin B1 antibodies were obtained
from Santa Cruz Biotechnology. Adenovirus carrying
dominant-negative (Ad-DN-Akt) and dominant-active
(Ad-myr-Akt) Aktl and control cytomegalovirus (Ad-
CMV-null) were obtained from Vector BioLabs (Phila¬
delphia, Pa). Adenoviral infection was performed at a
multiplicity of infection of 10 in the presence of 6
gg/mL polybrene for 24 hours. Experiments were
performed on cells 48 hours after infection.
Plasmid-mediated HMGA1 RNA interference
Hairpin RNA interference plasmids were obtained
from The RNA-mediated Interference (RNAi) Consor¬
tium (Mission TRC-Hs 1.0; Sigma Aldrich, St. Louis,
Mo). The sequences of short-hairpin RNA (shRNA)
targeting the human HMGA1 gene were as follows:
shHMGAl-1 plasmid, 5' -CAACTCCAGGAAGGAAACC
AA-3'; and shHMGAl-2 plasmid, 5'-CCTTGGCC
TCCAAGCAGGAAA-3'. The control plasmid, which
has a scrambled, nontargeting shRNA sequence, was
obtained from Addgene (Cambridge, Mass). Pooled
stable transfectants were established using puromy-
cin (InvivoGen, San Diego, Calif) selection.
Expression vector and transfection
The HMGA1 coding sequence was amplified by poly¬
merase chain reaction (PCR) from IMAGE clone
5399570 by using gene-specific primers that were
modified to include the appropriate restriction sites
at their 5' end. The following primers were used: for¬
ward, 5' -TTTTGATATCATGAGTGAGTCGAGCTCGAAG
-3' and backward, 5'-TTTTGAATTCTCACTGCTCCTCC
TCCGAGGA-3'. Purified PCR products were digested
with EcoRV and EcoRI before ligation into an EcoRV/
EcoRI-digested pIRES-puro3 vector (Clontech, Palo
Alto, Calif). The expression plasmids were named
pIRES-HMGAl. MiaPaCa2 cells were transfected
with pIRES-HMGAl or with empty pIRES-puro3,
which acted as a control, using Lipofectamine 2000
(Invitrogen). Clones pIRES-HMGAl.l and pIRES-
HMGA1.2 were selected by using puromycin (Invi¬
voGen) were used for further studies, because they
expressed the highest levels of HMGA.
Soft agar colony formation assay
Assays were performed by using a cell transformation
detection assay according to the manufacturer's
instructions (Chemicon, Temecula, Calif). Briefly,
assays were performed in 6-well plates with 5 X 103
cells, resuspended as a single cell suspension in 0.4%
agar, and layered on top of 0.8% agar. Plates were
incubated for 10 to 12 days. Colonies were stained
and counted manually at high-power magnification
(X40). The counting was performed for 10 fields in
each well, and at least 6 wells per condition were
counted in each experiment. Average values from 3
independent experiments were calculated. The rela¬
tive number of colonies was calculated by dividing
each value by the mean value of the control group.
Western blot analysis
Total cell extracts were prepared with Phosphosafe
lysis buffer (Novagen, San Diego, Calif). Nuclear
extracts were prepared by using NE-PER Nuclear
Extraction Reagents (Pierce, Rockford, 111). Protein
concentrations were measured by using a bicincho-
ninic acid assay kit (Sigma) with bovine serum albu¬
min as a standard. Cell lysates that contained 50 gg
protein or nuclear protein that contained 10 gg pro¬
tein were subjected to 10% sodium dodecyl sulfate/
polyacrylamide gel electrophoresis, as described pre¬
viously.11 Chemiluminescence detection (Amersham
Biosciences, NJ) was performed in accordance with
the manufacturer's instructions.
Nude mouse subcutaneous xenograft model
Male athymic nu/nu mice aged 5 weeks were obtained
from Harlan Sprague-Dawley (Indianapolis, Ind). Mice
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housed in a pathogen-free facility were observed for
signs of tumor growth, activity, feeding, and pain in ac¬
cordance with the guidelines of the Harvard Medical
Area Standing Committee on Animals. To determine
the effect of HMGA1 gene silencing on in vivo growth,
2 x 106 MiaPaCa2 cells and PANC1 stable transfectants
that expressed the control or HMGA1 shRNA
(shHMGAl.l plasmid) were implanted subcuta-
neously in nude mice. Tumor dimensions were meas¬
ured weekly by using micrometer calipers. Tumor
volumes were calculated as follows: volume = 1/2 a x
b2, where a and b represented the larger and smaller
tumor dimensions, respectively. Eight weeks after im¬
plantation, the primary tumor was excised, fixed in
formalin, and embedded in paraffin.
Immunohistochemistry
Xenograft tumor sections (5 |im) were deparaffinized
and processed by using the streptavidin-biotin-per-
oxidase complex method described above. Sections
were incubated with anti-Ki-67 (DAKO) at 4 °C over¬
night at 1:200 dilution. The secondary antibody was
biotinylated rabbit-antimouse antibody (DAKO),
which was used at 1:200 dilution for 30 minutes at
37 °C. Tumor cells were considered positive for the
Ki-67 antigen if there was intranuclear staining. Cells
with positively stained nuclei were counted at X40
magnification in 5 random fields from each section.
Apoptosis staining
After preparation of 5-gm tumor sections, apoptosis was
quantified by using a commercially available terminal
deoxynucleotidyl transferase nick-end labeling (TUNEL)
kit (Chemicon). The number of apoptotic cells was
counted in 5 random fields from each section.
Statistical Analysis
Differences between groups were analyzed using Stu¬
dent t tests, multifactorial analyses of variance of ini¬
tial measurements, and Mann-Whitney U tests for
nonparametric data, as appropriate, with Statistica
software (version 5.5; StatSoft, Inc., Tulsa, Okla). In
cases in which averages were normalized to controls,
the standard deviations of each nominator and de¬
nominator were taken into account in calculating the





The cohort consisted of 89 patients with pathologi¬
cally proven pancreatic adenocarcinoma (42 men
TABLE 1
Clinicopathologic Characteristics of the Pancreatic Adenocarcinoma
Cohort




































and 47 women). The mean age at diagnosis was 63
years (median age, 63 years; age range 34-84 years).
The median survival was 16.6 months (range, 91-
3462 days). The actuarial 1-year survival rate was
70.3%, and the 5-year survival rate was 8.1%. A sum¬
mary of the clinicopathologic characteristics of the
cohort is provided in Table 1.
HMGA1 Expression in Normal Tissue and Pancreatic
Adenocarcinoma Specimens
Paraffin-embedded specimens were used to con¬
struct a pancreatic adenocarcinoma TMA. For each
patient within the TMA, cores also were taken from
adjacent normal pancreas to act as internal controls
and to assess the expression of HMGA1 in normal
pancreas. After immunostaining with anti-HMGAl
antibody, HMGA1 expression was scored according
to nuclear intensity. Expression was dichotomized
into an HMGA1 -negative group (score 0) and an
HMGA1-positive group (scores >1). On immunohis-
tochemical analysis, we detected the presence of nu¬
clear HMGA1 expression in 83 of 89 (93%) pancreatic
adenocarcinoma specimens (Fig. 1C). The majority
of normal pancreatic ducts had no detectable nu¬
clear HMGA1 expression (Fig. 1A), whereas some
normal pancreatic ducts had very weak expression.
In the majority of tumor specimens (52%), the degree
of HMGA1 staining was graded with a score >2
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FIGURE 1. Immunohistochemical staining for high mobility group AT-hook 1 (HMGA1) in normal pancreas and pancreatic adenocarcinoma specimens using a
tissue microarray. (A) Normal pancreas (HMGA1 negative). (B) Pancreatic adenocarcinoma (HMGA1 negative). (C) Pancreatic adenocarcinoma (HMGA1 positive).
(D) High-power magnification (original magnification, X400) of an HMGA1-positive section that has intense nuclear staining for HMGA1 (indicated by red arrows)
with some staining of cytoplasm. (E) Kaplan-Meier analysis of overall survival for patients with pancreatic adenocarcinoma based on HMGA1 expression. Sur¬
vival of immunohistochemically HMGA1 -negative patients was compared with survival of HMGA1 -positive patients by using the log-rank test (P = .0028).
89 tumors]; score 3, 17% [5 of 89 tumors]). HMGA1
staining predominantly was localized to the nucleus
of cancerous cells with some staining of the cyto¬
plasm (Fig. 1C). A detailed pathology case review of
the 6 specimens with absent tumor HMGA1 expres¬
sion (Fig. IB) demonstrated no atypical features for
pancreatic adenocarcinoma.
Tumor HMGA1 Expression Status: Association With
Clinicopathologic Features
To identify associations of HMGA1 expression
(HMGA1-negative expression vs F1MGA1-positive-
expression) with clinicopathologic variables, the vari¬
ables were dichotomized as shown in Table 2. There
were no significant differences patients with positive
or negative tumor HMGA1 expression were com¬
pared with respect to patient age, sex, tumor size,
differentiation, LV1, PNI, receipt of chemotherapy,
margin status, lymph node involvement, and disease
stage (Fisher exact test; P>.05) (Table 2). In a
Kaplan-Meier analysis, patients who had no FIMGA1
expression (HMGA1-negative tumors) had signifi¬
cantly longer overall postoperative survival (mean,
5.7 years; median, 4.3 years) compared with patients
who had HMGA1-positive tumors (mean, 1.6 years;
median, 1.3 years; P = .0028; log-rank test) (Fig. ID).
For the patients who had positive HMGA1 expres¬
sion, increasing degree of HMGA1 expression was
not associated with worse clinicopathologic features
or shorter survival.
HMGA1 Represents an Independent Prognostic Indicator
in Pancreatic Adenocarcinoma
To assess whether HMGA1 expression was an inde¬
pendent predictor of overall postoperative survival, a
Cox proportional-hazards model was created in a for¬
ward fashion that included only the covariates that
had a statistically significant correlation (inclusion
threshold, P < .05) with postoperative survival. Uni¬
variate analysis demonstrated that increasing tumor
size, poor tumor differentiation, and HMGA1-positive
tumors were significant predictors of poorer survival
CP < .05) (Table 3). Furthermore, multivariate analysis
demonstrated that, after correction for confounding
variables, HMGA1 expression remained a significant
independent prognosticator for postoperative sur¬
vival (P = .001) (Table 3).
Stable RNAi-mediated Suppression of HMGA1 Expression
Inhibits Anchorage-independent Growth
Both MiaPaCa2 and PANC1 pancreatic adenocarci¬
noma cell lines expressed HMGA1, and MiaPaCa2
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TABLE 2
Associations of High Mobility Group AT-hook 1 Expression With
Clinicopathologic Features
HMGAl status
Variable Negative (N = 6) Positive (N = 83) P
Age, y
<64 3 44 1.000
>64 3 39
Sex
Men 2 40 .680
Women 4 43
Tumor grade (differentiation)




<2.5 3 38 .416
>2.5 3 55
Lymph node metastasis
No 4 30 .197
Yes 2 53
Lymphovascular invasion
No 5 49 .397
Yes 1 34
Perineural invasion
No 3 40 1.000
Yes 3 43
Microscopic margin status
Negative 3 49 .690
Positive 3 34
Tumor location
Head 6 77 1.000
Tail 0 6
Tumor classification
T1/T2 2 11 .210
T3/T4 4 72
Chemotherapy
No 1 4 .272
Yes 3 59
HMGAl indicates high mobility group AT-hook 1.
cells had a lower expression level of HMGAl at base¬
line. We used 2 independent shRNA target sequences
(called shHMGAl-1 and shHMGAl-2) to suppress
HMGAl expression. Each of these shRNA sequences
was associated with an approximately 80% reduction
in HMGAl expression in MiaPaCa2 cells (Fig. 2A), as
confirmed by Western blot analyses of nuclear
extracts. These same shRNA sequences were asso¬
ciated with approximately 55% to 60% reductions in
HMGAl expression in PANC1 cells (Fig. 2A).
In MiaPaCa2 cells, the high degree of HMGAl
silencing induced by each of the shRNA sequences
was associated with marked reductions in growth in
soft agar (Fig. 2C). Similar but less marked reduc¬
tions in growth in soft agar were observed for PANC1
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TABLE 3
Predictors of Postoperative Survival: High Mobility Group AT-hook 1 as an Independent Prognostic Indicator
Univariate analysis Multivariate analysis
Risk factor Hazard 95% CI P Hazard 95% CI P
Increasing age 1.015 0.994-1.037 .171 1.008 0.983-1.033 .545
Women 0.742 0.442-1.244 .258 1.056 0.576-1.936 .861
Increasing tumor size 1.217 1.022-1.450 .028* 1.398 1.130-1.730 .002*
Presence of lymph node metastasis 1.733 0.995-3.019 .052 1.551 0.781-3.082 .210
Advanced tumor stage (T3/T4 vs TIT/2) 2.034 0.906-4.567 .085
Local invasion 1.078 0.612-1.897 .796
Poor tumor differentiation 1.859 1.183-2.921 .007* 3.203 1.746-5.877 .000*
Presence of PNI 1.088 0.651-1.819 .746
Presence of LVI 1.704 0.982-2.958 .058 1.710 0.944-3.098 .077
Presence of tumor at microscopic margin 1.490 0.886-2.505 .133
Chemotherapy treatment 0.440 0.132-1.474 .183
HMGA1 expression 5.473 1.614-18.557 .006* 12.474 2.705-57.520 .001*
95% CI indicates 95% confidence interval; LVI, lymphovascular invasion; PNI, perineural invasion; HMGA1, high mobility group AT-hook 1.
* P < .05.
cells (Fig. 2D) corresponding to lower degrees of
HMGA1 silencing in this cell line.
Forced HMGA1 Overexpression Promotes
Anchorage-independent Growth
Given the relatively low baseline expression level of
HMGA1 in MiaPaCa2 cells, we chose this cell line to
test the effects of forced HMGA1 overexpression. We
transfected this cell line with an overexpression vec¬
tor that carried the full-length HMGA1 combina¬
tional DNA (cDNA). Two clones that stably
overexpressed HMGA1 were selected and named
pIRES-HMGAl.l and pIRES-HMGA1.2. The degree of
HMGA1 overexpression (2.5-fold and 3-fold overex¬
pression, respectively, over controls) was documen¬
ted on Western blot analyses of nuclear extracts (Fig.
2B). HMGA1 overexpression was associated with
increased colony formation in soft agar (Fig. 2E).
HMGA1 -induced Increases in Anchorage-independent
Growth Are PI3-K/Akt-dependent but Not MEK/
Extracellular Signal-regulated Kinase-dependent
The importance of the PI-3K/Akt and MEK/extracel-
lular signal-regulated kinase (ERK) pathways in tu¬
mor growth has been described previously.14,15 Our
group also previously demonstrated that Akt and
ERK activation depends on HMGA1 expression
levels.11,12 Therefore, we sought to determine the de¬
pendence of HMGA1 -induced increase in soft agar
growth on these pathways. Given the effects of
HMGA1 on Akt activation, we performed soft agar
assays in the presence of the PI-3K inhibitor
LY294002. At concentrations of either 25 pM or 50
pM, LY294002 was associated with significant reduc¬
tions in soft agar growth by the pIRES-HMGAl.l and
pIRES-HMGA1.2 clones at levels similar to those
exhibited by parental MiaPaCa2 cells and MiaPaCa2
cells stably transfected with empty pIRES-puro3 vec-
FIGURE 2. (A) Stable silencing of high mobility group AT-hook 1 (HMGA1) expression using 2 short-hairpin RNA (shRNA) expression vectors with independent
target sequences (shHMGAI -1 and shHMGAI -2) was confirmed on Western blot analysis of nuclear extracts. Controls were shRNA expression vectors with a
scrambled, nontargeting sequence. Greater suppression of HMGA1 expression was achieved in MiaPaCa2 cells, in which there was approximately 80% silencing
with shRNA sequences. In PANC1 cells, there was 55% to 60% suppression of HMGA1 expression with each shRNA sequence. (B) Results confirmed that 2
clones of MiaPaCa2 cells stably overexpressed HMGA1 (plRES-HMGA1.1 and plRES-HMGA1.2) on Western blot analysis of nuclear extracts. Blots shown are rep¬
resentative of 3 independent experiments. (C) The effects of modulating HMGA1 expression on anchorage-independent growth was assessed by using soft agar
assays. Stable HMGA1 silencing using each of 2 independent shRNA sequences (shHMGAI-1 and shHMGAI-2) resulted in reductions in soft agar colony forma¬
tion in both MiaPaCa2 cells and PANC1 cells compared with the scrambled control shRNA-transfected cells. Effects on soft agar growth were greater in Mia-
PaCa2 cells, corresponding to greater silencing of HMGA1 in these cells. An asterisk indicates P < .05 versus control shRNA. (D) Overexpression of HMGA1 in
MiaPaCa2 clones (plRES-HMGA1.1 and plRES-HMGA1.2) resulted in unequivocal increases in anchorage-independent growth in soft agar. The number and size
of colonies in soft agar clearly were larger with overexpression of HMGA1. An asterisk indicates P < .05 versus empty plRES-puro3-transfected cells. Values
are means (±standard deviation).
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tor (Fig. 3A). In contrast, the MEK/ERK inhibitor
PD98059 (at concentrations of either 50 gM and 100
pM) had no impact on soft agar growth by the
pIRES-HMGAl.l and pIRES-HMGA1.2 clones (Fig.
3B). In addition, infection of Ad-DN-Akt abrogated
soft agar growth in the pIRES-HMGAl.l and pIRES-
HMGA1.2 clones (Fig. 3C). Infection of Ad-myr-Akt
significantly increased the soft agar growth in Mia-
PaCa2 cells stably transfected with shHMGAl-1 and
shHMGAl-2 (Fig. 3D).
HMGA1 Silencing Resulted in Significant Inhibition of
Tumor Growth in Vivo
Tumors derived from the subcutaneous implantation
of MiaPaCa2 and PANC1 cells that were stably trans¬
fected with HMGA1 shRNA vectors exhibited reduced
growth rates in nude mice compared with the growth
in corresponding controls (tumors derived from Mia-
PaCa2 and PANC1 cells stably transfected with con¬
trol shRNA vectors) during the 8-week period after
implantation (Fig. 4A,B). Stable knockdown of
HMGA1 was confirmed by performing Western blot
analysis on nuclear extracts of tumor xenografts (Fig.
4A and B). Immunohistochemical analysis of tumors
that were harvested at the end of this observation
period suggested that HMGA1 silencing was asso¬
ciated with an inhibition of tumor cell proliferation
(Ki-67 reactivity) (Fig. 4C) and an increase in tumor
apoptosis (TUNEL staining) (Fig. 4D).
Modulation of HMGA1 expression had no impact
on cellular proliferation in monolayer culture (data
not shown). We previously demonstrated that modu¬
lation of HMGA1 expression did not affect the cellu¬
lar proliferation in standard monolayer culture.12
DISCUSSION
At the time of diagnosis, most patients with pancre¬
atic adenocarcinoma have metastatic or locally
advanced disease that precludes surgical resection.
Even among the few patients who are able to
undergo successful resection, most are destined to
die from recurrent cancer. Therefore, the identifica¬
tion of novel prognostic markers and molecular tar¬
gets for this disease is of high priority. In this study,
we focused on 1 such molecule: HMGA1. First, we
examined the clinical relevance of HMGA1 expres¬
sion in pancreatic adenocarcinomas. HMGA1 expres¬
sion was observed in >90% of pancreatic
adenocarcinoma specimens. Although HMGA1
expression was not associated significantly with any
of the clinicopathologic variables that were studied,
negative HMGA1 status predicted improved survival
in patients with pancreatic cancer, and this correla¬
tion persisted even after adjusting for other con¬
founding variables. More important, our study
demonstrated that HMGA1 expression may help to
identify subsets of patients with distinct clinical out¬
comes despite similar pathologic characteristics. The
median survival was significantly longer (up to 3-
fold) in HMGA1-negative patients than in HMGA1-
positive patients. Although it has been demonstrated
that HMGA1 is indicative of a poor prognosis in
patients with other cancers, our current study is
novel because, to our knowledge, it is the first study
to demonstrate that HMGA1 is an independent prog¬
nostic indicator in patients with pancreatic adeno¬
carcinoma. Clearly, the identification of HMGA1 as a
prognostic indicator potentially may be useful,
because it allows the identification of patients who
would benefit from more aggressive treatment of
their disease. Although our current study represents
1 of the largest immunohistochemical studies of pan¬
creatic adenocarcinoma, our relatively modest sam¬
ple size limits interpretation beyond the results
presented. Our preliminary data on the value of
HMGA1 as a prognostic marker is promising and
warrants future study with a larger series of pancre¬
atic cancer patients.
Having established the clinical relevance of
HMGA1 in patients with pancreatic cancer, we
embarked on studies to elucidate the roles of
HMGA1 in the aggressive phenotype of pancreatic
cancer cells by using in vitro and in vivo experi¬
ments. In this study, our findings indicate that
HMGA1 promotes anchorage-independent prolifera¬
tion by pancreatic cancer cells in vitro and tumori-
genesis in vivo. In contrast, our previous observation
suggested that modulating HMGA1 expression in
pancreatic cancer cells had no impact on their prolif¬
eration under standard monolayer culture condi¬
tions.12 These results suggest that HMGA1 does not
act simply as a mitogenic stimulus. The findings are
not surprising, because the kinetics of 3-dimensional
colony formation in vitro more closely approximate
those of in vivo tumor growth than cells in mono¬
layer culture.16 The normal cellular response to de¬
privation from appropriate contact with substratum
is to undergo apoptosis, which, in this context, is
termed anoikis.17 A defining feature of transformed
cells is resistance to anoikis and the ability to prolif¬
erate under anchorage-independent conditions (eg,
in soft agar).18"20 Anchorage-independent growth
probably is a result of the ability to proliferate in ab¬
sence of substratum and to resist apoptosis because
of the loss of substratum. To address the question of
which aspect is modulated by HMGA1, our group
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FIGURE 3. (A) Given the effect of high mobility group AT-hook 1 (HMGA1) on Akt activation, soft agar assays were performed in the presence of 25 pM and
50 pM of LY294002 (a specific phosphatidylinositol 3-kinase [PI3-K] inhibitor). Clones plRES-HMGA1.1 and plRES-HMGA1.2 exhibited significant inhibition of
soft agar growth in the presence of LY294002 at either concentration compared with the dimethyl sulfoxide (DMSO)-treated controls. Although LY294002 also
had an effect on soft agar growth in pIRES-empty puro3 controls, the degree of inhibition clearly was less marked compared with that in the plRES-HMGA1.1
and pIRES-HMGAI.2 clones. An asterisk indicates P < .05 versus DMSO-treated controls. (B) Mitogen-activated protein kinase(MEK)/extracellular signal-regu¬
lated kinase (ERK) inhibitor PD98059 had no effects on HMGA1 overexpression-induced increases in soft agar growth, because the pIRES-HMGAI.1 and pIRES-
HMGA1.2 clones exhibited no significant reductions in growth even in high concentrations (50 pM and 100 pM) of PD98059. This is in contrast to the signifi¬
cant inhibition of soft agar growth when the plRES-puro3 controls were exposed to PD98059. An asterisk indicates P < .05 versus DMSO-treated controls. (C)
Infection of the plRES-HMGA1.1 and plRES-HMGA1.2 clones with dominant-negative Akt adenovirus resulted in significant reductions in HMGA1 overexpression-
induced increase in soft agar growth. Dominant-negative Akt adenovirus resulted in a small effect on soft agar growth in the empty plRES-puro3 control cells.
An asterisk indicates P < .05 versus control adenovirus-cytomegalovirus (Ad-CMV-Null). (D) Conversely, infection of adenovirus-expressing, constitutively active
Akt (Ad-myr-Akt) rescued the ability to grow under anchorage-independent conditions in shHMGA1-1 and shHMGA1-2 stable transfectants. No effects were
observed when empty plRES-puro3 controls were infected with constitutively active Akt adenovirus. An asterisk indicates P < .05 versus control adenovirus
(Ad-CMV-Null). Values are means (±standard deviations).
previously investigated the specific roles of HMGA1
in anoikis by investigating the apoptotic status of
pancreatic adenocarcinoma cells grown in polyhy-
droxyethylmethacrylate-coated plates.12 We observed
that HMGA1 overexpression promoted anoikis resist¬
ance in pancreatic adenocarcinoma cells. Taken this
together, the findings indicate that HMGA1 mediates
its function in tumorigenesis through 2 aspects: 1) by
enhancing resistance to anoikis, as demonstrated in
our previous study,12 and 2) by allowing continued 3-
dimensional proliferation, as demonstrated in the
current study. Our in vivo data provide corroborating
findings: HMGA1 silencing was associated with
reductions in cellular proliferation (Ki-67 index) and
B
TUNEL
FIGURE 4. (A,B) Stable silencing of high mobility group AT-hook 1 (HMGA1) resulted in significant attenuation in the growth of tumors derived from subcuta¬
neous implantation of MiaPaCa2 cells and PANC1 cells in nude mice. Mice (n = 6 per group) were implanted subcutaneously with stably transfected cells
(either a scrambled short-hairpin RNA [shRNA] control or an shHMGAI -1 plasmid). Subcutaneous tumor size was monitored weekly for 8 weeks. Stable HMGA1
silencing was confirmed by Western blot analysis of nuclear extracts from explanted xenograft tumors. Values are means (±standard error of the means). An
asterisk indicates P < .05 versus control shRNA xenografts. Suppression of HMGA1 resulted in reduction of Ki-67 immunoreactivity in vivo. Each tumor slide
was stained for Ki-67, and the numbers of Ki-67-positive cells were counted in at least 5 randomly selected fields at x40 magnification. Representative tumor
sections stained for Ki-67 immunoreactivity in MiaPaCa2 and PANC1 tumor xenografts are shown. An asterisk indicates P < .05 versus control shRNA trasnfec-
tant-derived xenografts. (D) HMGA1 silencing led to increased apoptosis in tumor xenografts, as demonstrated on terminal deoxynucleotidyl transferase nick-end
labeling (TUNEL) staining. TUNEL-positive cells were counted in at least 5 randomly selected fields at X40 magnification in each xenograft slide. Representative
tumor sections stained for TUNEL in MiaPaCa2 and PANC1 tumor xenografts are shown. An asterisk indicates P < .05 versus control shRNA transfectant-derived
xenografts. Values are means (istandard deviation).
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increases in apoptosis (TUNEL staining), correspond¬
ing to overall reductions in tumor growth.
Our study further builds on this observation by
defining a novel mechanism through which HMGA1
mediates anchorage-independent cellular prolifera¬
tion: PI-3K/Akt signaling. Previously, we demon¬
strated that HMGA1 silencing is associated with
reductions in Akt phosphorylation at Ser473 (a
marker of Akt activation), whereas forced HMGA1
overexpression is associated with increases in Akt ki¬
nase activity and in Akt phosphorylation. Neither
HMGA1 silencing nor HMGA1 overexpression had
any impact on levels of total Akt expression.11 Our
current data clearly demonstrate that intact PI-3K/
Akt signaling is necessary for HMGA1 overexpression
to promote colony formation in soft agar. The find¬
ings also demonstrate that constitutively active PI-
3K/Akt signaling is sufficient to maintain the capa¬
city for colony formation in soft agar in the context
of HMGA1 silencing. In our previous study, we con¬
firmed the effects of modulating HMGA1 expression
on the functional status of Akt-dependent pathways
by assessing its effects on mammalian target rapa-
mycin (mTOR) phosphorylation, a well known down¬
stream target of Akt.11 We observed that modulation
of HMGA1 expression has a direct effect on mTOR
phosphorylation, indicating that HMGA1 does have a
functional effect on the PI3-K/Akt/mTOR pathway.
Although the mechanisms by which HMGA1 modu¬
lates the activity of PI3-K/Akt pathway remain
unknown, clues can be obtained from a previous
study that identified which genes are regulated by
HMGA1 using cDNA microarray analysis.21 Among
the list of genes, multiple fibroblast growth factor
(FGF) pathway components (eg, FGF receptor 1
[FGFR1], FGF2b, FGF6, FGF7, and FGF9) appear to
be regulated positively by HMGA1. It is plausible that
induction of the FGF pathway, by binding of FGF to
its receptors, could result in downstream stimulation
of survival signaling pathways like the PI3-K/Akt
pathway, as demonstrated in this study.22
Our group11 and others23 previously described a
role for HMGA1-dependent MEK/ERK signaling.
Thus, in the current study, we tested the effects of
inhibiting this pathway. We observed that the inhibi¬
tion of this pathway with the small-molecule inhibi¬
tor PD98059 had no impact on the proliferation in
soft agar of cells with ectopic HMGA1 overexpres¬
sion. MEK/ERK inhibitor did not even have a basal
effect (as demonstrated by control cells after inhibi¬
tion of MEK/ERK) in cells that overexpressed
HMGA1. These findings suggest that HMGA1 overex¬
pression reduced the sensitivity of the cells to MEK/
ERK inhibition. First, this implies that HMGA1-
induced colony formation is not dependent on the
ERK pathway and highlights the relative unimpor¬
tance of this pathway in the context of HMGA1 over-
expression. Second, HMGA1 overexpression likely has
effects on several pro-oncogenic pathways (1 of
which is described in this study: the PI3-K/Akt path¬
way). The effects on these other pathways may be
more crucial in promoting soft agar growth and,
hence, rendering the inhibition of a single pathway
like the MEK/ERK pathway ineffective in reducing
colony formation. In our previous study,11 we
demonstrated that HMGA1 silencing had no impact
on ERK phosphorylation, although HMGA1 silencing
clearly resulted in reductions in cellular proliferation
in soft agar. Taken together, these findings suggest
that HMGA1-induced cellular proliferation in soft
agar growth is independent of MEK/ERK signaling.
It is clear now that HMGA1 exerts its effects not
only by altering the conformational structure of
DNA. More important, accumulating evidence sug¬
gests that HMGA1 exerts its functions by other
mechanisms. Recent study has suggested that
HMGA1 is capable of inhibiting the functions of p53,
a well known oncosuppressor gene, by cytoplasmic
relocalization of its proapoptotic activator HIPK2.24,25
Nuclear HMGA1 also has been described to directly
influence mitochondrial functions.26 Further study is
likely to reveal increasing complexity in the mechan¬
isms that mediate the biologic actions of E1MGA1.
In summary, HMGA1 represents a novel prognos¬
tic marker in pancreatic cancer. Functionally,
HMGA1 mediates tumor progression by promoting
anchorage-independent proliferation by pancreatic
cancer cells through a PI-3K/Akt-dependent mecha¬
nism. Given the minimal or absent expression of
HMGA1 in normal adult tissues, HMGA1 warrants
further investigation as a tumor cell-specific thera¬
peutic target.
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